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1.1 Introduction 
Biocatalysis has evolved over the past decades towards a reliable tool in the field of 
organic chemistry.1 However, the use of enzymes is still not fully integrated in the 
synthetic community. To provide a better understanding of this important field, some 
essential background information on biocatalysis will be provided. Furthermore, 
enzymes that have found broad application in organic synthesis are briefly 
summarized in this chapter, being categorized according to the type of reaction that 
they catalyze. For each enzyme, the relevant biocatalytic strategies for their 
application are presented. 
Excellent reviews on the use of enzymes in organic chemistry have appeared 
in the literature, mostly focusing on the application of biocatalysis in the synthesis of 
either natural products or pharmaceuticals.2 To provide a guideline on how to further 
implement biocatalysis in organic synthesis, the most important asymmetric 
strategies in which enzymes can be applied are outlined, i.e. kinetic resolution (1), 
desymmetrization (2), deracemization (3), and stereoselective conversions of 
prochiral substrates (4). Stereoselective conversions of prochiral substrates can 
actually be considered as desymmetrization techniques (i.e. prochiral substrates have 
an internal mirror plane). However, we differentiate between symmetric molecules 
that have two identical reactive substituents (2) and prochiral molecules in which the 
attack of one side of a reactive moiety is favored (4). The relevant biocatalysts for the 
research in this thesis i.e. monoamine oxidases, transaminases and Baeyer-Villiger 
monooxygenases are categorized under the most important asymmetric strategies 
that exist for their application. As there is a plethora of total syntheses that exploit an 
enzymatic step, only a few examples that are illustrative to the topic of discussion will 
be discussed to underline the synthetic relevance of these asymmetric strategies.  
1.2 Biocatalysis 
Catalysts are substances which affect the rate of a reaction by lowering the activation 
energy.3 In this process, the catalyst is not consumed and may therefore be recovered 
after the reaction is complete. A large part of the proteins found in nature have this 
unique ability. Generally, catalysts from nature are known as enzymes and are 
produced in the cells of living organisms to a.o. accelerate reactions in metabolic 
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pathways.4 The application of enzymes as catalysts for chemical transformations in 
synthesis is referred to as biocatalysis. 
Enzymes are environmentally benign catalysts as a consequence of among 
others their reactivity under mild conditions and complete biodegradability. 
Biotransformations are generally performed in aqueous medium, although some 
enzymes tolerate high concentrations of organic solvents. Another advantageous 
property of biocatalysis is the exceptionally high efficiency of enzymes. Generally, 
significantly lower catalyst loadings are required in comparison with chemical 
catalysts. The most important strength of enzymes is their ability to exert high 
chemo-, regio- and stereoselectivity. The chemically unmatched, highly specific 
binding pocket of enzymes is responsible for this exceptional selectivity. In the ideal 
case, the substrate enters the binding pocket that is pre-organized in such a way that 
it will only allow a specific moiety (i.e. chemo- and regioselectively) to enter in a 
particular orientation (i.e. stereoselectively). Although this pathway follows the lowest 
energy barrier for the transformation and represents the preferred binding of the 
substrate to the enzyme, other binding modes can participate as well (Figure 1). The 
high selectivity of enzymes has many advantages such as fewer side reactions than 
chemical catalysis. Moreover, biocatalysts can be used in complex transformations as 
well as multi-enzyme cascades without the need for intermediate functional group 
protection and deprotection steps. 
 
Figure 1. A schematic representation of the specific binding pocket of enzymes. 
The use of enzymes also presents some disadvantages such as the fact that they are 
often unstable outside their natural environment. Although chemical reactions can be 
optimized by screening temperatures, solvents, additional reagents and other factors, 
enzymes maintain a much narrower optimization window.3 Moreover, the efficiency 
of enzymes can be negatively affected by the presence of high concentrations of 
organic compounds. Although the use of a low enzyme concentration is a favorable 
aspect, high substrate concentrations often lead to substrate or product inhibition.6 
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Furthermore, substrates suitable for biotransformation are generally small. However, 
alteration of enzyme function and properties can be achieved by directed evolution, a 
method to evolve enzymes by mimicking the natural selection process.5 Most 
biocatalytic conversions are performed in aqueous medium, which is a major 
advantage in terms of sustainability. However, low solubility of the reagents in water 
is often an issue when combining a biotransformation with diversifying chemical 
reactions in one pot. For this reason, co-solvents are frequently used to increase the 
solubility of the reagents. Some enzymes require a specific cofactor (e.g. NAD(P)H, 
flavin, heme) to catalyze the desired reaction. This is a major drawback as these 
cofactors are rather expensive and unstable. Additional enzymes are often required 
for regeneration of the cofactors or to drive the equilibrium towards the desired 
product. 
1.3 Enzymes 
The Enzyme Commission (EC) number nomenclature7 is a classification of specific 
enzymes into enzyme categories based on the type of reaction that they catalyze. The 
six main categories are: oxidoreductases (EC 1), transferases (EC 2), hydrolases (EC 
3), lyases (EC 4), isomerases (EC 5) and ligases (EC 6). In this section, enzymes that 
have found broad application in organic synthesis will be described, which belong to 
categories EC 1‒3. Other types of enzymes are not discussed, as their impact on 
organic chemistry has been relatively small. We categorized the selected enzymes 
according to the type of reaction that they catalyze and in order of popularity i.e. 
hydrolytic reactions, reduction and oxidation reactions, and finally followed by 
transfer reactions. For each enzyme, the relevant biocatalytic strategies for their 
application are discussed. 
1.3.1 Hydrolytic reactions 
The class of enzymes that catalyzes hydrolytic transformations of functional groups is 
referred to as hydrolases (EC 3). Of these reactions, the hydrolysis of amides and 
esters has clearly received major interest throughout the years.8 These reactions are 
readily performed with either proteases (to hydrolyze amide bonds, EC 3.4) or 
esterases (to hydrolyze ester bonds, EC 3.1). Lipases are a subclass of the esterases 
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that specifically hydrolyze lipids in nature. The key features that promote the 
popularity of hydrolases are the lack of cofactor requirement, their wide substrate 
scopes as well as high availability and stability. The reverse reaction to synthesize 
amide and ester bonds is most frequently performed in organic solvents to shift the 
thermodynamic equilibrium.9-11 Other hydrolases such as nitrilases (EC 3.5) and 
epoxide hydrolases (EC 3.3) have a smaller impact on organic chemistry, but their 
potential has been clearly demonstrated.12-15 
1.3.1.1 Proteases, lipases and other esterases 
In synthetic chemistry, proteases and esterases can be applied in (trans)esterification 
reactions or hydrolyses. Lipases are certainly the most widely applied biocatalysts in 
organic chemistry, as they have several advantageous characteristics.16 Since the 
natural function of lipases is the catabolism of a wide variety of nutrients in the 
digestion process, lipases accept a broad range of natural as well as non-natural 
substrates. Various lipases are commercially available and highly stable both in 
organic solvents and at elevated temperatures, while exhibiting high stereoselectivity. 
 Esterases and proteases are ideal for kinetic resolutions and 
desymmetrizations of carboxylic acids, alcohols, amides and amines (Scheme 1).8-10 In 
the past two decades, dynamic kinetic resolution methods have gained attention, 
predominantly for the deracemization of secondary alcohols by combining a lipase 
with a racemizing additive (e.g. bases, metal complexes, racemases).11 
 
Scheme 1. Generalized reaction catalyzed by esterases and proteases. 
1.3.1.2 Nitrilases 
Nitrilases catalyze the hydrolysis of cyano groups to the corresponding carboxylic acid 
derivative and ammonia (Scheme 2). Since the first nitrilase was discovered in the 
1960s,17 many different examples have been identified in animals, plants and 
micro-organisms. Nevertheless, there is still little understanding of the biological 
function of most nitrilases. Research on nitrilases and their role in plant-microbe 
interactions has been reviewed by Preston.18 Nitrilases have been applied in several 
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industrial biotransformations.19 Since their properties are comparable to lipases, 
nitrilases can also be applied in kinetic resolution, desymmetrization and 
deracemization strategies.12,20 
 
Scheme 2. Generalized reaction catalyzed by nitrile hydratases, nitrilases and epoxide hydrolases. 
1.3.1.3 Epoxide hydrolases 
Epoxide hydrolases are present in every living organism to catalyze the hydrolysis of 
epoxides into vicinal diols with inversion of one stereocenter (Scheme 2). The main 
functions of epoxide hydrolases are detoxification, catabolism, and regulation of 
signaling molecules. Micro-organisms are generally the source of epoxide hydrolases 
in organic synthesis, as they are easy to culture on large scale and hence give 
relatively fast access to large quantities of the biocatalyst.21 Epoxide hydrolases offer 
several advantageous properties. Like lipases, these enzymes do not require a cofactor 
and often exhibit high regio- and stereoselectivity. Moreover, epoxide hydrolases 
typically remain active in the presence of organic solvents. As a result of their ubiquity 
in nature, a large variety of epoxide hydrolases can be applied on various types of 
substrates.22 Epoxide hydrolases can logically be used in kinetic resolution13 and 
desymmetrization.14 However, a more interesting application is deracemization.15 
1.3.2 Reduction reactions 
Enzymes that catalyze redox reactions, called oxidoreductases (EC 1), can be classified 
into three important categories: dehydrogenases, oxygenases and oxidases.23 The EC 
classification depends on among others the donor molecule and cofactor. Since 
oxygenases and oxidases consume molecular oxygen during oxidation, these enzymes 
cannot be applied in reduction reactions. Dehydrogenases catalyze oxidation reactions 
by transferring hydrogen from a donor substrate to an acceptor cofactor such as a 
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ketone or an alkene. The redox cofactor is NAD(H) or NADP(H) in most cases. The 
reverse reaction (reduction) can be catalyzed by dehydrogenases as well, depending 
on the redox state of the cofactor. With the intention to avoid confusion, 
dehydrogenases used in reduction reactions are generally called reductases e.g. an 
alcohol dehydrogenase that is used for the reduction of a ketone, is then called 
ketoreductase. The most widely applied enzymes for reduction reactions are 
ketoreductases and ene reductases. 
1.3.2.1 Ketoreductases 
Carbonyl moieties are present in various endogenous (e.g. hormones, mediators, 
cofactors) and exogenous (e.g. food ingredients, drugs) compounds, and often play a 
vital role in the biological activity of these compounds. Therefore, an important 
function of ketoreductases (Scheme 3) is to regulate the concentration of these 
biologically active compounds in living organisms. Since these carbonyl compounds 
differ greatly in their chemical backbone, ketoreductases can accept a wide range of 
carbonyl compounds.24 There are several chemical processes equivalent to enzymatic 
ketoreduction, which have shown to be very robust and versatile.25 Nevertheless, 
ketoreductases deliver many advantages over chemical approaches in terms of regio- 
and stereoselectivity, reaction conditions (i.e. mild conditions), lack of H2 consumption 
or release, and low catalyst costs. A drawback of ketoreductases is that cofactors are 
required. Ketoreductases are mainly used in stereoselective transformations.26 In 
addition, some examples of kinetic resolution27 and deracemization28 are reported as 
well. 
 
Scheme 3. Generalized reaction catalyzed by ketoreductases and ene reductases. 
1.3.2.2 Ene reductases 
Enzymes belonging to the old yellow enzyme (OYE) family are surely the most 
commonly used ene reductases in organic chemistry. In 1932, Warburg and Christian 
were the first to isolate an OYE from brewers’ bottom yeast (Saccharomyces 
pastorianus).29 Homologous enzymes have been found in other yeasts, plants, bacteria 
and parasitic eukaryotes.30  
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Ene reductases catalyze the reduction of C=C bonds (Scheme 3) that are activated by 
electron-withdrawing groups (e.g. esters, ketones, amides). Although chemical 
equivalents are still very popular (i.e. Knowles and Noyori received the Nobel Prize for 
their work on asymmetric hydrogenation in 2001), ene reductases are gaining 
attention due to their high stereo- and regioselectivity, and rather broad substrate 
scopes. Most ene reductases use flavin mononucleotide (FMN) as the hydride donor, 
which is recycled during the reaction by NADH.31 Notably, the OYE family owes its 
name to the yellow color of oxidized FMN in aqueous solution. As might be expected, 
ene reductases are only applied in the stereoselective transformation of prochiral 
substrates.32 
1.3.3 Oxidation reactions 
Oxidoreductases such as oxygenases and oxidases are widely applied as catalysts for 
oxidation reactions.23 The name of the oxygenase subclass originates from their ability 
to transfer oxygen atoms from molecular oxygen to a substrate. Monooxygenases (EC 
1.14) transfer a single oxygen atom as a hydroxyl group to the substrate and reduce 
the other oxygen atom to water using cofactor NADPH or NADH. In most cases, 
activation of oxygen is achieved with a cofactor such as heme or flavin. Dioxygenases 
(EC 1.13) transfer both oxygen atoms to the substrate using an iron cofactor e.g. in the 
form of heme. Oxidases catalyze the abstraction of hydrogen from a donor substrate to 
molecular oxygen, which is reduced to water or hydrogen peroxide in the process. In 
contrast to dehydrogenases that generally use NAD(H) or NADP(H) as cofactor, 
oxidases are not able to catalyze the reverse reaction. The most widely applied 
oxidoreductases for oxidation reactions are amine oxidases (EC 1.4.3), dioxygenases 
and monooxygenases. 
1.3.3.1 Amine oxidases 
Amine oxidases are divided in type I (quinone-dependent family) and type II 
(flavin-dependent family). For synthetic chemists, enzymes of type I are less 
interesting as the product will be covalently bound to the enzyme.33 Monoamine 
oxidases of type II are enzymes that catalyze the oxidation of primary aliphatic and 
aromatic amines as well as some secondary and tertiary amines to imines (Scheme 4). 
Imines are generally unstable and readily hydrolyzed to the corresponding aldehyde 
or ketone and amine. In the human body, these enzymes function in the oxidative 
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deamination of neurotransmitters and exogenous amines.34 The monoamine oxidase 
from fungus Aspergillus niger (MAO-N) is so far the only monoamine oxidase that is 
well established in organic chemistry. This enzyme was identified by Schilling and 
Lerch35 in 1995, after which Sablin et al.36 overexpressed the gene in E. coli. In 
contrast to mammalian MAOs, MAO-N is soluble, peroxisomal, readily extractable and 
easy to isolate. Moreover, MAO-N shows no tendency to aggregate and the flavin 
cofactor FAD is non-covalently linked. Although wild-type MAO-N only catalyzes the 
oxidation of simple amines, several rounds of directed evolution5 have successfully 
broadened the substrate scope of this enzyme.37 
 
Scheme 4. Generalized reaction catalyzed by amine oxidases. 
While kinetic resolution and deracemization strategies of chiral amines are possible, 
all resolution protocols can in principle be converted into a dynamic kinetic resolution 
(see Chapter 1.4.3.2). Owing to the stability of cyclic imines, MAO-N is especially 
suitable for the desymmetrization of prochiral cyclic amines (see Chapter 1.4.2.2). 
1.3.3.2 Dioxygenases 
A key step in the catabolism of aromatic compounds by micro-organisms is 
cis-dihydroxylation catalyzed by microbial dioxygenases. In the presence of molecular 
oxygen, the biocatalyst oxidizes aromatic compounds towards the corresponding 
diols. In addition, this process is also crucial in the detoxification of aromatic 
pollutants.38,39 Dioxygenases have been applied in numerous asymmetric syntheses,40 
as two stereocenters are generated with high stereospecificity for a broad range of 
aromatic substrates. Alkenes have also been used, albeit in conjugation with an aryl 
group or another olefin (Scheme 5).41 Chemical dihydroxylations are well known, 
although most methods are only applicable on alkenes. As the substrates are generally 
achiral, these types of enzymes are only used in stereoselective biotransformations of 
prochiral substrates.42  
1.3.3.3 Baeyer-Villiger monooxygenases 
Baeyer-Villiger monooxygenases (BVMOs) are oxidoreductases that catalyze the 
conversion of ketones to esters (Scheme 5). BVMOs can be classified as type I or II 
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based on the difference in cofactors (i.e. type I uses FAD and NADPH, type II uses FMN 
and NADH) and structure.43 Only BVMOs of type I, exclusively found in bacteria and 
fungi, are integrated in organic chemistry. In Nature, these enzymes play a vital role in 
several degradation pathways and in the biosynthesis of complex molecules (e.g. 
steroids).44 Chemically, a Baeyer-Villiger reaction is performed with a ketone and a 
peroxy acid. Besides the fact that peroxy acids are non-selective, these oxidants are 
also harsh, toxic reagents. Highly stereoselective catalytic methods based on 
transition metals have been developed using less harsh reaction conditions. 
Nevertheless, BVMOs are superior in terms of sustainability, chemo-, regio-, and 
stereoselectivity, using molecular oxygen as the oxidant.45 Although BVMOs are 
well-known biocatalysts, not many applications in asymmetric synthetic strategies 
have appeared in the literature thus far. BVMOs are mostly applied in 
desymmetrization (Chapter 1.4.2.1) and deracemization strategies (Chapter 1.4.3.1). 
Examples of kinetic resolutions are known,46 but synthetic applications are lagging 
behind. 
 
Scheme 5. Generalized reaction catalyzed by dioxygenases and Baeyer-Villiger monooxygenases. 
1.3.3.4 Miscellaneous monooxygenases 
Sulfoxides are chiral molecules that are represented in various biologically active 
compounds. In addition, sulfoxides are used in asymmetric synthesis as chiral 
auxiliaries. Although asymmetric strategies to oxidize sulfides by means of 
organocatalysis47 or transition metal catalysis48 have been reported, biocatalysts 
remain superior in terms of enantioselectivity. Many types of oxidases catalyze this  
 
 
Scheme 6. Generalized reaction catalyzed by monooxygenases. 
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reaction, but no specific enzymes exist that only catalyze sulfur oxidation (Scheme 
6).49 To obtain enantiopure sulfoxides using biocatalysis, kinetic resolution can be 
applied by oxidation of one of the enantiomers to its corresponding sulfone.50 
However, stereoselective transformations of prochiral thioethers are a more 
attractive strategy.51 
1.3.4 Transfer reactions 
Enzymes that transfer specific functional groups from donor molecules to acceptor 
molecules are referred to as transferases (EC 2). Transaminases (EC 2.6.1) are the 
most popular and widely applied transferases in organic chemistry. 
1.3.4.1 Transaminases  
Transaminases are ubiquitous in nature, as these enzymes play a vital role in the 
biosynthesis of amino acids. The reaction that transaminases catalyze is the exchange 
of an amine moiety of one molecule with the carbonyl moiety of another molecule 
utilizing the cofactor pyridoxal 5’-phosphate (PLP). Formally, the molecule with the 
carbonyl moiety is reduced and the compound with the amine functionality is oxidized 
(Scheme 7). These enzymes are usually named α-transaminases if α-amino acids are 
formed. However, when a transaminase is also able to accept aliphatic ketones and 
amines as substrates, they are referred to as ω-transaminases. Alternatively, the latter 
class is named amine transaminases (ATAs).52 Unlike other biocatalytic reductions, 
transaminases do not require expensive redox cofactors. In addition to transaminases 
that produce L-amino acids, transaminases producing D-amino acids have also been 
identified in bacterial species.53 Consequently, both enantiomers of a desired amine 
may be produced by selecting enantio-complementary enzymes from different 
sources.  
 
Scheme 7. Generalized reaction catalyzed by transaminases. 
In Nature, transamination reactions are in constant equilibrium, which is undesirable 
when full conversion of the substrate is pursued. This drawback can be overcome by 
removing the undesired coproduct from the reaction by the use of additional 
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enzymatic systems, or using a large excess of a sacrificial amine or ketone cosubstrate. 
Transaminases are mostly used in the stereoselective transformation of prochiral 
compounds (see Chapter 1.4.4.1) and in the kinetic resolution of racemic amines (see 
Chapter 1.4.1.1), but deracemization methods have been developed as well (see 
Chapter 1.4.3.3). 
1.4 Biocatalytic Strategies 
Biocatalytic strategies that have found wide application in organic chemistry are 
outlined in this section. Furthermore, some interesting examples of their application 
in organic synthesis are presented for three important enzyme categories, namely 
Baeyer-Villiger monooxygenases, monoamine oxidases and transaminases. 
1.4.1 Kinetic resolution 
Enzymatic kinetic resolution (EKR) is of prime importance in asymmetric synthesis, 
both in industry and academia. Although many synthetic chemists regard this strategy 
as inelegant, it is still probably the most widely applied biocatalytic strategy in organic 
synthesis. The success of EKR depends on the difference in activation energy of the 
two enantiomers when reacted in the presence of an enzyme (i.e. kR ≠kS). The higher 
the difference in activation energy, the higher the preference for one of the 
enantiomers (Scheme 8). If both enantiomers of a natural compound or drug are 
desired, EKR is a highly suitable strategy. Unfortunately, the undesired enantiomer is 
generally a waste product after kinetic resolution. In this case, a purification step is 
required that is commonly rather laborious.  
 
Scheme 8. The principle of kinetic resolution. 
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1.4.1.1 Transaminases 
The yield limitation of EKR is frequently a justified reason for avoiding a resolution 
step in total syntheses. However, an example by Kroutil et al. shows an ingenious 
sequence consisting of a kinetic resolution step followed by a stereoselective 
amination with oppositely enantioselective transaminases (TAs, Scheme 9). This 
two-step deracemization strategy affords optically pure mexiletine (1). By simply 
switching the order of the enzymatic reactions, both enantiomers could be obtained as 
optically-pure products in near quantitative yields (97%).54 Although Kroutil and 
coworkers have demonstrated the resolution power of transaminases, preference is 
generally given to stereoselective conversions of prochiral ketones. Only if the racemic 
amine is more easily accessible than the prochiral ketone, such a deracemization 
strategy is an interesting alternative.    
 
  
Scheme 9. A one-pot two-step deracemization procedure towards mexiletine (S)-1.  
1.4.2 Desymmetrization 
Enzymatic desymmetrization is a powerful tool in numerous total syntheses. Unlike 
kinetic resolution, desymmetrization does not have the drawback of a maximal 
theoretical yield of 50%, as the substrates are achiral. The strategy is based on having 
two equivalent substituents of which only one will undergo a biocatalytic 
transformation. When the substrate is prochiral, transformation of one of these 
groups will lead to a chiral compound. Since enzymes have the beneficial property of 
having a very specific binding pocket, the substrate will usually be oriented in such a 
way that high selectivity can be achieved.  
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1.4.2.1 Baeyer-Villiger monooxygenases 
BVMOs have been applied in many desymmetrization approaches using cyclic 
prochiral ketones. Some examples of interesting products with predominantly high 
enantiopurity are shown in Figure 2. Although several BVMOs have been applied on a 
wide variety of substrates, the number of applications in total synthesis is lagging 
behind.55 However, optically pure lactones have proven to be versatile building blocks 
in the synthesis of various high-value target molecules, in particular β-aryl-γ-lactones. 
For instance, lactone 4 is introduced as a key intermediate in the total synthesis of 
biologically active (R)-baclofen.56 Another example is bicyclic lactone 8─an important 
building block in the synthesis of scholarisine A57─which is generally synthesized by a 
lipase-catalyzed desymmetrization strategy,58 followed by several synthetic steps. 
Although this procedure is applicable on a large scale, it may be interesting to 
consider a BVMO-catalyzed desymmetrization to provide this chiral intermediate.  
 
Figure 2. Interesting products attained by BVMOs. 
1.4.2.2 Amine oxidases 
Turner et al. subjected a series of meso-pyrrolidines to amine oxidation by an 
Aspergillus niger MAO-N mutant (Figure 3). Oxidation proved to be faster for 
substrates with increased bulk and lipophilicity. Stable bi- and tricyclic imines could 
be isolated with high enantioselectivity (>94% ee) as either the monomer, or the  
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Figure 3. Relative rates of biocatalytic oxidation with MAO-N D5 for pyrrolidines 11‒17. 
Rates are relative to (S)-α-methylbenzylamine (rate= 100). 
trimer.59 To date, no chemical procedures have been reported that can accomplish this 
asymmetric transformation. Imines are intermediates in various multicomponent 
reactions (MCRs), which is a category of reactions that create a high degree of 
diversity and complexity in a single step. Orru et al. illustrated the applicability of the 
biocatalytically generated 1-pyrrolines in Ugi-type MCRs to access enantio-enriched 
prolyl peptides in good yields (60‒85%) and with high stereoselectivity (84‒98% de, 
94‒99% ee).60 This combination of biocatalysis and multicomponent reactions was 
later applied in the synthesis of the hepatitis C virus protease inhibitor telaprevir (22, 
Scheme 10).61 In addition, a tandem MAO-N oxidation, Ugi 3CR, Adams Carroll-type 
cyclization sequence for rapid synthesis of alkaloid-like polycyclic structures was 
described.62 
 
Scheme 10. Chemoenzymatic total synthesis of hepatitis C virus protease inhibitor telaprivir. 
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1.4.3 Deracemization 
Deracemization strategies have gained much attention over the past decade, since the 
obvious disadvantages of kinetic resolution (50% maximum yield) and 
desymmetrization (limited substrate scope) are avoided. Although some enzymes can 
deracemize a substrate, most processes require an additional chemical reagent or 
enzyme for in situ deracemization. Deracemization strategies also include dynamic 
kinetic resolution (DKR) and dynamic kinetic asymmetric transformation (DYKAT) 
(Scheme 11). DYKAT is a process in which interconversion of the starting material 
takes place on the chiral catalyst. DYKATs proceed either by binding of either 
enantiomer to the chiral catalyst (i.e. giving two diastereomeric catalysts) after which 
one is converted by means of epimerization, or by eliminating the stereocenter (i.e. 
hence forming only one substrate/enzyme complex) after which addition to one side 
is preferred.63 This is in contrast with the DKR, in which racemization is induced by an  
 
 
Scheme 11. Schematic representation of dynamic kinetic resolution and dynamic kinetic asymmetric 
transformation. 
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achiral reagent or catalyst. The first examples of enzyme-catalyzed DKR procedures 
originate from the past century. These methods often benefit from the generally 
undesired racemization of base-sensitive substrates.64 Other methods are based on 
racemization by transition metals and racemases.65 
1.4.3.1 Baeyer-Villiger monooxygenases 
BVMOs hold great potential in deracemization strategies, although examples and 
applications are limited in the literature. The first DKR method employing a BVMO 
was reported by Furstoss et al., in which α-substituted cyclopentanone 23 was 
converted to lactone 24 (Scheme 12). The authors performed the oxidation at pH 9 to 
induce racemization of 23. The product could be obtained in 85% yield with high 
optical purity (96% ee).66 
 
Scheme 12. Conversion of  (±)-23 to lactone (R)-24 via a BVMO-catalyzed DKR procedure. 
 
A more recent example was reported by Gotor et al., in which α-substituted 
β-ketoesters 25 were subjected to biocatalyzed Baeyer-Villiger oxidations (Scheme 
13).67 Of the three BVMOs tested, phenylacetone monooxygenase (PAMO) and 
4-hydroxyacetophenone monooxygenase (HAPMO) displayed superior activity and 
selectivity. The resulting α-acylated hydroxyl esters 26 are valuable synthetic building 
blocks in various industrial processes. Most products were obtained in high optical 
purity, with high conversion within 2 days. Gotor and coworkers have also published 
other DKR methods with BVMOs, yet resulting in less attractive products for synthetic 
applications.68 
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Scheme 13. Conversion of acyclic α-substituted β-ketoesters to α-acylated hydroxyl esters via a 
BVMO-catalyzed DKR procedure followed by hydrolysis. 
1.4.3.2 Amine oxidases 
Deracemization methods that utilize amine oxidases are distinct from other 
deracemization processes, as amine oxidases selectively symmetrize chiral 
compounds. Combining the biocatalytic oxidation of one enantiomer with 
non-selective reduction of the imine allows the synthesis of enantiomerically pure 
amines after several redox cycles. Turner et al. were the first to illustrate this principle 
by combining a MAO-N-catalyzed oxidation with ammonia borane reduction in one 
pot. This method could be applied on a wide variety of structurally different amines 
giving high enantioselectivity (83‒99% ee).69 The fact that the substrate scope 
includes tertiary amines is considered a great asset for synthetic chemistry, since 
these compounds are typically difficult to oxidize enantioselectively.70 This method 
was successfully applied in the total synthesis of tetrahydroisoquinoline alkaloid 
(R)-crispine A (29, Scheme 14).71 The synthetic utility was further illustrated by the 
synthesis of active pharmaceutical ingredients solifenacin and levocetirizine, as well 
as natural products (R)-coniine, (R)-eleagnine and (R)-leptaflorine.37 In addition, one  
 
 
Scheme 14. MAO-N catalyzed DKR strategy in the total synthesis of (R)-crispine A (29). 
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of their MAO-N mutants was able to catalyze an exotic Pictet-Spengler/deracemization 
sequence towards (R)-harmicine in high yield and optical purity.37 
 Kroutil et al. combined a MAO-N-based deracemization with berberine bridge 
enzyme (BBE) to provide a one-pot cascade transformation. Full conversion towards 
the desired berberin products with high enantioselectivity (>97% ee) was achieved 
within two days.72 To date, no chemical reagent (or other biocatalyst) is able to 
perform either of the two biotransformations. Turner et al. showed that commercially 
available (S)-selective transaminase ATA-113 and (R)-selective transaminase 
ATA-117 can regioselectively convert 1,4-diketone 30 to optically-pure pyrrolines 33 
in good yields via a transamination/cyclization sequence. Subsequently, this method 
was successfully combined in one pot with MAO-N catalyzed deracemization to 
provide a small range of pyrrolidines with excellent stereoselectivity (Scheme 15).73,74  
  
Scheme 15. A regio- and stereoselective ATA/MAO cascade towards pyrrolidines 33.  
1.4.3.3 Transaminases 
Deracemization methods with transaminases are based on keto-enol tautomerization 
of the prochiral carbonyl substrate. Gotor et al. performed the deracemization of 
acyclic α-substituted β-keto esters with several (S)- and (R)-selective transaminases.75 
Although high ee´s were achieved in general, high diastereoselectivities (94‒96% de) 
were only achieved with cyclic analogs. Chung et al. used a deracemization strategy 
followed by lactamization in the synthesis of niraparib (37).76 Superior results were 
obtained in rather basic media (pH 10.5), using pyridoxal 5’-phosphate (PLP) as a 
cofactor and isopropylamine as the amine donor (Scheme 16).  
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Scheme 16. Transaminase DKR strategy in the total synthesis of niraparib (37). 
1.4.4 Stereoselective biotransformations of prochiral compounds 
Stereoselective biotransformations of prochiral compounds are strictly speaking 
desymmetrization reactions, as the achiral starting material is converted to a chiral 
product. However, stereoselective conversions of prochiral compounds by favored 
attack from one side of the reactive moiety, can be considered substantially different 
than preferential conversion of one of two identical moieties to give a chiral molecule 
during a desymmetrization. This distinction is more clearly depicted in scheme 17. 
 
 
Scheme 17. A discrimination between desymmetrization and stereoselective conversion. 
1.4.4.1 Transaminases 
Transaminases are mainly used in the stereoselective conversion of achiral ketones or 
aldehydes, which are synthetically easily accessible. However, these types of 
biotransformations require ingenious techniques to obtain high quantities of the 
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chiral amine, owing to the thermodynamic equilibrium. Kroutil and coworkers have 
developed such a method using ammonium as a cheap stoichiometric amine donor 
(Scheme 18).77 This process requires three enzymes: 1) a transaminase, 2) an amino 
acid dehydrogenase (AADH), and 3) a formate/glucose dehydrogenase. The 
transaminase (ATA-113) carries out the desired transformation with alanine as the 
direct amine donor. Pyruvate is subsequently recycled by L-alanine dehydrogenase 
(L-ADH) and ammonium. The third enzyme, formate dehydrogenase (FDH) or glucose 
dehydrogenase (GDH), is required for cofactor recycling. High conversions and ee´s 
were obtained with a variety of ketone substrates. The advantage of this cycle is that 
product inhibition by pyruvate is prevented. Nevertheless, an excess of alanine (5 
equiv) is required to achieve high conversion.  
 
Scheme 18. The use of ammonium as stoichiometric amine donor in biocatalytic transamination. 
 
Transaminases have already been included in many synthetic strategies, mostly to 
optimize a certain transformation. This surely applies for the enzymatic conversion of 
prositagliptin (40) to sitagliptin (41, Scheme 19).78 Sitagliptin could be synthesized in 
92% yield and 99.5% ee from the corresponding ketone using an engineered 
transaminase (ATA-117 mutant). The fact that ATA-117 (an enzyme that is only 
capable of converting small ketone substrates) could be modified to accept rather 
large ketones like prostagliptin, shows the great potential of directed evolution for the 
implementation of enzymes in total synthesis. The enzymatic route was clearly 
superior over the transition-metal based approach in both ee and sustainability and 
therefore represents a landmark of modern biocatalysis. 
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Scheme 19. Improvement of the chemical conversion of prositagliptin (40) to sitagliptin (41) by use of 
transaminase ATA-117. 
1.5 Conclusion & Outlook 
Enzymes are able to perform transformations that are chemically either less effective 
or not (yet) possible. Although chemical procedures are improving, the binding pocket 
of enzymes is chemically unmatched. The greatest strength that biocatalysts exhibit is 
their high chemo-, regio-, and enantioselectivity. Moreover, the diverse selection of 
biocatalytic strategies and biocatalysts gives access to a variety of building blocks. 
Biocatalysts have some obvious disadvantages, such as high substrate 
specificity, cofactor dependence and narrow optimization possibilities. Fortunately, 
the use of directed evolution provides the possibility to alter the properties of 
enzymes in order to overcome these drawbacks. In addition, new enzymes are 
discovered every day, and there is still a large domain of biocatalysts which remains 
unexplored. By accepting biocatalysis as an important tool in the synthetic toolbox, 
more handles are available to solve the chemical problems that we encounter.  
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1.7 Outline of this Thesis 
From this introductory chapter, it becomes clear that biocatalytic strategies have great 
potential for synthetic chemistry. Although numerous examples of the use of 
biotransformations in total syntheses have been described, only a limited number of 
enzymes is considered suitable for organic chemistry. Many enzymes find only little 
application because of limitations in their substrate scope and their instability in the 
presence of organic solvents and many reagents. However, directed evolution has 
provided some tailored variants of otherwise difficult-to-use enzymes with wider 
substrate scopes. In Chapter 2, we will describe the one-pot combination of a 
biocatalytic oxidation of meso-pyrrolidines—using an engineered monoamine oxidase 
(MAO-N D5)—with chemical transformations. This highly stereoselective 
chemoenzymatic cascade sequence provides 2-substituted pyrrolidines in a 
sustainable manner. Although this biocatalytic oxidation was previously only 
described for carbocycle-fused pyrrolidines, we were delighted to find that the 
incorporation of an oxygen atom in the substrate was allowed. Hereby, we show that 
MAO-N can be used for the synthesis of a wider variety of 1-pyrrolines in high optical 
purity. Since MAO-N only provides one of the enantiomers, we set out to develop a 
convenient chemical oxidation providing racemic 1-pyrrolines. In Chapter 3, we will 
describe the first o-iodoxybenzoic acid (IBX) mediated oxidation of unactivated 
pyrrolidines to the corresponding imines. We further explored the chemical space 
with one-pot oxidative diastereoselective Ugi-type and aza-Friedel‒Crafts reactions. 
With convenient methods towards either racemic or optically pure bicyclic imines in 
hand, we investigated their application in novel cascade reactions by considering 
them as amino aldehyde synthons. In Chapter 4, we will describe a switchable 
chemoenzymatic interrupted Fischer indole synthesis of either pyrroloindolines or 
constrained tryptamines. To account for the switch in reaction outcome based on the 
stoichiometry of the acid mediator, we will describe a plausible reaction mechanism. 
Furthermore, the synthetic utility of our method is illustrated with the synthesis of 
pharmaceutically relevant examples of both product classes. In Chapter 5, we will 
describe other envisioned opportunities for the use of monoamine oxidase in organic 
synthesis, using meso-pyrrolidines as a template. Evidently, other biocatalyst have 
great potential to be applied in synthetic chemistry as well. Therefore, we will also 
describe possibilities for the application of other biocatalysts i.e. Baeyer-Villiger 
monooxygenases and transaminases. 
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Stereoselective Chemoenzymatic Oxidative  
aza-Friedel‒Crafts Reactions in Aqueous Buffer 
 
 
 
Abstract: We disclose a highly diastereoselective chemoenzymatic oxidative aza-Friedel‒Crafts 
reaction of meso-pyrrolidines in aqueous buffer providing valuable enantioenriched 2-substituted 
pyrrolidines. A range of secondary as well as tertiary amines were shown to be suitable substrates 
for the biocatalytic oxidation and subsequent addition of variety of C-nucleophiles. 
1  
2  
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2.1 Introduction 
In the transition to sustainable chemistry, the demand for more sophisticated and 
efficient chemical processes that utilize and generate less hazardous chemicals is ever 
increasing.1,2 In order to reduce waste production and energy consumption, the one-
pot combination of substrate activation and synthetic transformations in benign 
media is of great interest. Biocatalysis is particularly useful in this respect, as enzymes 
are often able to mediate otherwise difficult activation of building blocks under mild 
conditions with unrivaled chemo-, regio- and stereoselectivity. The power of 
chemoenzymatic approaches has been convincingly demonstrated in the synthesis of 
well-known pharmaceuticals such as sitagliptin,3 singulair,4 posaconazole5 and 
telaprevir.6  
 In recent years, direct asymmetric α-functionalizations towards 2-substituted 
pyrrolidines have attracted great attention in view of the importance of this structural 
motif in organocatalysis (e.g. proline derivatives).7-9 Herein, we present a novel 
one-pot chemoenzymatic oxidative aza-Friedel‒Crafts sequence for the synthesis of 
such chiral 2-substituted pyrrolidines under mild conditions. This approach combines 
the biocatalytic oxidation of cyclic amines to the corresponding imine derivatives with 
the subsequent addition of C-nucleophiles in aqueous buffer to yield formally double 
C‒H activation products (Scheme 1).  
 
Scheme 1. One-pot chemoenzymatic oxidative aza-Friedel-Crafts sequence. 
The aza-Friedel‒Crafts (aza-FC) reaction10 can be defined as the 1,2-addition of 
aromatic and hetero-aromatic compounds to imine derivatives. This transformation 
typically requires organic solvents and strong Lewis or Brønsted acid catalysis, with 
the exception of a limited number of examples of activator-free phenolic Mannich 
reactions in aqueous medium.11 In these cases, the alcohol functionality is proposed to 
be responsible for both imine activation and regioselectivity control as a result of 
hydrogen bond formation. Other examples of aqueous aza-FC reactions without an 
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additional catalyst require a highly electrophilic imine.12,13 Besides the drawback of 
limited application, these procedures employ imine derivatives that are accessed 
through additional synthesis and purification steps which is undesirable from a green 
perspective. 
2.2 Results and Discussion 
We previously reported a biocatalytic oxidation of meso-pyrrolidines with an 
engineered monoamine oxidase (MAO-N D5) to give 1-pyrrolines with high 
enantioselectivity.14 In continuation of this research, we investigated the biocatalytic 
oxidation of exo-configured meso-pyrrolidine 1a in aqueous buffer.15 Intriguingly, 
2-pyrrolyl pyrrolidine 4a was obtained as the reaction product rather than the 
expected imine 2a. To unravel which chemoenzymatic reaction cascade is responsible 
for the formation of 4a, we investigated this reaction outcome in greater detail. 
 The mechanism for the formation of 4a likely starts with the usual 
biocatalytic oxidation of 1a to give imine 2a (Scheme 2). However, 2a is apparently 
unstable under the reaction conditions and undergoes a retro-Diels-Alder (rDA) 
reaction to give furan and pyrrole. Since rac-2a can readily be prepared with a 
different method,16 we hypothesize that the rDA reaction proceeds only from 
protonated 2a under aqueous conditions. Test experiments showed no reaction  
 
 
Scheme 2. Proposed mechanism for the formation of 2-pyrrolyl pyrrolidine 4a.  
PPB = potassium phosphate buffer 
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between rac-2a and pyrrole in organic solvents such as dichloromethane, methanol 
and acetonitrile, while 4a was isolated as a single product for the identical reaction in 
aqueous buffer. Based on these results, we believe that the aqueous buffer is a 
sufficiently good proton donor and/or hydrogen bond donor to activate 2a toward a 
rDA reaction or an aza-FC reaction. Therefore, the formed pyrrole adds to 
unconverted (protonated) 2a via an aza-FC reaction to afford the 2-pyrrolyl 
pyrrolidine 4a (25%) in a maximum theoretical yield of 50%. This one-stage sequence 
consisting of biocatalytic oxidation, rDA and aza-FC requires only a single purification 
step, which is a major advantage. 
 In terms of stereochemistry, we were delighted to obtain 2-pyrrolyl 
pyrrolidine 4a as a single diastereoisomer, albeit with 70% ee.14 The excellent 
diastereoselectivity of this aza-FC reaction is a highly interesting feature, since the 
corresponding Ugi-type three-component reaction (Ugi-type 3CR) with tert-butyl 
isocyanide and benzoic acid proceeds with only moderate diastereoselectivity 
(Scheme 3).16 The fact that a reaction between rac-2a and pyrrole in the presence of a 
Brønsted acid (TFA) is completely diastereoselective as well, implies that the 
C-nucleophile is responsible for the degree of stereoinduction rather than the reaction 
medium. Considering the steric properties of the nucleophile, tert-butyl isocyanide is 
rather linear compared to pyrrole with an sp-hybridized nitrogen separating the 
sp-hybridized nucleophilic carbon from the steric bulk. Therefore, the excellent 
diastereoselectivity towards 4a presumably results from a significantly larger 
stereodifferentiation between the diastereotopic faces of 3a,b by pyrrole compared to 
tert-butyl isocyanide. 
 
Scheme 3. Representation of diastereoselectivity for the aza-Friedel‒Crafts reaction of exo-configured 
3a,b with pyrrole compared to the Ugi-type 3CR with tert-butyl isocyanide. 
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Given these interesting observations, we proceeded to optimize the oxidative aza-FC 
reaction of meso-pyrrolidine 1a. Our initial oxidation of 1a with the biocatalyst 
afforded 2-pyrrolyl pyrrolidine 4a in 25% isolated yield (Table 1, entry 1). We slightly 
increased the yield by including pyrrole (2 equiv) in the reaction mixture (entry 2), 
but the rDA reaction of protonated 2a impeded further improvements. To circumvent 
this issue, we opted to employ a similar meso-pyrrolidine (1b) that is unable to 
undergo the rDA reaction. To our delight, product 4b was obtained with considerably 
increased enantioselectivity and yield compared to 4a (entries 2 and 4) while 
maintaining the diastereoselectivity. However, a side product was formed which is 
plausibly the addition product of 4b to iminium ion 3b (double aza-FC).17 In order to 
further optimize the reaction conditions, we performed the oxidative aza-FC reaction 
 
Table 1. Optimization of reaction conditions for the stereoselective oxidative  
aza-Friedel‒Crafts reaction of meso-pyrrolidines 1a,b.[a] 
 
Entry Pyrrolidine Product n Yield[b] (%) ee[c] (%) 
1 1a 4a 0 25 70 
2 1a 4a 2 36 70 
3 1b 4b 1 55[d] [12][e] 98 
4 1b 4b 2 56[d] [6][e] 92 
5 1b 4b 5 23[d] 89 
6 1b 4b 10 trace[d] 75 
7[f] 1b 4b 2 67 95 
[a] Conditions (one stage): pyrrolidine 1 (1 equiv), pyrrole (n equiv), MAO-N D5 freeze-dried whole cells 
(500 mg per mmol of 1), PPB (50 mL per mmol of 1, 200 mM, pH 7.5), 37 °C, 400 rpm shaking, 17 h. [b] 
Isolated yield, unless stated otherwise. [c] Determined with chiral HPLC by comparison with the racemic 
mixture. [d] Yield determined by NMR spectroscopy with 2,5-dimethylfuran (0.5 equiv) as an internal 
standard. [e] Yield of the proposed side product17 in square brackets as determined by NMR spectroscopy 
with 2,5-dimethylfuran (0.5 equiv) as an internal standard. [f] Conditions (two stages): pyrrolidine 1 (1 
equiv), MAO-N D5 freeze-dried whole cells (500 mg per mmol of 1), PPB (50 mL per mmol of 1, 200 mM, pH 
7.5), 37 °C, 400 rpm shaking, 17 h; then pyrrole (2 equiv), 37 °C, 400 rpm shaking, 24 h.  
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of 1b with varying equivalents of pyrrole (entries 3‒6). A significant decrease in 
conversion was observed with increasing pyrrole stoichiometry, which is probably 
caused by competitive enzyme inhibition by the excess of pyrrole. To our surprise, the 
enantioselectivity was also found to decrease with increasing pyrrole stoichiometry. 
Binding of pyrrole in one or more hydrophobic pockets in the enzyme may alter its 
conformation, thereby affecting the enantioselectivity. In order to maximize both yield 
and enantioselectivity, we performed the oxidative aza-FC reaction as a two-stage 
one-pot protocol, in which pyrrole (2 equiv) is added after the oxidation is complete 
(17 h). Using this procedure, 4b was isolated in improved yield and with high 
enantioselectivity without the formation of any side product (entry 7). We 
 
Table 2. Optimization of the reaction conditions for the asymmetric oxidative aza-Friedel–Crafts reaction of 
meso-pyrrolidines 1b.[a] 
 
Entry Buffer pH Yield[b] (%) ee[c] (%) 
1 200 mM PPB 7.5 66 95% 
2 200 mM PPB 6.5 67 93% 
3 200 mM PPB 7.0 73 94% 
4 200 mM PPB 8.0 56 94% 
5 200 mM PPB 8.5 49 92% 
6 100 mM PPB 7.5 63 95% 
7 500 mM PPB 7.5 65 95% 
8 50 mM Tris-HCl 7.5 66 92% 
9 20 mM HEPES 7.5 68 93% 
10[d] 200 mM PPB 7.5 63 94% 
11[e] 200 mM PPB 7.5 68 n.d. 
12[f] 200 mM PPB 7.5 54 [7][g] n.d. 
[a] Conditions (two stages): 1. pyrrolidine 1 (1 equiv), MAO-N D5 freeze-dried whole cells (500 mg per 
mmol of 1), PPB (50 mL per mmol of 1, 200 mM, pH 7.5), 37 °C, 400 rpm shaking, 17 h; 2. pyrrole (2 equiv), 
37 °C, 400 rpm shaking, 24 h. [b] Crude yield (>95% purity). [c] Determined with chiral HPLC by 
comparison with the racemic mixture. [d] Reaction performed at 30 °C. [e] Second stage: 5 h. [f] Second 
stage: 1 h. [g] Yield of the corresponding imine (2b) in square brackets, calculated by the molar ratio in 
NMR spectroscopy. 
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further explored the reaction conditions in terms of molarity, pH and type of buffer, 
but these factors did not significantly affect the reaction outcome (Table 2, entries 
1‒8). Notably, the aza-FC reaction proved to be relatively fast, since full conversion of  
2b was reached in a few hours (entries 11‒12). 
 With the optimized conditions in hand, the scope of the nucleophile was 
explored with a range of pyrroles and indoles. To our delight, the desired products 
4c‒i were obtained in moderate to good yields with high enantioselectivity (Table 3). 
In all cases, a clean conversion to single diastereoisomers of the products was 
observed. In order to determine the relative and absolute configuration of these 
adducts, 2-pyrrolyl pyrrolidine 4f was crystallized and its structure was confirmed by 
X-ray crystallography.18 The analogous products 4a‒e and 4g were assumed to have  
 
Table 3. Scope exploration for oxidative aza-Friedel─Crafts reaction.[a] 
 
X-ray structure of 4f with displacement ellipsoids drawn at 50% probability level.18 [a] Conditions (two 
stages): 1. pyrrolidine 1 (1 equiv), MAO-N D5 freeze-dried whole cells (500 mg per mmol of 1), PPB (50 mL 
per mmol of 1, 200 mM, pH 7.5), 37 °C, 400 rpm shaking, 17 h; 2. pyrrole (2 equiv) and DMSO (5% v/v, only 
for 4f,g), 37 °C, 400 rpm shaking, 24 h. Single diastereoisomers were observed by NMR analysis of the crude 
product. [b] Approximate value as a result of overlap with small impurities in the HPLC chromatogram.  
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the same relative configuration,19 which is supported by the absence of a NOESY 
correlation between the protons at the 2- and 3-positions of the pyrrolidine (as 
indicated in Scheme 3). Other heteroaromatic nucleophiles, including 3-methylindole, 
2-methylfuran, 2-methoxyfuran and N-phenyl pyrrole, were found to be unreactive 
towards 2b20 under these conditions. Further investigation showed that a range of 
other C-nucleophiles (N,N-dimethylaniline, 1,3-dimethoxy-benzene, p-cresol, 
1-phenyl-1-trimethylsiloxyethylene, ethyl vinyl ether and 4-(cyclohex-1-en-1-yl)-
morpholine) did not show significant reactivity either. To further evaluate the 
reaction scope, we tested different meso-pyrrolidines. Pleasingly, the examined  
 
Table 4. Oxidative aza-Friedel‒Crafts reaction with N-methylpyrrolidines 1e.[a] 
 
X-ray structure of 5b with displacement ellipsoids drawn at 50% probability level.18 [a] Conditions (two 
stages): 1. pyrrolidine 1e (1 equiv), MAO-N D5 freeze-dried whole cells (500 mg per mmol of 1e), PPB (50 
mL per mmol of 1e, 200 mM, pH 7.5), 37 °C, 400 rpm shaking, 17 h; 2. pyrrole (2 equiv) and DMSO (10% 
v/v, only for 5c), 37 °C, 400 rpm shaking, 24 h. Single diastereoisomers were observed with NMR 
spectroscopy of the crude mixture. [b] Conditions (one stage): pyrrolidine 1e (1 equiv), pyrrole (2 equiv), 
MAO-N D5 freeze-dried whole cells (500 mg per mmol of 1e), PPB (50 mL per mmol of 1e, 200 mM, pH 7.5), 
37 °C, 400 rpm shaking, 17 h. Compound 5a was isolated as an inseparable mixture with 6 (6%) and the 
yields were calculated based on the molar ratio as determined by NMR analysis.22  
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substrates 1c and 1d underwent clean conversion to the desired 2-pyrrolyl 
pyrrolidines 4h and 4i as single diastereoisomers. Their relative and absolute 
configurations were deduced from our previous studies on diastereoselective α-
functionalizations of 1c,d.8c 
 Next, we investigated the application of N-methyl pyrrolidine 1e in the 
oxidative aza-FC reaction with different nucleophiles. To our delight, a wider variety 
of aromatic and heteroaromatic nucleophiles could be combined with this substrate, 
presumably as a result of the increased electrophilicity of the iminium ion 2e. The 
desired 2-substituted pyrrolidines 5a‒d were obtained in reasonable to good yield 
and as single diastereoisomers (Table 4). In order to determine the relative 
stereochemistry, 2-pyrrolyl pyrrolidine 5b was crystallized and its structure was 
corroborated by X-ray crystallography.18 Disappointingly, products 5a‒c were 
isolated with low optical purity (≤16% ee). Possibly, the biocatalyst has low 
stereoselectivity in the oxidation of meso-pyrrolidine 1e. However, in this case one 
would expect to find identical ee values for 5a‒d. Another plausible explanation is a 
post-oxidation racemization by an internal redox-neutral hydride transfer 
mechanism, as commonly observed for cyclic iminium ions.21 This racemization has 
been described to proceed through an azomethine ylide intermediate as depicted in 
Scheme 4. The low optical purity of 5a‒c may be caused by a combination of low 
stereoselectivity during the biocatalytic oxidation of 1e and subsequent partial 
racemization.22 Despite the decreased enantioselectivity for 1e, our method is 
significantly more benign than many other direct α-functionalizations of tertiary 
amines.7 Moreover, the synthesis of rac-5a‒c (as racemic standards for ee 
determination) required a laborious three-step protocol involving oxidation, Brønsted 
acid-mediated addition and N-methylation.23 Thus, our one-pot oxidative aza-FC 
reaction has many advantages over conventional chemical synthesis of 2-substituted 
pyrrolidines. 
 
Scheme 4. Proposed mechanism for racemization of 2e through an internal redox-neutral hydride transfer. 
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2.3 Conclusion 
We developed an one-pot chemoenzymatic oxidative aza-Friedel‒Crafts reaction 
under benign conditions for the direct α-functionalization of a range of pyrrolidines 
including both secondary and tertiary amines. These typically unreactive substrates 
were activated by means of biocatalytic oxidation in aqueous buffer, followed by the 
addition of a variety of C-nucleophiles without the requirement of an additional 
catalyst. The desired 2-substituted pyrrolidines were obtained in reasonable to good 
yield and as single diastereoisomers with generally high enantioselectivity. This 
contribution demonstrates the high potential of one-pot chemoenzymatic 
transformations to produce functionalized chiral small molecules in a sustainable 
manner.  
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2.5 Experimental Section 
General comments 
Starting materials were purchased from Sigma Aldrich, Alfa Aesar, Acros Organics and used without 
treatment. Unless stated otherwise, the solvents were purchased from VWR Chemicals or Biosolve and were 
used without further treatment. Cyclohexane (cHex) was purified by distillation before use. The 
meso-pyrrolidines 1a-d and racemic imines rac-2a and S2c-d were synthesized according to previously 
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reported procedures.16 The procedure for in situ biocatalytic oxidation of meso-pyrrolidines with an 
engineered monoamine oxidase was adapted from a previously reported procedure.14 Celite® 512 medium 
was purchased from Sigma Aldrich. Column Chromatography was performed on Silica-P Flash Silica Gel 
(particle size 40-63 μm, pore diameter 60 Å) from Silicycle or aluminiumoxide (activated, basic, Brockmann 
I) from Sigma Aldrich. Thin Layer Chromatography (TLC) was performed using TLC plates F254 (silica gel 60 
on aluminium) from Merck Serono KGaA (Darmstadt) and compounds were visualized by UV detection (254 
or 366 nm) and stained with basic aq. KMnO4 or ninhydrin/ethanol. 1H, 13C, COSY, HSQC, HMBC and NOESY 
nuclear magnetic resonance (NMR) spectra were recorded on a Bruker Avance 500 (500.23 MHz for 1H and 
125.78 MHz for 13C) in CDCl3 using the residual solvent as internal standard (CDCl3: δ = 7.26 for 1H NMR and 
δ = 77.16 for 13C NMR)  or Bruker Avance 400 (400.13 MHz for 1H and 100.62 MHz for 13C) using the 
residual solvent as internal standard (CDCl3: δ = 7.26 for 1H NMR and δ = 77.16 for 13C NMR) or Bruker 
Avance 250 (250.13 MHz for 1H) in CDCl3 using the residual solvent as internal standard (CDCl3: δ = 7.26 for 
1H NMR). Chemical shifts (δ) are given in ppm and coupling constants (J) are quoted in hertz (Hz). 
Resonances are described as s (singlet), d (doublet), t (triplet), q (quartet), bs (broad singlet) and m 
(multiplet) or combinations thereof. The COSY-, HMBC- and HSQC-NMR spectra were used for the 
assignment of the proton signals. The APT-NMR spectra were used for the assignment of the carbon signals. 
NMR data was processed using MestReNova. Names of chemical structures were deduced from generic 
names and/or important functionalities. Electrospray Ionization (ESI) high resolution mass spectrometry 
(HRMS) was carried out using a Bruker micrOTOF-Q instrument in positive ion mode (capillary potential of 
4500 V). Infrared (IR) spectra were recorded neat using a FTIR-8400s from Shimadzu. Signal intensities are 
described as strong (s), medium (m), weak (w) or broad (br). Melting points were recorded on a Büchi 
M-565 and are not corrected. Chiral HPLC was recorded using a LC10VP with a SCL-10A VP system 
controller, LC-10AT VP liquid chromatograph, SPD-M10A VP diode array detector and CTO-10AC VP column 
oven from Shimadzu. Data was processed using Shimadzu Labsolutions. UPC2-MS analysis was recorded 
using an Acquity UPC2 system consisting of a SFC Manager, Column Manager, Sample Manager, Binary 
Solvent Manager, SFC PDA Detector, Isocratic Solvent Manager, QDa Detector from Waters using Acquity 
Trefoil method development strategy. Specific rotations were measured with an automatic AA-10 
polarimeter. X-ray single crystal data for 4f were collected at 101K on an Agilent Supernova diffractometer, 
with Cu microsource and mirror optics. ω-scans were employed, to collect a full sphere of reflections to 
θ=66.97°. 44692 reflections were measured, of which 2643 unique, with Rint 6.91%.  Data were reduced and 
corrected for absorption with the Agilent CrysAlisPro software v1.171.37.35.26 For 5b, data were collected 
on a Bruker X8 Prospector diffractometer with Cu microsource and focusing optics, and an ApexII detector. 
Here also, a full sphere of reflections was collected with ω-scans up to θ=66.97°. 11332 reflections were 
measured, of which 2174 were unique, with Rint = 5.44%. Data were reduced with Bruker SAINT v8.34A27 
and corrected for absorption with SADABS 2012/1.28 The structures were solved and refined with the 
SHELX suite of software29 and the shelXle graphical interface.30 Nu unusual values were encountered in the 
bond distances and angles, and the crystal packing also contained no unusual or unexpected features. 
Figures were prepared with Ortep3 for Windows.31 In both cases, the space group was chiral, and the 
absolute configuration of the enantiomers could be derived from the Friedel differences. Using Parsons’s 
method,32 for 4f, the Flack parameter is -0.18(10) , whereas for 5b, it equals  -0.13(12). The significance of 
these values was cross checked by using the Bayesian approach of Hooft33 with PLATON.34 For 4f, this leads 
to a probability that the absolute configuration is incorrectly assigned of 10-29, and a probability that the 
crystal is a racemic twin of 10-9. Hooft y equals -0.15(10). For 5b, those same probabilities are 10-27 and 10-8, 
respectively. Hooft y equals -0.11(10). 
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General procedure for the reaction of rac-2a with pyrrole in organic solvent: To a solution of imine 
rac-2a  (0.25 mmol, 1.0 equiv) in solvent (0.2 M) was added nucleophile pyrrole (0.50 mmol, 2.0 equiv). The 
reaction mixture was stirred at rt for 17 h and quenched by the addition of sat. aq. Na2CO3 (10 mL), 
extracted with DCM (2 x 10 mL), dried (Na2SO4) and concentrated in vacuo. The crude product was analyzed 
with NMR spectroscopy. No conversion of rac-2a was observed in the investigated solvents: MeOH, MeCN 
and DCM. 
 
General procedure for the reaction of rac-2a with pyrrole in aqueous buffer: To a solution of imine 
rac-2a  (0.25 mmol, 1.0 equiv) in aq. sodium phosphate buffer (0.2 M, 200 mM, pH 7.5) was added 
nucleophile pyrrole (0.50 mmol, 2.0 equiv). The reaction mixture was stirred at rt for 17 h, after which the 
pH was adjusted to 12-13 with 2M aq. NaOH. The aqueous layer was extracted with DCM (2 x 10 mL) and 
the combined organic layers were dried (Na2SO4) and concentrated in vacuo. The yield of 4a (42%) was 
determined with 1H-NMR spectroscopy after dissolving the crude product in CDCl3 and adding 
2,5-dimethylfuran (0.125 mmol, 0.5 equiv) as internal standard. 
 
Substrate synthesis 
pyrrolidine 1e: To a solution of pyrrolidine 1b (2.10 g, 15.1 mmol, 1.0 equiv) in methanol 
(100 mL) at 0 °C under N2 atmosphere were added formaldehyde (1.68 mL, 22.5 mmol, 1.5 
equiv), acetic acid (1.75 mL, 30.0 mmol, 2.0 equiv) and sodium cyanoborohydride (1.46 g, 
22.5 mmol, 1.5 equiv). The reaction mixture was stirred for 2 h at rt and quenched by the 
addition of sat. aq. Na2CO3 (100 mL), extracted with DCM (3 x 100 mL), dried (Na2SO4) and concentrated in 
vacuo.  Purification was achieved with flash chromatography (SiO2) with an eluent gradient of MeOH (1- 
5%) in DCM to obtain compound 1e (1.70 g, 11.1 mmol, 74%) as a light orange oil. 1H NMR (500 MHz, 
CDCl3): δ 4.24 (dd, J = 3.2, 2.3 Hz, 2H, CHO), 3.10 – 3.04 (m, 2H, CH2NCH2), 2.42 – 2.37 (m, 2H, NCH2CH), 2.29 
(s, 3H, NCH3), 1.98 – 1.91 (m, 2H, CH2NHCH2), 1.69 – 1.63 (m, 2H, CH2CH2), 1.40 – 1.34 (m, 1H, CH2CH2). 13C 
NMR (126 MHz, CDCl3): δ 78.9 (CH), 60.6 (CH2), 49.3 (CH), 41.3 (CH), 28.5 (CH2). IR (neat): vmax (cm-1) = 
2949 (m), 2783 (m), 1655 (w), 1448 (m), 1219 (m), 1136 (m), 972 (m), 928 (s), 806 (s), 592 (s). HRMS 
(ESI): m/z calculated for C9H16NO [M+H]+: 154.1226, found: 154.1232.  
 
hemiaminal S2b and 1-pyrroline 2b:33,34 To a suspension of 
rehydrated freeze-dried MAO-N cells (6 x 125 mg, 30 min, 37 °C, 400 
rpm) in aq. phosphate buffer (6 x 12.5 mL, 200mM, pH 7.5) was added 
pyrrolidine (6 x 36 mg, 1.5 mmol, 1.0 equiv). The reaction mixture was 
shaken for 17 h (400 rpm, 37 °C). The suspension was centrifuged (1 h, 4000 rpm, 4 °C)35 and the 
supernatant was collected, adjusted to pH 12-13 with 2M aq. NaOH, extracted with DCM (3 x 150 mL), dried 
(Na2SO4) and concentrated in vacuo, to obtain compound S2b (180 mg, 1.21 mmol, 81%) as a light yellow 
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solid without the need of purification. m.p.: 152 – 155 °C. 1H NMR (500 MHz, CDCl3): δ 4.34 – 4.30 (m, 1H, 
CH(OH)CHCHO), 4.26 – 4.21 (m, 1H, CH2CHCHO), 3.15 (t, J = 8.0 Hz, 1H, NHCH2), 2.47 (d, J = 6.7 Hz, 1H, 
NHCHOH), 2.39 (q, J = 8.0 Hz, 1H, NHCH2CH), 2.18 – 2.09 (m, 2H, NHCH2CHCHCH(OH)), 1.74 – 1.62 (m, 2H, 
CH2CH2), 1.44 – 1.35 (m, 2H, CH2CH2) ppm. 13C NMR (126 MHz, CDCl3): δ 86.1 (CH), 78.5 (CH), 78.0 (CH), 
52.8 (CH), 51.4 (CH2), 47.5 (CH), 28.8 (CH2), 28.6 (CH2) ppm. IR (neat): vmax (cm-1) = 2949 (m), 1655 (w), 
1393 (m), 1315 (m), 1225 (s), 1215 (s), 1175 (s), 1047 (m), 972 (s), 924 (s), 805 (s), 623 (s). HRMS (ESI): 
m/z calculated for C8H12NO [M+H]+: 138.0913, found: 138.0916. Specific rotation: [ߙ]஽ଶ଴ = +4 ° (c = 0.5, 
CHCl3). 
hemiaminal rac-S2b and 1-pyrroline rac-2b:36 To a solution of meso-pyrrolidine 1b (2.72 g, 19.2 mmol, 
1.0 equiv) in DCM (120 mL) was slowly added N-chlorosuccinimide (2.64 g, 19.2 mmol, 1.0 equiv) at 0°C. 
The reaction mixture was stirred for 2 h at rt, washed with H2O (2 x 100 mL) and brine (1 x 100 mL), 
extracted with DCM (2 x 75 mL), dried (Na2SO4) and concentrated to 50 mL in vacuo. The resulting solution 
was slowly added this to a solution of KOH (1.62 g, 28.8 mmol, 1.5 equiv) in EtOH (25 mL). The reaction 
mixture was stirred for 24 h at rt, after which it was concentrated in vacuo. The crude product was then 
redissolved in DCM (100 mL), washed with sat. NaHCO3 (50 mL), extracted with DCM (2 x 50 mL), dried 
(Na2SO4) and concentrated in vacuo. Purification was achieved by flash chromatography (SiO2) with an 
eluent gradient (DCM → 19:1 v/v DCM:MeOH) to obtain compound rac-S2b (2.25 mg, 16.4 mmol, 75%) as a 
light yellow solid without the need of purification. 1H NMR (500 MHz, CDCl3): δ 4.33 – 4.30 (m, 1H, 
CH(OH)CHCHO), 4.28 – 4.21 (m, 1H, CH2CHCHO), 3.15 (t, J = 8.0 Hz, 1H, NHCH2), 2.47 (d, J = 6.8 Hz, 1H, 
NHCHOH), 2.40 (q, J = 7.8 Hz, 1H, NHCH2CH), 2.20 – 2.08 (m, 2H, NHCH2CHCHCHOH), 1.75 – 1.59 (m, 2H, 
CH2CH2), 1.43 – 1.33 (m, 2H, CH2CH2) ppm. 13C NMR (126 MHz, CDCl3): δ 86.2 (CH), 78.5 (CH), 78.0 (CH), 
52.8 (CH), 51.4 (CH2), 47.5 (CH), 28.8 (CH2), 28.6 (CH2) ppm. 
 
Synthetic procedures and spectral data 
 
General procedure 1 (two stages): To a suspension of rehydrated freeze-dried MAO-N cells (500 mg per 
mmol of 1, 30 min, 37 °C, 400 rpm) and aq. phosphate buffer (50 mL per mmol, 200mM, pH 7.5) was added 
pyrrolidine 1 (1.0 equiv). The reaction mixture was shaken for 17 h (400 rpm, 37 °C) after which the 
nucleophile (2.0 equiv) were added, followed by continued shaking for 24 h. The suspension was 
centrifuged (1 h, 4000 rpm, 4 °C)35 and the supernatant was collected, adjusted to pH 12-13 with 2M aq. 
NaOH, extracted with DCM (3 x 100 mL per mmol of 1), dried (Na2SO4) and concentrated in vacuo. 
Purification was achieved with flash chromatography (SiO2) with an eluent gradient of MeOH (1- 5%) in 
DCM. 
 
General procedure 2 (two stages with DMSO): To a suspension of rehydrated freeze-dried MAO-N cells 
(500 mg per mmol of 1, 30 min, 37 °C, 400 rpm) and phosphate buffer (50 mL per mmol of 1, 200mM, pH 
7.5) was added pyrrolidine 1 (1.0 equiv). The reaction mixture was shaken for 17 h (400 rpm, 37 °C) after 
which the nucleophile (0.50 mmol, 2.0 equiv) and DMSO (10% v/v) were added, followed by continued 
shaking for 24 h. The workup was performed as described in general procedure 1. 
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General procedure 3 (one stage): To a suspension of rehydrated freeze-dried MAO-N cells (500 mg per 
mmol of 1, 30 min, 37 °C, 400 rpm) and phosphate buffer (50 mL per mmol of 1, 200mM, pH 7.5) was added 
pyrrolidine 1 (1.0 equiv) and pyrrole (2.0 equiv). The reaction mixture was shaken for 17 h (400 rpm, 37 
°C) and the workup was performed as described in general procedure 1. 
 
General procedure 4: To a solution of nucleophile (1.0 equiv) in DCM (0.2 M) were added imine 2 (1.1 
equiv) and TFA (2.0 equiv). The reaction mixture was stirred for 30 min at 60°C under microwave 
irradiation and quenched by the addition of sat. aq. Na2CO3 (10 mL per mmol of 2), extracted with DCM (2 x 
10 mL per mmol of 2), dried (Na2SO4) and concentrated in vacuo. 
 
General procedure 5: To a solution of nucleophile (2.0 equiv) in DCM (0.2 M) were added imine 2 (1.0 
equiv) and TFA (2.0 equiv). The reaction mixture was stirred for 30 min at 60°C under microwave 
irradiation and quenched by the addition of sat. aq. Na2CO3 (10 mL per mmol of 2), extracted with DCM (2 x 
10 mL per mmol of 2), dried (Na2SO4) and concentrated in vacuo. 
 
pyrrolyl pyrrolidine 4a: Prepared from pyrrolidine 1a (118 mg [13% THF], 0.75 
mmol, 1.0 equiv) and nucleophile pyrrole (105 µL, 1.5 mmol, 2.0 equiv) according to 
general procedure 3 to obtain compound 4a (55 mg, 0.27 mmol, 36%) as a light brown 
solid. m.p.: >152 °C (decomposition). 1H NMR (500 MHz, CDCl3) δ 9.30 (bs, 1H, NHC*), 
6.74 (q, J = 2.5 Hz, 1H, C*NHCH), 6.38 (s, 2H, CH=CH), 6.13 (q, J = 2.8 Hz, 1H, C*NHCHCH), 6.06 – 6.03 (m, 1H, 
C*NHCHCHCH), 4.82 (s, 1H, NHCHCHCHO), 4.72 (s, 1H, NHCH2CHCHO), 4.09 (d, J = 4.9 Hz, 1H, NHCHC*), 
3.18 (bs, 1H, NHCH2), 3.06 (dd, J = 11.1, 7.7 Hz, 1H, NHCH2), 2.78 (dd, J = 11.1, 5.2 Hz, 1H, NHCH2), 2.50 – 
2.38 (m, 2H, NHCH2CHCHCHO) ppm. 13C NMR (126 MHz, CDCl3) δ 136.8 (CH), 136.7 (CH), 132.1 (C*), 117.7 
(CH), 108.2 (CH), 105.5 (CH), 82.7 (CH), 82.0 (CH), 59.7 (CH), 52.6 (CH), 49.6 (CH2), 46.8 (CH) ppm. IR 
(neat): vmax (cm-1) = 3258 (w), 3126 (w), 2997 (w), 1437 (m), 1028 (s), 932 (m), 897 (s), 814 (s), 714 (s), 
696 (s), 609 (m). HRMS (ESI+) calculated for C12H15N2O (MH+) 203.1179, found 203.1184. Chirality: 70% ee 
[Dr. Maisch Chiral AM, heptane/IPA = 85/15, v = 0.9 mL/min, column temperature: 30 °C, λ = 235 nm, t 
(major) = 10.205 min, t (minor) = 13.011 min]. Specific rotation: [ߙ]஽ଶ଴ = –8 ° (c = 0.5, EtOH). 
rac-pyrrolyl pyrrolidine 4a: Prepared from hemiaminal S2b (75.4 mg, 0.55 mmol, 1.0 equiv) and 
nucleophile pyrrole (76.3 µL, 1.10 mmol, 2.0 equiv) according to general procedure 5 to obtain compound 
rac-4a (100 mg, 0.50 mmol, 90%) as a light brown solid. 1H NMR (500 MHz, CDCl3) δ 8.92 (bs, 1H, C*NH), 
6.72 (s, 1H, C*NHCHCHCH), 6.38 (s, 2H, CH=CH), 6.15 (s, 1H, C*NHCHCH), 6.04 (s, 1H, NHC*CH), 4.85 (s, 1H, 
NHCHCHCHO), 4.73 (s, 1H, NHCH2CHCHO), 4.08 (d, J = 4.4 Hz, 1H, NHCHC*), 3.07 (dd, J = 11.0, 7.3 Hz, 1H, 
NCH2), 2.83 (dd, J = 11.2, 4.6 Hz, 1H, NCH2), 2.59 – 2.36 (m, 2H, NCH2CHCHCOH), 2.33 (s, 1H, CH2NH) ppm. 
13C NMR (126 MHz, CDCl3) δ 136.9 (CH), 136.7 (CH), 133.3 (C*), 117.0 (CH), 108.4 (CH), 104.9 (CH), 83.0 
(CH), 82.2 (CH), 59.9 (CH), 53.1 (CH), 50.1 (CH2), 47.1 (CH) ppm.  
 
pyrrolyl pyrrolidine 4b: Prepared from pyrrolidine 1b (151 mg, 1.09 mmol, 1.0 equiv) 
and nucleophile pyrrole (150 µL, 2.18 mmol, 2.0 equiv) according to general procedure 1 
to obtain compound 4b (149 mg, 0.73 mmol, 67%) as an off-white solid. m.p.: >115 °C 
(decomposition). 1H NMR (500 MHz, CDCl3) δ 8.81 (s, 1H, NHC*), 6.73 (s, 1H, C*NHCH), 
6.15 (s, 1H, C*NHCHCH), 6.05 (s, 1H, C*NHCHCHCH), 4.49 – 4.39 (m, 1H, NHCHCHCHO), 
4.36 – 4.29 (m, 1H, NHCH2CHCHO), 3.93 (d, J = 5.5 Hz, 1H, NHCHC*), 3.20 – 3.12 (m, 1H, NHCH2), 2.71 (dd, J = 
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10.3, 6.2 Hz, 1H, NHCH2), 2.43 – 2.31 (m, 2H, NHCH2CHCHCHO), 2.15 – 2.01 (m, 1H, NHCH2), 1.76 – 1.61 (m, 
2H, CH2CH2), 1.47 – 1.37 (m, 2H, CH2CH2) ppm. 13C NMR (126 MHz, CDCl3) δ 132.6 (C*), 117.6 (CH), 108.1 
(CH), 105.2 (CH), 80.4 (CH), 79.6 (CH), 61.6 (CH), 56.3 (CH), 51.5 (CH2), 50.0 (CH), 28.7 (CH2), 28.6 (CH2) 
ppm. IR (cm-1): vmax = 3263 (m), 2968 (m), 2864 (m), 2750 (m), 1456 (m), 1427 (m), 1294 (m), 1222 (m), 
1199 (m), 1097 (m), 1022 (s), 960 (s), 927 (s), 881 (s), 798 (s), 711 (s), 609 (s). HRMS (ESI+) calculated for 
C12H17N2O (MH+) 205.1335, found 205.1331. Chirality: 95% ee [Dr. Maisch Chiral AM, heptane/IPA = 90/10, 
v = 0.7 mL/min, column temperature: 30 °C, λ = 220 nm, t (major) = 14.115 min, t (minor) = 21.383 min]. 
Specific rotation: [ߙ]஽ଶ଴ = –28 ° (c = 0.5, EtOH). 
 rac-pyrrolyl pyrrolidine 4b: Prepared from hemiaminal S2b (273 mg, 1.75 mmol, 1.1 equiv) and 
nucleophile pyrrole (110 µL, 1.59 mmol, 1.0 equiv) according to general procedure 4 to obtain compound 
rac-4b (231 mg,  1.13 mmol, 71%) as an off-white solid. 1H NMR (500 MHz, CDCl3) δ 8.90 (s, 1H, NHC*), 6.74 
(s, 1H, C*NHCH), 6.16 – 6.12 (m, 1H, C*NHCHCH), 6.06 (s, 1H, C*NHCHCHCH), 4.42 (d, J = 3.7 Hz, 1H, 
NHCHCHCHO), 4.32 (d, J = 3.8 Hz, 1H, NHCH2CHCHO), 3.93 (d, J = 5.5 Hz, 1H, NHCHC*), 3.17 (dd, J = 10.5, 7.9 
Hz, 1H, NHCH2), 2.70 (dd, J = 10.5, 5.9 Hz, 1H, NHCH2), 2.43 – 2.33 (m, 2H, NHCH2CHCH), 2.01 (bs, 1H, 
NHCH2), 1.75 – 1.62 (m, 2H, CH2CH2), 1.42 (d, J = 7.2 Hz, 2H, CH2CH2) ppm. 13C NMR (126 MHz, CDCl3) δ 
132.7 (C*), 117.5 (CH), 108.2 (CH), 105.1 (CH), 80.5 (CH), 79.6 (CH), 61.6 (CH), 56.3 (CH), 51.6 (CH2), 50.0 
(CH), 28.7 (CH2), 28.6 (CH2) ppm.  
 
N-methylpyrrolyl pyrrolidine 4c: Prepared from pyrrolidine 1b (147 mg, 1.05 mmol, 
1.0 equiv) and nucleophile N-methylpyrrole (186 µL, 2.10 mmol, 2.0 equiv) according to 
general procedure 1 to obtain compound 4c (135.2 mg, 0.62 mmol, 59%) as a light 
yellow oil. 1H NMR (500 MHz, CDCl3) δ 6.63 – 6.58 (m, 1H, NCH), 6.09 – 6.03 (m, 2H, 
NCHCHCH), 4.38 – 4.29 (m, 2H, CHOCH), 3.78 (d, J = 6.9 Hz, 1H, NHCH), 3.69 (s, 3H, NCH3), 3.27 (dd, J = 11.5, 
8.0 Hz, 1H, NHCH2), 2.63 (dd, J = 11.5, 6.9 Hz, 1H, NHCH2), 2.52 – 2.45 (m, 1H, NHCHCH), 2.45 – 2.36 (m, 1H, 
NHCH2CH), 1.82 (bs, 1H, NH), 1.75 – 1.65 (m, 2H, CH2CH2), 1.47 – 1.39 (m, 2H, CH2CH2) ppm. 13C NMR (126 
MHz, CDCl3) δ 133.1 (C*), 123.0 (CH), 106.5 (CH), 105.9 (CH), 80.2 (CH), 79.5 (CH), 60.6 (CH), 56.1 (CH), 
52.2 (CH2), 51.2 (CH), 34.3 (CH3), 28.8 (CH2), 28.7 (CH2) ppm. IR (neat): vmax (cm-1) = 2957 (m), 1491 (w), 
1298 (m), 1088 (w), 926 (m), 812 (m), 729 (s), 709 (s), 600 (m). HRMS (ESI+) calculated for C13H19N2O 
(MH+) 219.1492, found 219.1498. Chirality: 93% ee [Dr. Maisch Chiral AM, heptane/IPA = 90/10, v = 0.7 
mL/min, column temperature: 30 °C, λ = 220 nm, t (minor) = 14.309 min, t (major) = 34.281 min]. 
rac-N-methylpyrrolyl pyrrolidine 4c: Prepared from hemiaminal S2b (109 mg, 0.70 mmol, 1.1 equiv) and 
nucleophile N-methylpyrrole (55.9 µL, 0.63 mmol, 1.0 equiv) according to general procedure 4 to obtain 
compound rac-4c (109 mg, 0.50 mmol, 79%) as a yellow oil. 1H NMR (500 MHz, CDCl3) δ 6.63 – 6.58 (m, 1H, 
NCH), 6.08 – 6.03 (m, 2H, NCHCHCH), 4.39 – 4.28 (m, 2H, CHOCH), 3.77 (d, J = 6.8 Hz, 1H, NHCH), 3.69 (s, 3H, 
NCH3), 3.27 (dd, J = 11.5, 8.0 Hz, 1H, NHCH2), 2.63 (dd, J = 11.2, 7.1 Hz, 1H, NHCH2), 2.52 – 2.46 (m, 1H, 
NHCHCH), 2.45 – 2.36 (m, 1H, NHCH2CH), 1.79 – 1.59 (m, 3H, NH, CH2CH2), 1.48 – 1.39 (m, 2H, CH2CH2) ppm. 
13C NMR (126 MHz, CDCl3) δ 133.2 (C*), 123.0 (CH), 106.5 (CH), 105.9 (CH), 80.3 (CH), 79.5 (CH), 60.6 (CH), 
56.1 (CH), 52.3 (CH2), 51.2 (CH), 34.3 (CH3), 28.8 (CH2), 28.8 (CH2) ppm.  
 
2,5-dimethylpyrrolyl pyrrolidine 4d: Prepared from pyrrolidine 1b (161 mg, 1.15 
mmol, 1.0 equiv) and nucleophile 2,5-dimethylpyrrole (233 µL, 2.30 mmol, 2.0 equiv) 
according to general procedure 1 to obtain compound 4d (112 mg,  0.48 mmol, 42%) 
as a brown solid. m.p.: 84 – 87 °C.1H NMR (500 MHz, CDCl3) δ 7.57 (s, 1H, NHC*), 
5.80 (s, 1H, NHC*CH), 4.30 (dd, J = 7.7, 3.8 Hz, 2H, CHOCH), 3.65 (d, J = 7.6 Hz, 1H, 
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NHCH), 3.33 (t, J = 9.3 Hz, 1H, NHCH2), 2.60 (t, J = 8.9 Hz, 1H, NHCH2), 2.43 (q, J = 8.2 Hz, 1H, NHCH2CH), 2.30 
– 2.17 (m, 7H, NHCH2CH, C(CH3)NHC(CH3)), 1.74-1.61 (m, 2H, CH2CH2), 1.47 – 1.31 (m, 2H, CH2CH2) ppm. 13C 
NMR (126 MHz, CDCl3) δ 126.0 (C*), 123.6 (C*), 119.7 (C*), 104.2 (CH), 79.7 (CH), 78.9 (CH), 60.4 (CH), 57.9 
(CH), 51.6 (CH2), 50.8 (CH), 28.7 (CH2), 28.6 (CH2), 13.09 (CH3), 11.3 (CH3) ppm. IR (cm-1): vmax = 2950 (s), 
2871 (w), 1458 (s), 1218 (s), 1159 (m), 1027 (s), 987 (s), 925 (s), 896 (s), 856 (w), 792 (s), 713 (m), 599 (s), 
567 (m). HRMS (ESI+) calculated for C14H21N2O (MH+) 233.1648, found 233.1636. Chirality: 95% ee [Dr. 
Maisch Chiral AM, heptane/IPA = 90/10, v = 0.7 mL/min, column temperature: 30 °C, λ = 220 nm, t (minor) 
= 27.338 min, t (major) = 34.831 min]. Specific rotation: [ߙ]஽ଶ଴  = –4 ° (c = 0.5, EtOH). 
rac-2,5-dimethylpyrrolyl pyrrolidine 4d: Prepared from hemiaminal S2b (106 mg, 0.68 mmol, 1.1 equiv) 
and nucleophile 2,5-dimethylpyrrole (64.1 µL, 0.63 mmol, 1.0 equiv) according to general procedure 4 to 
obtain compound rac-4d (101 mg, 0.43 mmol, 69%) as a brown solid. 1H NMR (500 MHz, CDCl3) δ 7.75 (s, 
1H, NHC*), 5.78 (s, 1H, NHC*CH), 4.30 (dd, J = 7.6, 4.1 Hz, 2H, CHOCH), 3.63 (d, J = 7.5 Hz, 1H, NHCH), 3.33 (t, 
J = 9.3 Hz, 1H, NHCH2), 2.59 (t, J = 9.5 Hz, 1H, NHCH2), 2.42 (q, J = 8.2 Hz, 1H, NHCH2CH), 2.24 – 2.12 (m, 7H, 
NHCH2CH, C(CH3)NHC(CH3)), 1.66 (s, 2H, CH2CH2), 1.45 – 1.30 (m, 2H, CH2CH2) ppm. 13C NMR (126 MHz, 
CDCl3) δ 125.8 (C*), 123.3 (C*), 120.0 (C*), 103.9 (CH), 79.6 (CH), 78.8 (CH), 60.3 (CH), 58.0 (CH), 51.7 (CH2), 
50.9 (CH), 28.7 (CH2), 28.6 (CH2), 13.0 (CH3), 11.1 (CH3) ppm.  
 
2,4-dimethylpyrrolyl pyrrolidine 4e: Prepared from pyrrolidine 1b (145 mg, 1.04 
mmol, 1.0 equiv) and nucleophile 2,4-dimethylpyrrole (214 µL, 2.08 mmol, 2.0 equiv) 
according to general procedure 1 to obtain compound 4e (150 mg, 0.64 mmol, 62%) 
as a brown solid. m.p.: >70 °C (decomposition). 1H NMR (250 MHz, CDCl3) δ 8.71 (s, 
1H, CH3C*NH), 5.65 (d, J = 2.1 Hz, 1H, CH3C*CH), 4.36 (d, J = 4.6 Hz, 1H, NHCHCHCHO), 
4.29 (d, J = 4.4 Hz, 1H, NHCH2CHCHO), 3.91 (d, J = 7.9 Hz, 1H, NHCH), 3.29 (t, J = 8.9 Hz, 1H, NHCH2), 2.64 (t, J 
= 8.6 Hz, 1H, NHCH2), 2.48 – 2.39 (m, 2H, NHCH2CH), 2.28 (t, J = 8.3 Hz, 1H, NHCHCH), 2.21 (s, 3H, CH3), 2.05 
(s, 3H, CH3), 1.73 – 1.62 (m, 2H, CH2CH2), 1.43 – 1.30 (m, 2H, CH2CH2) ppm. 13C NMR (126 MHz, CDCl3) δ 
126.7 (C*), 125.9 (C*), 115.4 (C*), 107.7 (CH), 79.4 (CH), 78.6 (CH), 58.8 (CH), 56.4 (CH), 50.7 (CH2), 49.1 
(CH), 28.5 (CH2), 28.3 (CH2), 12.9 (CH3), 11.0 (CH3) ppm. IR (cm-1): vmax = 2962 (w), 2931 (w), 2871 (m), 
1683 (s), 1436 (s), 1400 (s), 1267 (w), 1218 (s), 1201 (s), 1056 (s), 985 (s), 921 (s), 850 (s), 800 (s), 661 
(m), 607 (s). HRMS (ESI+) calculated for C14H21N2O (MH+) 233.1648, found 233.1636. Chirality:37 ±94% ee 
[Dr. Maisch Chiral AM, heptane/IPA = 90/10, v = 0.7 mL/min, column temperature: 30 °C, λ = 220 nm, t 
(major) = 8.950 min, t (minor) = 11.879 min]. Specific rotation: [ߙ]஽ଶ଴  = –20 ° (c = 0.3, CHCl3). 
rac-2,4-dimethylpyrrolyl pyrrolidine 4e: Prepared from hemiaminal S2b (109 mg, 0.70 mmol, 1.1 equiv) 
and nucleophile 2,4-dimethylpyrrole (64.9 µL, 0.63 mmol, 1.0 equiv) according to general procedure 4 to 
obtain compound rac-4e (109 mg,  0.47 mmol, 67%) as a brown solid. 1H NMR (400 MHz, CDCl3) δ 8.58 (s, 
1H, CH3C*NH), 5.66 (s, 1H, CH3C*CH), 4.37 (d, J = 4.7 Hz, 1H, NHCHCHCHO), 4.29 (d, J = 4.7 Hz, 1H, 
NHCH2CHCHO), 3.92 (d, J = 7.8 Hz, 1H, NHCH), 3.28 (t, J = 9.0 Hz, 1H, NHCH2), 2.71 – 2.59 (m, 1H, NHCH2), 
2.44 (q, J = 8.3 Hz, 1H, NHCH2CH), 2.28 (t, J = 8.3 Hz, 1H, NHCHCH), 2.20 (s, 3H, CH3), 2.05 (s, 3H, CH3), 1.78 – 
1.62 (m, 2H, CH2CH2), 1.55 – 1.28 (m, 2H, CH2CH2) ppm. 13C NMR (126 MHz, CDCl3) δ 127.2 (C*), 125.0 (C*), 
116.0 (C*), 107.9 (CH), 79.5 (CH), 78.7 (CH), 59.0 (CH), 56.2 (CH), 50.5 (CH2), 49.0 (CH), 28.5 (CH2), 28.3 
(CH2), 13.0 (CH3), 11.0 (CH3) ppm.  
 
indolyl pyrrolidine 4f: Prepared from pyrrolidine 1b (210 mg, 1.51 mmol, 1.0 
equiv), nucleophile indole (354 mg, 3.02 mmol, 2.0 equiv) and DMSO (5% v/v) 
according to general procedure 2 to obtain compound 4f (200 mg, 0.79 mmol, 52%) 
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as a yellow solid. m.p.: >136 °C (decomposition). 1H NMR (500 MHz, CDCl3) δ 8.52 (bs, 1H, NHC*), 7.74 (d, J 
= 7.8 Hz, 1H, NHC*C*CH), 7.35 (d, J = 8.0 Hz, 1H, NHC*CH), 7.21 (t, J = 7.5 Hz, 1H, NHC*CHCH), 7.19 – 7.12 
(m, 2H, NHC*CHCHCH/C*NHCH), 4.48 (d, J = 3.5 Hz, 1H, NHCHCHCHO), 4.37 (d, J = 3.4 Hz, 1H, 
NHCH2CHCHO), 4.10 (d, J = 6.5 Hz, 1H, CH2NHCH), 3.40 (dd, J = 10.5, 7.7 Hz, 1H, NHCH2), 2.75 (dd, J = 10.5, 
6.9 Hz, 1H, NHCH2), 2.57 – 2.44 (m, 2H, NHCH2CHCHCHO), 1.99 (bs, 1H, CH2NH), 1.76 – 1.63 (m, 2H, CH2CH2), 
1.48 – 1.33 (m, 2H, CH2CH2) ppm. 13C NMR (126 MHz, CDCl3) δ 136.8 (C*), 126.4 (C*), 122.2 (CH), 121.8 
(CH), 119.54 (CH), 119.52 (CH), 117.4 (C*), 111.6 (CH), 80.0 (CH), 79.4 (CH), 61.0 (CH), 57.0 (CH), 51.8 
(CH2), 50.8 (CH), 28.71 (CH2), 28.67 (CH2) ppm. IR (cm-1): vmax = 3317 (m), 3037 (w), 2858 (w), 2800 (w), 
1448 (s), 1402 (s), 1323 (m), 1218 (s), 1174 (m), 1110 (s), 991 (s), 964 (s), 925 (s), 877 (m), 811 (m), 792 
(m), 750 (s), 603 (s), 572 (m). HRMS (ESI+) calculated for C16H19N2O (MH+) 255.1492, found 255.1494. 
Chirality: 95% ee [Dr. Maisch Chiral AM, heptane/IPA = 90/10, v = 0.7 mL/min, column temperature: 30 °C, 
λ = 220 nm, t (minor) = 37.513 min, t (major) = 42.266 min]. Specific rotation: [ߙ]஽ଶ଴ = –28 ° (c = 0.5, EtOH). 
rac-indolyl pyrrolidine 4f: Prepared from hemiaminal S2b (106 mg, 0.68 mmol, 1.1 equiv) and indole (73 
mg, 0.62 mmol, 1.0 equiv) according to general procedure 4 to obtain compound rac-4f (118 mg, 0.47 mmol, 
75%) as a light brown solid. 1H NMR (500 MHz, CDCl3) δ 8.60 (bs, 1H, NHC*), 7.73 (d, J = 7.9 Hz, 1H, 
NHC*C*CH), 7.36 (d, J = 8.1 Hz, 1H, NHC*CH), 7.20 (t, J = 7.5 Hz, 1H, NHC*CHCH), 7.16 – 7.08 (m, 2H, 
NHC*CHCHCH/C*NHCH), 4.47 (d, J = 4.0 Hz, 1H, NHCHCHCHO), 4.37 (d, J = 4.0 Hz, 1H, NHCH2CHCHO), 4.10 
(d, J = 6.5 Hz, 1H, CH2NHCH), 3.40 (dd, J = 9.5, 3.5 Hz, 1H, NHCH2), 2.75 (dd, J = 10.3, 7.0 Hz, 1H, NHCH2), 2.57 
– 2.43 (m, 2H, NHCH2CHCHCHO), 1.98 (bs, 1H, CH2NH), 1.76 – 1.64 (m, 2H, CH2CH2), 1.48 – 1.33 (m, 2H, 
CH2CH2) ppm. 13C NMR (126 MHz, CDCl3) δ 136.8 (C*), 126.3 (C*), 122.2 (CH), 121.7 (CH), 119.64 (CH), 
119.57 (CH), 117.7 (C*), 111.5 (CH), 80.0 (CH), 79.4 (CH), 61.1 (CH), 57.0 (CH), 51.9 (CH2), 50.8 (CH), 28.7 
(CH2), 28.7 (CH2) ppm.  
 
N-methylindolyl pyrrolidine 4g: Prepared from pyrrolidine 1b (216 mg, 1.55 
mmol, 1.0 equiv), nucleophile N-methylindole (407 mg, 3.10 mmol, 2.0 equiv) and 
DMSO (5% v/v) according to general procedure 2 to obtain compound 4g (100.2 mg 
[17% CH2Cl2], 0.31 mmol, 20%) as a light brown solid. m.p.: 155 – 156 °C. 1H NMR 
(500 MHz, CDCl3) δ 7.73 (d, J = 7.9 Hz, 1H, NC*C*CH), 7.31 (d, J = 8.1 Hz, 1H, NC*CH). 
7.24 (t, J = 8.1 Hz, 1H, NC*C*CHCH), 7.12 (t, J = 7.4 Hz, 1H, NC*CHCH), 7.08 (s, 1H, CH3NCH), 4.45 (s, 1H, 
NHCHCHCHO), 4.35 (s, 1H, NHCH2CHCHO), 4.10 (d, J = 6.9 Hz, 1H, NHCH), 3.75 (s, 3H, NCH3), 3.39 (t, J = 9.3 
Hz, 1H, NHCH2), 2.73 (t, J = 8.4 Hz, 1H, NHCH2), 2.52 – 2.47 (m, 2H, NHCHCHCHCH2), 2.01 (s, 1H, NH), 1.70 (s, 
2H, CH2CH2), 1.45 – 1.25 (m, 2H, CH2CH2). 13C NMR (126 MHz, CDCl3) δ 137.2 (2x C*), 128.1 (CH), 126.8 (C*), 
122.2 (CH), 119.7 (CH), 119.5 (CH), 109.6 (CH), 79.4 (CH), 78.8 (CH), 60.3 (CH), 56.2 (CH), 50.4 (CH2), 49.0 
(CH), 32.9 (CH3), 28.4 (CH2), 28.2 (CH2) ppm. IR (neat): vmax (cm-1) = 2949 (m), 1393 (m), 1223 (s), 1175 (s), 
1140 (w), 972 (s), 926 (s), 806 (s), 721 (s), 623 (s). HRMS (ESI+) calculated for C17H21N2O (MH+) 269.1648, 
found 269.1657. Chirality: 94% ee [Dr. Maisch Chiral AM, heptane/IPA = 90/10, v = 0.7 mL/min, column 
temperature: 30 °C, λ = 220 nm, t (major) = 18.527 min, t (minor) 31.832 = min]. 
rac-N-methylindolyl pyrrolidine 4g: Prepared from hemiaminal S2b (109 mg, 0.70 mmol, 1.1 equiv) and 
nucleophile N-methylindole (82.6 mg, 0.63 mmol, 1.0 equiv) according to general procedure 4 to obtain 
compound rac-4g (147 mg, 0.55 mmol, 87%) as an off-white solid. 1H NMR (400 MHz, CDCl3) δ 7.71 (d, J = 
7.9 Hz, 1H, NC*C*CH), 7.30 (d, J = 8.2 Hz, 1H, NC*CH), 7.24 (t, J = 7.6 Hz, 1H, NC*C*CHCH), 7.13 (d, J = 7.2 Hz, 
1H, NC*CHCH), 7.09 (s, 1H, CH3NCH), 4.44 (d, J = 4.4 Hz, 1H, NHCHCHCHO), 4.33 (d, J = 4.4 Hz, 1H, 
NHCH2CHCHO), 4.09 (d, J = 6.7 Hz, 1H, NHCH), 3.74 (s, 3H, NCH3), 3.36 (dd, J = 10.6, 7.5 Hz, 1H, NHCH2), 2.70 
(dd, J = 10.4, 6.9 Hz, 1H, NHCH2), 2.59 – 2.42 (m, 2H, NHCHCHCHCH2), 1.83 – 1.65 (m, 2H, CH2CH2), 1.51 – 
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1.28 (m, 2H, CH2CH2) ppm.  
 
pyrrolyl pyrrolidine 4h: Prepared from pyrrolidine 1b (134 mg, 0.97 mmol, 1.0 equiv) 
and nucleophile pyrrole (139 µL, 1.94 mmol, 2.0 equiv) according to general procure 1 
to obtain compound 4h (168 mg, 0.82 mmol, 85%) as an orange solid. m.p.: 89 – 93 °C. 
1H NMR (500 MHz, CDCl3) δ 8.92 (bs, 1H, C*NH), 6.69 (s, 1H, C*NHCH), 6.14 (s, 1H, 
C*NHCHCH), 5.94 (s, 1H, C*NHCHCHCH), 4.19 (s, 1H, CH2NHCH), 2.89 (d, J = 12.0 Hz, 1H, 
NHCH2), 2.79 – 2.66 (m, 1H, NHCH2, NHCHCH), 2.59 – 2.48 (m, 2H, NHCH2CH), 2.35 (s, 1H, 
NHCHCHCHCH2CH), 2.19 (s, 1H, NHCH2CHCHCH2), 1.67 – 1.33 (m, 6H, CH2CHCH2CH2) ppm. 13C NMR (126 
MHz, CDCl3) δ 134.8 (C*), 116.6 (CH), 108.4 (CH), 104.2 (CH), 56.5 (CH), 52.5 (CH), 46.48 (CH2), 46.45 (CH), 
43.4 (CH2), 40.62 (CH), 40.55 (CH), 23.6 (CH2), 22.8 (CH2) ppm. IR (cm-1): vmax = 2945 (s), 1392 (m), 1328 
(m), 1301 (m), 1286 (m), 1130 (s), 1105 (s), 1024 (s), 950 (s), 919 (s), 879 (s), 763 (s), 711 (s). HRMS (ESI+) 
calculated for C13H19N2O (MH+) 203.1543, found 203.1551. Chiral SFC: >99% ee [Acquity Trefoil CEL2 (2.1 x 
150 mm, 2.5 μm), modifier: EtOH/ACN (1:1) + 0.2% TFA,  t  = 3.30 min]. Specific rotation: [ߙ]஽ଶ଴ = +26 ° (c = 
0.5, EtOH). 
rac-pyrrolyl pyrrolidine 4h: Prepared from imine S2c (106 mg, 0.68 mmol, 1.0 equiv) and nucleophile 
pyrrole (94.3 µL, 1.36 mmol, 2.0 equiv) according to general procedure 5 to obtain the compound rac-4h 
(111 mg, 0.55 mmol, 81%) as a light brown solid. 1H NMR (500 MHz, CDCl3) δ 8.96 (bs, 1H, C*NH), 6.69 (s, 
1H, C*NHCH), 6.14 (s, 1H, C*NHCHCH), 5.94 (s, 1H, C*NHCHCHCH), 4.18 (s, 1H, CH2NHCH), 2.88 (d, J = 12.0 
Hz, 1H, NHCH2), 2.80 – 2.65 (m, 2H, NHCH2, NHCHCH), 2.61 – 2.44 (m, 2H, NHCH2CH), 2.34 (s, 1H, 
NHCHCHCHCH2), 2.19 (s, 1H, NHCH2CHCH CH2), 1.64 – 1.35 (m, 6H, CH2CHCH2CH2). 13C NMR (126 MHz, 
CDCl3) δ 135.2 (C*), 116.5 (CH), 108.4 (CH), 104.1 (CH), 56.5 (CH), 52.6 (CH), 46.6 (CH2), 46.5 (CH), 43.4 
(CH2), 40.7 (CH), 40.6 (CH), 23.7 (CH2), 22.8 (CH2).  
 
pyrrolyl pyrrolidine 4i: Prepared from  pyrrolidine 1b (89.0 mg, 0.80 mmol, 1.0 equiv) 
and nucleophile pyrrole (111 µL, 1.60 mmol, 2.0 equiv) according to general procedure 1 to 
obtain compound 4i (94.5 mg, 0.54 mmol, 67%) as a yellow solid. m.p.: 90 – 93 °C. 1H NMR 
(500 MHz, CDCl3) δ 8.99 (bs, 1H, C*NH), 6.74 (s, 1H, C*NHCH), 6.14 (s, 1H, C*NHCHCH), 
6.06 (s, 1H, C*NHCHCHCH), 3.64 (d, J = 7.3 Hz, 1H, CH2NHCH), 3.30 (t, J = 9.3 Hz, 1H, NHCH2), 2.77 – 2.64 (m, 
1H, NHCH2CH), 2.62 – 2.53 (m, 1H, NHCHCH), 2.52-2.42 (m, 1H, NHCH2), 2.12 (bs, 1H, CH2NH), 1.68 – 1.34 
(m, 6H CH2CH2CH2). 13C NMR (126 MHz, CDCl3) δ 133.7 (C*), 117.3 (CH), 108.0 (CH), 104.9 (CH), 63.7 (CH), 
54.0 (CH2), 51.1 (CH), 44.3 (CH), 32.2 (CH2), 31.2 (CH2), 25.4 (CH2). IR (cm-1): vmax = 2927 (s), 2854 (m), 
1436 (s), 1444 (s), 1288 (s), 1132 (s), 1027 (m), 987 (s), 927 (s), 916 (w), 881 (m), 856 (m), 790 (s), 711 
(s). HRMS (ESI+) calculated for C11H17N2 (MH+) 177.1386, found 177.1390. Chiral SFC: 97% ee [Acquity 
Trefoil AMY1 (2.1 x 150 mm, 2.5 μm), modifier: EtOH/IPA (1:1) + 0.2% TFA,  t (minor) = 3.75 min, t (major) 
= 3.94 min]. Specific rotation: [ߙ]஽ଶ଴ = +38 ° (c = 0.5, EtOH). 
rac-pyrrolyl pyrrolidine 4i: Prepared from imine S2d (76.4 mg, 0.70 mmol, 1.0 equiv) and nucleophile 
pyrrole (97.1 µL, 1.40 mmol, 2.0 equiv) according to general procedure 5 to obtain compound rac-4i (120 
mg, 0.68 mmol, 97%) as a light brown solid. 1H NMR (500 MHz, CDCl3) δ 8.95 (bs, 1H, C*NH), 6.74 (s, 1H, 
C*NHCHCHCH), 6.13 (s, 1H, C*NHCHCH), 6.06 (s, 1H, NHC*CH), 3.64 (d, J = 7.2 Hz, 1H, CH2NHCH), 3.28 (t, J = 
9.3 Hz, 1H, NHCH2), 2.75 – 2.63 (m, 1H, NHCH2CH), 2.63 – 2.52 (m, 1H, NHCHCH), 2.48 (t, J = 7.9 Hz, 1H, 
NHCH2), 2.24 (bs, 1H, CH2NH), 1.71 – 1.35 (m, 6H CH2CH2CH2). 13C NMR (126 MHz, CDCl3) δ 133.4 (C*), 
117.4 (CH), 108.0 (CH), 104.9 (CH), 63.6 (CH), 53.8 (CH2), 51.0 (CH), 44.2 (CH), 32.1 (CH2), 31.2 (CH2), 25.4 
(CH2).  
N
H
H
N
HH
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pyrrolyl pyrrolidine 5a: Prepared from pyrrolidine 1e (124 mg, 0.77 mmol, 1.0 equiv) 
and nucleophile pyrrole (109 µL, 1.54 mmol, 2.0 equiv) according to general procedure 1 
to obtain compound 5a (137 mg, 0.63 mmol, 82%) as an off-white solid. m.p.: 89 – 92 
°C. 1H NMR (500 MHz, CDCl3) δ 8.67 (s, 1H, NH), 6.76 (bs, 1H, NHCH), 6.13 (d, J = 10.8 
Hz, 2H, NHCHCHCH), 4.35 (d, J = 3.8 Hz, 1H, NCHCHCHO), 4.28 (d, J = 3.7 Hz, 1H, NCH2CHCHO), 3.30 (t, J = 8.6 
Hz, 1H, NCH2), 2.95 (d, J = 8.0 Hz, 1H, NCHC*), 2.40 (q, J = 8.4 Hz, 1H, NCHCH), 2.25 (t, J = 8.3 Hz, 1H, NCH2), 
2.10 (s, 3H, NCH3), 2.06 (t, J = 8.8 Hz, 1H, NCH2CH), 1.68 (s, 2H, CH2CH2), 1.51 – 1.21 (m, 2H, CH2CH2) ppm. 
13C NMR (126 MHz, CDCl3) δ 131.8 (C*), 117.9 (CH), 108.0 (CH), 107.1 (CH), 79.2 (CH), 78.4 (CH), 68.9 (CH), 
61.0 (CH2), 57.7 (CH), 47.3 (CH), 40.1 (CH3), 28.6 (CH2), 28.3 (CH2) ppm. IR (cm-1): vmax = 1463 (s), 1444 (s), 
1288 (s), 1220 (s), 1213 (w), 1132 (s), 1091 (s), 1027 (s), 987 (s), 927 (s), 881 (m), 856 (m), 790 (s), 711 
(s). HRMS (ESI+) calculated for C13H19N2O (MH+) 219.1492, found 219.1498. Chirality: 18% ee [Dr. Maisch 
Chiral AM, heptane/IPA = 98/2, v = 0.3 mL/min, column temperature: 30 °C, λ = 215 nm, t (minor) = 27.635 
min, t (major) = 31.723 min]. 
 
pyrrolyl pyrrolidines 5a and 6/6’ (one-
stage procedure):38 Prepared from 
pyrrolidine 1e (132 mg, 0.75 mmol, 1.0 
equiv) and nucleophile pyrrole (106 µL, 1.50 
mmol, 2.0 equiv) according to general 
procedure 3 to obtain a mixture of compound 
5a (69 mg, 0.32 mmol, 42%) and 6/6’ (15 mg, 0.041 mmol, 5%) in a 7.6:1 ratio as an off-white solid. 6/6’: 
1H NMR (500 MHz, CDCl3) δ 8.69 (bs, 1H, NH), 6.00 (dd, J = 5.3, 2.6 Hz, 2H, NCHC*CH), 4.35 (d, J = 3.8 Hz, 2H, 
NCHCHCHO),39 4.28 (d, J = 3.7 Hz, 2H, NCH2CHCHO),39 3.29 – 3.23 (m, 2H, NCH2), 2.90 (dd, J = 8.0, 3.0 Hz, 2H, 
NCHC*), 2.40 (q, J = 8.4 Hz, 2H, NCHCH),39 2.25 (t, J = 8.3 Hz, 2H, NCH2),39 2.10 (s, 6H, NCH3),39 2.06 (t, J = 8.8 
Hz, 2H, NCH2CH),39 1.68 (s, 4H, CH2CH2),39 1.51 – 1.21 (m, 4H, CH2CH2)39 ppm. 13C NMR (126 MHz, CDCl3):39 δ 
132.0 (C*), 106.6 (CH), 79.2 (CH), 78.4 (CH), 68.9 (CH), 61.0 (CH2), 57.7 (CH), 47.3 (CH), 40.1 (CH3), 28.6 
(CH2), 28.3 (CH2) ppm. HRMS (ESI+) calculated for C22H32N3O2 (MH+) 370.2489, found 370.2494. 5a: 
Chirality: ±10% ee [Dr. Maisch Chiral AM, heptane/IPA = 98/2, v = 0.3 mL/min, column temperature: 30 °C, 
λ = 215 nm, t (minor) = 29.306 min, t (major) = 33.845 min]. 
 rac-pyrrolyl pyrrolidine 5a: Prepared from hemiaminal S2b (77 mg, 0.50 mmol, 1.0 equiv) and 
nucleophile pyrrole (69.4 μL, 1.0 mmol, 2.0 equiv) according to general procedure 5. To a solution of the 
crude product in methanol (5 mL) were added sodium cyanoborohydride (49 mg, 0.75 mmol, 1.5 equiv), 
acetic acid (58 uL, 1.0 mmol, 2.0 equiv) and aq. formaldehyde (56 μL [37%], 0.75 mmol, 1.5 equiv) at 0 °C 
under N2-atmosphere. The reaction mixture was stirred for 2 hours at rt and quenched by de addition of sat. 
aq. Na2CO3 (15 mL), extracted with DCM (3 x 15 mL), dried (Na2SO4) and concentrated in vacuo to obtain 
compound rac-5a (80 mg, 0.37 mmol, 73%) as an off-white solid. 1H NMR (500 MHz, CDCl3) δ 8.55 (bs, 1H), 
6.76 (q, J = 1.1 Hz, 1H, NHCH), 6.17 – 6.08 (m, 2H, NHCHCHCH), 4.35 (d, J = 4.8 Hz, 1H, NCHCHCHO), 4.28 (d, 
J = 4.8 Hz, 1H, NCH2CHCHO), 3.30 (t, J = 8.6 Hz, 1H, NCH2), 2.96 (d, J = 8.0 Hz, 1H, NCHC*), 2.40 (q, J = 8.4 Hz, 
1H, NCHCH), 2.25 (t, J = 8.3 Hz, 1H, NCH2), 2.11 (s, 3H, NCH3), 2.06 (t, J = 8.9 Hz, 1H, NCH2CH), 1.73 – 1.62 (m, 
2H, CH2CH2), 1.42 – 1.24 (m, 2H, CH2CH2) ppm. 13C NMR (126 MHz, CDCl3) δ 131.9 (C*), 117.8 (CH), 108.0 
(CH), 107.0 (CH), 79.2 (CH), 78.4 (CH), 68.9 (CH), 61.0 (CH2), 57.8 (CH), 47.3 (CH), 40.1 (CH3), 28.6 (CH2), 
28.3 (CH2) ppm.  
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pyrrolyl pyrrolidine 5b: Prepared from  pyrrolidine 1e (132 mg, 0.758 mmol, 1.0 
equiv) and nucleophile N-methylpyrrole (136 μL, 1.52 mmol, 2.0 equiv) according to 
general procedure 1 to obtain compound 5b (109 mg, 0.47 mmol, 62%) as a light yellow 
oil. 1H NMR (500 MHz, CDCl3) 6.57 (t, J = 2.2 Hz, 1H, C*N(CH3)CH), 6.08 (d, J = 2.2 Hz, 
2H, C*N(CH3)CHCHCH), 4.30 (dd, J = 15.5, 4.8 Hz, 2H, CHOCH), 3.70 (s, 3H, C*NCH3), 3.29 (t, J = 8.4 Hz, 1H, 
NCH2), 2.96 (d, J = 8.0 Hz, 1H, NCHC*), 2.48 – 2.34 (m, 2H, NCHCHCHCHO), 2.07 (s, 3H, CH2NCH3), 2.00 (t, J = 
8.7 Hz, 1H, NCH2), 1.74 – 1.62 (m, 2H, CH2CH2), 1.45 – 1.28 (m, 2H, CH2CH2) ppm. 13C NMR (126 MHz, CDCl3) 
δ 131.9 (C*), 123.0 (CH), 108.5 (CH), 106.9 (CH), 79.1 (CH), 78.3 (CH), 68.2 (CH), 60.8 (CH2), 57.0 (CH), 47.3 
(CH), 39.9 (CH3), 34.6 (CH3), 28.5 (CH2), 28.4 (CH2) ppm. IR (neat): vmax (cm-1) = 2947 (m), 1497 (w), 1292 
(m), 1221 (m), 1146 (m), 928 (s), 793 (s), 706 (s), 588 (s). HRMS (ESI+) calculated for C14H21N2O (MH+) 
233.1648, found 233.1659. Chirality: 12% ee [Dr. Maisch Chiral AM, heptane/IPA = 99/5, v = 0.2 mL/min, 
column temperature: 30 °C, λ = 240 nm, t (minor) = 23.293 min, t (major) = 24.837 min]. 
rac-pyrrolyl pyrrolidine 5b: Prepared from hemiaminal S2b (82 mg, 0.53 mmol, 1.0 equiv) and 
nucleophile N-methylpyrrole (47 μL, 0.53 mmol, 1.0 equiv) according to general procedure 3. To a solution 
of the crude product in methanol (5 mL) were added sodium cyanoborohydride (52 mg, 0.79 mmol, 1.5 
equiv), acetic acid (62 uL, 1.06 mmol, 2.0 equiv) and aq. formaldehyde (59 μL [37%], 0.79 mmol, 1.5 equiv) 
at 0 °C under N2-atmosphere. The reaction mixture was stirred for 2 hours at rt and quenched by de 
addition of sat. aq. Na2CO3 (15 mL), extracted with DCM (3 x 15 mL), dried (Na2SO4) and concentrated in 
vacuo to obtain compound rac-5b (122 mg, 0.53 mmol, 99%) as a light yellow oil. 1H NMR (500 MHz, CDCl3) 
δ 6.56 (t, J = 2.3 Hz, 1H, C*N(CH3)CH), 6.11 – 6.05 (m, 2H, C*N(CH3)CHCHCH), 4.30 (dd, J = 14.9, 4.8 Hz, 2H, 
CHOCH), 3.70 (s, 3H, C*NCH3), 3.29 (t, J = 8.4 Hz, 1H, NCH2), 2.97 (d, J = 8.0 Hz, 1H, NCHC*), 2.47 – 2.34 (m, 
2H, NCHCHCHCHO), 2.07 (s, 3H, CH2NCH3), 2.01 (t, J = 8.7 Hz, 1H, NCH2), 1.74 – 1.62 (m, 2H, CH2CH2), 1.46 – 
1.29 (m, 2H, CH2CH2) ppm. 13C NMR (126 MHz, CDCl3) δ 131.8 (C*), 123.0 (CH), 108.4 (CH), 106.8 (CH), 79.1 
(CH), 78.3 (CH), 68.1 (CH), 60.7 (CH2), 56.9 (CH), 47.2 (CH), 39.8 (CH3), 34.6 (CH3), 28.5 (CH2), 28.4 (CH2) 
ppm.  
 
pyrrolyl pyrrolidine 5c: Prepared from  pyrrolidine 1e (132 mg, 0.758 mmol, 1.0 
equiv), nucleophile 2-napthol (221 mg, 1.52 mmol, 2.0 equiv) and DMSO (10% v/v) 
according to general procedure 2 to obtain compound 5c (127 mg [1% CH2Cl2], 0.423 
mmol, 56%) as a light yellow foamy solid. m.p.: >116 °C (decomposition).  1H NMR 
(500 MHz, CDCl3) δ 8.05 (d, J = 8.6 Hz, 1H, C(OH)C*C*CH), 7.78 (d, J = 8.0 Hz, 1H, 
C(OH)CHCHC*CH), 7.70 (d, J = 8.8 Hz, 1H, C(OH)CHCH), 7.50 – 7.44 (m, 1H, C(OH)C*C*CHCH), 7.30 (t, J = 7.3 
Hz, 1H, C(OH)CHCHC*CHCH), 7.12 (d, J = 8.8 Hz, 1H, C(OH)CH), 4.60 (d, J = 5.3 Hz, 1H, NCHCHCHO), 4.37 (d, J 
= 5.2 Hz, 1H, NCH2CHCHO), 4.08 (d, J = 8.1 Hz, 1H, NCH), 3.52 – 3.46 (m, 1H, NCH2), 2.57 (q, J = 8.5 Hz, 1H, 
NCH2CH), 2.48 (t, J = 8.4 Hz, 1H, NCHCH), 2.31 – 2.25 (s, 4H, CH3, NCH2), 1.77 – 1.57 (m, 2H, CH2CH2), 1.44 – 
1.35 (m, 1H, CH2CH2), 1.29 – 1.18 (m, 1H, CH2CH2) ppm. 13C NMR (126 MHz, CDCl3) δ 156.0 (C*), 133.1 (C*), 
129.4 (CH), 129.1 (CH), 128.6 (C*), 126.6 (CH), 122.6 (CH), 121.2 (CH), 119.7 (CH), 115.0 (C*), 79.1 (CH), 
78.3 (CH), 69.3 (CH), 60.1 (CH2), 57.7 (CH), 47.8 (CH), 39.3 (CH3), 28.5 (CH2), 28.3 (CH2) ppm. IR (neat): vmax 
(cm-1) = 2949 (w), 1620 (m), 1466 (m), 1271 (m), 1240 (s), 1140 (m), 959 (m), 872 (s), 748 (s), 592 (s). 
HRMS (ESI+) calculated for C19H22NO2 (MH+) 296.1645, found 296.1657. Chirality: 10% ee [Dr. Maisch 
Chiral AM, heptane/IPA = 95/5, v = 0.9 mL/min, column temperature: 30 °C, λ = 230 nm, t (minor) = 7.096 
min, t (major) = 9.297 min]. 
rac-pyrrolyl pyrrolidine 5c: To a solution of hemiaminal S2b (80 mg, 0.52 mmol, 1.0 equiv) in DCM (2.5 
mL) was added nucleophile 2-napthol (75 mg, 0.52 mmol, 1.0 equiv). The reaction mixture was stirred for 
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17 h at rt and quenched by the addition of sat. aq. Na2CO3 (2.5 mL), extracted with DCM (3 x 5 mL), dried 
(Na2SO4) and concentrated in vacuo. To a solution of the crude product in EtOAc (5 mL) were added sodium 
cyanoborohydride (50 mg, 0.77 mmol, 1.5 equiv), acetic acid (60 uL, 1.03 mmol, 2.0 equiv) and aq. 
formaldehyde (58 μL [37%], 0.77 mmol, 1.5 equiv) at 0 °C under N2-atmosphere. The reaction mixture was 
stirred for 17 h at rt and quenched by de addition of sat. aq. Na2CO3 (15 mL), extracted with DCM (3 x 15 
mL), dried (Na2SO4) and concentrated in vacuo to obtain compound rac-5c (132 mg, 0.47 mmol, 87%) as a 
light yellow oil. 1H NMR (500 MHz, CDCl3) δ 7.99 (d, J = 8.6 Hz, 1H, C(OH)C*C*CH), 7.78 (d, J = 8.0 Hz, 1H, 
C(OH)CHCHC*CH), 7.73 (d, J = 8.8 Hz, 1H, C(OH)CHCH), 7.51 – 7.45 (m, 1H, C(OH)C*C*CHCH), 7.34 – 7.29 
(m, 1H, C(OH)CHCHC*CHCH), 7.22 (d, J = 8.9 Hz, 1H, C(OH)CH), 4.54 (d, J = 5.2 Hz, 1H, NCHCHCHO), 4.38 (d, 
J = 5.2 Hz, 1H, NCH2CHCHO), 4.24 (d, J = 7.6 Hz, 1H, NCH), 3.77 – 3.70 (m, 1H, NCH2), 2.72 – 2.61 (m, 2H, 
NCH2CHCH), 2.47 – 2.32 (m, 4H, CH3NCH2), 1.78 – 1.59 (m, 2H, CH2CH2), 1.44 – 1.34 (m, 1H, CH2CH2), 1.28 – 
1.21 (m, 1H, CH2CH2) ppm. 13C NMR (126 MHz, CDCl3) δ 155.5 (C*), 133.0 (C*), 130.2 (CH), 129.1 (CH), 
128.6 (C*), 127.0 (CH), 122.8 (CH), 120.7 (CH), 119.7 (CH), 113.2 (C*), 78.9 (CH), 78.2 (CH), 69.6 (CH), 59.8 
(CH2), 56.4 (CH), 47.3 (CH), 39.1 (CH3), 28.2 (CH2), 28.1 (CH2) ppm.  
 
pyrrolyl pyrrolidine 5d: Prepared from pyrrolidine 1e (132 mg, 0.758 mmol, 
1.0 equiv) and nucleophile 2-methoxyfuran (72 μL, 0.758 mmol, 1.0 equiv) 
according to general procedure 1 to obtain compound 5d (81 mg, 0.33 mmol, 
43%) as a light yellow oil. 1H NMR (500 MHz, CDCl3) δ 6.10 (d, J = 3.1 Hz, 1H, 
C(OMe)CHCH), 5.04 (d, J = 3.1 Hz, 1H, C(OMe)CH), 4.31 – 4.23 (m, 2H, CHOCH), 
3.80 (s, 3H, OCH3), 3.30 (t, J = 8.5 Hz, 1H, NCH2), 2.73 (d, J = 8.0 Hz, 1H, NCH), 2.51 (t, J = 8.3 Hz, 1H, NCHCH), 
2.42 (q, J = 8.4 Hz, 1H, NCH2CH), 2.14 (s, 3H, NCH3), 1.99 (t, J = 8.8 Hz, 1H, NCH2), 1.72 – 1.60 (m, 2H, 
CH2CH2), 1.44 – 1.30 (m, 2H, CH2CH2) ppm. 13C NMR (126 MHz, CDCl3) δ 161.7 (C*), 143.6 (C*), 109.3 (CH), 
79.6 (CH), 79.2 (CH), 78.3 (CH), 68.5 (CH), 61.0 (CH2), 57.8 (CH3), 55.0 (CH), 47.1 (CH), 39.8 (CH3), 28.5 
(CH2), 28.3 (CH2) ppm. IR (neat): vmax (cm-1) = 2947 (m), 1751 (m), 1616 (m), 1583 (s), 1439 (m), 1259 (s), 
1219 (m), 1146 (m), 1007 (s), 926 (s), 789 (m), 735 (m), 592 (m). HRMS (ESI+) calculated for C14H20NO3 
(MH+) 250.1438, found 250.1446.  
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Chapter 3 
 
IBX-Mediated Oxidative Ugi-type MCRs  
and aza-Friedel–Crafts reactions 
 
 
Abstract: The first o-iodoxybenzoic acid (IBX) mediated oxidation of unactivated amines to imines 
is described. A range of meso-pyrrolidines were shown to be suitable substrates. The chemical 
space was further explored with one-pot oxidative Ugi-type and aza-Friedel‒Crafts reactions, 
which proved to be highly diastereoselective. 
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3.1 Introduction 
The chemistry of hypervalent iodine reagents (Figure 1) has received major interest in 
recent years as a result of the increasing number of new reagents and their 
application in diverse chemical transformations.1 In particular, o-iodoxy-benzoic acid 
(IBX)2 has experienced increasing attention owing to its broad applicability and high 
chemoselectivity. Santagostino et al. developed a convenient and cost-efficient 
synthesis of high purity IBX by the treatment of 2-iodobenzoic acid with oxone in 
aqueous medium,3 which renders IBX an easily accessible reagent. Chemical 
transformations mediated by IBX include the selective oxidation of primary and 
secondary alcohols to the corresponding aldehydes and ketones as well as 
dehydrogenation of aldehydes and ketones to α,β-unsaturated carbonyl compounds. 
Nicolaou et al. described the oxidation of benzylic amines as well as amines that 
aromatize upon oxidation,4,5 however, the oxidation of unactivated aliphatic amines 
with IBX was not investigated.6 
The direct α-functionalization of amines is a highly interesting transformation 
that attracted great attention in recent years.7 Consequently, transition 
metal-catalyzed oxidative versions of important C–C bond-forming reactions such as 
Mannich, Strecker, aza-Henry and aza-Friedel–Crafts reactions have been developed.8 
A limited number of examples of the application of IBX in oxidative multicomponent 
reactions has been described, i.e. oxidative Strecker,9 Passerini,10 Ugi and Ugi-type11 
reactions. Although unactivated alcohols were suitable substrates, the scope of the 
amine component is basically unexplored with the exception of a small selection of 
α-activated amines, such as benzylic amines, α-amino nitriles and α-amino esters.  
 
Figure 1.  A selection of commonly used and commercially available hypervalent iodine reagents and their 
acronyms. 
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In this Chapter, we describe a mild and selective oxidation of unactivated cyclic 
amines with IBX to access the corresponding imines. The oxidation can be combined 
in one pot with the addition of C-nucleophiles, providing oxidative Ugi-type and 
aza-Friedel–Crafts reactions. 
3.2 Results and Discussion 
In light of our continued interest in the functionalization of imines, in particular 
1-pyrrolines,12 we envisioned a clean and fast oxidation of unactivated 
meso-pyrrolidines. Examination of the currently available methods revealed that the 
oxidation of unactivated secondary amines is rather challenging.13 Given the recent 
regained interest in hypervalent iodine reagents, we decided to explore their ability to  
Table 1. Optimization of reaction conditions for the oxidation of meso-pyrrolidine 1a.[a] 
 
Entry Oxidant Solvent T, t Yield[b] 
1 PIDA DMSO rt, 30 min 38% 
2 PIFA DMSO rt, 30 min 33% 
3 DMP DMSO rt, 30 min 55% 
4 IBX DMSO rt, 30 min 90% 
5 IBX DMF rt, 30 min 92% 
6 IBX MeCN rt, 1h 19% 
7[c] IBX MeCN 60 °C, 1h 78% 
8[c] IBX MeOH 60 °C, 1h 81% 
9[c] IBX CH2Cl2 60 °C, 1h 95% 
10[c] IBX THF/DMSO (9:1) 60 °C, 1h 94% 
11[c] IBX THF 60 °C, 1h 58% 
12[c] IBX CF3CH2OH 60 °C, 1h 47% 
13[c] IBX (MeO)2CO 60 °C, 1h 31% 
14[c] IBX EtOAc 60 °C, 1h 19% 
15[c] IBX toluene 60 °C, 1h 10% 
[a] Conditions: amine (1.0 equiv), oxidant (1.0 equiv), solvent (0.2 M). [b] Yield determined by adding 2,5-
dimethylfuran (0.5 equiv) after the reaction workup as standard for NMR spectroscopy. [c] Closed vessel. 
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oxidize aliphatic amines. We started our investigation with the oxidation of 
meso-pyrrolidine 1a with different commercially available hypervalent iodine 
reagents at room temperature in the typically used solvent DMSO (Table 1, entries 
1‒4).4 The desired 1-pyrroline (2a) was obtained in high yield with only 1.0 equiv of 
IBX (entry 4), while oxidants such as (diacetoxy)iodobenzene (PIDA), bis(trifluoro-
acetoxy)iodobenzene (PIFA) and Dess-Martin periodinane (DMP) gave poor to 
moderate yields (entry 1‒3). A solvent screen (entries 5‒15) revealed that the 
oxidation proceeds well in a range of protic as well as aprotic solvents in which IBX is 
virtually insoluble, although an increased temperature and reaction time were 
sometimes required. Superior results were obtained using CH2Cl2 (entry 9),14 which 
prompted us to select this solvent for a screening of the substrate scope. 
To our delight, a range of aliphatic meso-pyrrolidines was selectively oxidized 
by IBX towards the corresponding 1-pyrrolines in good to excellent yield (Table 2, 
70‒97%). Hemiaminal 2f is a highly interesting building block for the synthesis of 
aza-sugars, but was obtained in moderate yield presumably as a result of instability 
due to its increased electrophilicity.15,16 Under the same conditions, reactions of 
monocyclic pyrrolidines gave mixtures of the corresponding 1-pyrrolines and 
pyrroles. We hypothesize that this overoxidation is caused by tautomerization of the 
initially formed imines to the corresponding enamines, which subsequently undergo a 
second oxidation leading to pyrroles. In case of bi- and tricyclic 1-pyrrolines 2a–f, 
tautomerization is prevented and overoxidation does not occur. Piperidine 
 
Table 2. Scope study for oxidation of meso-pyrrolidines 1 with IBX.[a] 
 
[a] Conditions: amine (1.0 equiv), IBX (1.0 equiv), CH2Cl2 (0.2 M), 60 °C, 1h, closed vessel. Isolated yield, 
unless stated otherwise. [b] MeCN as solvent. Yield determined by adding 2,5-dimethylfuran (0.5 equiv) 
after the reaction workup as standard for NMR spectroscopy and proposed compound 2f was not isolated.15 
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derivatives and acyclic secondary amines were not converted under these conditions. 
Imines are interesting inputs for a wide variety of complexity-generating 
reactions as a result of their electrophilic as well as nucleophilic character. For 
example, imines serve as templates for many multicomponent reactions (MCRs), a 
category of reactions that create a high degree of diversity and complexity in a single 
step.17 One of the most studied and widely applied MCRs is the Ugi reaction, which has 
proven to be a powerful tool for rapid synthesis of lead compounds in drug 
discovery.18 Consequently, we envisioned a diastereoselective oxidative Ugi-type 
three-component reaction for the synthesis of N-acylprolyl amide derivatives.19 
 For a screening of the reaction conditions, the reaction between 
meso-pyrrolidine 1a, benzoic acid and tert-butyl isocyanide was investigated (Table 
3). In agreement with earlier reports,10,11 a high concentration of reagents proved to 
be beneficial for the reaction outcome (entries 1‒2). The solvent of choice for most 
Ugi reactions, MeOH, was used as reaction medium with modest efficiency (entry 3). 
Competing oxidation of the solvent could pose a problem, although previous reports 
suggest that the oxidation of amines is generally much faster than alcohols.4,11c 
Considering the complexity of the reaction, satisfactory results were obtained using 
either MeCN or CH2Cl2 as the solvent (entries 4‒5). As a consequence of the superior  
results obtained for the oxidation of a variety of meso-pyrrolidines in CH2Cl2, this 
solvent was selected for investigation of the reaction scope. 
Table 3.  Optimization of reaction conditions for the oxidative Ugi-type three-component reaction.[a] 
 
Entry Solvent T Yield[b] 
1 DMSO[c] rt 26% 
2 DMSO rt 37% 
3 MeOH 60 °C 25% 
4 MeCN 60 °C 50% 
5 CH2Cl2 60 °C 54% 
[a] Conditions: amine (1.0 equiv), benzoic acid (1.5 equiv), tert-butyl isocyanide (1.5 equiv), IBX (1.0 equiv), 
solvent (0.5 M), 60 °C, 24 h, closed vessel. [b] Yield determined by adding 2,5-dimethylfuran (0.5 equiv) 
after the reaction workup as standard for NMR spectroscopy. [c] 0.2 M. 
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Gratifyingly, we could employ a large variety of inputs for the one-pot oxidative 
Ugi-type three-component reaction (Table 4). In total, 10 examples of prolyl peptide 3 
were synthesized in modest to good yields (35‒61%) using 6 isocyanides, 6 secondary 
amines and 6 carboxylic acids. A range of electronically diverse carboxylic acids were 
suitable reaction partners, although it should be noted that lower yields were 
observed for aliphatic acids such as acetic acid (3e, 43%). Despite the instability of the 
intermediate hemiaminal 2f upon isolation, Ugi adduct 3h could be obtained in 45% 
yield as a single diastereoisomer. Notably, 3,3-dimethylindoline―with blocked 
benzylic positions to prevent benzylic oxidation20―could also be applied with modest 
efficiency (3j, 35%).21 For the majority of examples, a single diastereoisomer of the 
 
Table 4. Oxidative Ugi-type three-component reaction[a] 
 
[a] Conditions: amine (1.0 equiv), carboxylic acid (1.5 equiv), isocyanide (1.5 equiv), IBX (1.0 equiv), CH2Cl2 
(0.5 M), 60 °C, 48 h, closed vessel. Isolated yield. Only one diastereoisomer observed, unless stated 
otherwise. [b] Ratio determined by NMR analysis of the crude mixture.22,23 
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Scheme 1. Steric rationalization for superior diastereoselectivity for the Ugi-type reaction of 
endo-configured 2a compared to exo-2c. X-ray structure of major diastereoisomer 3i with  
displacement ellipsoids drawn at 50% probability.23 
dipeptide was isolated (3a‒h). However, exo-configured dipeptide 3i was obtained as 
a mixture of diastereoisomers.22 The increased diastereoselectivity with 
endo-configured imines12b such as 2a is explained by steric congestion on the concave 
face of the molecule, facilitating selective attack of the nucleophile from the other side 
(Scheme 1). For exo-configured 2c, the steric effect is expected to be less pronounced.  
Table 5. Oxidative aza-Friedel‒Crafts reaction[a] 
 
[a] Conditions: 1. amine (1.0 equiv), IBX (1.0 equiv), CH2Cl2 (0.2 M), 60 °C, 1 h; 2. nucleophile (2.0 equiv), 
TFA (2.0 equiv), 60 °C, 1 h, closed vessel. Isolated yield. Only a single diastereoisomer was observed, unless 
stated otherwise. [b] Diastereomeric ratio determined by NMR analysis of the crude mixture. 
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In order to expand the molecular diversity available by reactions of in situ-generated 
bicyclic pyrrolines, we decided to explore the  aza-Friedel‒Crafts reaction.24 Our 
one-pot methodology showed to be effective in an oxidative aza-Friedel‒Crafts 
reaction with pyrrole and indoles as a two-step procedure, giving 2-substituted 
pyrrolidines in modest to good yields (Table 5, 48‒75%) and with high to excellent 
diastereoselectivities. The yield of pyrrolidine 4c even exceeded the yield of its 
hemiaminal intermediate 2f, supporting our hypothesized instability of the latter 
species. Unfortunately, 6-nitro- and 3-methyl-substituted indoles were not suitable 
reaction partners, presumably as a result of their reduced nucleophilicity. 
3.3 Conclusion 
We have developed the first IBX-mediated oxidation of unactivated aliphatic amines. 
This method gives access to bi- and tricyclic imines, but is limited to 1-pyrrolines that 
do not tautomerize under the reaction conditions. An efficient one-pot protocol for 
diastereoselective α-functionalization of meso-pyrrolidines in oxidative Ugi-type and 
aza-Friedel‒Crafts reactions was presented as well.  
3.4 Acknowledgements 
We thank E. Janssen (VU University) for technical assistance, S. Bouwman (VU 
University) for HRMS measurements, and Dr. A. W. Ehlers (VU University) for NMR 
maintenance. R. C. Cioc (VU University) is kindly acknowledged for his contribution to 
this chapter. We kindly acknowledge Dr. M. Zeller (Youngstown State University) for 
collecting the X-ray data and Dr. C. M. L. Vande Velde (University of Antwerp) for the 
refinement of the X-ray structure of 3i. The diffractometer was funded by NSF Grant 
1337296.  
  
IBX-Mediated Oxidative Ugi-type MCRs and aza-Friedel–Crafts reactions 
 
71 
3.5 Experimental Section 
3.5.1 General comments 
Starting materials were purchased from Sigma Aldrich, Fisher Scientific and Acros Organics and were used 
without purification, unless stated otherwise. (3aR,6aS)-Octahydrocyclopenta[c]pyrrole hydrochloride was 
purchased from AK Scientific and dissolved in CH2Cl2, washed with sat. aq. Na2CO3, extracted with CH2Cl2, 
dried (Na2SO4) and concentrated in vacuo before use. Unless stated otherwise, the solvents were purchased 
from VWR Chemicals and were used without further treatment. Cyclohexane (cHex) was purified by 
distillation before use. THF was distilled from sodium/benzophenone under nitrogen before use. Celite® 
512 medium was purchased from Sigma Aldrich. Column Chromatography was performed on Silica-P Flash 
Silica Gel (particle size 40-63 μm, pore diameter 60 Å) from Silicycle. Preparative thin layer 
chromatography was performed on Silica Gel plates F254 (20 x 20 cm, 2000 µm, pore diameter 60 Å) from 
Silicycle. Thin Layer Chromatography (TLC) was performed using TLC plates F254 (silica gel 60 on 
aluminium) from Merck Serono KGaA (Darmstadt) and compounds were visualized by UV detection (254 or 
366 nm) and stained with basic aq. KMnO4 or ninhydrin/ethanol. 1H, 13C, COSY, HSQC, HMBC and NOESY 
nuclear magnetic resonance (NMR) spectra were recorded on a Bruker Avance 500 (500.23 MHz for 1H and 
125.78 MHz for 13C) in CDCl3 or DMSO-d6 using the residual solvent as internal standard (CDCl3: δ = 7.26 for 
1H NMR and δ = 77.16 for 13C NMR, DMSO-d6: δ = 2.50 for 1H NMR and δ = 39.52 for 13C NMR) or Bruker 
Avance 400 (400.13 MHz for 1H and 100.62 MHz for 13C) using the residual solvent as internal standard 
(CDCl3: δ = 7.26 for 1H NMR and δ = 77.16 for 13C NMR, DMSO-d6: δ = 2.50 for 1H NMR and δ = 39.52 for 13C 
NMR). Chemical shifts (δ) are given in ppm and coupling constants (J) are quoted in hertz (Hz). Resonances 
are described as s (singlet), d (doublet), t (triplet), q (quartet), bs (broad singlet) and m (multiplet) or 
combinations thereof. The COSY-, HMBC- and HSQC-NMR spectra were used for the assignment of the 
proton signals and the NOESY-NMR spectra were used for the assignment of the relative stereochemistry. 
The APT-NMR spectra were used for the assignment of the carbons. Names of chemical structures were 
deduced from generic names and/or important functionalities. Electrospray Ionization (ESI) high resolution 
mass spectrometry was carried out using a Bruker micrOTOF-Q instrument in positive ion mode (capillary 
potential of 4500 V). Infrared (IR) spectra were recorded neat using a FTIR-8400s from Shimadzu. Signal 
intensities are described as strong (s), medium (m), weak (w) or broad (br). Melting points were 
determined on a Büchi M-565 and are not corrected. X-ray single crystal data were collected at 100Kon a 
Bruker X8 Prospector with Cu microsource and focusing optics, and Apex II detector. Data were integrated 
and corrected for absorption with SAINT V8.34A and SADABS 2012/1, and the structure was solved and 
refined with SHELX 2014 and shelXle. Hydrogen atoms were detected in the Fourier difference maps, those 
on C were refined with constraints on bond lengths and angles, those on N were refined freely. 
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3.5.2 Substrate synthesis 
 
o-iodoxybenzoic acid (IBX, S1):3 To a solution of Oxone® (74.3 g, 242 mmol, 6.0 equiv) in 
H2O (0.2 M) was added 2-iodobenzoic acid (10.0 g, 40.3 mmol, 1.0 equiv). The reaction 
mixture was stirred for 3 h at 70 °C and then cooled to rt. The solid was filtered off, washed 
with cold H2O (500 mL) and cold acetone (300 mL) and dried in vacuo (60 °C, 18 h). 
Compound S1 (7.17 g, 25.5 mmol, 63%) was obtained without the need of purification as an off-white solid. 
1H NMR (500 MHz, DMSO-d6): δ 8.15 (d, J = 8.0 Hz, 1H), 8.06 – 7.97 (m, 2H), 7.84 (t, J = 7.3 Hz, 1H) ppm. 13C 
NMR (126 MHz, DMSO-d6): δ 167.6 (C*), 146.6 (C*), 133.5 (CH), 133.1 (CH), 131.5 (C*), 130.1 (CH), 125.1 
(CH) ppm. IR (neat): vmax (cm-1) = 3097 (w), 1636 (m), 1560 (w), 1331 (m), 1294 (s), 1246 (m), 1138 (m), 
831 (m), 773 (m), 748 (s), 692 (s), 673 (s), 648 (m), 592 (s), 577 (s). 
 
imide S2a: To a solution of maleimide (7.28 g, 75.0 mmol, 1.0 equiv) in diethyl ether 
(0.68 M) was added cyclopentadiene (7.0 mL, 80.0 mmol, 1.06 equiv) dropwise. The reaction 
mixture was stirred for 2 h at rt. The product was filtered off and washed with diethyl ether. 
Compound S2a (12.0 g, 73.5 mmol, 98%) was obtained without the need of purification as 
an off-white solid. Rf = 0.30 (CH2Cl2:MeOH 100:1 v/v). m.p.: 184.4 – 188.6 °C. 1H NMR (500 MHz, CDCl3): δ 
8.47 (bs, 1H, NH), 6.17 (d, J = 2.0 Hz, 2H, CH=CH), 3.36 (s, 2H, C(O)CHCHCH2), 3.31 – 3.22 (m, 2H, C(O)CH), 
1.72 (d, J = 8.8 Hz, 1H, CH2), 1.51 (d, J = 8.8 Hz, 1H, CH2) ppm. 13C NMR (126 MHz, CDCl3): δ 178.5 (C*), 134.7 
(CH), 52.4 (CH2), 47.4 (CH), 45.0 (CH) ppm. IR (neat): vmax (cm-1) = 3159 (m), 2991 (m), 1753.17 (m), 1697 
(s), 1352 (m), 1294 (m), 1186 (s), 1120 (s), 991 (m), 839 (s), 829 (s), 729 (s), 660 (s), 604 (s). HRMS (ESI): 
m/z calulated for C9H10NO2 [M+H]+:164.0706, found: 164.0711. 
 
imide S2b: To a solution of palladium on carbon 10% (15 mg, 0.04 mol%) in CH2Cl2 
(0.1 mL) and methanol (27 mL) was added imide S2a (6.56 g, 4.0 mmol). The reaction 
mixture was stirred for 63 h at rt under H2 atmosphere (1 atm.). The reaction mixture was 
filtered over Celite®, washed with methanol and concentrated in vacuo. Compound S2b 
(5.86 g, 36.3 mmol, 90%) was obtained without the need of purification as an off-white solid. Rf = 0.21 
(CH2Cl2:MeOH 100:1 v/v). m.p.: 175 – 177 °C. 1H NMR (500 MHz, CDCl3): δ 9.01 (bs, 1H, NH), 3.10 (s, 2H, 
C(O)CH), 2.72 (s, 2H, C(O)CHCHCH2), 1.76 – 1.48 (m, 4H, CH2CHCH2CH2), 1.46 – 1.25 (m, 2H, CH2CH2) ppm. 
13C NMR (126 MHz, CDCl3): δ 179.6 (C*), 50.3 (CH), 42.2 (CH2), 39.3 (CH), 24.8 (CH2) ppm. IR (neat): vmax 
(cm-1) = 3173 (w), 1695 (s), 1350 (m), 1177 (s), 995 (m), 822 (m), 588 (s), 459 (s). HRMS (ESI): m/z 
calulated for C9H11NNaO2 [M+Na]+:188.0682, found: 188.0689. 
 
imide S2c: To a solution of maleimide (1.46 g, 15 mmol, 1.0 equiv) in H2O (1.07 M) was 
added furan (1.34 mL, 18 mmol, 1.2 equiv) dropwise. The reaction mixture was stirred for 1 
h at 90 °C under microwave irradiation and then cooled to rt. The product was filtered off 
and washed with H2O (100 mL) and diethyl ether (20 mL). Compound S2c (1.38 g, 
N
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0.84 mmol, 54%) was obtained without the need of purification as an off-white solid. Rf = 0.23 
(CH2Cl2:MeOH 100:1 v/v). m.p.: 168.6 - 171.3 °C. 1H NMR (500 MHz, CDCl3): δ 8.15 (bs, 1H, NH), 6.52 (s, 2H, 
CH=CH), 5.32 (s, 2H, OCH), 2.89 (s, 2H, C(O)CH) ppm. 13C NMR (126 MHz, CDCl3): δ 176.1 (C*), 136.7 (CH), 
81.1 (CH), 48.9 (CH) ppm. IR (neat): vmax (cm-1) = 3148 (w), 1772 (m), 1701 (s), 1352 (m), 1287 (m), 1204 
(m), 1186 (s), 897 (m), 820 (s), 733 (s), 633 (s), 582 (s). HRMS (ESI): m/z calulated for C8H7NNaO3 [M+Na]+: 
188.0318, found: 188.0320. 
 
imide S2d: To a solution of palladium on carbon 10% (0.10 g, 0.04 mol%) in CH2Cl2 
(0.1 mL) and methanol (100 mL) was added imide S2c (10.19 g, 62.0 mmol). The reaction 
mixture was stirred for 48 h at rt under H2 atmosphere (1 atm.). The reaction mixture was 
filtered over Celite®, washed with methanol and concentrated in vacuo. Compound S2d 
(9.9 g, 59.0 mmol, 96%) was obtained without the need of purification as an off-white solid. Rf = 0.21 
(CH2Cl2:MeOH 100:1 v/v). m.p.: 184 - 186 °C. 1H NMR (500 MHz, CDCl3): δ 8.76 (bs, 1H, NH), 4.94 – 4.86 (m, 
2H, OCH), 2.91 (s, 2H, NC(O)CH), 1.90 – 1.83 (m, 2H, CH2CH2), 1.62 – 1.54 (m, 2H, CH2CH2) ppm. 13C NMR 
(126 MHz, CDCl3): δ 177.8 (C*), 79.2 (CH), 51.4 (CH), 28.6 (CH) ppm. IR (neat): vmax (cm-1) = 3004 (w), 1672 
(s), 1306 (m), 1182 (s), 899 (m), 839 (m), 815 (s), 559 (m), 455 (s).  
 
imide S2f:25 To a solution of Mn(ClO4)2∙6 H2O (15 mg, 0.3 mol%) in acetone (100 mL) was 
added picolic acid (44 mg, 1.8 mol%) and maleimide (1.94 g, 20.0 mmol, 1.0 equiv). The 
reaction mixture was cooled to 0 °C and an aq. sodiumacetate solution (1.0 mL, 0.6 M) and 
hydrogen peroxide (2.58 mL, 30.0 mmol, 1.5 equiv) were added. The solution was stirred for 
29 h at rt, after which it was quenched with solid sodium thiosulfate. The suspension was filtered, washed 
with acetone, dried (Na2SO4) and concentrated in vacuo. The resulting oil was diluted in acetone (100 mL) 
and 2,2-dimethoxypropane (9.2 mL, 74.9 mmol, 4.0 equiv) and p-toluenesulfonic acid monohydrate 
(356 mg, 1.9 mmol, 0.1 equiv) were added. The solution was stirred 144 h at rt (until conversion was 
complete according to TLC). The reaction was quenched with sat. aq. NaHCO3 (20 mL), extracted with 
CH2Cl2 (3 x 20 mL), dried (Na2SO4) and concentrated in vacuo. The crude product was purified by flash 
chromatography (SiO2) with an eluent gradient (10:1 → 1:1 v/v cHex:EtOAc) to obtain compound S2f 
(740 mg, 4.30 mmol, 22%) as a colourless oil. Rf = 0.31 (cHex:EtOAc 1:1 v/v). m.p.: 143.4 – 146.4 °C. 1H 
NMR (500 MHz, CDCl3): δ 8.13 (bs, 1H, NH), 4.88 (s, 2H, CH), 1.51 (s, 3H, CH3), 1.44 (s, 3H, CH3) ppm. 13C 
NMR (126 MHz, CDCl3): δ 172.2 (C*), 116.5 (C*), 76.1 (CH), 26.8 (CH3), 25.7 (CH3) ppm. IR (neat): vmax (cm-1) 
= 3205 (m), 3094 (w), 1717 (s), 1375 (m), 1354 (m), 1192 (s), 1153 (m), 1097 (s), 987 (m), 849 (m), 756 
(s), 712(m), 633 (w), 575 (s).  
 
pyrrolidine 1a: To a solution of LiAlH4 (3.5 g, 92.0 mmol, 1.5 equiv) in THF (500 mL, anh.) 
was slowly added imide S2a (10.0 g, 61.0 mmol, 1.0 equiv) under N2 atmosphere at 0 °C. The 
reaction mixture was stirred for 18 h at 45 °C, after which the reaction was quenched with 
H2O (5 mL) to remove the excess of LiAlH4. The suspension was filtered over Celite®, washed 
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with THF and concentrated in vacuo to give compound 1a (3.0 g, 22.0 mmol, 36%) as a yellow solid. 
Rf = 0.09 (CH2Cl2:MeOH:NEt3 100:1:0.5 v/v). m.p.: 100.5 – 109.4 °C. 1H NMR (500 MHz, CDCl3): δ 6.24 – 6.15 
(m, 2H, CH=CH), 2.84 – 2.78 (m, 2H, NHCH2CHCHCH2), 2.76 – 2.64 (m, 3H, NHCH2CH), 2.57 (d, J = 12.2 Hz, 
2H, NHCH2), 1.78 (bs, 1H, NH), 1.47 – 1.36 (m, 2H, CHCH2CH) ppm. 13C NMR (126 MHz, CDCl3): δ 135.8 (CH), 
53.1 (CH2), 50.1 (CH2), 48.2 (CH), 46.5 (CH) ppm. IR (neat): vmax (cm-1) = 3051 (w), 2957 (m), 2930 (s), 1344 
(m), 1250 (m), 1092 (m), 895 (m), 870 (m), 800 (s), 743 (s), 689 (m). HRMS (ESI): m/z calculated for 
C9H14N [M+H]+: 136.1121, found: 136.1126. 
 
 pyrrolidine 1b: To a solution of LiAlH4 (2.0 g, 54.0 mmol, 1.5 equiv) in THF (300 mL, anh.) 
was slowly added imide S2b (5.8 g, 36.0 mmol, 1.0 equiv) under N2 atmosphere at 0 °C. The 
reaction mixture was stirred for 18 h at 70 °C, after which the reaction was quenched with 
H2O (4 mL) to remove the excess of LiAlH4. The suspension was filtered over Celite®, washed 
with THF and concentrated in vacuo to give compound 1b (3.6 g, 26.0 mmol, 72%) as a yellow solid. 
Rf = 0.66 (CH2Cl2:MeOH:NEt3 100:1:0.5 v/v). m.p.: 96.8 – 103.3 °C. 1H NMR (500 MHz, CDCl3): δ 2.91 (d, J = 
12.0 Hz, 2H, NHCH2), 2.64 – 2.55 (m, 2H, NHCH2), 2.41 – 2.35 (m, 2H, NHCH2CH), 2.13 (s, 2H, 
NHCH2CHCHCH2), 1.88 (bs, 1H, NH), 1.54 – 1.26 (m, 6H, CH2CHCH2CH2) ppm. 13C NMR (126 MHz, CDCl3): δ 
48.3 (CH2), 45.8 (CH), 43.0 (CH2), 41.1 (CH), 23.3 (CH2) ppm. IR (neat): vmax (cm-1) = 2937 (s), 2864 (m), 
1290 (m), 1250 (m), 1221 (w), 1184 (w), 1111 (m), 1005 (m), 961 (w), 910 (m), 843 (s), 797 (m), 598 (s). 
HRMS (ESI): m/z calculated for C9H16N [M+H]+: 138.1277, found: 138.1291. 
 
 pyrrolidine 1c: To a solution of LiAlH4 (1.7 g, 45.0 mmol, 1.5 equiv) in THF (250 mL, anh.) 
was slowly added imide S2c (5.0 g, 30.0 mmol, 1.0 equiv) under N2 atmosphere at 0 °C. The 
reaction mixture was stirred for 18 h at 40 °C, after which the reaction was quenched with 
H2O (4 mL) to remove the excess of LiAlH4. The suspension was filtered over Celite®, washed 
with THF and concentrated in vacuo to give compound 1c (3.1 g, 20.0 mmol, 65%) as a red oil. Rf = 0.07 
(CH2Cl2:MeOH:NEt3 100:1:0.5 v/v). 1H NMR (500 MHz, CDCl3): δ 6.36 (s, 2H, CH=CH), 4.70 (s, 2H, OCH), 2.92 
– 2.83 (m, 4H, CH2), 2.45 (bs, 1H, NH), 2.30 – 2.22 (m, 2H, CH2CH) ppm. 13C NMR (126 MHz, CDCl3): δ 137.1 
(CH), 83.9 (CH), 51.6 (CH2), 46.8 (CH) ppm. IR (neat): vmax (cm-1) = 3258 (w), 2991 (w), 2926 (w), 1308 (w), 
1067 (w), 949 (m), 891 (s), 964 (s), 843 (s), 810 (s), 712 (s), 692 (s), 590 (s). HRMS (ESI): m/z calculated 
for C8H12NO [M+H]+: 138.0913, found: 138.0920. 
 
 pyrrolidine 1d: To a solution of LiAlH4 (3.4 g, 86.0 mmol, 1.5 equiv) in THF (500 mL, anh.) 
was slowly added imide S2d (9.6 g, 58.0 mmol, 1.0 equiv) under N2 atmosphere at 0 °C. The 
reaction mixture was stirred for 19 h at 45 °C, after which the reaction was quenched with 
H2O (5 mL) to remove the excess of LiAlH4. The suspension was filtered over Celite®, washed 
with THF and concentrated in vacuo to give compound 1d (6.0 g, 43.0 mmol, 75%) as a yellow oil. Rf = 0.07 
(CH2Cl2:MeOH:NEt3 100:1:0.5 v/v). 1H NMR (400 MHz, CDCl3): δ 4.30 – 4.23 (m, 2H, OCH), 2.92 (dd, J = 
11.3 Hz, 6.4 Hz, 2H, NCH2), 2.69 (dd, J = 11.3, 2.4 Hz, 2H, NCH2), 2.40 (bs, 1H, NH), 2.24 – 2.20 (m, 2H, 
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NCH2CH), 1.64 – 1.56 (m, 2H, CH2CH2), 1.42 – 1.35 (m, 2H, CH2CH2) ppm. 13C NMR (126 MHz, CDCl3): δ 81.3 
(CH), 53.3 (CH2), 49.9 (CH), 28.9 (CH2) ppm. IR (neat): vmax (cm-1) = 3173 (m), 2945 (s), 2909 (m), 2853 (s), 
1221 (m), 1182 (s), 1082 (s), 1024 (s), 1005 (s), 989 (s), 959 (s), 912 (s), 901 (s), 795 (s), 629 (s), 584 (s). 
HRMS (ESI): m/z calculated for C8H14NO [M+H]+:140.1070, found: 140.1069. 
 
 pyrrolidine 1f: To a solution of LiAlH4 (230 mg, 6.1 mmol, 1.5 equiv) in THF (35 mL, anh.) was 
slowly added imide S2f (700 mg, 4.1 mmol, 1.0 equiv) under N2 atmosphere at 0 °C. The reaction 
mixture was stirred for 18 h at 55 °C, after which the reaction was quenched with H2O (2 mL) to 
remove the excess of LiAlH4. The suspension was filtered over Celite®, washed with THF and 
concentrated in vacuo to give compound 1f (444 mg, 3.1 mmol, 51%) as a colourless oil. Rf = 0.16 
(CH2Cl2:MeOH:NEt3 100:1:0.5 v/v). 1H NMR (500 MHz, CDCl3): δ 4.65 (s, 2H, NHCH2CH), 3.11 (d, J = 14.0 Hz, 
2H NHCH2), 2.51 (d, J = 13.3 Hz, 2H, NHCH2), 1.75 (bs, 1H, NH), 1.45 (s, 3H, CH3), 1.31 (s, 3H, CH3) ppm. 13C 
NMR (126 MHz, CDCl3): δ 110.3 (C*), 81.7 (CH), 54.4 (CH2), 26.1 (CH3), 23.9 (CH3) ppm. IR (neat): vmax (cm-1) 
= 2980 (m), 2928 (s), 1373 (m), 1207 (s), 1150 (m), 1080 (m), 1034 (s), 897 (m), 851 (s), 822 (m), 625 (m). 
HRMS (ESI): m/z calculated for C7H14NO2 [M+H]+: 144.1019, found: 144.1025. 
 
3.5.3 Synthetic procedures and spectral data 
General procedure for optimization of the reaction conditions for the oxidation of meso-pyrrolidine 
1a with IBX in Table 1: To a solution of pyrrolidine 1a (0.25 mmol, 1.0 equiv) in CH2Cl2 (0.2 M) was added 
IBX (70 mg, 0.25 mmol, 1.0 equiv). The reaction mixture was stirred for 0.5 - 1 h at rt or 60 °C (oil bath, 
closed vessel). The reaction mixture was cooled to rt, quenched with sat. aq. Na2S2O4 (1 mL), washed with 
sat. aq. Na2CO3/brine (3:1, 10 mL), extracted with CH2Cl2 (2 x 10 mL), dried (Na2SO4) and concentrated in 
vacuo. Subsequently, the yield of 2a was determined with 1H-NMR spectroscopy after dissolving the crude 
product in CDCl3 and adding 2,5-dimethylfuran (0.125 mmol, 0.5 equiv) as standard for NMR spectroscopy. 
 
General procedure for optimization of the reaction conditions for the oxidative Ugi-type reaction in 
Table 3: To a solution of pyrrolidine 1a (0.25 mmol, 1.0 equiv) in CH2Cl2 (0.5 m) were added IBX (70 mg, 
0.25 mmol, 1.0 equiv), benzoic acid (0.375 mmol, 1.5 equiv) and tert-butyl isocyanide (0.375 mmol, 1.5 
equiv). The reaction mixture was stirred for 24 h at rt or 60 °C (oil bath, closed vessel). The suspension was 
cooled to rt, quenched with sat. aq. Na2S2O4 (1 mL), washed with sat. aq. Na2CO3/brine (3:1, 10 mL), 
extracted with CH2Cl2 (2 x 10 mL), dried (Na2SO4) and concentrated in vacuo. Subsequently, the yield of 3a 
was determined with 1H-NMR spectroscopy after dissolving the crude product in CDCl3 and adding 2,5-
dimethylfuran (0.125 mmol, 0.5 equiv) as standard for NMR spectroscopy. 
 
General procedure 1 for the oxidation of meso-pyrrolidines 1: To a solution of the pyrrolidine 
(0.5 mmol, 1.0 equiv) in CH2Cl2 (0.2 M) was added IBX (140 mg, 0.5 mmol, 1.0 equiv). The reaction mixture 
was stirred for 1 h at 60 °C (oil bath) in a closed vessel. The reaction was cooled to rt, quenched with sat. aq. 
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Na2S2O4 (2 mL), washed with sat. aq. Na2CO3/brine (3:1, 20 mL), extracted with CH2Cl2 (2 x 20 mL), dried 
(Na2SO4) and concentrated in vacuo. If necessary, the crude product was purified by flash chromatography. 
 
General procedure 2 for oxidative Ugi-type three-component reactions: To a solution of the 
pyrrolidine (0.5 mmol, 1.0 equiv) in CH2Cl2 (0.5 M) were added IBX (140 mg, 0.5 mmol, 1.0 equiv), the 
carboxylic acid (0.75 mmol, 1.5 equiv) and the isocyanide (0.75 mmol, 1.5 equiv). The reaction mixture was 
stirred for 48 h at 60 °C  (oil bath) in a closed vessel.  The suspension was cooled to rt, quenched with sat. 
aq. Na2S2O4 (2 mL), washed with sat. aq. Na2CO3/brine (3:1, 20 mL), extracted with CH2Cl2 (2 x 20 mL), 
dried (Na2SO4) and concentrated in vacuo. If necessary, the crude product was purified by flash 
chromatography or preparative thin layer chromatography. Two sets of resonances were observed in all 1H 
and 13C spectra, corresponding to different rotamers. Incomplete coalencence was observed at 100 °C for 
3b, as depicted in Figure 2. 
 
Figure 2. High temperature NMR spectra of 3b in DMSO-d6, showing incomplete coalescence at 100 °C. 
 
General procedure 3 for oxidative aza-Friedel‒Crafts reaction: To a solution of the pyrrolidine 
(0.25 mmol, 1.0 equiv) in CH2Cl2 (0.25 M) were added IBX (70 mg, 0.25 mmol, 1.0 equiv). The reaction 
mixture was stirred for 1 h at 60 °C (oil bath) in a closed vessel. The suspension was cooled to rt and 
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trifluoroacetic acid (38 µL, 0.5 mmol, 2.0 equiv) and the pyrrole or indole (0.5 mmol, 2.0 equiv) were added. 
The reaction mixture was stirred for 1 h at 60 °C (oil bath) in a closed vessel. The suspension was cooled to 
rt, quenched with sat. aq. Na2S2O4 (2 mL), washed with sat. aq. Na2CO3/brine (3:1, 20 mL), extracted with 
CH2Cl2 (2 x 20 mL), dried (Na2SO4) and concentrated in vacuo. If necessary, the crude product was purified 
by flash chromatography. 
 
1-pyrroline 2a: Prepared from pyrrolidine 1a (69 mg, 0.50 mmol, 1.0 equiv) according to 
general procedure 1. Purification was achieved by flash chromatography (SiO2) with an eluent 
gradient (1:1 → 1:2 v/v cHex:EtOAc, 100:1 → 50:1 v/v CH2Cl2:MeOH), to obtain compound 2a 
(59 mg, 0.44 mmol, 88%) as a light yellow solid. Rf = 0.24 (CH2Cl2:MeOH 100:1 v/v). m.p.: 81.0 – 85.0 °C. 1H 
NMR (500 MHz, CDCl3): δ 7.28 (s, 1H, N=CH), 6.11 – 5.94 (m, 2H, HC=CH), 3.72 – 3.62 (m, 1H, NCH2), 3.55 – 
3.41 (m, 1H, N=CHCH), 3.24 – 3.11 (m, 1H, NCH2), 3.03 (s, 1H, N=CHCHCHCH2), 2.92 (s, 1H, NCH2CHCHCH2), 
2.83 – 2.73 (m, 1H, NCH2CH), 1.52 (d, J = 8.1 Hz, 1H, CHCH2CH), 1.36 (d, J = 8.2 Hz, 1H, CHCH2CH) ppm. 13C 
NMR (126 MHz, CDCl3): δ 167.2 (CH), 135.5 (CH), 133.6 (CH), 62.9 (CH2), 60.3 (CH), 51.1 (CH2), 45.4 (CH), 
44.2 (CH), 41.0 (CH) ppm. IR (neat): vmax (cm-1) = 2958 (m), 2918 (m), 2798 (m), 1339 (s), 1207 (m), 1182 
(s), 1096 (m), 953 (m), 899 (m), 841 (m), 800 (m), 739 (s), 725 (s). HRMS (ESI): m/z calculated for C9H12N 
[M+H]+: 134.0964, found: 110.0966. 
 
1-pyrroline 2b: Prepared from pyrrolidine 1b (73 mg, 0.50 mmol, 1.0 equiv) according to 
general procedure 1. Purification was achieved by flash chromatography (SiO2) with an eluent 
gradient (1:1 v/v cHex:EtOAc, 100:1 v/v CH2Cl2:MeOH), to obtain compound 2b (65 mg, 
0.48 mmol, 97%) as a light yellow solid. Rf = 0.24 (CH2Cl2:MeOH 100:1 v/v). m.p.: 81.0 – 88.1 °C. 1H NMR 
(500 MHz, CDCl3): δ 7.41 (s, 1H, N=CH), 3.84 – 3.77 (m, 1H, NCH2), 3.70 – 3.61 (m, 1H, NCH2), 3.23 – 3.13 (m, 
1H, N=CHCH), 2.64 – 2.53 (m, 1H, NCH2CH), 2.50 (s, 1H, N=CHCHCHCH2), 2.16 (s, 1H, NCH2CHCHCH2), 1.52 
(d, J = 9.4 Hz, 1H, CHCH2CH), 1.43 (d, J = 9.0 Hz, 1H, CHCH2CH), 1.31 (d, J = 6.3 Hz, 2H, CH2CH2), 1.19 (d, J = 
7.4 Hz, 2H, CH2CH2) ppm. 13C-NMR (126 MHz, CDCl3): δ 169.2 (CH), 60.9 (CH2), 58.3 (CH), 42.6 (CH), 42.1 
(CH2), 40.0 (CH), 38.5 (CH), 26.0 (CH2), 22.1 (CH2) ppm. IR (neat): vmax (cm-1) = 2945 (s), 2860 (m), 1670 
(w), 1381 (w), 1298 (m), 1225 (m), 1177 (m), 1161 (m), 1119 (s), 1092 (s), 1018 (w), 995 (w), 889 (m), 
822 (w), 656 (w). HRMS (ESI): m/z calculated for C9H14N [M+H]+: 136.1121, found: 136.1125. 
 
1-pyrroline 2c: Prepared from pyrrolidine 1c (79 mg, 0.50 mmol, 1.0 equiv) according to 
general procedure 1. Purification was achieved by flash chromatography (SiO2) with an eluent 
gradient (1:1 v/v cHex:EtOAc, 100:1 → 10:1 v/v CH2Cl2:MeOH), to obtain compound 2c (66 
mg [3% cHex], 0.47 mmol, 95%)  as a reddish brown solid. Rf = 0.18 (CH2Cl2:MeOH 100:1 v/v). m.p.: 100.0 –
 109.2 °C. 1H NMR (500 MHz, CDCl3): δ 7.49 – 7.36 (m, 1H, N=CH), 6.46 – 6.29 (m, 2H, CH=CH), 4.95 (s, 1H, 
NCH2CHCHO), 4.75 (s, 1H, N=CHCHCHO), 4.04 – 3.86 (m, 1H, NCH2), 3.72 – 3.59 (m, 1H, NCH2), 3.10 (dd, J = 
7.1 Hz, J = 2.9 Hz, 1H, N=CHCH), 2.57 – 2.44 (m, 1H, NCH2CH) ppm. 13C NMR (126 MHz, CDCl3): δ 164.1 (CH), 
137.5 (CH), 136.2 (CH), 84.2 (CH), 79.7 (CH), 63.6 (CH2), 59.7 (CH), 42.3 (CH) ppm. IR (neat): vmax (cm-1) = 
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2978 (m), 1458 (w), 1342 (m), 1229 (m), 1190 (m), 1157 (s), 1032 (s), 997 (m), 949 (s), 897 (s), 866 (m), 
810 (s), 723 (s), 692 (s), 681 (s), 625 (s).  HRMS (ESI): m/z calculated for C8H10NO [M+H]+: 136.0757, found: 
136.0758. 
 
1-pyrroline 2d: Prepared from pyrrolidine 1d (72 mg, 0.50 mmol, 1.0 equiv) according to 
general procedure 1. Purification was achieved by flash chromatography (SiO2) with an eluent 
gradient (1:1 cHex:EtOAc, 100:1 → 20:1 v/v CH2Cl2:MeOH), to obtain compound 2d (60 mg 
[17% CH2Cl2], 0.36 mmol, 71%) as a light yellow solid. Rf = 0.18 (CH2Cl2:MeOH 100:1 v/v).m.p.: 150.6 –
 157.2 °C. 1H NMR (500 MHz, CDCl3): δ 7.35 (d, J = 3.3 Hz, 1H, N=CH), 4.51 (d, J = 4.7 Hz, 1H, NCH2CHCHO), 
4.34 (d, J = 4.7 Hz, 1H, N=CHCHCHO), 4.10 – 4.00 (m, 1H, NCH2), 3.74 – 3.65 (m, 1H, NCH2), 3.03 (dd, J = 
7.8 Hz, J = 2.9 Hz, 1H, N=CHCH), 2.42 – 2.34 (m, 1H, NCH2CH), 1.79 – 1.64 (m, 2H, CH2CH2), 1.58 – 1.43 (m, 
2H, CH2CH2) ppm. 13C NMR (126 MHz, CDCl3): δ 165.1 (CH), 82.6 (CH), 77.4 (CH), 67.9 (CH2), 61.1 (CH), 44.1 
(CH), 29.3 (CH2), 28.7 (CH2) ppm. IR (neat): vmax (cm-1) = 2949 (m), 1655 (w), 1393 (m), 1315 (m), 1225 (s), 
1215 (s), 1175 (s), 1047 (m), 972 (s), 924 (s), 805 (s), 623 (s). HRMS (ESI): m/z calculated for C8H12NO 
[M+H]+: 138.0913, found: 138.0916.  
 
1-pyrroline 2e:26 Prepared from pyrrolidine 1e (56 mg, 0.50 mmol, 1.0 equiv) according to general 
procedure 1. Compound 2e (38 mg, 0.35 mmol, 70%) was obtained without the need of purification 
as a light yellow solid. Rf = 0.38 (CH2Cl2:MeOH 100:1 v/v). m.p.: 99.8 – 111.7 °C. 1H NMR (500 MHz, 
CDCl3): δ 7.32 – 7.28 (m, 1H, NHCH), 4.11 – 3.98 (m, 1H, NHCH2), 3.57 – 3.46 (m, 1H, NHCH2), 3.27 (t, J = 8.9 
Hz, 1H, NHCHCH), 2.72 – 2.57 (m, 1H, NHCH2CH), 1.73 – 1.19 (m, 6H, CH2CH2CH2) ppm. 13C NMR (126 MHz, 
CDCl3): δ 169.6 (CH), 70.3 (CH2), 55.2 (CH), 38.7 (CH), 34.8 (CH2), 29.4 (CH2), 25.0 (CH2) ppm. IR (neat): vmax 
(cm-1) = 2931 (s), 2901 (m), 1466 (m), 1306 (m), 1204 (s), 1182 (s), 1157 (m), 1134 (s), 1070 (m), 932 (s),. 
HRMS (ESI): m/z calculated for C7H12N [M+H]+: 110.0964, found: 110.0973. 
 
 
α-hydroxypyrrolidine 2f:15 To a solution of pyrrolidine 1f (0.25 mmol, 1.0 equiv) in CH2Cl2 
(0.2 M) was added IBX (70 mg, 0.25 mmol, 1.0 equiv). The reaction mixture was stirred for 1 h 
at 60 °C in an oil bath. The reaction was cooled to rt, quenched with sat. aq. Na2S2O4 (1 mL), 
washed with sat. aq. Na2CO3/brine (3:1, 10 mL), extracted with CH2Cl2 (2 x 10 mL), dried 
(Na2SO4) and concentrated in vacuo. Compound 2f was obtained in 48% yield, as determined with 1H-NMR 
spectroscopy after dissolving the crude product in CDCl3 and adding 2,5-dimethylfuran (0.125 mmol, 0.5 
equiv) as standard for NMR spectroscopy. 1H NMR (500 MHz, CDCl3) δ 4.72 – 4.66 (m, 1H, NHCH2CH), 4.37 
(dd, J = 7.1, 3.9 Hz, 1H, NHCHOCH), 3.33 (dd, J = 9.9, 6.1 Hz, 1H, NHCH2), 3.26 (d, J = 4.1 Hz, 1H, NHCHO), 2.59 
(dd, J = 9.8, 3.5 Hz, 1H, NHCH2), 1.51 (s, 1H, CH3), 1.32 (s, 1H, CH3) ppm.13C NMR (126 MHz, CDCl3) δ 113.6 
(C*), 85.4 (CH), 80.8 (CH), 77.4 (CH), 52.5 (CH2), 27.0 (CH3), 25.2 (CH3). 
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prolyl peptide 3a: Prepared from pyrrolidine 1a (69 mg, 0.50 mmol, 1.0 equiv), 
benzoic acid (92 mg, 0.75 mmol, 1.5 equiv) and t-butyl isocyanide (87 µL, 
0.75 mmol, 1.5 equiv) according to general procedure 2. Purification was achieved 
by flash chromatography (SiO2) with an eluent gradient (4:1 → 2:1 v/v 
cHex:EtOAc), to obtain compound 3a (99 mg, 0.29 mmol, 59%) as an off-white 
solid. Rf = 0.48 (cHex:EtOAc 1:1 v/v). m.p.: 191.0 – 193.7 °C (decomposition).1H NMR (500 MHz, CDCl3): δ 
7.45 – 7.32 (m, 5H, Ph), 6.64 (s, 1H, NH), 6.20 (dd, J = 5.7 Hz, J = 3.0 Hz, 1 H, NCH2CHCHCH=CH), 5.91  (dd, J = 
5.7 Hz, J = 3.0 Hz, 1H, C(O)CHCHCHCH=CH), 4.43 (s, 1H, C(O)CH), 3.55 (dd, J = 11.7 Hz, J = 8.6 Hz, 1H, NCH2), 
3.45 – 3.38 (m, 1H, C(O)CHCH), 3.08 – 2.98 (m, 2H, NCH2CHCHCH2CH), 2.93 – 2.84 (m, 1H, NCH2CHCHCH2), 
2.82 – 2.74  (m, 1H, NCH2CH), 1.49 – 1.36 (m, 2H, CHCH2CH), 1.32 (s, 9H C(CH3)3) ppm. 13C NMR (126 MHz, 
CDCl3): δ 170.3 (C*), 169.7 (C*), 136.7 (C*), 134.9 (CH), 134.4 (CH), 130.1 (CH), 128.5 (CH), 126.6 (CH), 63.0 
(CH), 52.1 (CH2), 51.7 (CH2), 47.1 (CH), 46.6 (CH), 45.6 (CH), 45.0 (CH), 28.8 (CH3) ppm. IR (neat): vmax (cm-1) 
= 3300 (w), 2935 (w), 1670 (m), 1599 (s), 1566 (s), 1535 (s), 1410 (s), 1389 (m), 1317 (m), 1223 (m), 1205 
(m), 731 (m), 716 (s), 621 (m). HRMS (ESI): m/z calculated for C21H27N2O2 [M+H]+: 339.2067, found: 
339.2056. 
 
prolyl peptide 3b: Prepared from pyrrolidine 1a (69 mg, 0.50 mmol, 1.0 
equiv), 4-nitrobenzoic acid (125 mg, 0.75 mmol, 1.5 equiv) and t-butyl 
isocyanide (87 µL, 0.75 mmol, 1.5 equiv) according to general procedure 2. 
Purification was achieved by flash chromatography (SiO2) with an eluent 
gradient (4:1 → 2:1 v/v cHex:EtOAc), to obtain compound 3b (114 mg [12% 
CH2Cl2], 0.26 mmol, 52%) as an off-white solid. Rf = 0.40 (cHex:EtOAc 1:1 
v/v). m.p.: >150 °C decomposition. 1H NMR (500 MHz, CDCl3): δ 8.27 (d, J = 8.3 Hz, 2H, C(NO2)CH), 7.59 – 
7.51 (m, 2H, C(NO2)CHCH), 6.40 (s, 1H, NH), 6.22 (dd, J = 5.7 Hz, J = 3.0 Hz, 1H, CH=CH), 5.93 (dd, J = 5.8 Hz, J 
= 3.0 Hz, 1H, CH=CH), 4.37 (d, J = 2.0 Hz, 1H, NCH), 3.60 (dd, J = 11.7 Hz, J = 8.9 Hz, 1H, NCH2), 3.43 –3.31 (m, 
1H, NCH2), 3.04 (s, 1H, CH), 2.97 – 2.89 (m, 2H, CH), 2.81 (s, 1H, CH), 1.51 (d, J = 8.6 Hz, 1H, CHCH2CH), 1.42 
(d, J = 8.6 Hz, 1H, CHCH2CH), 1.34 (s, 9H, C(CH3)3) ppm. 13C NMR (126 MHz, CDCl3): δ 169.9 (C*), 167.4 (C*), 
148.7 (C*), 142.6 (C*), 135.1 (CH), 134.5 (CH), 127.8 (CH), 124.0 (CH), 63.5 (CH), 52.2 (CH2), 51.8 (CH2), 
51.4 (C*), 47.0 (CH), 46.7 (CH), 45.7 (CH), 28.9 (CH3) ppm. IR (neat): vmax (cm-1) = 3308 (m), 2976 (m), 2932 
(m), 1599 (m), 1520 (s), 1437 (m), 1340 (s), 1313 (m), 1227 (m), 1209 (m), 1016 (w), 854 (m), 831 (m), 
602 (m). HRMS (ESI): m/z calculated for C21H26N3O4 [M+H]+: 384.1918, found: 384.1908. 
 
prolyl peptide 3c: Prepared from pyrrolidine 1a (69 mg, 0.50 mmol, 1.0 
equiv), 2-(4-methoxyphenyl)acetic acid (126 mg, 0.75 mmol, 1.5 equiv) and 
t-butyl isocyanide (87 µL, 0.75 mmol, 1.5 equiv) according to general 
procedure 2. Purification was achieved by flash chromatography (SiO2) with 
an eluent gradient (10:1 → 1:1 v/v cHex:EtOAc), to obtain compound 3c (103 mg, 0.28 mmol, 56%) as an 
off-white solid. Rf = 0.34 (cHex:EtOAc 1:1 v/v). m.p.: 133.7 – 140.9 °C (decomposition). 1H NMR (500 MHz, 
N
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H
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CDCl3): δ 7.12 (d, J = 9.0 Hz, 2H, C(OMe)CHCH), 6.84 (d, J = 8.0 Hz, 2H, C(OMe)CH), 6.10 – 6.03 (m, 1H, 
CH=CH), 5.74 – 5.63 (m, 1H, CH=CH), 4.14 (s, 1H, NCH), 3.78 (s, 3H, H3CO), 3.52 – 3.45 (m, 2H, C*CH2), 3.36 – 
3.22 (m, 2H, NCH2, CH), 3.24 – 3.15 (m, 1H, NCH2), 2.94 (s, 1H, CH), 2.91 – 2.87 (m, 1H, CH), 2.83 (s, 1H, CH), 
1.66 (s, 1H, NH), 1.39 – 1.34 (m, 1H, CHCH2CH), 1.31 – 1.25 (m, 10H, C(CH3)3, CHCH2CH) ppm. 13C NMR (126 
MHz, CDCl3): δ 170.5 (C*), 170.0 (C*), 158.7 (C*), 135.2 (CH), 134.5 (CH), 129.9 (CH), 126.3 (C*), 114.2 (CH), 
63.2 (CH), 55.4 (CH3), 51.7 (CH2), 51.1 (C*), 50.0 (CH2), 47.1 (CH), 46.6 (CH), 45.8 (CH), 45.2 (CH), 41.8 
(CH2), 28.8 (CH3) ppm. IR (neat): vmax (cm-1) = 3283 (w), 2934 (w), 1647 (s), 1626 (s), 1516 (m), 1389 (w), 
1290 (w), 1277 (w), 1250 (s), 1219 (m), 1024 (m), 856 (w), 820 (m), 735 (m). HRMS (ESI): m/z calculated 
for C23H31N2O3 [M+H]+: 383.2329, found: 383.2331. 
 
prolyl peptide 3d: Prepared from pyrrolidine 1b (73 mg, 0.50 mmol, 1.0 equiv), 
benzoic acid (92 mg, 0.75 mmol, 1.5 equiv) and 1,3-dimethylbenzene isocyanide 
(98 mg, 0.75 mmol, 1.5 equiv) according to general procedure 2. Purification was 
achieved by flash chromatography (SiO2) with an eluent gradient (100:1 → 5:1 
v/v cHex:EtOAc), to obtain compound 3d (118 mg, 0.30 mmol, 61%) as an off-
white solid. Rf = 0.64 (cHex:EtOAc 1:1 v/v). m.p.: 77.7 – 91.8 °C. 1H NMR (500 MHz, CDCl3): δ 8.09 (bs, 1H, 
NH), 7.59 – 7.37 (m, 5H, Ph), 7.12 – 7.01 (m, 3H, C(CH3)CHCHCH), 5.22 (s, 1H, NCH), 3.62 (dd, J = 11.9 Hz, J = 
8.4 Hz, 1H, NCH2), 3.49 (d, J = 12.0 Hz, 1H, NCH2), 3.30 – 3.17 (m, 1H, NCHCH), 2.78 – 2.66 (m, 1H, NCH2CH), 
2.42 (s, 1H, NCHCHCHCH2CH), 2.33 – 2.14 (m, 7H, CH3, CH3, NCH2CHCHCH2), 1.72 – 1.19 (m, 6H, 
CH2CHCH2CH2) ppm. 13C NMR (126 MHz, CDCl3): δ 169.57 (C*), 169.58 (C*), 136.1 (C*), 135.2 (C*), 133.9 
(C*), 130.5 (CH), 128.6 (CH), 128.3 (CH), 127.3 (CH), 126.8 (CH), 60.6 (CH), 50.3 (CH2), 44.4 (CH), 44.3 (CH), 
42.0 (CH2), 41.5 (CH), 41.0 (CH), 23.3 (CH2), 22.9 (CH2), 18.6 (CH3) ppm. IR (neat): vmax (cm-1) = 3263 (br), 
2953 (w), 1684 (s), 1609 (s), 1516 (s), 1447 (s), 1420 (s), 1398 (s), 1375 (s), 1296 (w), 1175 (m), 881 (m), 
766 (s), 721 (s), 698 (s). HRMS (ESI): m/z calculated for C25H29N2O2 [M+H]+: 389.2224, found: 389.2221. 
 
prolyl peptide 3e: Prepared from pyrrolidine 1b (73 mg, 0.50 mmol, 1.0 equiv), 
acetic acid (43 µL, 0.75 mmol, 1.5 equiv) and 1,3-dimethylbenzene isocyanide 
(98 mg, 0.75 mmol, 1.5 equiv) according to general procedure 2. Purification was 
achieved by preparative thin layer chromatography (SiO2, cHex:EtOAc 1:1 v/v), to 
obtain compound 3e (70 mg, 0.22 mmol, 43%) as an off-white solid. Two-step 
procedure: To a solution of pyrrolidine 1b (72 mg, 0.5 mmol, 1.0 equiv) in CH2Cl2 (0.2 M) were added IBX 
(140 mg, 0.5 mmol, 1.0 equiv). The reaction mixture was stirred for 1 h at 60 °C (oil bath) in a closed vessel. 
The suspension was cooled to rt and acetic acid (43 µL, 0.75 mmol, 1.5 equiv) and 1,3-dimethylbenzene 
isocyanide (98 mg, 0.75 mmol, 1 equiv) were added, after which stirring was proceeded for 23 h at 60 °C 
(oil bath) in a closed vessel. The suspension was cooled to rt, quenched with sat. aq. Na2S2O4 (2 mL), washed 
with sat. aq. Na2CO3/brine (3:1, 20 mL), extracted with CH2Cl2 (2 x 20 mL), dried (Na2SO4) and concentrated 
in vacuo. Purification was achieved by preparative thin layer chromatography (SiO2, cHex:EtOAc 1:1 v/v), to 
obtain compound 3e (88 mg, 0.27 mmol, 54%) as an off-white solid. Rf = 0.73 (cHex:EtOAc 1:1 v/v). m.p.: 
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171.6 – 179.5 °C. 1H NMR (500 MHz, CDCl3): δ 8.18 (bs, 1H, NH), 7.16 – 7.00 (m, 3H, Ar), 4.89 (s, 1H, NCH), 
3.62 (d, J = 11.5 Hz, 1H, NCH2), 3.47 (dd, J = 11.7 Hz, J = 8.3 Hz, 1H, NCH2), 3.18 (dd, J = 10.9 Hz, J = 4.9 Hz, 1H, 
NCHCH), 2.81 – 2.68 (m, 1H, NCH2CH), 2.44 – 2.34 (m, 1H, NCHCHCHCH2), 2.34 – 2.30 (m, 1H, 
NCH2CHCHCH2), 2.18 (d, J = 5.1 Hz, 6H, CH3), 1.60 – 1.58 (m, 1H, CHCH2CH), 1.54 – 1.49 (m, 1H, CHCH2CH), 
1.45 – 1.39 (m, 2H, CH2CH2), 1.35 – 1.27 (m, 2H, CH2CH2) ppm. 13C NMR (126 MHz, CDCl3): δ 169.8 (C*), 
169.6 (C*), 135.2 (C*), 134.0 (C*), 128.2 (CH), 127.1 (CH), 77.4 (CH), 60.2 (CH), 48.4 (CH2), 44.6 (CH), 43.8 
(CH), 42.0 (CH2), 41.5 (CH), 40.9 (CH), 23.3 (CH2), 22.9 (CH2), 22.6 (CH3), 18.5 (CH3) ppm. IR (neat): vmax (cm-
1) = 3309 (w), 1647 (s), 1506 (m), 1471 (m), 1406 (s), 1375 (m), 1192 (m), 1034 (w), 847 (w), 773 (m), 640 
(m). HRMS (ESI): m/z calculated for C20H26N2NaO2 [M+Na]+: 349.1886, found: 349.1879. 
 
prolyl peptide 3f: Prepared from pyrrolidine 1e  (56 mg, 0.50 mmol, 1.0 equiv), 
benzoic acid (92 mg, 0.75 mmol, 1.5 equiv) and cyclohexyl isocyanide (95 µL, 
0.75 mmol, 1.5 equiv) according to general procedure 2. Purification was 
achieved by flash chromatography (SiO2) with an eluent gradient (100:1 → 8:1 
v/v cHex:EtOAc), to obtain compound 3f (96 mg, 0.27 mmol, 54%) as a yellow 
oil. Rf = 0.45 (cHex:EtOAc 1:1 v/v). 1H NMR (500 MHz, CDCl3): δ 7.52 – 7.32 (m, 5H, Ph), 6.73 (d, J = 8.3 Hz, 
1H NH), 4.65 – 4.54 (m, 1H, CHC(O)), 3.85 – 3.67 (m, 2H, NCH2, NCHCH), 3.29 (d, J = 11.3 Hz, 1H, NCH2), 3.24 
– 3.13 (m, 1H, NCH2CH), 2.75 – 2.68 (m, 1H, C(O)NHCH), 2.02 – 1.51 (m, 10H, CH2),27 1.42 – 1.03 (m, 6H, 
CH2)27 ppm. 13C NMR (126 MHz, CDCl3): δ 170.6 (C*), 170.1 (C*), 136.3 (C*), 130.3 (CH), 128.6 (CH), 127.0 
(CH), 66.6 (CH), 56.0 (CH2), 48.3 (CH), 44.3 (CH), 43.4 (CH), 33.1 (CH2), 32.8 (CH2), 26.3 (CH2), 25.6 (CH2), 
24.7 (CH2) ppm. IR (neat): vmax (cm-1) = 3302 (br), 2928 (s), 1616 (s), 1541 (s), 1522 (m), 1418 (s), 1225 
(w), 891 (w), 725 (m), 698 (s). HRMS (ESI): m/z calculated for C21H29N2O2 [M+H]+: 341.2224, found: 
341.2207. 
 
prolyl peptide 3g: Prepared from pyrrolidine 1e  (56 mg, 0.50 mmol, 1.0 
equiv), benzoic acid (92 mg, 0.75 mmol, 1.5 equiv) and benzyl isocyanide 
(86 µL, 0.75 mmol, 1.5 equiv) according to general procedure 2. Purification 
was achieved by flash chromatography (SiO2) with an eluent gradient (100:1 → 
2:1 v/v cHex:EtOAc) and by preparative thin layer chromatography (SiO2, 
cHex:EtOAc 1:1 v/v), to obtain compound 3g (72 mg, 0.21 mmol, 41%) as a yellow oil. Rf = 0.35 (cHex:EtOAc 
1:1 v/v). 1H NMR (500 MHz, CDCl3): δ 7.46 – 7.09 (m, 10H, Ph),27 4.63 (s, 1H, CHC(O)), 4.47 – 4.31 (m, 2H, 
NHCH2),27 3.67 (dd, J = 11.3Hz, J = 7.4 Hz, 1H, NCH2), 3.26 (dd, J = 11.2 Hz, J = 2.8 Hz, 1H, NCH2), 3.22 – 3.12 
(m, 1H, NCHCH), 2.78 – 2.58 (m, 1H, NCH2CH), 1.97 – 1.16 (m, 6H, CH2CH2CH2)27 ppm. 13C NMR (126 MHz, 
CDCl3): δ 171.1 (C*), 170.7 (C*), 138.5 (C*), 136.1 (C*), 128.5 (CH), 128.4 (CH), 127.6 (CH), 127.4 (CH), 127.2 
(CH), 127.1 (CH), 66.5 (CH), 56.0 (CH2), 44.6 (CH), 43.6 (CH2), 43.5 (CH), 33.1 (CH2), 32.7 (CH2), 31.1 (CH2), 
26.3 (CH2), 25.7 (CH2) ppm. IR (neat): vmax (cm-1) = 3290 (br), 2945 (w), 1616 (s), 1541 (m), 1497 (m), 1447 
(m), 1418 (s), 1361 (w), 1228 (m), 721 (m), 696 (s), 677 (m), 663 (m). HRMS (ESI): m/z calculated for 
C22H25N2O2 [M+H]+: 349.1911, found: 349.1895. 
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 prolyl peptide 3h: Prepared from pyrrolidine 1f (72 mg, 
0.50 mmol, 1.0 equiv), cinnamic acid (109 mg, 0.75 mmol, 1.5 equiv) 
and 1-(isocyanomethyl)-3,5-dimethoxybenzyl (117 µL, 0.75 mmol, 
1.5 equiv) according to general procedure 2. Purification was 
achieved by flash chromatography (SiO2) with an eluent gradient 
(20:1 → 1:2 v/v cHex:EtOAc) and by preparative thin layer 
chromatography (SiO2, cHex:EtOAc 1:1 v/v), to obtain compound 3h (110 mg [3% CH2Cl2], 0.23 mmol, 45%) 
as a yellow solid. Rf = 0.34 (cHex:EtOAc 1:1 v/v). m.p.: 52.1 – 61.5 °C. 1H NMR (500 MHz, CDCl3): δ 7.71 (d, J 
= 15.4 Hz, 1H, C(O)CH=CH), 7.53 (dd, J = 6.5 Hz, J = 3.0 Hz, 2H, Ph), 7.43 – 7.35 (m, 3H, Ph), 7.12 (d, J = 8.0 Hz, 
1H, CH2C*CH), 6.72 (d, J = 15.5 Hz, 1H, C(O)CH=CH), 6.43 – 6.37 (m, 2H, CH2C*CHC(OMe)CH), 5.13 (d, J = 5.7 
Hz, 1H, NCH), 4.95 – 4.89 (m, 2H, CHO), 4.41 – 4.33 (m, 1H, NHCH2), 4.31 – 4.23 (m, 1H, NHCH2), 4.00 (d, J = 
11.9 Hz, 1H, NCH2), 3.81 (s, 3H, OCH3), 3.77 (s, 3H, OCH3), 3.72 – 3.66 (m, 1H, NCH2), 1.75 (bs, 1H, NH), 1.41 
(s, 3H, C*CH3), 1.32 (s, 3H, C*CH3) ppm. 13C NMR (126 MHz, CDCl3): δ 168.7 (C*), 165.8 (C*), 160.6 (C*), 
158.6 (C*), 143.7 (CH), 134.9 (C*), 130.2 (CH), 129.0 (CH), 128.1 (CH), 118.6 (C*), 117.2 (CH), 112.0 (C*), 
103.9 (CH), 98.6 (CH), 80.6 (CH), 79.8 (CH), 65.7 (CH), 55.5 (CH3), 53.2 (CH2), 39.1 (CH2), 26.9 (CH3), 24.9 
(CH3) ppm. IR (neat): vmax (cm-1) = 3294 (br), 2935 (w), 1647 (s), 1610 (m), 1578 (w), 1508 (s), 1418 (s), 
1373 (m), 1261 (m), 1205 (s), 1155 (s), (m), 1034 (m), 974 (m), 764 (m), 702 (m), 565 (w). HRMS (ESI): 
m/z calculated for C26H31N2O6 [M+H]+: 467.2177, found: 467.2167. 
 
prolyl peptide 3i (major) and prolyl peptide 3i’ 
(minor): Prepared from pyrrolidine 1c (40 mg [87% 
pure], 0.25 mmol, 1.0 equiv), benzoic acid (46 mg, 
0.38 mmol, 1.5 equiv) and t-butyl isocyanide (44 µL, 
0.38 mmol, 1.5 equiv) according to general procedure 2. 
Purification was achieved by preparative thin layer chromatography (SiO2, cHex:EtOAc 1:3, v/v), to obtain 
the compound 3i (32 mg, 0.09 mmol, 38%) as an off-white solid and the diastereoisomer 3i’ (16 mg, 
0.05 mmol, 19%) as an off-white solid in a 2:1 diastereoisomeric ratio. 3i: Rf = 0.14 (cHex:EtOAc 1:1 v/v). 
m.p.: 176.8 – 185.3 °C. 1H NMR (500 MHz, CDCl3): δ 7.49 – 7.38 (m, 5H, Ph), 6.93 (s, 1H, NH), 6.42 (dd, J = 
6.1 Hz, J = 1.9 Hz, 1H, NCH2CHCHCH=CH), 6.35 (dd, J = 1.5 Hz, J = 1.5 Hz, 1H, NCH2CHCHCH=CH), 4.95 – 4.84 
(m, 2H, NCH2CHCHO, NCH), 4.65 (s, 1H, NCHCHCHO), 3.73 (dd, J = 11.9 Hz, J = 8.3 Hz, 1H, NCH2), 3.52 (dd, J = 
12.0 Hz, J = 1.9 Hz, 1H, NCH2), 2.98 (d, J = 7.1 Hz, 1H, NCHCH), 2.42 (t, J = 7.8 Hz, 1H, NCH2CH), 1.35 (s, 9H, 
C(CH3)3) ppm. 13C NMR (126 MHz, CDCl3): δ 170.1 (C*), 169.8 (C*), 137.1 (CH), 136.6 (CH), 136.2 (CH), 
130.3 (CH), 128.6 (CH), 127.0 (C*), 84.0 (CH), 83.7 (CH), 64.1 (CH), 52.9 (CH2), 51.4 (C*), 44.7 (CH), 44.3 
(CH), 28.8 (CH3) ppm. IR (neat): vmax (cm-1) = 3292 (w), 2966 (w), 1676 (s), 1601 (s), 1570 (s), 1541 (s), 
1447 (m), 1425 (s), 1356 (m), 1281 (w), 1259 (w), 1223 (m), 1030 (w), 941 (w), 903 (s), 868 (w), 847 (w), 
719 (s), 692 (s), 665 (s), 619 (m). HRMS (ESI): m/z calculated for C20H25N2O3 [M+H]+: 341.1860, found: 
341.1849. 3i’: Rf = 0.10 (cHex:EtOAc 1:1 v/v). m.p.: 184.0 – 190.0 °C (decomposition). 1H NMR (500 MHz, 
DMSO-d6): δ 7.59 – 7.19 (m, 5H, Ph), 6.50 – 6.31 (m, 2H, HC=CH), 4.86 (s, 1H, CHO), 4.78 – 4.59 (m, 2H, NCH, 
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CHO), 3.53 (t, J = 9.7 Hz, 1H), 3.40 – 3.30 (m, 1H, NCH2),28 2.68 – 2.56 (m, 1H, NHCH2CH), 2.54 – 2.40 (m, 1H, 
NCHCH),27 1.30 (s, 9H, C(CH3)3,) ppm.27 13C NMR (126 MHz, DMSO-d6): δ 168.4 (C*), 168.0 (C*), 137.2 (CH), 
137.1 (C*), 136.7 (CH), 130.3 (CH), 128.7 (CH), 127.6 (CH), 79.4 (CH, CH), 60.5 (CH), 53.0 (CH2), 50.7 (C*), 
47.2 (CH), 45.4 (CH), 29.1 (CH3) ppm. IR (neat): vmax (cm-1) = 2974 (w), 1670 (s), 1624 (s), 1418 (s), 1313 
(w), 1223 (m), 1142 (m), 986 (m), 951 (m), 906 (m), 822 (w), 661 (m). HRMS (ESI): m/z calculated for 
C20H25N2O3 [M+H]+: 341.1860, found: 341.1850. 
 
prolyl peptide 3j: To a solution of 3,3-dimethylindoline (37 mg, 0.25 mmol, 1.0 
equiv) in DMSO (0.5 M) were added IBX (70 mg, 0.25 mmol, 1.0 equiv), furoic acid 
(43 mg, 0.38 mmol, 1.5 equiv) and i-propyl isocyanide (35 µL, 0.38 mmol, 1.5 equiv). 
The reaction mixture was stirred for 48 h at rt. The suspension was quenched with 
sat. aq. Na2S2O4 (2 mL), washed with sat. aq. Na2CO3/brine (3:1, 20 mL), extracted 
with CH2Cl2 (2 x 20 mL), dried (Na2SO4) and concentrated in vacuo. Purification was achieved by flash 
chromatography (SiO2) with an eluent gradient (100:1 → 5:1 v/v cHex:EtOAc)  and by preparative thin layer 
chromatography (SiO2, cHex:EtOAc 1:1, v/v), to obtain compound 3j (32 mg [13% CH2Cl2], 0.09 mmol, 35%) 
as a yellow solid. Rf = 0.32 (cHex:EtOAc 1:1 v/v). m.p.: 63.2 – 73.8 °C. 1H NMR (500 MHz, CDCl3): δ 8.17 (d, J 
= 8.2 Hz, 1H, NC*CH), 7.59 – 7.55 (m, 1H, OCHCHCH), 7.31 – 7.27 (m, 2H, OCHCHCH, NC*CHCH), 7.20 – 7.13 
(m, 2H, NC*C*CHCH), 6.54 (dd, J = 3.5 Hz, J = 1.8 Hz, 1H, OCHCH), 5.43 – 5.35 (m, 1H, NH) 4.95 (s, 1H, NCH), 
4.07 – 3.93 (m, 1H, NHCH), 1.43 (s, 3H, C*CH3), 1.40 (s, 3H, C*CH3), 0.94 (dd, J = 13.5 Hz, J = 6.5 Hz, 6H, 
CH(CH3)2) ppm. 13C NMR (126 MHz, CDCl3): δ 168.6 (C*), 158.1 (C*), 147.5 (C*), 145.3 (CH), 141.1 (C*), 
139.9 (C*), 128.3 (CH), 125.5 (CH), 122.5 (CH), 118.4 (CH), 118.0 (CH), 112.2 (CH), 75.0 (CH), 45.0 (C*), 41.4 
(CH), 32.7 (CH3), 29.8 (C*), 22.9 (CH3), 22.6 (CH3), 22.4 (CH3) ppm. IR (neat): vmax (cm-1) = 3285 (br), 2966 
(w), 1653 (s), 1558 (m), 1477 (s), 1456 (s), 1394 (s), 1366 (s), 1283 (m), 1171 (w), 885 (w), 750 (s), 594 
(w). HRMS (ESI): m/z calculated for C19H23N2O3 [M+H]+: 327.1703, found: 327.1707. 
 
pyrrolyl pyrrolidine 4a: Prepared from pyrrolidine 1a (33 mg, 0.25 mmol, 1.0 equiv) 
and pyrrole (35 µL, 0.50 mmol, 2.0 equiv) according to general procedure 3. Purification 
was achieved by flash chromatography (SiO2) with an eluent gradient (100:0 →  20:1 v/v 
CH2Cl2:MeOH), to obtain compound 4a (24 mg, 0.12 mmol, 48%) as a grey solid. Rf = 0.32 
(CH2Cl2:MeOH 20:1 v/v). m.p.: > 86.3 °C decomposition. 1H NMR (500 MHz, CDCl3): δ 9.04 (bs, 1H, C*NH), 
6.72 – 6.64 (m, 1H,C*NHCH), 6.32 – 6.21 (m, 2H, HC=CH), 6.20 – 6.14 (m, 1H, C*NHCHCH), 6.05 – 5.95 (m, 
1H, C*NHCHCHCH), 3.82 (d, J = 4.5 Hz, 1H, C*CHNH), 3.06 (dt, J = 9.0 Hz, J = 4.4 Hz, 1H, NHCHCH), 3.00 – 2.95 
(m, 1H, CHCH2CH), 2.93 – 2.78 (m, 3H, CHCH2CH, NHCH2CH), 2.50 (dd, J = 11.8 Hz, J = 4.6 Hz, 1H, NHCH2), 
2.29 – 2.06 (bs, 1H, CH2NH), 1.60 (dt, J = 8.2 Hz, J = 1.8 Hz, 1H, CHCH2CH), 1.52 (dt, J = 8.2 Hz, J = 1.5 Hz, 1H, 
CHCH2CH) ppm. 13C NMR (126 MHz, CDCl3): δ 155.5 (C*), 136.5 (CH), 116.7 (CH), 108.5 (CH), 104.4 (CH), 
58.7 (CH), 54.7 (CH), 53.6 (CH2), 49.0 (CH2), 48.7 (CH), 46.0 (CH), 45.8 (CH) ppm. IR (neat): vmax (cm-1) = 
3072 (w), 2934 (m), 2862 (m), 1448 (w), 1414 (w), 1028 (w), 918 (m), 879 (m), 833 (m), 725 (s), 563 (w). 
HRMS (ESI): m/z calculated for C13H17N2 [M+H]+: 201.1386, found: 201.1394. 
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 pyrrolyl pyrrolidine 4b: Prepared from pyrrolidine 1b (38 mg, 0.26 mmol, 1.0 
equiv) and 5-methoxy-1H-indole (77 µL, 0.52 mmol, 2.0 equiv) according to general 
procedure 3. Purification was achieved by flash chromatography (SiO2) with an 
eluent gradient (100:0 → 20:1 v/v CH2Cl2:MeOH), to obtain compound 4b (44 mg, 
0.16 mmol, 60%) as a dark yellow oil. Rf = 0.66 (CH2Cl2:MeOH 50:1 v/v). 1H NMR (500 MHz, CDCl3): δ 7.94 
(bs, 1H, C*NH), 7.23 (d, J = 8.7 Hz, 1H, NHC*CH), 7.09 (s, 1H, C*CHC(OMe)), 6.98 (s, 1H, C*NHCHC*), 6.85 (d, J 
= 9.0 Hz, 1H, C(OMe)CH), 4.45 (s, 1H, CH2NHCH), 3.86 (s, 3H, OCH3), 3.03 – 2.91 (m, 2H, NHCH2), 2.78 – 2.54 
(m, 2H, NHCH2CH, NHCHCH), 2.46 – 2.36 (m, 1H, NHCH2CHCHCH2CH), 2.27 – 2.19 (m, 1H, NHCH2CHCHCH2), 
2.01 (bs, 1H, CH2NH), 1.80 (t, J = 9.4 Hz, 1H, CH2), 1.71 – 1.36 (m, 5H, CH2CHCH2CH2) ppm. 13C NMR (126 
MHz, CDCl3): δ 154.0 (C*), 131.9 (C*), 126.8 (C*), 121.4 (CH), 119.9 (C*),29 112.3 (CH), 112.0 (CH), 101.0 
(CH), 56.1 (CH), 55.0 (CH3), 52.0 (CH), 46.4 (CH2), 45.9 (CH), 43.4 (CH2), 40.9 (CH), 40.8 (CH), 23.6 (CH2), 
23.1 (CH2) ppm. IR (neat): vmax (cm-1) = 2941 (w), 1481 (m), 1437 (m), 1290 (w), 1209 (s), 1171 (m), 1101 
(w), 1051 (w), 1028 (m), 924 (m), 795 (m), 733 (m), 640 (m), 606 (m). HRMS (ESI): m/z calculated for 
C18H23N2O [M+H]+: 283.1805, found: 283.1801. 
 
 pyrrolyl pyrrolidine 4c: Prepared from pyrrolidine 1f (36 mg, 0.25 mmol, 1.0 equiv) and 
pyrrole (35 µL, 0.50 mmol, 2.0 equiv) according to general procedure 3. Purification was 
achieved by flash chromatography (SiO2) with an eluent gradient (100:0 → 20:1 v/v 
CH2Cl2:MeOH), to obtain compound 4c (27 mg, 0.13 mmol, 52%, dr > 13:1) as a brown 
solid. Rf = 0.92 (CH2Cl2:MeOH 50:1 v/v). m.p.: 112.0 – 124.2 °C. 1H NMR (500 MHz, CDCl3): δ 8.80 (bs, 1H, 
NHC*), 6.77 – 6.65 (m, J = 3.1 Hz, J = 1.7 Hz, 1H, C*NHCH), 6.16 (q, J = 2.9 Hz, 1H, C*NHCHCH), 6.05 – 6.00 (m, 
1H, C*NHCHCHCH), 4.95 (d, J = 5.4 Hz, 1H, NHCHCH), 4.67 (dd, J = 5.4 Hz, J = 3.7 Hz, 1H, NHCH2CH), 4.34 (s, 
1H, NHCHC*), 3.03 (d, J = 13.6, 1H, NHCH2), 2.63 (dd, J = 13.6, 3.9 Hz, 1H, NHCH2), 2.47 (bs, 1H, CH2NH), 1.50 
(s, 3H, C*CH3), 1.36 (s, 3H, C*CH3) ppm. 13C NMR (126 MHz, CDCl3): δ 129.3 (C*), 116.7 (CH), 110.6 (C*), 
108.8 (CH), 105.1 (CH), 86.0 (CH), 82.3 (CH), 62.5 (CH), 52.6 (CH2), 26.1 (CH3), 23.9 (CH3) ppm. IR (neat): 
vmax (cm-1) = 3265 (w), 1381 (w), 1367 (w), 1204 (m), 1090 (m), 1045 (m), 1030 (s), 947 (w), 891 (m), 881 
(m), 866 (m), 851 (m), 710 (s), 604 (s). HRMS (ESI): m/z calculated for C18H23N2O [M+H]+: 209.1285, found: 
209.1279. 
 
pyrrolyl pyrrolidine 4d: Prepared from pyrrolidine 1e  (29 mg, 0.25 mmol, 1.0 equiv) 
and indole (60 mg, 0.50 mmol, 2.0 equiv) according to general procedure 3. Purification 
was achieved by flash chromatography (SiO2) with an eluent gradient (100:0 – 20:1 v/v 
CH2Cl2:MeOH), to obtain compound 4d (43 mg, 0.19 mmol, 75%) as a brown solid. 
Rf = 0.10 (CH2Cl2:MeOH 20:1 v/v). m.p.: > 69.8 °C decomposition.1H NMR (500 MHz, CDCl3) δ 8.22 (bs, 1H, 
NHC*), 7.74 (d, J = 7.9 Hz, 1H, NHC*C*CH), 7.35 (d, J = 8.0 Hz, 1H, NHC*CH), 7.23 – 7.06 (m, 3H, 
CHNHC*CHCHCH), 3.92 (d, J = 7.1 Hz, 1H, NHCHCH), 3.40 (dd, J = 10.7, 8.0 Hz, 1H, NHCH2), 2.89 – 2.73 (m, 
2H, NHCH2CHCH), 2.55 (dd, J = 10.7, 7.1 Hz, 1H, NHCH2), 2.40 (bs, 1H, NHCH2), 1.74 – 1.43 (m, 6H, 
N
H
H
N
OO
N
H NH
H H
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CH2CH2CH2) ppm. 13C NMR (126 MHz, CDCl3) δ 136.7 (C*), 126.6 (C*), 122.2 (CH), 122.0 (CH), 119.6 (CH), 
119.6 (CH), 117.1 (C*), 111.5 (CH), 63.1 (CH), 53.7 (CH2), 50.8 (CH), 44.3 (CH), 32.1 (CH2), 31.4 (CH2), 25.5 
(CH2) ppm. IR (neat): vmax (cm-1) = 2930 (w), 2860 (w), 1456 (w), 1448 (w), 1339 (w), 735 (s), 608 (m), 426 
(m). HRMS (ESI): m/z calculated for C15H19N2 [M+H]+: 227.1543, found: 227.1542. 
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1386‒1395. (c) T. Ngouansavanh and J. Zhu, Angew. Chem. Int. Ed. 2007, 46, 5775‒5778. (c)  
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13 Standard procedures for the oxidation of  aliphatic amines to imines are performed using a 
two-step protocol of N-halogenation followed by base-mediated elimination. Unfortunately, we 
experienced these procedures to be highly dependent on concentration and batch of 
halogenation reagent and therefore difficult to reproduce. 
14 The oxidation was amenable to scale up (4 mmol) with minor changes to the general procedure 
(0.4 M, 2 h), affording imine 2a in 76% yield. 
15 Full characterization was not possible due to instability of compound 2f towards aqueous 
workup and silica gel chromatography. The proposed structure was determined with 2D-NMR 
spectroscopy as described in: C. de Graaff, L. Bensch, M. J. van Lint, E. Ruijter and R. V. A. Orru, 
Org. Biomol. Chem. 2015, 13, 10108–10112. 
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Dömling, W. Wang and K. Wang, Chem. Rev. 2012, 112, 3083‒3135. (d) C. de Graaff, E. Ruijter and 
R. V. A. Orru, Chem. Soc. Rev. 2012, 41, 3969‒4009. 
18 For selected reviews, see: (a) A. Dömling, Chem. Rev. 2006, 106, 17‒89. (b) A. Dömling and I. Ugi, 
Angew. Chem. Int. Ed. 2000, 39, 3169‒3210. 
19 For the corresponding diastereoselective Ugi-type reaction from 1-pyrrolines, see ref. 12b. For 
examples of photoredox, aerobic and transition metal-catalyzed oxidative Ugi-type 
three-component reactions with either carboxylic acid or water, see (a) Y. Chen, G. Feng, Org. 
Biomol. Chem. 2015, 13, 4260‒4265. (b) S. U. Dighe, S. Kolle, S. Batra, Eur. J. Org. Chem. 2015, 
4238‒4245. (c) C. Xie, L. Han, Tetrahedron Lett. 2014, 55, 240‒243. (d) C. Vila, M. Rueping, Green 
Chem. 2013, 15, 2056‒2059. (e) X. Ye, C. Xie, R. Huang, J. Liu, Synlett 2012, 23, 409‒412. (f) G. 
Jiang, J. Chen, J. -S. Huang, C. -M. Che, Org. Lett. 2009, 11, 4568‒4571. 
20 K. C. Nicolaou, T. Montagnon, P. S. Baran and Y. L. Zhong, J. Am. Chem. Soc. 2002, 124, 2245‒2258. 
21 The oxidation of dihydroindoline and tetrahydroquinoline was only selective when using an 
excess of IBX (2.0 equiv) and a stoichiometric amount of radical inhibitor TEMPO (1.0–1.5 
equiv), providing the aromatized products. This observation supports previous hypotheses by 
Nicolaou et al. that the oxidation of amines with IBX proceeds via an ionic mechanism, while 
benzylic oxidation towards acetophenone derivatives follows a single electron transfer (SET) 
mechanism. TEMPO itself does not facilitate the oxidation. 
22 The relative configurations of the major diastereoisomer 3i, determined by X-ray 
crystallography, and minor diastereoisomer 3i’ are depicted in Scheme 1. 
23 CCDC 1400648 contains the supplementary crystallographic data for 3i. These data are provided 
free of charge by The Cambridge Crystallographic Data Centre. 
24 For examples of  transition metal-catalyzed oxidative aza-Friedel‒Crafts reactions with a 
stoichiometric oxidant, see ref. 8 and references therein, as well as: (a) A. J. Catino, J. M. Nichols, 
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W. de Boer, R. Hage, P. L. Alsters, B. L. Feringa, W. R. Browne, Org. Biomol. Chem. 2010, 8, 
4444‒4450. 
26 Signals of the trimerized product were visible in the NMR spectrum. 
27 Signals are overlapped with the signals of the rotamers and/or the solvent. 
28 Signal is overlapped with the H2O peak. The H2O was an impurity in the solvent MeOD-d4. 
29 Very weak signal assigned by HMBC. 
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Switchable Cascade Reaction towards either 
Pyrroloindolines or Constrained Tryptamines 
 
 
Abstract: The interrupted Fischer indole synthesis of arylhydrazines and biocatalytically 
generated chiral bicyclic imines selectively affords either tetracyclic pyrroloindolines or tricyclic 
tryptamine analogs depending on the reaction conditions. We demonstrate that the reaction is 
compatible with a variety of functional groups. The products are obtained in high optical purity 
and in reasonable to good yield. We present a plausible reaction mechanism to explain the 
observed reaction outcome depending on the stoichiometry of the acid mediator. To demonstrate 
the synthetic utility of our method, pharmaceutically relevant examples of both product classes 
were synthesized in highly efficient reaction sequences, including a phenserine analog as a 
potential cholinesterase inhibitor and constrained tryptamine derivatives as selective inhibitors of 
the 5-HT6 serotonin receptor and the TRPV1 ion channel. 
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4.1 Introduction 
Nature has been a major inspiration in the development of new reactions and the 
quest for novel bioactive compounds. As Waldmann’s Biology-Oriented Synthesis 
(BIOS) concept states, the chemical space can be effectively explored by the 
application of natural product scaffolds as starting points for selective diversification 
in order to identify potent bioactive molecules.1 Certainly, this strategy has provided 
several new molecular probes for the selective and reversible modulation of cellular 
functions.2 Besides its chiral pool of molecules, Nature provides another attractive tool 
for the introduction of asymmetry in the form of enzymes, which offer unrivaled 
chemo-, regio- and stereoselectivity. For example, we employed an engineered 
monoamine oxidase3 in the synthesis of the hepatitis C drug telaprevir (Scheme 1).4 
 The synthesis of complex biologically relevant molecules is often achieved 
with lengthy linear syntheses.  In this respect, the development of more sophisticated 
and efficient synthetic methods is a continuing challenge. The use of convergent 
strategies starting from small building blocks presents the opportunity to build novel 
analogs with several diversification points. Moreover, the number of synthetic steps 
and related waste production and energy consumption can be reduced by combining 
several chemical transformations in one pot. Cascade reactions are important tools to 
achieve these goals.5 
 Indole derivatives exhibit a privileged position within the rich molecular 
diversity of natural products as well as in lead discovery.6 As a result, numerous 
synthetic strategies were developed to construct and modify indoles. We envisioned 
direct access to complex polycyclic indole derivatives in a stereoselective fashion by 
employing readily available reactants in novel cascade reactions. Our success in 
chemoenzymatic multicomponent processes4 prompted us to investigate the utility of 
biocatalytically generated chiral building blocks such as bicyclic imines 2 in cascade 
reactions by considering them as amino aldehyde synthons. We hypothesized a 
reaction between 2 and arylhydrazines to afford pyrroloindolines 6 with cis-junction 
of both [3.3.0] bicyclic systems via an ‘interrupted’ Fischer indole synthesis (Scheme 
1).7,8 Herein, we describe the acid-switchability of this reaction to provide either 
pyrroloindolines 6 or constrained tryptamines 8 and 9 by a Plancher rearrangement 
of the former species. 
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Scheme 1. The application of biocatalytically generated chiral bicyclic imines 2 in the synthesis of 
telaprevir (3) and tetracyclic pyrroloindolines 6 or constrained tryptamines 8/9. 
Although several representatives of the pyrroloindoline natural product class have 
been prepared—generally by electrophilic C3-alkylation of 3-substituted indoles9,10—
these synthetic routes do not allow straightforward systematic variation of the 
substituents and scaffold. The application of the interrupted Fischer indole synthesis 
in pyrroloindoline synthesis was shown in a limited number of examples. Most 
significantly, Garg and List described a convergent synthesis of pyrroloindolines by a 
cascade reaction between arylhydrazines and cyclic hemiaminals.7 An asymmetric 
variant of the interrupted Fischer indolization to form pyrroloindolines was reported 
by List, who used a sterically congested chiral phosphoric acid.11 However, the 
presence of a Nβ-benzyl group on the hydrazine fragment was essential for high 
enantioselectivity.  
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4.2 Results and Discussion 
We started our investigations with the benchmark reaction between bicyclic imine12 
(±)-2a and phenylhydrazine 10a for the synthesis of pyrroloindoline 6a. Our initial 
screening with a range of solvents and acid mediators resulted in only modest success 
(Table 1, entries 1‒6). To our delight, the envisioned stereoselective interrupted 
Fischer indolization proceeded smoothly with a range of Brønsted acids in toluene 
(entries 7‒10). Additional experiments showed that increasing or decreasing the 
temperature led to slightly reduced yields (data not shown). Although microwave 
heating did not have a beneficial effect compared to conventional heating in an oil 
bath (entries 10‒11), the microwave was used for convenience. Optimal conversion of 
(±)-2a to the desired tetracyclic pyrroloindoline 6a was achieved with 
phenylhydrazine hydrochloride (10b) and 1.0 equiv of TsOH in toluene with  
 
Table 1. Exploration of reaction conditions for the interrupted Fischer indole synthesis.  
 
Entry Acid  Solvent Yield[a] 
1 - excess AcOH <5%  
2 HCl [1.25 M] excess MeOH <5% 
3 HCl [4.0 M] excess dioxane 36% 
4 TsOH  2.0 equiv MeOH 30% 
5 TsOH  2.0 equiv DCE 44% 
6 TsOH  2.0 equiv (MeO)2CO 36% 
7 F3CSO3H  2.0 equiv toluene 46% 
8 EtSO3H 2.0 equiv toluene 52% 
9 MeSO3H 2.0 equiv toluene 60% 
10 TsOH  2.0 equiv toluene 68% 
11[b] TsOH  2.0 equiv toluene 68% 
12[c] TsOH  1.0 equiv toluene 71% 
[a] Yield determined by adding 2,5-dimethylfuran (0.5 equiv) after the reaction workup as standard for 
NMR spectroscopy. [b] Conventional heating (oil bath). [c] Phenylhydrazine∙HCl salt (10b) was used.  
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microwave heating to 130 °C for 30 min (entry 12).  
 With the optimized reaction conditions in hand, we explored the reaction 
scope with respect to para-, meta-, and ortho-substituents on phenylhydrazine 
employing (±)-2a (Scheme 2).13 To our delight, a range of electronically and sterically 
diverse para-substituted arylhydrazines were suitable substrates, giving the 
corresponding pyrroloindolines 6b‒g in modest to good yield (18‒73%). Electron-
rich inputs with substituents such as methoxy and isopropyl were readily converted 
(6b,c) and even a more challenging trifluoromethoxy substituent was tolerated (6d). 
A bromide substituent was also allowed at the para-position (6e), providing a 
convenient handle for a multitude of transition metal-catalyzed cross-coupling 
reactions. Interestingly, strongly electron-withdrawing substituents could be 
introduced (6f,g), while previous reports on interrupted Fischer indole syntheses 
showed only trace amounts of product.7a,b The lower efficiency of these substrates is 
most likely caused by slower formation of the hydrazone intermediate and/or slower 
sigmatropic rearrangement. The application of meta-substituted arylhydrazines gave 
rise to the formation of two regioisomeric pyrroloindolines in modest to reasonable 
yield (26‒52%). The 6-substituted regioisomers 6h‒k were formed as the major 
products in all cases, in combination with varying amounts of the 4-substituted 
isomers 6h’‒k’. We recognized that the regioselectivity is mainly governed by the 
steric properties of the meta-substituent that are most accurately described by the 
Winstein-Holness A-values.14 In correspondence with increasing steric bulk, the ratio 
between 6-substituted and 4-substituted pyrroloindolines increases moving from 
substituents with a low to a high A-value. Complete regioselectivity could be induced 
by a meta-substituent with a sufficiently high A-value, such as tert-butyl (6k). Notably, 
pyrroloazaindoline 6l could be obtained in reasonable yield as a single regioisomer as 
a result of electronic control.15 In agreement with earlier reports on the classic Fischer 
indole synthesis, the use of ortho-substituted arylhydrazines led to a more sluggish 
reaction.16 Nevertheless, the desired pyrroloindolines 6m‒o could be isolated in 
modest yield (19‒27%). 
 To further evaluate the reaction scope, we tested Nα-substituted 
arylhydrazines in the interrupted Fischer indolization. Gratifyingly, the application of 
both Nα-methyl and Nα-benzyl phenylhydrazine resulted in the formation of the 
desired pyrroloindolines 6p,q in moderate yield (51‒54%). Furthermore, highly 
strained pentacyclic pyrroloindoline derivative 11a could be isolated in optically pure 
form after o-nosylation by the application of enantiopure (−)-2a (99% ee). After 
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crystallization, the structure of 11a was confirmed by X-ray crystallography.17 As 
expected, (−)-2a could be used for the synthesis of 6b and 6e in excellent optical 
purity (99% ee) as well. During our investigation of the behavior of tricyclic imine  
 
 
Scheme 2. Synthesis of diverse pyrroloindolines 6 and 11. X-ray structure of 11a with displacement 
ellipsoids drawn at 50% probability level.17 [a] Free hydrazine used (instead of HCl salt) in combination 
with 2.0 equiv TsOH. [b] Determined by comparison with the racemate using HPLC on a chiral stationary 
phase. (−)-2a was used. [c] Determined by comparison with the racemate using HPLC on a chiral stationary 
phase. Tricyclic imine (−)-2b was used in combination with 1.0 equiv PPTS and a reaction time of 5 min. 
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Table 2. Exploration of the acid switchability of the cascade sequence.19 
 
Entry Acid  Yield for 6a[a] Yield for 8a[a] 
1 TsOH 1.0 equiv 71% 14% 
2 TsOH 1.5 equiv - 61% 
3[b] TsOH 1.5 equiv - 61% 
4 PPTS 1.0 equiv 76% <5% 
5 PPTS  1.5 equiv 70% 9% 
6 TFA 1.0 equiv 73% <5% 
7 TFA 1.5 equiv 64% <5% 
[a] Yield was determined with 1H NMR using 2,5-dimethylfuran as standard. [b] Reaction time of 5 min. 
(−)-2b in the interrupted Fischer indole synthesis, we found that the desired 
pyrroloindoline could only be obtained by the use of 1.0 equiv of the mild acid 
pyridinium para-toluenesulfonate (PPTS) and by shortening the reaction time (5 min). 
Subsequent o-nosylation afforded the desired pentacyclic pyrroloindoline 11b in 57% 
yield with 99% ee.  
 During additional experiments regarding the reaction mechanism, we 
discovered that the yield of 6 is highly dependent on the stoichiometry and strength of 
the acid mediator.18 Under otherwise identical conditions, the use of 1.5 equiv of TsOH 
(instead of 1.0 equiv) led to full conversion to tricyclic tryptamine derivative 8a 
(Table 2, entries 1‒2), along with its regioisomer 9a.19 The pyrroloindoline product 6a 
was not observed under these conditions. Most likely, 8a and 9a are formed via a 
rearrangement of 6a (see page 95‒98). Intriguingly, this highly complex cascade 
reaction consisting of the interrupted Fischer indolization and rearrangement was 
completed within 5 minutes (entry 3). When exploring different acid mediators, we 
observed that weaker acids such as TFA and PPTS were not able to facilitate this 
selective product switch (entries 4‒7). Although we synthesized the library of 
pyrroloindolines (Scheme 2) with TsOH, TFA and PPTS proved to be more efficient 
and selective acid mediators for the formation of 6a.  
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To facilitate separation of regioisomers 8a and 9a, the constrained tryptamines were 
subjected to in situ o-nosylation. With a two-stage procedure, we could synthesize 
compounds 12a‒d and 13a‒d in a ~4:1 ratio and very good yields considering the 
complexity of the transformation (59‒81%, Scheme 3). Advantageously, regioisomers 
12 and 13 were readily separated by flash chromatography. We showed the 
generality of this strategy by the synthesis of relatively electron-rich as well as  
 
 
Scheme 3. Synthesis of tricyclic tryptamine analogs 12 and regioisomers 13. [a] Free hydrazine used 
(instead of HCl salt) in combination with 2.5 equiv TsOH. [b] Free hydrazine used; TsOH (3.5 equiv), 150 °C, 
60 min. [c] ee = 99% (12a,b) ee = 98% (12d, 13d). Determined by comparison with the racemate using 
HPLC on a chiral stationary phase. [d] Presumed optically pure by detection of a single peak by HPLC (chiral 
stationary phase) and in analogy to 12a, 12b and 12d. [e] (Partially) racemized as determined by chiral 
HPLC comparison with the racemate (13a,b) or by detection of two peaks by HPLC analysis on a chiral 
stationary phase (13c). [f] (±)-2a was used. 
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electron-poor systems and even heteroaromatic derivatives. The minor regioisomer of 
para-bromo and N-benzyl derivatives 12e‒f was not isolated, however, the 
debenzylated product 12a was isolated as a side product in the latter case. By 
employing (‒)-2a, the major regioisomers 12a‒d were isolated in excellent optical 
purity (98‒99% ee). However, the minor regioisomers 13a‒c were found to be 
partially or completed racemized. We hypothesize that the racemization is acid 
mediated and occurs only after the cascade process (see page 98‒100). In contrast to 
13a‒c, heteroaromatic derivative 13d was obtained with high optical purity, 
presumably because of the presence of the additional basic nitrogen. 
 Thus, our novel cascade reaction provides either pyrroloindolines 6 or 
constrained tryptamines 8 and 9 based on the stoichiometry of the acid mediator. To 
account for these experimental observations, we propose the following mechanism 
(Scheme 4). As envisioned, amino aldehyde synthon 2a undergoes a “transimination” 
reaction with arylhydrazine 10 to form hydrazone intermediate A. This intermediate 
is in tautomeric equilibrium with ene-hydrazine B that undergoes a [3,3]-sigmatropic 
rearrangement via either E-C or Z-C to produce iminium ion D or D’. Evidently, D’ 
cannot provide 6 and also is not able to undergo an addition of the aliphatic amine to 
the iminium ion as it would lead to an energetically unfavorable system of trans-fused 
five-membered rings. If D’ is formed at all, we hypothesize that it might undergo 
addition of the aromatic amine to the iminium ion to give the trans-isomer of E 
followed by acid-mediated migration. However, 6 was obtained as the major product 
experimentally, which is plausibly formed via D. The clear selectivity for the formation 
of D over D’ is hypothesized to be induced during the sigmatropic rearrangement of 
Z-ene-hydrazine C, as a result of chirotopic shielding by the cationic ammonium 
group.20 Subsequently, intermediate D undergoes intramolecular addition of either 
the aromatic (pathway a) or aliphatic (pathway b) amine to the iminium moiety to 
afford intermediates E and F, respectively, with loss of an ammonium ion. The Fischer 
indole synthesis is then interrupted by an intramolecular addition of the pendant 
amino group to give (protonated) pyrroloindoline 6 due to the lack of a proton at C3 
necessary for indole formation.7 Plausibly, the latter species is in dynamic equilibrium 
with intermediates E and F under the reaction conditions. Only in the presence of 
additional strong acid, intermediate E can undergo a second protonation to bivalent 
cation G.21 This highly reactive intermediate can undergo a Wagner‒Meerwein-type 
cationic shift known as the Plancher rearrangement22 via either pathway c of d. 
Pathway c will give cationic intermediate H that produces regioisomer 8 after loss of 
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Scheme 4. Proposed mechanism for the formation of 6, 8 and 9. 
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two protons. Similarly, pathway d affords regioisomer 9. The formation of these 
regioisomeric products directly results from the presence of two inequivalent 
migratory carbons in intermediate G. An evident regiopreference (4:1 for 
12a‒d/13a‒d) was observed in favor of the regioisomer that is formed by migration 
of the secondary carbon instead of the tertiary carbon. Tertiary carbons can generally 
stabilize (partial) positive charges more efficiently than secondary carbons. However, 
destabilization of the partial positive charge on the tertiary carbon by the nearby 
cationic ammonium group plausibly explains the regioselectivity in our case.  
Two possible mechanisms exist for the Plancher rearrangement, i.e. concerted 
or stepwise migration (Scheme 5). The concerted mechanism proceeds through a 
three-center-two-electron-type transition state with preservation of stereochemistry 
at the migrating carbon. The stepwise mechanism proceeds through bond scission and 
subsequent bond formation with concomitant epimerization at the migratory carbon. 
You et al. investigated the Plancher rearrangement of sp3 carbons in 
C3-spiroindolenines─such as G and G’─with theoretical calculations and experimental 
tests.23 This study showed that the higher the ability of the migratory group to 
stabilize the accumulating positive charge, the easier migration occurs and the more 
likely the reaction mechanism is stepwise rather than concerted. For example,  
 
 
Scheme 5. Stepwise and concerted mechanism of the Plancher rearrangement. 
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when a nitrogen atom is attached to the migratory carbon, a retro-Mannich/Mannich 
equilibrium can exist with concomitant racemization at the migratory carbon.24 The 
migration can then occur through a stepwise retro-Mannich/Mannich mechanism, but 
participation of the concerted mechanism should not be excluded. However, in the 
absence of an electron-donating substituent next to the migratory group, migration 
almost certainly occurs by a concerted process through a three-center-two-electron-
type transition state.23,25 The alternative would be scission of the bond between the 
spirocarbon and migrating carbon, which is highly implausible in this case. Therefore, 
we propose a concerted mechanism for the Plancher rearrangement of bivalent 
cationic intermediate G with preservation of stereochemistry at the migratory carbon. 
We believe that the observed racemization of 13a‒c is acid-mediated and occurs only 
after the cascade process through imine/enamine tautomerization. Based on this 
hypothesis, we envisioned that the treatment of 2,3-dimethylindole with TsOD (130 
°C, 30 min, μW) would lead to deuteration at the C3’ position (Scheme 6). Indeed, a 
mixture of compounds (14‒16) with varying degree of deuteration at the C3’-position 
was obtained, as determined by 13C NMR analysis (Figure 1). Thus, a racemizing 
imine/enamine equilibrium in protonated indoles proved to be feasible.  
 
 
Figure 1. 13C NMR spectrum after treatment of 2,3-dimethylindole with TsOD. 
14 
15 
16 
C3‘:
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Scheme 6. Working hypothesis for C3’ deuteration of 2,3-dimethylindole with TsOD. 
To investigate the temperature dependence of the racemization of 13a after the 
rearrangement, we used 11c in a temperature screen (Table 3). As a result of the low 
basicity of the o-nosylated amine group, it cannot scavenge protons and formation of a 
bivalent cation is not required for migration. Therefore, 0.5 equiv of TsOH is sufficient 
to facilitate the rearrangement of 11c. Although full racemization of 13a was 
observed at temperatures of 100 °C and higher (entries 1‒2), 13a was only partially 
racemized at 85 °C with complete conversion of 11c (entry 3). Racemization was even 
further reduced by shortening the reaction time (entry 4). Moreover, no racemization  
 
Table 3. Screening to investigate temperature and time dependence of the racemization of 13a. 
N
H
N
H NH
N
H NHoNs
NHoNs
*
TsOH (0.5 equiv)
toluene, W
+
12a11c 13a
oNs
 
Entry Temperature Time (min) Conversion of 11c[a] ee[b] 12a ee[b] 13a 
1 130 30 >99% 99% ~0% 
2 100 30 >99% 99% ~0% 
3 85 30 >99% 99% 57% 
4 85 15 >95% 99% 88% 
5 70 30 31% 99% 99% 
[a] Determined by NMR spectroscopy according to the molar ratio between 11c and 12a/13a. 
[b] Determined by comparison with the racemate using HPLC on a chiral stationary phase. 
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of 13a was observed at 70°C, but the conversion of 11c was only 31% in 30 min. Thus, 
we observed a clear temperature as well as time dependence for the racemization of 
13a, which supports our hypothesis of a post-cascade racemization. 
 When investigating the behavior of tricyclic imines e.g. (–)-2b in the 
interrupted Fischer indole synthesis, we observed that the resulting pentacyclic 
pyrroloindolines are more prone to undergo a rearrangement than their tetracyclic 
analogs, presumably as a result of increased strain. A clean conversion towards 
17a/18a was achieved with 1.0 equiv of the mild acid PPTS after a reaction time of 3 
hours (Scheme 7). Since the corresponding pyrroloindoline 11b was obtained under 
identical conditions but with a shorter reaction time (5 min, see page 92), this reaction 
proves to be time switchable. An interesting phenomenon is the observed inversion of 
regioselectivity for the Plancher rearrangement towards 17a/18a (1:7) compared to 
12a‒d/13a‒d (4:1). In contrast to the requirement of bivalent cationic intermediate 
G for the formation of 12/13, a doubly protonated species is plausibly not formed in 
the synthesis of 17a/18a when using the mild acid PPTS. Therefore, the pendant 
amine can presumably stabilize (rather than destabilize) the partial positive charge 
accumulating on the migrating carbon in TS5 by neighboring group participation, 
leading to preferred formation of 18a over 17a. We anticipated that the use of an 
excess of strong acid (TsOH) would result in partial protonation of the pendant amine. 
In this case, one would expect that migration through a bivalent cationic transition 
state would predominantly give 17a and a monovalent cationic transition state would 
favor formation of 18a based on electronic arguments.  We observed that the use of 
1.5 equiv of TsOH (130 °C, 30 min, μW) led to the formation of 17a/18a in 1:4 
regioisomeric ratio (compared to 1:7 when using 1.0 equiv PPTS). This may either 
imply that the rearrangement proceeds predominantly via the monoprotonated 
intermediate, or that other factors (e.g. sterics, strain release) are responsible for the 
observed regioselectivity. Epimerization at the C3’ position of 18a under acidic 
conditions apparently does not occur, since a single diastereoisomer was obtained. A 
plausible explanation is that an imine/enamine equilibrium does not exist in this case, 
because of the increased strain that it would cause. By the application of (+)-2c, a 
double bond is introduced that presumably provides allylic stabilization of the 
accumulating positive charge during the Plancher rearrangement. We hypothesize 
that this stabilization favors TS4 over TS5 in the concerted mechanism and could also 
induce participation of a stepwise mechanism (TS3) to a certain extent. Therefore, the 
regioselectivity is again reversed and 17b is the main product of this cascade reaction,  
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Scheme 7. Synthesis of tetracyclic tryptamine analogs 17 and regioisomers 18. X-ray structures of ent-18a 
and (±)-17b with displacement ellipsoids drawn at 50% probability level.17 [a] Determined by comparison 
with the racemate using HPLC on a chiral stationary phase. [b] 1.5 equiv TsOH instead of 1.0 equiv PPTS.  
[c] An isomer of 17b was observed in the crude 1H NMR spectrum, but could not be isolated. 
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albeit in low yield (34%). In order to verify the reversed regioselectivity of the 
migration when using 2b or 2c, the corresponding major regioisomers 18a and 17b 
were crystallized and their structures were corroborated by X-ray crystallography 
(Scheme 7). Although we provided a plausible explanation for the regioselectivity of 
the migration―using either substrate 2a, 2b or 2c―based on electronic arguments, a 
thorough computational study is required to investigate the importance of strain 
release and/or steric factors. 
Having established some mechanistic understanding of the switchability of our 
reaction to form either 6 or 8/9, we set out to investigate applications of our 
methodology in the synthesis of bioactive compounds with high pharmaceutical 
relevance. Pyrroloindoline alkaloids constitute a diverse class of natural products that 
exhibit interesting biological properties including antibacterial26 and antitumor27 
activity. The acetylcholinesterase inhibitor (‒)-physostigmine (23, Scheme 9) has 
been applied in the treatment of neurodegenerative diseases,28 but suffers from short 
duration of action, low therapeutic window and negative side effects.29 Its 
semisynthetic derivative phenserine (24) advanced as far as Phase III clinical trials for 
the treatment of Alzheimer’s disease (AD) owing to its more beneficial characteristics 
in terms of activity and selectivity.29,30 Interestingly, its enantiomer ent-24 (posiphen) 
is currently also in clinical development for the treatment of AD, but seems to have a 
different mode of action.31 We soon realized that phenserine analog 28 should be 
rapidly accessible via our interrupted Fischer indole synthesis in a stereoselective 
fashion. However, initial studies showed that post-cascade methylation of the 
aromatic NH is rather challenging. In an attempt to reductively methylate both 
nitrogen atoms of pyrroloindoline 6a with formaldehyde, we observed the formation 
of a highly crystalline compound in very good yield with significantly reduced polarity 
compared to 6a (Scheme 8). X-ray structural analysis revealed that this compound 
(20) has a dimeric structure with an eight-membered ring consisting of alternating 
carbon and nitrogen atoms. Notably, the reductive methylation of the corresponding 
phenserine precursor did not lead to formation of the analog of dimer 20.32 We 
propose that compound 20 is formed through iminium ion formation of the more 
nucleophilic aliphatic nitrogen of 6a with formaldehyde to form 19, followed by a 
dimerization reaction with a second molecule of 19. Although aminal formation 
between two aliphatic nitrogens from different molecules of 6a and formaldehyde 
plausibly occurs, this reaction does not lead to a stable product and is expected to be  
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Scheme 8. Reactivity of tetracyclic pyrroloindoline 6a with ninhydrin and formalin. X-ray structure of 20 
with displacement ellipsoids drawn at 50% probability level.17 
reversible. However, intermolecular double addition of the aromatic nitrogen atom of 
19 to the iminium functionality of another molecule of 19 and vice-versa apparently 
leads to a stable dimer (20). During a screening of the reactivity of 6a with other 
electrophilic carbonyl compounds, we found that ninhydrin selectively reacts with 6a 
to form an eight-membered ring compound in excellent yield as a single regio- and 
stereoisomer. Plausibly, the mechanism proceeds through double hemiaminal 
formation between the nitrogen atoms of 6a and two carbonyl functionalities of 
ninhydrin to form 21, followed by a ring expansion step and tautomerization to give 
22. Its regioisomer 22’, can be formed from the regioisomer of 21. Initial bond 
formation between the more nucleophilic aliphatic nitrogen of 6a with the central and 
most electrophilic carbonyl of ninhydrin is most probable and will lead to regioisomer 
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22. However, we were not able to distinguish between the regioisomers by means of 
NMR analysis and attempts to crystallize the product were thus far unsuccessful.   
 To circumvent the necessity of post-cascade methylation of the aromatic NH 
in the synthesis of 28, we opted to employ an Nα-methylated hydrazine derivative in 
the cascade process (Scheme 9). Conveniently, di-Nα,Nβ-Boc-protected arylhydrazines 
can be prepared by CuII-catalyzed addition of boronic acids to di-tert-butyl azodi-
carboxylate.33 We discovered that chemoselective reduction of the Nα-Boc group can 
be achieved with LiAlH4 at room temperature to provide Nα-Me-Nβ-Boc-protected 
arylhydrazine 26. The cascade reaction of 26 and (–)-2a with in situ Boc deprotection 
(1.0 equiv TsOH, 60 °C, 1 h), proceeded most smoothly with 1.0 equiv of PPTS. After 
isolation of 27, N-methylation of the aliphatic nitrogen atom was readily achieved by 
reductive methylation with formaldehyde. Finally, phenserine analog 28 was readily 
synthesized by hydrogenolysis of the benzyl ether and subsequent carbamoylation. 
The corresponding (±)-28―that provides access to the posiphen analog―was 
conveniently produced by employing readily available (±)-2a.  
 
Scheme 9. Synthesis of phenserine analog 28.  
[a] Determined by comparison with the racemate using HPLC on a chiral stationary phase. 
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Like the pyrroloindoline compound class, tricyclic constrained tryptamine analogs 
have been reported to have several conceivable therapeutic applications. For example, 
they are potent and selective inhibitors of serotonin34 and melatonin35 receptors as  
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Scheme 10. Stereoselective synthesis of serotonin receptor inhibitor 30 and TRPV1 inhibitor 31.  
[a] Determined by comparison with the racemate using HPLC on a chiral stationary phase. 
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well as the TRPV1 (transient receptor potential vanilloid 1) ion channel.36 The 
important lead compound MS-245 (29) is a tryptamine derivative with potent 5-HT6 
receptor inhibitor activity (IC50 = 2.1 nM).34 By acting on this receptor, MS-245 has 
high therapeutic potential for the treatment of Alzheimer’s disease.38 The constrained 
tricyclic analog of this species (rac-30) is an even more potent inhibitor (IC50 = 1.5 
nM).37 Enders and co-workers described the asymmetric synthesis of (R)-30 by an 
organocatalytic cascade reaction via a Plancher rearrangement.39 They reacted 
5-methoxyindole (32) and iodonitroalkene 33 to obtain precursor 34 with 87% ee 
before recrystallyzation (Scheme 10). Finally, they obtained (R)-30 after an additional 
three-step reaction sequence. We envisioned the application of our cascade 
methodology to provide a more efficient and selective process, starting from readily 
available substrates arylhydrazine 35 and (−)-2a (Scheme 10). The cascade reaction 
was found to proceed most efficiently in a one-pot, two-stage process involving the 
interrupted Fischer indolization (1.0 equiv PPTS, 130 °C, 30 min.) and the 
rearrangement (1.0 equiv TsOH, 130 °C, 30 min.). The resulting tricyclic tryptamine 
derivative 36 was then modified by N-methylation and sulfonylation of the indole 
nucleus, without purification of the intermediates. To our delight, we obtained (R)-30 
in excellent enantioselectivity and in a more time- and step-efficient manner than 
Enders’ route. 
  As a potent and selective inhibitor of the TRPV1 ion channel, (±)-31 has 
therapeutic potential in the treatment of neuropathic pain.36 We envisioned rapid and 
stereoselective access to this compound with our methodology (Scheme 10). In this 
case, the in situ Boc deprotection (1.0 equiv TsOH, toluene, 60 °C, 1 h) of 26 was 
followed by the cascade reaction with (−)-2a as developed for 35 (1.0 equiv PPTS, 130 
°C, 30 min., then 1.0 equiv TsOH, 130 °C, 30 min.). After acylation of tricyclic 
tryptamine derivative 37, hydrogenolysis of the benzyl ether afforded (R)-31 in 26% 
overall yield with excellent enantioselectivity (99% ee). 
4.3 Conclusion 
We developed an acid-switchable chemoenzymatic interrupted Fischer indole 
synthesis of either tetracyclic pyrroloindolines 6 or tricyclic tryptamines derivatives 8 
and 9 with multiple diversification points. This novel cascade process either affords 6 
or can undergo an additional Plancher rearrangement to give 8 and 9 depending on 
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the stoichiometry of the acid mediator. Both compounds classes are easily accessible 
with our strategy in either optically pure or racemic form by employing a bicyclic 
imine synthesized by either biocatalytic (Chapter 2) or IBX-mediated oxidation 
(Chapter 3). A range of electron-rich and deficient arylhydrazines were compatible 
with this cascade process in combination with a small range of chiral bicyclic imines. 
We applied our concise methodology in the synthesis of pharmaceutically releveant 
compounds in high optical purity.  Notably, examples from both scaffold types have 
high therapeutic potential in the treatment of Alzheimer‘s disease. These findings 
clearly illustrate the fruitful union of biocatalysis and cascade reactions.  
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4.5 Experimental Section 
General comments 
Starting materials were purchased from Sigma Aldrich, Alfa Aesar, Apollo Scientific, Enamine, Acros 
Organics and used without treatment. Unless stated otherwise, the solvents were purchased from VWR 
Chemicals or Biosolve and were used without further treatment. Cyclohexane (cHex) was purified by 
distillation before use. (3aR,6aS)-Octahydrocyclopenta[c]pyrrole hydrochloride was purchased from AK 
Scientific and dissolved in CH2Cl2, washed with sat. aq. Na2CO3, extracted with CH2Cl2, dried (Na2SO4) and 
concentrated in vacuo before use. Enantioenriched 1-pyrrolines 2 were be synthesized by biocatalytic 
oxidation with an engineered monoamine oxidase according to a previously reported procedure.3 A batch of 
(–)-2a (99% ee) was generously provided by Dr. G. Barreca (Chemessentia S.r.L.). Celite® 512 medium was 
purchased from Sigma Aldrich. All yields were calculated taking the solvent traces into account. Column 
Chromatography was performed on Silica-P Flash Silica Gel (particle size 40-63 μm, pore diameter 60 Å) 
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from Silicycle or aluminiumoxide (activated, basic, Brockmann I) from Sigma Aldrich. Preparative thin layer 
chromatography was performed on Silica Gel plates F254 (20 x 20 cm, 2000 µm, pore diameter 60 Å) from 
Silicycle. Thin Layer Chromatography (TLC) was performed using TLC plates F254 (silica gel 60 on 
aluminium) from Merck Serono KGaA (Darmstadt) and compounds were visualized by UV detection (254 or 
366 nm) and stained with basic aq. KMnO4 or ninhydrin/ethanol. 1H, 13C, COSY, HSQC, HMBC and NOESY 
nuclear magnetic resonance (NMR) spectra were recorded on a Bruker Avance 500 (500.23 MHz for 1H and 
125.78 MHz for 13C) in CDCl3 using the residual solvent as internal standard (CDCl3: δ = 7.26 for 1H NMR and 
δ = 77.16 for 13C NMR)  or Bruker Avance 400 (400.13 MHz for 1H and 100.62 MHz for 13C) using the 
residual solvent as internal standard (CDCl3: δ = 7.26 for 1H NMR and δ = 77.16 for 13C NMR). Chemical shifts 
(δ) are given in ppm and coupling constants (J) are quoted in hertz (Hz). Resonances are described as s 
(singlet), d (doublet), t (triplet), q (quartet), bs (broad singlet) and m (multiplet) or combinations thereof. 
The COSY-, HMBC- and HSQC-NMR spectra were used for the assignment of the proton signals. The APT-
NMR spectra were used for the assignment of the carbon signals. NMR data was processed using 
MestReNova. Names of chemical structures were deduced from generic names and/or important 
functionalities. Electrospray Ionization (ESI) high resolution mass spectrometry (HRMS) was carried out 
using a Bruker micrOTOF-Q instrument in positive ion mode (capillary potential of 4500 V). Infrared (IR) 
spectra were recorded neat using a FTIR-8400s from Shimadzu. Signal intensities are described as strong (s), 
medium (m), weak (w) or broad (br). Melting points were recorded on a Büchi M-565 and are not corrected. 
Chiral HPLC was recorded using a LC10VP with a SCL-10A VP system controller, LC-10AT VP liquid 
chromatograph, SPD-M10A VP diode array detector and CTO-10AC VP column oven from Shimadzu. Data 
was processed using Shimadzu Labsolutions. Chiral SFC analysis was recorded using an Acquity UPC2 
system consisting of a Convergence Manager, Sample Manager FL, Binary Solvent Manager, PDA Detector, 
Isocratic Solvent Manager, QDa Detector and 30S column manager from Waters. Specific rotations were 
measured with an automatic AA-10 polarimeter. Microwave assisted reactions were performed in a sealed 
vessel using a Biotage Initiator+ and reaction temperatures were measured using IR. Reaction times refer to 
the hold time at the desired set temperature and not to total irradiation time. The external standard was 
added to the reaction mixture after the work up. X-ray single crystal data were collected at 100Kon a Bruker 
X8 Prospector with Cu microsource and focusing optics, and Apex II detector. Data were integrated and 
corrected for absorption with SAINT V8.34A and SADABS 2012/1, and the structure was solved and refined 
with SHELX 2014 and shelXle. Hydrogen atoms were detected in the Fourier difference maps, those on C 
were refined with constraints on bond lengths and angles, those on N were refined freely. 
Substrate synthesis 
1-pyrroline rac-2a:3 To a solution of meso-pyrrolidine 1a (2.00 g, 18 mmol, 1.0 equiv) in DCM 
(108 mL) was slowly added N-chlorosuccinimide (2.50 g, 18.9 mmol, 1.05 equiv) at 0°C. The 
reaction mixture was stirred for 3 hours at room temperature. The resulting solution was washed 
with H2O (2 x 50 mL) and brine (1 x 50 mL). The combined organic layers were dried (Na2SO4) and 
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concentrated in vacuo. The resulting solution was added this to a solution of KOH (2.00 g, 36 mmol, 2.0 
equiv) in EtOH (25 mL). The reaction mixture was stirred for 24 hours at room temperature, after which it 
was concentrated in vacuo. The crude product was then dissolved in 100 mL of DCM, washed with sat. 
NaHCO3 and subsequently the water layer was extracted with DCM (50 mL). The combined organic layers 
were dried over Na2SO4 and concentrated in vacuo. Purification was achieved by flash chromatography 
(SiO2) with an eluent gradient (1:1 v/v cHex/EtOAc → 19:1 v/v DCM:MeOH), to obtain compound (±)-2a 
(752 mg, 6.90 mmol, 38%) as a light yellow solid. 1H NMR (500 MHz, CDCl3): δ 7.31 – 7.27 (m, 1H, NHCH), 
4.11 – 3.98 (m, 1H, NHCH2), 3.57 – 3.46 (m, 1H, NHCH2), 3.27 (t, J = 8.9 Hz, 1H, NHCHCH), 2.72 – 2.57 (m, 1H, 
NHCH2CH), 1.73 – 1.19 (m, 6H, CH2CH2CH2) ppm. 13C NMR (126 MHz, CDCl3): δ 169.6 (CH), 70.3 (CH2), 55.2 
(CH), 38.7 (CH), 34.8 (CH2), 29.4 (CH2), 25.0 (CH2) ppm. 
Synthetic procedures and spectral data 
General procedure for optimization of reaction conditions of interrupted Fischer indole reaction in 
Table 1: To a solution of 1-pyrroline 2a (0.10 mmol, 1.0 equiv) in solvent (0.1 M) were added  
phenylhydrazine 10a (1.05 equiv) and the source of acid (0.20 mmol, 2.0 equiv) under nitrogen. The 
reaction mixture was stirred for 30 min at 130 °C under microwave irradiation. The suspension was cooled 
to rt, washed with sat. aq. Na2CO3/brine (3:1, 20 mL), extracted with DCM (2 x 10 mL), dried (Na2SO4) and 
concentrated in vacuo. Subsequently, the yield of pyrroloindoline 6a was determined with 1H-NMR 
spectroscopy after dissolving the crude product in CDCl3 and adding 2,5-dimethylfuran (0.125 mmol, 0.5 
equiv) as internal standard. 
General procedure for exploration of the acid switchability of the reaction outcome of the 
interrupted Fischer indole synthesis in Table 2: To a solution of 1-pyrroline 2a (30 mg, 0.25 mmol, 1.0 
equiv) in toluene (0.1 M) were added  phenylhydrazine hydrochloride 10b (0.26 mmol, 1.05 equiv) and the 
source of acid (48 mg, 0.25 mmol, 1.0 equiv). The reaction mixture was stirred for 30 min at 130 °C under 
microwave irradiation. The suspension was cooled to rt, washed with sat. aq. Na2CO3/brine (3:1, 20 mL), 
extracted with DCM (3 x 15 mL), dried (Na2SO4) and concentrated in vacuo. Subsequently, the yield was 
determined with 1H-NMR spectroscopy after dissolving the crude product in CDCl3 and adding 2,5-
dimethylfuran (0.125 mmol, 0.5 equiv) as internal standard. 
Procedure for deuteration experiment in Scheme 6: To a solution of 2,3-dimethylindole (1.0 equiv) in 
toluene (0.1 M) was added p-TsOD (3.0 equiv; prepared by dissolving pTsOH monohydrate in D2O and 
subsequent concentration in vacuo). The reaction mixture was stirred for 30 min at 130 °C under 
microwave irradiation. The suspension was cooled to rt, dissolved in methanol (3 mL), washed with sat. aq. 
Na2CO3 (20 mL), extracted with DCM (3 x 15 mL), dried (Na2SO4) and concentrated in vacuo. The crude 
product was analysed with NMR spectroscopy, clearly showing a combination of the non-deuterated 14, 
mono-deuterated 15 and di-deuterated 16 species. This experiment shows the feasibility of an 
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imine/enamine equilibrium (see working hypothesis) in protonated indoles, plausibly accounting for the 
observed racemization of 13a-c. The product was analyzed with NMR spectroscopy.  
Procedure for the screening of temperature and time dependence of the racemization of 13a in 
Table 3: To a solution of o-nosylated pyrroloindoline 11c (1.0 equiv) in toluene (0.1 M) was added TsOH 
(0.5 equiv). The reaction mixture was stirred at elevated temperature under microwave irradiation. The 
suspension was cooled to rt, washed with sat. aq. Na2CO3/brine (3:1, 20 mL), extracted with DCM (3 x 15 
mL), dried (Na2SO4) and concentrated in vacuo. Subsequently, conversion was determined by analysis with 
NMR spectroscopy according to the molar ratio between 11c and 12a/13a. The enantiomeric excess of 12a 
and 13a was determined by comparison with the racemates using HPLC on a chiral stationary phase.  
Pyrroloindoline synthesis 
General procedure 1: To a solution of 1-pyrroline 2a (30 mg, 0.25 mmol, 1.0 equiv) in toluene (0.1 M) were 
added the hydrazine hydrochloride 10 (0.26 mmol, 1.05 equiv) and p-toluenesulfonic acid monohydrate 
(48 mg, 0.25 mmol, 1.0 equiv). The reaction mixture was stirred for 30 min at 130 °C under microwave 
irradiation. The suspension was cooled to rt, washed with sat. aq. Na2CO3/brine (3:1, 20 mL), extracted with 
DCM (2 x 10 mL), dried (Na2SO4) and concentrated in vacuo. If necessary, the crude product was purified by 
flash chromatography. 
General procedure 2: To a solution of 1-pyrroline 2a (30 mg, 0.25 mmol, 1.0 equiv) in toluene (0.1 M) were 
added the hydrazine 10 (0.26 mmol, 1.05 equiv) and p-toluenesulfonic acid monohydrate (95 mg, 
0.50 mmol, 2.0 equiv). The reaction was proceeded as described in general procedure 1. 
 
pyrroloindoline 6a: Prepared from phenylhydrazine hydrochloride (38 mg, 0.26 mmol, 
1.05 eq) according to general procedure 1. Purification was achieved by flash 
chromatography (Al2O3 basic) with an eluent gradient (200:1 → 20:1 v/v DCM:MeOH), to 
obtain compound 6a (31 mg, 0.15 mmol, 61%) as a red oil. Rf = 0.78 (DCM:MeOH 100:1 
v/v). 1H NMR (400 MHz, CDCl3): δ 7.06 (d, J = 7.4 Hz, 1H, NHC*C*CH), 7.02 (t, J = 7.5 Hz, 1H, NHC*CHCH), 
6.73 (t, J = 7.4 Hz, 1H, NHC*C*CHCH), 6.56 (d, J = 7.8 Hz, 1H, CHC*CH), 4.88 (s, 1H, NHCHNH), 3.14 (dd, J 
= 11.0, 6.6 Hz, 1H, NHCH2), 2.79 – 2.73 (m, 1H, NHCH2), 2.52 – 2.43 (m, 1H, NHCH2CH), 2.13 – 1.71 (m, 6H, 
CHCH2CH2CH2, NH), 1.53 – 1.42 (m, 1H, NHCH2CHCH2) ppm. 13C NMR (101 MHz, CDCl3): δ 149.5 (C*), 135.5 
(C*), 127.7 (CH), 123.2 (CH), 119.0 (CH), 108.8 (CH), 87.2 (CH), 65.4 (C*), 54.5 (CH), 51.4 (CH2), 40.7 (CH2), 
33.5 (CH2), 27.8 (CH2) ppm. IR (neat): vmax (cm-1) = 3275 (br), 2941 (m), 2858 (m), 1607 (m), 1485 (m), 
1466 (m), 1396 (m), 1248 (m), 1196 (w), 903 (w), 636 (m). HRMS (ESI): m/z calculated for C13H17N2 
[M+H]+: 201.1386, found: 201.1393. 
5-methoxypyrroloindoline 6b: Prepared from 4-methoxyphenylhydrazine 
hydrochloride (39 mg, 0.26 mmol, 1.05 eq) and (‒)-2a according to general procedure 
1. Purification was achieved by flash chromatography (Al2O3 basic) with an eluent 
gradient (100:1 → 20:1 v/v DCM:MeOH), to obtain compound 6b (44 mg [2.5% 
CH2Cl2], 0.19 mmol, 73%) as a dark red oil. Rf = 0.73 (DCM:MeOH 100:1 v/v). 1H NMR (500 MHz, CDCl3): δ 
N
H
NH
H
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6.67 (d, J = 2.6 Hz, 1H, NHC*C*CH), 6.60 (dd, J = 8.4, 2.6 Hz, 1H, NHC*CHCH), 6.51 (d, J = 8.4 Hz, 1H, NHC*CH), 
4.85 (s, 1H, NHCHNH), 3.75 (s, 3H, CH3), 3.16 (dd, J = 10.8, 6.7 Hz, 1H, NHCH2), 2.74 (dd, J = 10.8, 3.0 Hz, 1H, 
NHCH2), 2.52 – 2.44 (m, 1H, NHCH2CH), 2.09 – 1.72 (m, 6H, CH2CH2CH2, NH), 1.53 – 1.42 (m, 1H, 
NHCH2CHCH2) ppm. 13C NMR (126 MHz, CDCl3): δ 153.9 (C*), 143.4 (C*), 137.4 (C*), 112.5 (CH), 110.1 (CH), 
109.7 (CH), 87.6 (CH), 65.8 (C*), 56.1 (CH3), 54.2 (CH), 51.3 (CH2), 40.5 (CH2), 33.5 (CH2), 27.7 (CH2) ppm. IR 
(neat): vmax (cm-1) = 3281 (br), 2932 (m), 2858 (m), 1489 (s), 1435 (w), 1205 (s), 1176 (m), 1140 (w), 1099 
(w), 1032 (s), 845 (w), 804 (m), 602 (w). HRMS (ESI): m/z calculated for C14H19N2O [M+H]+: 231.1492, 
found: 231.1497. Chiral HPLC 99% ee [Dr. Maisch Chiral AM, heptane/2-propanol = 85/15, v = 0.9 mL/min, 
column temperature: 30 °C, λ = 260 nm, t (major) = 17.926, t (minor) = 31.018 min]. Specific rotation: 
[ߙ]஽ଶ଴ = −42 ° (c = 1.0, EtOH).  
5-(iso-propyl)pyrroloindoline 6c: Prepared from 4-isopropylphenyl-hydrazine 
hydrochloride (50 mg, 0.26 mmol, 1.05 eq) according to general procedure 1. 
Purification was achieved by flash chromatography (Al2O3 basic) with an eluent 
gradient (200:1 → 20:1 v/v DCM:MeOH), to obtain compound 6c (42 mg, 0.17 mmol, 
69%) as a dark red oil. Rf = 0.82 (DCM:MeOH 100:1 v/v). 1H NMR (500 MHz, CDCl3): δ 
6.97 – 6.87 (m, 2H, CHC(iPr)CH), 6.51 (d, J = 7.8 Hz, 1H, NHC*CH), 4.86 (s, 1H, NHCHNH), 3.16 (dd, J = 10.9, 
6.7 Hz, 1H, NHCH2), 2.82 (hept, J = 6.9 Hz, 1H, CH(CH3)2), 2.73 (dd, J = 10.9, 2.8 Hz, 1H, NHCH2), 2.52 – 2.45 
(m, 1H NHCH2CH), 2.12 – 1.65 (m, 6H, CH2CH2CH2, NH), 1.55 – 1.43 (m, 1H, NHCH2CHCH2), 1.21 (d, J = 6.9 Hz, 
6H, CH3CHCH3) ppm. 13C NMR (126 MHz, CDCl3): δ 147.8 (C*), 140.3 (C*), 136.0 (C*), 125.7 (CH), 121.5 (CH), 
109.1 (CH), 87.8 (CH), 65.8 (C*), 54.5 (CH), 51.7 (CH2), 41.0 (CH2), 34.1 (CH), 33.8 (CH2), 28.0 (CH2), 24.9 
(CH3), 24.8 (CH3) ppm. IR (neat): vmax (cm-1) = 2951 (s), 2862 (m), 1616 (m), 1489 (s), 1447 (w), 1396 (w), 
1362 (w), 1333 (w), 1257 (m), 1190 (w), 1101 (w), 881 (w), 812 (s), 613 (m). HRMS (ESI): m/z calculated 
for C15H23N2 [M+H]+: 243.1856, found: 243.1860. 
5-(trifluoromethoxy)pyrroloindoline 6d: Prepared from 
4-(trifluormethoxy)phenylhydrazine hydrochloride (61 mg, 0.26 mmol, 1.05 eq) 
according to general procedure 1. Purification was achieved by flash 
chromatography (Al2O3 basic) with an eluent gradient (200:1 → 50:1 v/v 
DCM:MeOH), to obtain compound 6d (32 mg, 0.11 mmol, 45 %) as a dark red oil. Rf = 0.80 (DCM:MeOH 
100:1 v/v). 1H NMR (500 MHz, CDCl3): δ 6.90 – 6.84 (m, 2H, NHC*CHCH, NHC*C*CH), 6.48 (d, J = 8.4 Hz, 1H, 
NHC*CH), 4.93 (s, 1H, NHCHNH), 4.29 (bs, 1H, NH), 3.14 (dd, J = 10.9, 6.6 Hz, 1H, NHCH2), 2.77 (dd, J = 11.0, 
2.7 Hz, 1H, NHCH2), 2.51 – 2.44 (m, 1H, NHCH2CH), 2.25 (s, 1H, NH), 2.08 – 1.99 (m, 2H, CH2CH2CH2), 1.98 – 
1.90 (m, 1H, CHCH2CH2CH2), 1.90 – 1.73 (m, 2H, CHCH2CH2), 1.52 – 1.46 (m, 1H, NHCH2CHCH2) ppm. 13C 
NMR (126 MHz, CDCl3): δ 148.1 (C*), 142.0 (C*), 136.9 (C*), 120.82 (q, J = 255.6 Hz, C*), 120.80 (CH), 116.9 
(CH), 108.5 (CH), 87.6 (CH), 65.4 (C*), 54.6 (CH), 51.3 (CH2), 40.6 (CH2), 33.4 (CH2), 27.7 (CH2) ppm. 19F 
NMR (235 MHz, CDCl3): δ -58.39 ppm. IR (neat): vmax (cm-1) = 2943 (w), 2866 (w), 1489 (s), 1244 (s), 1213 
(s), 1148 (s), 873 (w), 816 (m), 800 (w), 613 (m), 600 (m). HRMS (ESI): m/z calculated C14H16F3N2O [M+H]+: 
285.1209, found: 285.1205. 
5-bromopyrroloindoline 6e: Prepared from 4-bromophenylhydrazine hydrochloride 
(59 mg, 0.26 mmol, 1.05 eq) and (‒)-2a according to general procedure 1. Purification 
was achieved by flash chromatography (Al2O3 basic) with an eluent gradient (200:1 → 
50:1 v/v DCM:MeOH), to obtain compound 6e (34 mg, 0.12 mmol, 50%) as a red solid. 
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Rf = 0.59 (DCM:MeOH 100:1 v/v). m.p.: 80.0 – 94.8 °C. 1H NMR (500 MHz, CDCl3): δ 7.12 (d, J = 2.0 Hz, 1H, 
CBrCH), 7.09 (dd, J = 8.2, 2.1 Hz, 1H, NHC*CHCH) 6.42 (d, J = 8.3 Hz, 1H, NHC*CH), 4.90 (s, 1H, NHCHNH), 
3.11 (dd, J = 11.1, 6.7 Hz, 1H, NHCH2), 2.76 (dd, J = 11.1, 2.6 Hz, 1H, NHCH2), 2.52 – 2.41 (m, 1H, NHCH2CH), 
2.09 – 1.96 (m, 2H, CH2CH2CH2), 1.94 – 1.87 (m, 1H, CHCH2CH2CH2), 1.85 – 1.70 (m, 2H, CHCH2CH2), 1.52 – 
1.40 (m, 1H, NHCH2CHCH2) ppm. 13C NMR (126 MHz, CDCl3): δ 148.5 (C*), 137.9 (C*), 130.3 (CH), 126.2 
(CH), 110.3 (C*), 110.0 (CH), 87.4 (CH), 65.4 (C*), 54.7 (CH), 51.2 (CH2), 40.6 (CH2), 33.4 (CH2), 27.7 
(CH2) ppm. IR (neat): vmax (cm-1) = 3171 (br), 2926 (m), 2858 (m), 1601 (m), 1475 (s), 1448 (m), 1420 (m), 
1261 (s), 1097 (m), 901 (m), 864 (m), 837 (m), 800 (s), 741 (w), 671 (m), 561 (m). HRMS (ESI): m/z 
calculated for C13H16BrN2 [M+H]+: 279.0491, found: 279.0490. Chiral HPLC 99% ee [Dr. Maisch Chiral AM, 
heptane/2-propanol = 95/5, v = 0.9 mL/min, column temperature: 30 °C, λ = 210 nm, t (major) = 22.180, t 
(minor) = 28.864 min]. Specific rotation: [ߙ]஽ଶ଴ = +8 ° (c = 0.5, EtOH). 
 
5-(trifluoromethyl)pyrroloindoline 6f: Prepared from 
4-(trifluormethyl)phenylhydrazine (48 mg, 0.26 mmol, 1.05 eq) according to general 
procedure 2. Purification was achieved by flash chromatography (Al2O3 basic) with an 
eluent gradient (100:1 → 20:1 v/v DCM:MeOH), to obtain compound 6f (32 mg, 
0.12 mmol, 48%) as a red solid. Rf = 0.62 (DCM:MeOH 100:1 v/v). m.p.: 97.4 – 113.7 °C. 1H NMR (500 MHz, 
CDCl3): δ 7.33 – 7.17 (m, 2H, NHC*CHCH, NHC*C*CH), 6.52 (d, J = 8.1 Hz, 1H, NHC*CH), 4.96 (s, 1H, 
NHCHNH), 4.45 (bs, 1H, NH), 3.11 (dd, J = 11.1, 6.4 Hz, 1H, NHCH2), 2.81 (dd, J = 11.1, 2.3 Hz, 1H, NHCH2), 
2.55 – 2.39 (m, 1H, NHCH2CH), 2.15 – 1.76 (m, 6H, CH2CH2CH2, NH), 1.53 – 1.38 (m, 1H, NHCH2CHCH2) ppm. 
13C NMR (126 MHz, CDCl3) δ 152.2 (C*), 135.4 (C*), 125.4 (q, J = 4.0 Hz, CH), 125.1 (q, J = 271.5 Hz, C*), 
120.2 (q, J = 32.3 Hz, C*), 120.1 (q, J = 3.6 Hz, CH), 107.0 (CH), 87.4 (CH), 64.9 (C*), 54.9 (CH), 51.3 (CH2), 
40.5 (CH2), 33.4 (CH2), 27.7 (CH2) ppm. 19F NMR (235 MHz, CDCl3): δ -60.54 ppm. IR (neat): vmax (cm-1) = 
3178 (br), 2943 (m), 2862 (m), 1616 (s), 1506 (m), 1323 (s), 1269 (s), 1153 (s), 1140 (s), 1121 (s), 1080 
(s), 1055 (s), 986 (m), 901 (s), 841 (m), 812 (s), 642 (m). HRMS (ESI): m/z calculated for C14H16F3N2 
[M+H]+: 269.1260, found: 269.1260. 
 
5-cyanopyrroloindoline 6g: Prepared from 4-hydrazinobenzonitrile hydrochloride 
(44 mg, 0.26 mmol, 1.05 eq) according to general procedure 1. Purification was 
achieved by flash chromatography (SiO2) with an eluent gradient (200:1 → 20:1 v/v 
DCM:MeOH), to obtain compound 6g (10 mg [4.0% CH2Cl2], 0.04 mmol, 18%)40 as a 
dark yellow oil. Rf = 0.53 (DCM:MeOH 100:1 v/v). 1H NMR (500 MHz, CDCl3): δ 7.32 – 7.22 (m, 2H, 
CHC(CN)CH), 6.48 (d, J = 8.2 Hz, 1H, NHC*CH), 5.00 (s, 1H, NHCHNH), 4.90 (s, 1H, NH), 3.14 (s, 1H, NH), 3.06 
(dd, J = 11.2, 6.4 Hz, 1H, NHCH2), 2.82 (dd, J = 11.3, 1.8 Hz, 1H, NHCH2), 2.50 – 2.43 (m, 1H, NHCH2CH), 2.12 – 
1.99 (m, 2H, CH2CH2CH2), 1.96 – 1.75 (m, 3H, CHCH2CH2CH2), 1.50 – 1.39 (m, 1H, NHCH2CHCH2) ppm. 13C 
NMR (126 MHz, CDCl3): δ 153.0 (C*), 135.8 (C*), 133.3 (CH), 126.8 (CH), 120.8 (C*), 107.5 (CH), 100.0 (C*), 
87.2 (CH), 64.8 (C*), 55.2 (CH), 51.1 (CH2), 40.5 (CH2), 33.3 (CH2), 27.8 (CH2). IR (neat): vmax (cm-1) = 2928 
(s), 2856 (s), 2206 (s), 1609 (s), 1558 (m), 1522 (m), 1491 (s), 1458 (s), 1271 (m), 1167 (m), 1103 (m), 814 
(m), 600 (m), 567 (w). HRMS (ESI): m/z calculated for C14H16N3 [M+H]+: 226.1339, found: 226.1340. 
 
6-nitropyrroloindoline 6h and 4-nitropyrroloindoline 
6h’: Prepared from 3-nitrophenylhydrazine hydrochloride 
(50 mg, 0.26 mmol, 1.05 eq) according to general procedure 1. 
Purification was achieved by flash chromatography (SiO2) 
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with an eluent gradient (200:1 → 50:1 v/v DCM:MeOH), to obtain compounds 6h and 6h’ (16 mg, 
0.07 mmol, 27%) in a 1.25:1 ratio as determined with the crude NMR spectrum. Pure fractions of both 
compound 6h (major), as an orange foam, and compound 6h’ (minor), as a red oil, were used for full 
identification. 6h: Rf = 0.56 (DCM:MeOH 100:1 v/v). 1H NMR (400 MHz, CDCl3) δ 7.58 (dd, J = 8.1, 1.8 Hz, 1H, 
C(NO2)CHCH), 7.29 – 7.21 (m, 1H, NHC*CH), 7.09 (d, J = 8.1 Hz, 1H, C(NO2)CHCH), 5.01 (s, 1H, NHCHNH), 
4.46 (s, 1H, NH), 3.13 (dd, J = 10.9, 6.5 Hz, 1H, NHCH2), 2.83 (dd, J = 10.9, 2.0 Hz, 1H, NHCH2), 2.53 – 2.44 (m, 
1H, NHCH2CH), 2.19 – 1.78 (m, 6H, CH2CH2CH2), 1.54 – 1.43 (m, 1H, NHCH2CHCH2). 13C NMR (101 MHz, 
CDCl3) δ 150.3 (C*), 148.5 (C*), 143.2 (C*), 122.9 (CH), 114.5 (CH), 102.3 (CH), 87.7 (CH), 65.1 (C*), 55.4 
(CH), 51.4 (CH2), 40.5 (CH2), 33.6 (CH2), 28.1 (CH2). 6h’:40 1H NMR (400 MHz, CDCl3) δ 7.40 (d, J = 8.2 Hz, 1H, 
C(NO2)CH), 7.15 (t, J = 8.0 Hz, 1H, C(NO2)CHCH), 6.81 (d, J = 7.8 Hz, 1H, NHC*CH), 4.82 – 4.66 (m, 2H, 
NHCHNH), 3.14 (dd, J = 11.0, 7.3 Hz, 1H, NHCH2), 3.07 – 2.98 (m, 1H, NHCH2CH), 2.68 (dd, J = 11.1, 4.3 Hz, 
1H, NHCH2), 2.35 – 2.20 (m, 2H, C*CH2CH2CH2), 1.99 – 1.80 (m, 2H, C*CH2CH2CH2), 1.77 – 1.62 (m, 1H, 
C*CH2), 1.58 – 1.51 (m, 1H, C*CH2CH2CH2). 13C NMR (101 MHz, CDCl3) δ 152.3 (C*), 146.5 (C*),41 129.0 (CH), 
128.2 (C*), 114.8 (CH), 113.8 (CH), 87.2 (CH), 67.3 (C*), 52.1 (CH2), 51.3 (CH), 37.0 (CH2), 33.3 (CH2), 26.4 
(CH2). IR (neat): vmax (cm-1) = 2935 (m), 2862 (m), 1614 (w), 1522 (s), 1340 (s), 1250 (w), 1074 (w), 907 
(m), 856 (w), 816 (w), 727 (s), 644 (w). HRMS (ESI): m/z calculated for C13H16N3O2 [M+H]+: 246.1237, 
found: 246.1228. 
 
6-methylpyrroloindoline 6i and 4-methylpyrrolo-indoline 6i’: 
Prepared from m-tolylhydrazine hydrochloride (42 mg, 0.26 mmol, 
1.05 eq) according to general procedure 1. Purification was 
achieved by flash chromatography (Al2O3 basic) with an eluent 
gradient (200:1 → 20:1 v/v DCM:MeOH), to obtain compounds 6i 
and 6i’ (28 mg, 0.13 mmol, 52%, inseparable mixture) as a dark yellow oil in a 2.0:1 ratio as determined 
with the crude NMR spectrum. Rf = 0.38 (DCM:MeOH 100:1 v/v). IR (neat): vmax (cm-1) = 2941 (m), 2860 
(m), 1616 (w), 1591 (w), 1259 (m), 1159 (w), 1078 (s), 1013 (s), 945 (w), 793 (s), 737 (m), 696 (w), 679 
(w), 596 (w). HRMS (ESI): m/z calculated for C14H19N2 [M+H]+: 215.1543, found: 215.1549. 6i: 1H NMR (500 
MHz, CDCl3): δ 6.94 (d, J = 7.3 Hz, 1H, NHC*C*CH),42 6.57 – 6.54 (m, 1H, C(CH3)CH), 6.40 (s, 1H, NHC*CH), 
4.86 (s, 1H, NHCHNH), 3.17 – 3.07 (m, 1H, NHCH2), 2.77 – 2.71 (m, 1H, NHCH2),42 2.47 – 2.40 (m, 1H, 
NHCH2CH), 2.26 (s, 3H, CH3), 2.12 – 1.97 (m, 2H, CH2CH2CH2),42 1.94 – 1.85 (m, 1H, CHCH2CH2CH2),42 1.84 – 
1.68 (m, 2H, CHCH2CH2),42 1.48 – 1.40 (m, 1H, NHCH2CHCH2) ppm. 13C NMR (126 MHz, CDCl3): δ 149.7 (C*), 
137.5 (C*), 132.6 (C*), 122.8 (CH), 119.6 (CH), 109.5 (CH), 87.4 (CH), 65.1 (C*), 54.4 (CH), 51.4 (CH2), 40.6 
(CH2), 33.5 (CH2), 27.7 (CH2), 21.6 (CH3) ppm. 6i’: 1H NMR (500 MHz, CDCl3): δ 6.98 – 6.92 (m, 1H, 
NHC*CHCH),42 6.55 (d, J = 7.9 Hz, 1H, Ar), 6.45 (d, J = 7.7 Hz, 1H, Ar), 4.59 (s, 1H, NHCHNH), 3.17 – 3.07 (m, 
1H, NHCH2),42 2.77 – 2.71 (m, 1H, NHCH2),42 2.61 – 2.58 (m, 1H, NHCH2CH), 2.29 (s, 3H, CH3), 2.12 – 1.97 (m, 
2H, CH2CH2CH2),42 1.94 – 1.85 (m, 2H, CHCH2CH2CH2),42 1.84 – 1.68 (m, 1H, CHCH2CH2),42 1.58 – 1.52 (m, 1H, 
NHCH2CHCH2) ppm. 13C NMR (126 MHz, CDCl3): δ 149.5 (C*), 134.5 (C*), 131.2 (C*), 127.8 (CH), 121.4 (CH), 
107.0 (CH), 87.0 (CH), 66.1 (C*), 51.5 (CH2), 50.7 (CH), 37.2 (CH2), 32.6 (CH2), 26.3 (CH2), 18.4 (CH3) ppm.  
6-(trifluoromethyl)pyrroloindoline 6j and 
4-trifluoromethylpyrroloindoline 6j’: Prepared from 3-
(trifluormethyl)phenylhydrazine hydrochloride (57 mg, 
0.26 mmol, 1.05 eq) according to general procedure 1. 
Purification was achieved by flash chromatography (Al2O3 
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basic) with an eluent gradient (200:1 → 50:1 v/v DCM:MeOH), to obtain compounds 6j and 6j’ (16 mg, 
0.06 mmol, 26%) in a 1:0.2 ratio as determined with the crude NMR spectrum. A pure fraction of compound 
6j (major), as an orange foam, was used for full identification. 6j: Rf = 0.62 (DCM:MeOH 100:1 v/v). m.p.: 
35.1 – 44.8 °C. 1H NMR (400 MHz, CDCl3): δ 7.10 (d, J = 7.7 Hz, 1H, NHC*C*CH), 6.96 (d, J = 7.7 Hz, 1H, 
NHC*C*CHCH), 6.73 (s, 1H, NHC*CH), 4.95 (s, 1H, NHCHNH), 4.37 (bs, 1H, NH), 3.13 (dd, J = 11.0, 6.7 Hz, 1H, 
NHCH2), 2.79 (dd, J = 11.1, 2.6 Hz, 1H, NHCH2), 2.53 – 2.42 (m, 1H, NHCH2CH), 2.26 – 1.74 (m, 6H, NH, 
CH2CH2CH2), 1.55 – 1.41 (m, 1H, NHCH2CHCH2) ppm. 13C NMR (101 MHz, CDCl3): δ 149.7 (C*), 139.3 (C*), 
130.1 (q, J = 32 Hz, C*), 124.7 (q, J = 272 Hz, C*), 123.0 (CH), 115.6 (q, J = 4.1 Hz, CH), 104.6 (q, J = 3.7 Hz, 
CH), 87.2 (CH), 65.0 (C*), 54.8 (CH), 51.2 (CH2), 40.4 (CH2), 33.4 (CH2), 27.7 (CH2) ppm. 19F NMR (235 MHz, 
CDCl3): δ -62.25 ppm. IR (neat): vmax (cm-1) = 2934 (w), 2862 (w), 1614 (w), 1336 (m), 1317 (s), 1155 (m), 
1107 (s), 1059 (m), 984 (w), 857 (m), 810 (m), 737 (w), 700 (m), 679 (w), 665 (m). HRMS (ESI): m/z 
calculated for C14H16F3N2 [M+H]+: 269.1260, found: 269.1254. 6j’:43 1H NMR (500 MHz, CDCl3): δ 7.16 – 7.11 
(m, 1H, NHC*CHCH), 6.99 (d, J = 7.7 Hz, 1H, NHC*CH), 6.77 (d, J = 7.8 Hz, 1H, NHC*CHCHCH), 4.78 (s, 1H, 
NHCHNH), 3.13 (dd, J = 11.4, 7.1 Hz, 1H, NHCH2), 2.96 – 2.89 (m, 1H, NHCH2CH), 2.71 (dd, J = 11.4, 4.3 Hz, 
1H, NHCH2), 2.24 – 1.50 (m, 6H, CH2CH2CH2). 13C NMR (126 MHz, CDCl3): δ 150.9 (C*), 128.7 (CH), 127.0 (q, J 
= 32 Hz, C*), 124.7 (q, J = 273 Hz, C*) 117.2 (CH), 112.5 (CH), 87.0 (CH), 66.9 (C*), 51.4 (CH2), 51.3 (CH), 38.2 
(CH2), 32.6 (CH2), 25.9 (CH2). 19F NMR (235 MHz, CDCl3): δ -57.11 ppm. 
 
6-(tert-butyl)pyrrolodindoline 6k: Prepared from 3-(t-butyl)phenyl-hydrazine 
hydrochloride (53 mg, 0.26 mmol, 1.05 eq) according to general procedure 1. 
Purification was achieved by flash chromatography (Al2O3 basic) with an eluent 
gradient (200:1 → 50:1 v/v DCM:MeOH), to obtain compound 6k (28 mg, 
0.11 mmol, 44%) as a yellow solid. Rf = 0.47 (DCM:MeOH 100:1 v/v). m.p.: 80.0 – 100.1 °C. 1H NMR (500 
MHz, CDCl3): δ 6.98 (d, J = 7.6 Hz, 1H, NHC*C*CH), 6.77 (dd, J = 7.8, 1.8 Hz, 1H, NHC*C*CHCH), 6.63 (d, J = 1.8 
Hz, 1H, NHC*CH), 4.88 (s, 1H, NHCHNH), 3.16 (dd, J = 10.9, 6.7 Hz, 1H, NHCH2), 2.75 (dd, J = 11.0, 2.8 Hz, 1H, 
NHCH2), 2.52 – 2.43 (m, 1H, NHCH2CH), 2.14 – 1.96 (m, 4H, NH, CH2CH2CH2), 1.95 – 1.87 (m, 1H, 
CHCH2CH2CH2), 1.86 – 1.71 (m, 2H, CHCH2CH2), 1.55 – 1.42 (m, 1H, NHCH2CHCH2), 1.32 – 1.20 (m, 9H, 
C(CH3)3) ppm. 13C NMR (126 MHz, CDCl3): δ 151.2 (C*), 149.4 (C*), 132.6 (C*), 122.5 (CH), 116.2 (CH), 106.4 
(CH), 87.4 (CH), 65.2 (C*), 54.1 (CH), 51.4 (CH2), 40.6 (CH2), 34.8 (C*), 33.5 (CH2), 31.7 (CH3), 27.7 
(CH2) ppm. IR (neat): vmax (cm-1) = 2947 (s), 2926 (s), 2905 (s), 2858 (s), 1611 (m), 1458 (s), 1448 (s), 1362 
(w), 1261 (m), 1099 (m), 1086 (m), 852 (m), 803 (s), 737 (s), 654 (s). HRMS (ESI): m/z calculated for 
C17H25N2 [M+H]+: 257.2012, found: 257.2003. 
 
pyrroloazaindoline 6l: Prepared from 2-chloro-5-hydrazinylpyridine (39 mg, 
0.26 mmol, 1.05 eq) according to general procedure 2. Purification was achieved by 
flash chromatography (Al2O3 basic) with an eluent gradient (100:1 → 20:1 v/v 
DCM:MeOH), to obtain compound 6l (36 mg [3.1% CH2Cl2, 9.4% acetone], 0.13 mmol, 
53%) as a dark red oil. Rf = 0.46 (DCM:MeOH 100:1 v/v). 1H NMR (500 MHz, CDCl3): δ 6.90 (d, J = 8.2 Hz, 1H, 
NHC*CHCH), 6.72 (d, J = 8.2 Hz, 1H, NHC*CH), 4.95 (s, 1H, NHCHNH), 4.29 (s, 1H, NH), 3.10 (dd, J = 11.0, 6.5 
Hz, 1H, NHCH2), 2.84 (dd, J = 11.1, 2.5 Hz, 1H, NHCH2), 2.76 – 2.67 (m, 1H, NHCH2CH), 2.36 – 2.27 (m, 1H, 
CHCH2CH2CH2), 2.14 – 2.00 (m, 1H, NHCH2CHCH2), 1.97 – 1.82 (m, 2H, CHCH2CH2CH2), 1.81 – 1.70 (m, 1H, 
CHCH2CH2), 1.52 – 1.41 (m, 1H, NHCH2CHCH2) ppm. 13C NMR (126 MHz, CDCl3): δ 156.4 (C*), 142.5 (C*), 
140.3 (C*), 122.1 (CH), 116.8 (CH), 86.1 (CH), 65.7 (C*), 53.2 (CH), 51.7 (CH2), 38.5 (CH2), 33.4 (CH2), 27.5 
(CH2) ppm. IR (neat): vmax (cm-1) = 3277 (w), 2935 (m), 2864 (m), 1593 (m), 1429 (s), 1356 (w), 1244 (m), 
N
H
NH
H
N
N
H
NH
H
Cl
Switchable Cascade Reaction towards either Pyrroloindolines or Constrained Tryptamines 
 
115 
2298 (m), 1101 (m), 903 (w), 816 (m), 733 (w), 683 (w), 602 (m). HRMS (ESI): m/z calculated for 
C12H15ClN3 [M+H]+: 236.0949, found: 236.0938. 
 
3,5-difluoropyrroloindoline 6m: Prepared from 2,4-difluorophenylhydrazine 
hydrochloride (48 mg, 0.26 mmol, 1.05 eq) according to general procedure 1. 
Purification was achieved by flash chromatography (Al2O3 basic) with an eluent 
gradient (200:1 → 50:1 v/v DCM:MeOH), to obtain compound 6m (13 mg, 0.06 mmol, 
22%) as a dark red oil. Rf = 0.66 (DCM:MeOH 100:1 v/v). 1H NMR (500 MHz, CDCl3): δ 6.64 – 6.52 (m, 2H, 
CHCFCH), 4.97 (s, 1H, NHCHNH), 3.19 (dd, J = 10.7, 6.6 Hz, 1H, NHCH2), 2.80 (dd, J = 10.7, 2.8 Hz, 1H, 
NHCH2), 2.51 – 2.43 (m, 1H, NCH2CH), 2.08 – 1.97 (m, 2H, CH2CH2CH2), 1.98 – 1.89 (m, 1H, CHCH2CH2CH2), 
1.86 – 1.77 (m, 2H, CHCH2CH2), 1.57 – 1.44 (m, 1H, NHCH2CHCH2) ppm. 13C NMR (126 MHz, CDCl3): δ 156.6 
(dd, J = 238.5, 9.6 Hz, C*), 147.1 (dd, J = 243.4, 12.7 Hz, C*), 139.6 (dd, J = 8.6, 6.0 Hz, C*), 132.6 (dd, J 
= 12.3, 2.0 Hz, C*), 105.9 (dd, J = 23.4, 3.4 Hz, CH), 102.3 (dd, J = 27.2, 21.8 Hz, CH), 87.8 (CH), 66.1 (C*), 54.2 
(CH), 51.2 (CH2), 40.3 (CH2), 33.4 (CH2), 27.7 (CH2) ppm. 19F NMR (235 MHz, CDCl3): δ -122.77 (t, J = 8.6 Hz), 
-131.99 (d, J = 10.1 Hz) ppm. IR (neat): vmax (cm-1) = 2941 (m), 2862 (m), 1607 (w), 1489 (s), 1418 (w), 
1340 (m), 1215 (m), 1094 (m), 982 (m), 845 (m), 735 (w), 721 (w), 638 (w), 588 (m). HRMS (ESI): m/z 
calculated for C13H15F2N2 [M+H]+: 237.1198, found: 237.1200. 
 
3-methoxy-6-chloropyrroloindoline 6n: Prepared from 5-chloro-2-methoxy-
phenylhydrazine hydrochloride (56 mg, 0.26 mmol, 1.05 eq) according to general 
procedure 1. Purification was achieved by flash chromatography (Al2O3 basic) with an 
eluent gradient (200:1 → 20:1 v/v DCM:MeOH), to obtain compound 6n (18 mg, 
0.07 mmol, 27%) as a dark yellow oil. Rf = 0.54 (DCM:MeOH 100:1 v/v). 1H NMR (500 
MHz, CDCl3): δ 6.64 (d, J = 8.6 Hz, 1H, OC*CH), 6.58 (d, J = 8.5 Hz, 1H, OC*CHCH), 4.69 (s, 1H, NHCHNH), 4.36 
(s, 1H, NH), 3.79 (d, J = 3.2 Hz, 3H, CH3), 3.18 – 3.05 (m, 1H, NHCH2), 2.93 – 2.80 (m, 1H, NHCH2CH), 2.64 (dd, 
J = 10.9, 4.8 Hz, 1H, NHCH2), 2.32 (ddd, J = 12.8, 10.3, 7.1 Hz, 1H, CHCH2CH2CH2), 2.11 – 2.02 (m, 1H, 
NHCH2CHCH2), 2.00 – 1.91 (m, 1H, CHCH2CH2), 1.88 – 1.63 (m, 3H, NH, CHCH2CH2CH2), 1.56 – 1.46 (m, 1H, 
NHCH2CHCH2) ppm. 13C NMR (126 MHz, CDCl3): δ 143.5 (C*), 139.9 (C*), 130.6 (C*), 122.4 (C*), 119.4 (CH), 
110.6 (CH), 86.9 (CH), 67.2 (C*), 55.6 (CH3), 51.3 (CH2), 50.3 (CH), 36.4 (CH2), 32.4 (CH2), 26.4 (CH2) ppm. IR 
(neat): vmax (cm-1) = 2932 (m), 2858 (m), 1612 (w), 1583 (w), 1481 (s), 1460 (m), 1439 (m), 1275 (m), 1213 
(s), 1180 (w), 1092 (m), 1003 (w), 924 (w), 777 (m), 655 (w), 635 (w). HRMS (ESI): m/z calculated for 
C14H18ClN2O [M+H]+: 265.1102, found: 265.1095. 
 
3-(trifluoromethyl)pyrroloindoline 6o: Prepared from 2-
(trifluormethyl)phenylhydrazine hydrochloride (56 mg, 0.26 mmol, 1.05 eq) according 
to general procedure 1. Purification was achieved by flash chromatography (Al2O3 
basic) with an eluent gradient (100:0 → 100:1 v/v DCM:MeOH), to obtain compound 6o 
(13 mg, 0.05 mmol, 19%) as a dark yellow solid. Rf = 0.88 (DCM:MeOH 100:1 v/v). m.p.: 36.2 – 47.6 °C. 1H 
NMR (500 MHz, CDCl3): δ 7.19 (d, J = 7.9 Hz, 1H, CF3C*CH), 7.15 (d, J = 7.3 Hz, 1H, NHC*C*CH), 6.71 (t, J = 7.6 
Hz, 1H, F3CC*CHCH), 4.99 (d, J = 2.3 Hz, 1H, NHCHNH), 4.71 (s, 1H, NH), 3.14 (dd, J = 10.9, 6.4 Hz, 1H, 
NHCH2), 2.81 (dd, J = 10.9, 2.3 Hz, 1H, NHCH2), 2.49 – 2.40 (m, 1H, NHCH2CH), 2.11 – 1.77 (m, 6H, NH, 
CH2CH2CH2), 1.51 – 1.42 (m, 1H, NHCH2CHCH2) ppm. 13C NMR (126 MHz, CDCl3): δ 146.8 (C*), 137.5 (C*), 
126.3 (CH), 125.1 (q, J = 272 Hz, C*), 124.3 (q, J = 4.4 Hz, CH), 109.0 (q, J = 29.6 Hz, C*), 87.4 (CH), 64.5 (C*), 
55.2 (CH), 51.3 (CH2), 40.7 (CH2), 33.6 (CH2), 28.0 (CH2) ppm. 19F NMR (235 MHz, CDCl3): δ -61.75 ppm. IR 
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(neat): vmax (cm-1) = 3236 (w), 2932 (m), 2868 (m), 1603 (m), 1354 (m), 1313 (m), 1281 (m), 1163 (s), 2092 
(s), 1080 (s), 1064 (s), 1032 (s), 988 (m), 854 (m), 785 (w), 746 (m). HRMS (ESI): m/z calculated for 
C14H16F3N2 [M+H]+: 269.1260, found: 269.1250. 
 
N1-methylpyrroloindoline 6p: Prepared from 1-methyl-1-phenylhydrazine (32 µL, 
0.26 mmol, 1.05 eq) according to general procedure 2. Purification was achieved by flash 
chromatography (Al2O3 basic) with an eluent gradient (200:1 → 50:1 v/v DCM:MeOH), 
to obtain compound 6p (29 mg, 0.14 mmol, 54%) as a yellow oil. Rf = 0.94 (DCM:MeOH 
100:1 v/v). 1H NMR (500 MHz, CDCl3): δ 7.07 (t, J = 7.4 Hz, 1H, CH3NC*C*CHCH), 7.03 (d, 
J = 7.2 Hz, 1H, CH3NC*C*CH), 6.65 (t, J = 7.3 Hz, 1H, CH3NC*CHCH), 6.35 (d, J = 7.8 Hz, 1H, CH3NC*CH), 4.52 
(s, 1H, NCHNH), 3.08 (dd, J = 11.1, 6.6 Hz, 1H, NHCH2), 2.81 (s, 3H, CH3), 2.81 – 2.76 (m, 1H, NHCH2), 2.43 (q, 
J = 7.1 Hz, 1H, NHCH2CH), 2.21 – 1.97 (m, 3H, CH2CH2CH2, NH), 1.87 – 1.76 (m, 3H, CHCH2CH2CH2), 1.48 – 
1.38 (m, 1H, NHCH2CHCH2) ppm. 13C NMR (126 MHz, CDCl3): δ 151.2 (C*), 135.8 (C*), 127.7 (CH), 122.5 
(CH), 117.3 (CH), 105.5 (CH), 94.6 (CH), 63.7 (C*), 54.8 (CH), 51.9 (CH2), 40.9 (CH2), 34.2 (CH2), 32.5 (CH3), 
28.3 (CH2) ppm. IR (neat): vmax (cm-1) = 2941 (m), 2856 (m), 1605 (s), 1489 (s), 1448 (w), 1296 (w), 1252 
(w), 1099 (w), 1022 (w), 941 (w), 920 (w), 843 (w), 733 (s), 635 (w), 602 (w). HRMS (ESI): m/z calculated 
for C14H19N2 [M+H]+: 215.1543, found: 215.1547. 
 
 N1-methylpyrroloindoline 6q: Prepared from 1-benzyl-1-phenylhydrazine 
hydrochloride (61 mg, 0.26 mmol, 1.05 eq) according to general procedure 1. Purification 
was achieved by flash chromatography (Al2O3 basic) with an eluent gradient (100:0 → 
100:1 v/v DCM:MeOH), to obtain compound 6q (37 mg, 0.13 mmol, 51%) as a dark 
yellow oil. Rf = 0.86 (DCM). 1H NMR (500 MHz, CDCl3): δ 7.32 – 7.28 (m, 5H, Ph), 7.12 – 
6.96 (m, 2H, NC*C*CHCHCH), 6.70 (td, J = 7.4, 1.0 Hz, 1H, NC*C*CHCH), 6.37 (d, J = 7.8 Hz, 1H, NC*CH), 4.84 
(s, 1H, NCHNH), 4.62 – 4.46 (m, 2H, NCH2), 3.19 (dd, J = 11.0, 6.6 Hz, 1H, NHCH2), 2.90 (dd, J = 11.1, 2.2 Hz, 
1H, NHCH2), 2.59 – 2.53 (m, 1H, NHCH2CH), 2.20 – 2.00 (m, 2H, CH2CH2CH2), 1.95 – 1.79 (m, 3H, 
CHCH2CH2CH2), 1.63 – 1.53 (m, 1H, NHCH2CHCH2) ppm. 13C NMR (126 MHz, CDCl3): δ 150.1 (C*), 138.4 (C*), 
134.8 (C*), 128.8 (CH), 128.0 (CH), 127.5 (CH), 127.2 (CH), 122.6 (CH), 118.1 (CH), 106.3 (CH), 91.8 (CH), 
63.9 (C*), 54.2 (CH), 50.7 (CH2), 50.0 (CH2), 40.6 (CH2), 33.5 (CH2), 27.9 (CH2) ppm. IR (neat): vmax (cm-1) = 
2941 (m), 2858 (m), 1603 (s), 1489 (s), 1452 (m), 1354 (m), 1296 (w), 1267 (w), 1252 (w), 1157 (w), 1099 
(w), 1028 (w), 941 (w), 920 (w), 841 (w), 799 (w), 733 (s), 696 (s), 633 (s), 606 (m), 540 (s). HRMS (ESI): 
m/z calculated for C20H23N2 [M+H]+: 291.1856, found: 291.1840. 
 
pentacyclic pyrroloindoline 11a: Prepared from 1-pyrroline (–)-2a (30 mg, 
0.25 mmol, 1.0 equiv) and 1-amineindoline hydrochloride (46 mg, 0.26 mmol, 
1.05 equiv), according to general procedure 1. The crude product was dissolved 
DCM (0.1 M), after which Et3N (42 μL, 0.30 mmol, 1.2 equiv) and o-nosyl chloride 
(68 mg, 0.30 mmol, 1.2 equiv) were added. The reaction mixture was stirred for 
2 h at rt, washed with brine (20 mL), extracted with DCM (3 x 15 mL), dried 
(Na2SO4) and concentrated in vacuo. The crude product was impregnated on SiO2 and purification was 
achieved by flash chromatography (SiO2) with an eluent gradient (20:1 → 10:1 v/v cHex:EtOAc), to obtain 
the compound 11a (43 mg, 0.093 mmol, 37 %) as a light yellow foam. Crystallization was achieved by slow 
evaporation from dichloromethane. Rf = 0.33 (cHex:EtOAc 4:1 v/v). m.p.: >157 °C (decomposition).  1H 
NMR (500 MHz, CDCl3): δ 8.25 – 8.15 (m, 1H, C(NO2)CH), 7.78 – 7.68 (m, 3H, o-NO2Ph), 6.94 (d, J = 7.2 Hz, 
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1H, CH2C*CH), 6.81 (d, J = 7.3 Hz, 1H, CH2C*CHCHCH), 6.66 (t, J = 7.3 Hz, 1H, CH2C*CHCH), 5.24 (s, 1H, 
NCHN), 3.87 (dd, J = 10.1, 7.4 Hz, 1H, NCH2CH), 3.62 (t, J = 8.2 Hz, 1H, NCH2CH2), 3.43 (dd, J = 10.2, 1.6 Hz, 
1H, NHCH2CH), 3.32 (m, 1H, NCH2CH2), 3.22 – 3.14 (m, 1H, NCH2CH2), 3.09 (dd, J = 14.5, 7.8 Hz, 1H, 
NCH2CH2), 2.76 (q, J = 6.6 Hz, 1H, CH), 2.19 – 2.12 (m, 1H, CH2CH2CH2CH), 2.09 – 2.00 (m, 1H, CH2CH2CH), 
1.91 – 1.82 (m, 1H, CH2CH2CH2CH), 1.82 – 1.65 (m, 2H, CH2CH2CH), 1.45 – 1.32 (m, 1H, CH2CH2CH) ppm. 13C 
NMR (126 MHz, CDCl3): δ 161.4 (C*), 148.1 (C*), 133.8 (C*), 133.7 (CH), 132.0 (CH), 130.6 (CH), 127.3 (C*), 
124.7 (CH), 123.3 (CH), 123.1 (C*), 120.7 (CH), 119.7 (CH), 95.8 (CH), 72.2 (C*), 56.7 (CH2), 54.5 (CH2), 51.1 
(CH), 39.7 (CH2), 34.3 (CH2), 34.1 (CH2), 27.4 (CH2) ppm. IR (neat): vmax (cm-1) = 2949 (w),  2864 (w), 1537 
(s), 1348 (s), 1330 (m), 1169 (s), 1122 (m), 1040 (m), 1026 (m), 763 (m), 308 (m), 561 (s). HRMS (ESI): 
m/z calculated for C21H21N3NaO4S [M+Na]+: 434.1145, found: 434.1135. Chiral HPLC 99% ee [Dr. Maisch 
Chiral AM, heptane/2-propanol = 85/15, v = 0.9 mL/min, column temperature: 30 °C, λ = 220 nm, t (minor) 
= 9.703, t (major) = 15.158 min]. Specific rotation: [ߙ]஽ଶ଴ = −72 ° (c = 0.18, EtOH). 
 
 pentacyclic pyrroloindoline 11b: To a solution of 1-pyrroline (–)-2b (29 mg, 
0.20 mmol, 1.0 equiv) in toluene (2.5 mL) were added phenylhydrazine 
hydrochloride (31 mg, 0.21 mmol, 1.05 equiv) and pyridinium p-toluenesulfonic 
acid (52 mg, 0.20, 1.0 equiv). The reaction mixture was stirred for 5 min at 130 °C 
under microwave irradiation. The suspension was cooled to rt, dissolved in 
methanol (3 mL), washed with sat. aq. Na2CO3 (20 mL), extracted with DCM (3 x 
15 mL), dried (Na2SO4) and concentrated in vacuo. The crude product was dissolved DCM (2.5 mL), after 
which Et3N (34 μL, 0.25 mmol, 1.2 equiv) and o-nosyl chloride (55 mg, 0.25 mmol, 1.2 equiv) were added. 
The reaction mixture was stirred for 2 h at rt, washed with brine (20 mL), extracted with DCM (3 x 15 mL), 
dried (Na2SO4) and concentrated in vacuo. The crude product was impregnated on SiO2 and purified by flash 
chromatography (SiO2) with an eluent gradient (6:100 → 10:100 v/v acetone/cHex), to obtain compound 
11b (51 mg, 0.12 mmol, 57%) as a light yellow oil. Rf = 0.53 (cHex:acetone 2:1 v/v). m.p.: 154 – 160 °C. 1H 
NMR (500 MHz, CDCl3) δ 8.11 – 8.04 (m, 1H, C(NO2)CH), 7.78 – 7.70 (m, 2H, C(NO2)C*CHCHCH), 7.69 – 7.63 
(m, 1H, SO2C*CH), 7.23 (d, J = 7.5 Hz, 1H, NHC*C*CH), 7.04 (t, J = 7.6 Hz, 1H, NHC*CHCH), 6.75 (t, J = 7.5 Hz, 
1H, NHC*C*CHCH), 6.50 (d, J = 7.8 Hz, 1H, NHC*CH), 5.95 (d, J = 2.4 Hz, 1H, NHCHN), 4.83 (s, 1H, NH), 3.73 
(d, J = 10.1 Hz, 1H, NCH2), 3.46 (dd, J = 10.0, 7.7 Hz, 1H, NCH2), 2.59 – 2.54 (m, 1H, C*CHCH2CH), 2.49 – 2.44 
(m, 1H, NCH2CH), 2.43 – 2.39 (m, 1H, C*CHCH2CH), 2.17 (d, J = 9.9 Hz, 1H, C*CHCH2CH), 1.79 – 1.68 (m, 2H, 
C*CHCH2CH, CH2CH2), 1.64 – 1.55 (m, 1H, CH2CH2), 1.50 – 1.35 (m, 2H, CH2CH2). 13C NMR (126 MHz, CDCl3) δ 
148.5 (C*), 148.2 (C*), 134.2 (C*), 133.7 (CH), 133.0 (C*), 131.9 (CH), 130.4 (CH), 128.1 (CH), 124.2 (CH), 
122.8 (CH), 119.5 (CH), 109.1 (CH), 81.8 (CH), 64.2 (C*), 55.4 (CH), 47.5 (CH2), 47.1 (CH), 42.7 (CH2), 41.4 
(CH), 24.0 (CH2), 21.8 (CH2). IR (neat): vmax (cm-1) = 2957 (w), 1541 (s), 1350 (s), 1168 (m), 1153 (m), 1128 
(m), 1041 (m), 1026 (m), 989 (m), 734 (s), 605 (s), 569 (m). HRMS (ESI): m/z calculated for C21H22N3O4S 
[M+H]+: 412.1326, found: 412.1321. Chiral HPLC 99% ee [Dr. Maisch Chiral AM, heptane/2-propanol = 
85/15, v = 0.9 mL/min, column temperature: 30 °C, λ = 210 nm, t (minor) = 29.300, t (major) = 46.092 min]. 
Specific rotation: [ߙ]஽ଶ଴ = −49.0 ° (c = 0.5, CDCl3). 
 
pyrroloindoline 11c: To a solution of 1-pyrroline (–)-2a (450 mg, 4.12 mmol, 
1.0 equiv) in toluene (10 mL) were added phenylhydrazine hydrochloride (631 
mg, 4.32 mmol, 1.05 equiv) and TFA (52 mg, 3.18 mmol, 1.0 equiv). The reaction 
mixture was stirred for 30 min at 130 °C under microwave irradiation. The 
suspension was cooled to rt, dissolved in methanol (5 mL), washed with sat. aq. 
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Na2CO3 (50 mL), extracted with DCM (3 x 35 mL), dried (Na2SO4) and concentrated in vacuo. The crude 
product was dissolved DCM (2.5 mL), after which Et3N (692 μL, 4.94 mmol, 1.2 equiv) and o-nosyl chloride 
(1115 mg, 4.94 mmol, 1.2 equiv) were added. The reaction mixture was stirred for 2 h at rt, washed with 
brine (20 mL), extracted with DCM (3 x 15 mL), dried (Na2SO4) and concentrated in vacuo. The crude 
product was impregnated on SiO2 and purified by flash chromatography with an eluent gradient (6:100 → 
12:100 v/v acetone:cHex), to obtain compound 11c (1022 mg, 2.65 mmol, 64%) as a yellow oil. Rf = 0.21 
(cHex:EtOAc 4:1 v/v). 1H NMR (500 MHz, CDCl3) δ 8.04 (d, J = 7.4 Hz, 1H, C(NO2)CH), 7.74 – 7.63 (m, 3H, 
C(SO2)CHCHCH), 7.05 (t, J = 6.5 Hz, 2H, NHC*C*CHCHCH), 6.76 (t, J = 7.4 Hz, 1H,  NHC*CHCH), 6.55 (d, J = 8.0 
Hz, 1H, NHC*CH), 5.53 (s, 1H, NHCHN), 4.89 (s, 1H, NH), 3.48 (dd, J = 9.9, 6.4 Hz, 1H, NCH2), 3.41 (d, J = 10.1 
Hz, 1H, NCH2), 2.64 – 2.56 (m, 1H, NCH2CH), 2.11 – 2.01 (m, 3H, CHCH2CH2CH2), 1.81 (q, J = 6.9 Hz, 2H, 
CHCH2CH2), 1.52 – 1.41 (m, 1H, CHCH2CH2). 13C NMR (126 MHz, CDCl3) δ 148.7 (C*), 148.2 (2 x C*), 133.7 
(CH), 133.0 (C*), 131.9 (CH), 130.7 (CH), 128.3 (CH), 124.3 (CH), 122.6 (CH), 119.5 (CH), 109.0 (CH), 85.9 
(CH), 65.6 (C*), 52.6 (CH2), 52.5 (CH), 40.1 (CH2), 33.1 (CH2), 26.8 (CH2). IR (neat): vmax (cm-1) = 2947 (w), 
2866 (w), 1541 (s), 1344 (m), 1164 (m), 1029 (m), 850 (m), 739 (s), 729 (s), 600 (m), 569 (m). HRMS (ESI): 
m/z calculated for C19H20N3O4S [M+H]+: 386.1169, found: 386.1159. Chiral HPLC 99% ee [Dr. Maisch Chiral 
AM, heptane/2-propanol = 80/20, v = 0.9 mL/min, column temperature: 30 °C, λ = 210 nm, t (minor) = 
27.055, t (major) = 38.032 min]. Specific rotation: [ߙ]஽ଶ଴ = −82 ° (c = 1.15, EtOH). 
Synthesis of constrained tryptamines 
 
constrained tryptamine 8a: To a solution of 1-pyrroline 2a (30 mg, 0.25 mmol, 1.0 
equiv) in toluene (0.1 M) were added phenylhydrazine hydrochloride (38 g, 0.26 mmol, 
1.05 equiv) and p-toluenesulfonic acid monohydrate (71 mg, 0.38 mmol, 1.5 equiv). The 
reaction mixture was stirred for 30 min at 130 °C under microwave irradiation. The 
suspension was cooled to rt, washed with sat. aq. Na2CO3/brine (3:1, 20 mL), extracted 
with DCM (2 x 10 mL), dried (Na2SO4) and concentrated in vacuo. Purification was achieved by flash 
chromatography (Al2O3 basic) with an eluent gradient (100:1 → 10:1 v/v DCM:MeOH), to obtain compound 
8a (20 mg, 0.10 mmol, 40%)40 as a yellow solid. Rf = 0.05 (DCM:MeOH 100:1 v/v). m.p.: 62.0 – 72.5 °C. 1H 
NMR (500 MHz, CDCl3): δ 7.83 (s, 1H, NH), 7.57 (d, J = 7.7 Hz, 1H, NHC*C*CH), 7.29 (d, J = 8.0 Hz, 1H, 
NHC*CH), 7.11 (t, J = 7.1 Hz, 1H, NHC*CHCH), 7.07 (t, J = 7.4 Hz, 1H, NHC*C*CHCH), 3.17 (dd, J = 12.5, 3.9 Hz, 
1H, NH2CH2), 3.11 – 3.04 (m, 1H, NH2CH2CH), 2.99 (dd, J = 12.5, 7.9 Hz, 1H, NH2CH2), 2.75 – 2.70 (m, 2H, 
NHC*CH2), 2.07 – 1.69 (m, 6H, NH2, NHC*CH2CH2CH2) ppm. 13C NMR (126 MHz, CDCl3): δ 135.8 (C*), 135.3 
(C*), 127.5 (C*), 121.1 (CH), 119.4 (CH), 118.6 (CH), 111.2 (C*), 110.7 (CH), 46.1 (CH2), 35.9 (CH), 26.5 
(CH2), 23.5 (CH2), 20.2 (CH2) ppm. IR (neat): vmax (cm-1) = 2922 (m), 2862 (m), 1618 (w), 1580 (w), 1452 
(m), 1325 (m), 1261 (w), 1234 (w), 1012 (w), 912 (w), 808 (w), 735 (s). HRMS (ESI): m/z calculated for 
C13H14N [M+H-NH3]+: 184.1121, found: 184.1117. 
General procedure 3: To a solution of 1-pyrroline 2a (1.0 equiv) in toluene (0.1 M) were added the 
hydrazine hydrochloride 10 (1.05 equiv) and p-toluenesulfonic acid monohydrate (1.5 equiv). The reaction 
mixture was stirred for 30 min at 130 °C under microwave irradiation. The suspension was cooled to rt, 
dissolved in MeOH (3 mL), washed with sat. aq. Na2CO3/brine (3:1, 20 mL), extracted with DCM (3 x 15 mL), 
dried (Na2SO4) and concentrated in vacuo. The crude product was dissolved DCM (0.1 M), after which Et3N 
(1.2 equiv) and o-nosyl chloride (1.2 equiv) were added. The reaction mixture was stirred for 2 h at rt, 
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washed with brine (20 mL), extracted with DCM (3 x 15 mL), dried (Na2SO4) and concentrated in vacuo. The 
crude product was impregnated on SiO2 and purified by flash chromatography. 
General procedure 4: To a solution of 1-pyrroline 2a (1.0 equiv) in toluene (0.1 M) were added the 
hydrazine 10 (1.05 equiv) and p-toluenesulfonic acid monohydrate (2.5 equiv). The reaction was proceeded 
as described in general procedure 3. 
 
 tricyclic tryptamine 12a and 13a: 
Prepared from 1-pyrroline (–)-2a (61 mg, 
0.56 mmol, 1.0 equiv) and phenylhydrazine 
hydrochloride (85 mg, 0.59 mmol, 1.05 equiv) 
according to general procedure 3. Purification 
was achieved by flash chromatography (SiO2) 
with an eluent gradient (10:100 → 20:100 v/v acetone:cHex), to obtain a mixture of compounds 12a and 
13a (175 mg, 0.45 mmol, 81%) in a 4:1 ratio as determined by NMR analysis of the crude mixture. Pure 
fractions of both compound 12a (major), a light yellow solid, and compound 13a (minor), a yellow oil, were 
used for full identification. 12a: Rf = 0.31 (cHex:acetone 2:1 v/v). m.p.: 79 – 82 °C.  1H NMR (500 MHz, 
CDCl3) δ 8.10 (dd, J = 7.1, 1.9 Hz, 1H, C(NO2)CH), 7.84 (s, 1H, C*NH), 7.75 – 7.64 (m, 3H, C(NO2)CHCHCHCH), 
7.29 – 7.17 (m, 2H, NHC*CHCHCHCH), 7.05 (t, J = 7.6 Hz, 1H, NHC*CHCH), 6.86 (t, J = 7.5 Hz, 1H, 
NHC*C*CHCH), 5.39 – 5.34 (m, 1H, NHCH2), 3.60 – 3.52 (m, 1H, NHCH2), 3.39 – 3.23 (m, 2H, NHCH2CH), 2.75 
– 2.62 (m, 2H, NHC*CH2), 2.00 – 1.89 (m, 3H, CHCH2CH2), 1.86 – 1.76 (m, 1H, CHCH2CH2) ppm. 13C NMR (126 
MHz, CDCl3) δ 147.7 (C*), 136.4 (C*), 135.8 (C*), 133.5 (CH), 133.3 (C*), 132.8 (CH), 131.1 (CH), 126.6 (C*), 
125.7 (CH), 121.2 (CH), 119.5 (CH), 117.6 (CH), 110.9 (CH), 108.4 (C*), 47.1 (CH2), 32.5 (CH), 26.5 (CH2), 
23.2 (CH2), 20.2 (CH2) ppm. IR (neat): vmax (cm-1) = 2949 (w), 1541 (m), 1489 (m), 1342 (m), 1165 (m), 
1126 (m), 1026 (m), 731 (s), 608 (m), 569 (m). HRMS (ESI): m/z calculated for C19H19N3NaO4S+ [M+Na]+: 
408.0988, found: 408.0976. Chiral HPLC: 99% ee [Dr. Maisch Chiral AM, heptane/2-propanol = 85/15, v = 
0.9 mL/min, column temperature: 30 °C, λ = 220 nm, t (minor) = 35.787, t (major) = 37.930 min]. Specific 
rotation: [ߙ]஽ଶ଴ = +2 ° (c = 0.5, EtOH). 13a:40 Rf = 0.36 (cHex:acetone 2:1 v/v).  1H NMR (500 MHz, CDCl3) δ 
8.23 (s, 1H, C*NH), 8.07 (dd, J = 7.5, 1.7 Hz, 1H, C(NO2)CH), 7.83 (dd, J = 7.6, 1.5 Hz, 1H, C(NO2)C*CH), 7.71 – 
7.62 (m, 2H, C(NO2)CHCHCH), 7.43 (d, J = 7.8 Hz, 1H, NHC*C*CH), 7.30 (d, J = 8.0 Hz, 1H, NHC*CHCH), 7.14 (t, 
J = 7.5 Hz, 1H, NHC*CHCH), 7.07 (t, J = 7.1 Hz, 1H, NHC*C*CHCH), 5.66 (t, J = 6.3 Hz, 1H, NHCH2), 3.40 – 3.27 
(m, 2H, NHCH2), 3.19 – 3.11 (m, 1H, NHCH2CH), 2.74 – 2.56 (m, 2H, NHC*C*CH2), 2.02 – 1.85 (m, 2H, 
CHCH2CH2), 1.83 – 1.73 (m, 1H, CHCH2CH2), 1.70 – 1.60 (m, 1H, CHCH2CH2) ppm. 13C NMR (126 MHz, CDCl3) 
δ 148.0 (C*), 136.0 (C*), 133.8 (CH), 133.7 (C*), 133.2 (C*), 133.0 (CH), 131.1 (CH), 127.2 (C*), 125.5 (CH), 
121.9 (CH), 119.4 (CH), 118.2 (CH), 111.7 (C*), 111.1 (CH), 48.3 (CH2), 34.4 (CH), 27.3 (CH2), 21.2 (CH2), 
21.0 (CH2) ppm. HRMS (ESI): m/z calculated for C19H19BrN3O4S [M+H]+: 408.0988, found: 408.0975. Chiral 
HPLC: rac [Dr. Maisch Chiral AM, heptane/2-propanol = 85/15, v = 0.9 mL/min, column temperature: 30 °C, 
λ = 220 nm, t = 25.789, 31.172 min]. 
 
tricyclic tryptamine 12b and 13b: 
Prepared from 1-pyrroline (–)-2a 
(30 mg, 0.27 mmol, 1.0 equiv) and 4-
isopropylphenylhydrazine 
hydrochloride (55 mg, 0.29 mmol, 
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1.05 equiv) according to general procedure 3. Purification was achieved by flash chromatography (SiO2) 
with an eluent gradient (10:100 → 15:100 v/v acetone:cHex), to obtain a mixture of compounds 12b and 
13b (94 mg, 0.22 mmol, 80%) in a 4:1 ratio as determined by NMR analysis of the crude mixture. Pure 
fractions of both compound 12b (major), as a grey solid, and compound 13b (minor), as light yellow foam, 
were used for full identification. 12b: Rf = 0.29 (cHex:acetone 2:1 v/v). m.p.: >118 °C (decomposition). 1H 
NMR (500 MHz, CDCl3) δ 8.12 (dd, J = 5.9, 3.3 Hz, 1H, C(NO2)CH), 7.79 (dd, J = 5.9, 3.3 Hz, 1H, C(NO2)C*CH), 
7.72 (s, 1H, C*NH), 7.67 (dd, J = 5.9, 3.4 Hz, 2H, C(NO2)CHCHCH), 7.20 (m, 2H, CHCHC(iPr)CH), 7.00 (d, J = 8.3 
Hz, 1H, NHC*CHCH), 5.46 – 5.40 (m, 1H, NHCH2), 3.62 – 3.53 (m, 1H, NHCH2), 3.34 – 3.21 (m, 2H, NHCH2CH), 
2.91 (hept, J = 6.9 Hz, 1H, CH3CHCH3), 2.73 – 2.59 (m, 2H, NHC*CH2), 1.98 – 1.86 (m, 3H, CHCH2CH2), 1.86 – 
1.74 (m, 1H, CHCH2CH2), 1.26 (dd, J = 14.2, 6.9 Hz, 6H, CH3CHCH3) ppm. 13C NMR (126 MHz, CDCl3) δ 147.9 
(C*), 140.2 (C*), 136.2 (C*), 134.3 (C*), 133.7 (C*), 133.5 (CH), 132.8 (CH), 131.2 (CH), 126.8 (C*), 125.5 
(CH), 120.4 (CH), 114.9 (CH), 110.6 (CH), 108.7 (C*), 47.2 (CH2), 34.3 (CH), 32.7 (CH), 26.2 (CH2), 24.9 (CH3), 
24.7 (CH3), 23.2 (CH2), 19.8 (CH2) ppm. IR (neat): vmax (cm-1) = 2957 (w), 1535 (m), 1491 (m), 1342 (m), 
1161 (s), 1124 (m), 731 (m), 694 (m), 652 (m), 582 (m), 571 (m).  HRMS (ESI): m/z calculated for 
C22H25N3O4S+ [M+H]+: 450.1458, found: 450.1457. Chiral HPLC: 99% ee [Dr. Maisch Chiral AM, heptane/2-
propanol = 88/12, v = 0.9 mL/min, column temperature: 30 °C, λ = 220 nm, t (major) = 34.608 min, t 
(minor) = 44.359]. Specific rotation: [ߙ]஽ଶ଴ = −23 ° (c = 2.5, EtOH). 13b:40 Rf = 0.34 (cHex:acetone 2:1 v/v).  
1H NMR (500 MHz, CDCl3) δ 8.15 – 8.02 (m, 2H, C*NH, C(NO2)CH), 7.84 (dd, J = 7.6, 1.5 Hz, 1H, C(NO2)C*CH), 
7.74 – 7.61 (m, 2H, C(NO2)CHCHCH), 7.23 (d, J = 8.3 Hz, 2H, CHCHC(iPr)CH), 7.05 (d, J = 8.3 Hz, 1H, 
C(iPr)CHCH), 5.62 (t, J = 6.3 Hz, 1H, NHCH2), 3.39 – 3.29 (m, 2H, NHCH2), 3.22 – 3.08 (m, 1H, NHCH2CH), 3.06 
– 2.90 (m, 1H, CH3CHCH3), 2.77 – 2.56 (m, 1H, NHC*C*CH2), 2.04 – 1.84 (m, 2H, CHCH2CH2), 1.83 – 1.71 (m, 
1H, CHCH2CH2), 1.69 – 1.59 (m, 1H, CHCH2CH2), 1.30 (d, J = 6.9 Hz, 6H, CH3CHCH3) ppm. 13C NMR (126 MHz, 
CDCl3) δ 148.0 (C*), 140.3 (C*), 134.6 (C*), 133.9 (C*), 133.8 (CH), 133.3 (C*), 133.0 (CH), 131.1 (CH), 127.3 
(C*), 125.5 (CH), 121.1 (CH), 115.1 (CH), 111.6 (C*), 110.8 (CH), 48.3 (CH2), 34.5 (CH), 34.4 (CH), 27.4 (CH2), 
24.92 (CH3), 24.91 (CH3), 21.2 (CH2), 21.1 (CH2) ppm. HRMS (ESI): m/z calculated for C22H25N3O4S+ [M+H]+: 
450.1458, found: 450.1457. Chiral HPLC: rac [Dr. Maisch Chiral AM, heptane/2-propanol = 88/12, v = 0.9 
mL/min, column temperature: 30 °C, λ = 275 nm, t = 30.697, 41.988 min]. 
 
 tricyclic tryptamine 12c and 13c: 
Prepared from 1-pyrroline (–)-2a (59 
mg, 0.55 mmol) and 4-
(trifluoromethyl)phenylhydrazine 
(105 mg, 0.57 mmol, 1.05 equiv) 
according to general procedure 4. 
Purification was achieved by flash 
chromatography (SiO2) with an eluent gradient (10:100 → 22.5:100 v/v acetone:cHex), to obtain a mixture 
of compounds 12c and 13c (145 mg, 0.32 mmol, 59%) in a 4:1 ratio  as determined by NMR analysis of the 
crude mixture. Pure fractions of both compound 12c (major), a light yellow foamy oil, and compound 13c 
(minor), a yellow oil, were used for full identification. 12c: Rf = 0.32 (cHex:acetone 2:1 v/v).  1H NMR (500 
MHz, CDCl3) δ 8.13 (d, J = 8.1 Hz, 1H, C(NO2)CH), 8.02 (s, 1H, C*NH), 7.75 – 7.65 (m, 3H, C(NO2)C*CHCHCH), 
7.43 (s, 1H, C(CF3)CHC*), 7.34 – 7.28 (m, 2H, NHC*CHCH), 5.31 – 5.26 (m, 1H, NHCH2), 3.57 – 3.48 (m, 1H, 
NHCH2), 3.40 – 3.30 (m, 2H, NHCH2CH), 2.82 – 2.67 (m, 2H, NHC*CH2), 2.08 – 1.95 (m, 3H, CHCH2CH2), 1.91 – 
1.81 (m, 1H, CHCH2CH2) ppm. 13C NMR (126 MHz, CDCl3) δ 147.7 (C*), 138.6 (C*), 137.3 (C*), 133.9 (CH), 
132.9 (CH), 132.8 (C*), 131.3 (CH), 126.0 (C*), 125.7 (CH), 125.3 (C*, q, J = 277 Hz), 121.6 (C*, q, J = 38 Hz), 
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118.3 (CH), 115.2 (CH), 111.0 (CH), 109.4 (C*), 47.0 (CH2), 32.3 (CH), 26.4 (CH2), 23.2 (CH2), 20.2 (CH2) ppm. 
19F NMR (235 MHz, CDCl3): δ -60.03 ppm. IR (neat): vmax (cm-1) = 1533 (s), 1362 (m), 1319 (m), 1161 (m), 
1124 (m), 1103 (m), 1051 (m), 740 (m), 586 (m), 507 (m). HRMS (ESI): m/z calculated for C20H18F3N3NaO4S 
[M+Na]+: 476.0862, found: 476.0860. Chiral HPLC: enantiopure44 [Dr. Maisch Chiral AM, heptane/2-
propanol = 85/15, v = 0.9 mL/min, column temperature: 30 °C, λ = 285 nm, t (major) = 19.060 min].   
Specific rotation: [ߙ]஽ଶ଴ = −3 ° (c = 1.27, EtOH). 13c: Rf = 0.37 (cHex:acetone 2:1 v/v). 1H NMR (500 MHz, 
CDCl3) δ 8.61 (s, 1H, C*NH), 8.07 (dd, J = 7.4, 1.7 Hz, 1H, C(NO2)CH), 7.84 (dd, J = 7.4, 1.7 Hz, 1H, 
C(NO2)C*CH), 7.72 – 7.64 (m, 3H, C(NO2)CHCHCH, NHC*CHCH), 7.36 (s, 2H, CHCHC(CF3)CH), 5.75 (s, 1H, 
NHCH2), 3.40 – 3.29 (m, 2H, NHCH2), 3.23 – 3.14 (m, 1H, NHCH2CH), 2.76 – 2.60 (m, 2H, NHC*C*CH2), 2.05 – 
1.87 (m, 2H, CHCH2CH2), 1.84 – 1.74 (m, 1H, CHCH2CH2), 1.69 – 1.60 (m, 1H, CHCH2CH2). 13C NMR (126 MHz, 
CDCl3) δ 147.9 (C*), 137.4 (C*), 135.8 (C*), 134.0 (CH), 133.1 (CH), 133.0 (C*), 126.6 (CH), 125.6 (C*, q, J = 
272 Hz), 125.6 (CH), 121.7 (C*, q, J = 32 Hz), 118.5 (CH), 116.0 (CH), 112.5 (C*), 111.2 (CH), 48.2 (CH2), 34.5 
(CH), 27.3 (CH2), 21.1 (CH2), 20.8 (CH2). 19F NMR (235 MHz, CDCl3): δ -60.15 ppm. IR (neat): vmax (cm-1) = 
1541 (s), 1361 (m), 1323 (m), 1161 (m), 1124 (m), 1101 (m), 1047 (m), 740 (m), 654 (m), 586 (m), 507 
(m). HRMS (ESI): m/z calculated for C20H18F3N3NaO4S [M+Na]+: 476.0862, found: 476.0860. Chiral HPLC: 
±13% ee [Dr. Maisch Chiral AM, heptane/2-propanol = 88/12, v = 0.8 mL/min, column temperature: 30 °C, λ 
= 225 nm, t (minor) = 32.682 min, t (major) = 35.450 min]. 
 
tricyclic azaindole 12d and 13d: 
Prepared from 1-pyrroline (–)-2a (52 
mg, 0.48 mmol) and 2-chloro-5-
hydrazinylpyridine (76 mg, 0.50 mmol, 
1.05 equiv) according to general 
procedure 4 with the following 
adjustments: p-toluenesulfonic acid 
monohydrate (3.5 equiv), 1 h, 150°C. Purification was achieved by flash chromatography (SiO2) with an 
eluent gradient (17.5:100 → 27.5:100 v/v acetone:cHex), to obtain a mixture of compounds 12d and 13d 
(122 mg, 0.29 mmol, 61%) in a 5:1 ratio  as determined by NMR analysis of the crude mixture. Pure 
fractions of both compound 12d (major), as a light brown foamy oil, and compound 13d (minor), as a light 
brown foam, were used for full identification. 12d: Rf = 0.23 (cHex:acetone 2:1 v/v). 1H NMR (500 MHz, 
CDCl3) δ 8.35 (s, 1H, C*NH), 8.22 – 8.13 (m, 1H, C(NO2)CH), 7.97 – 7.89 (m, 1H, NHCH2), 7.73 – 7.62 (m, 3H, 
C(NO2)CHCHCHCH), 7.50 (d, J = 8.4 Hz, 1H, NHC*CH), 6.94 (d, J = 8.4 Hz, 1H, NHC*CHCH), 3.63 (m, 1H, 
NHCH2), 3.24 (m, 1H, NHCH2), 3.17 – 3.09 (m, 1H, NHCH2CH), 2.76 – 2.67 (m, 2H, NHC*CH2), 2.06 – 1.94 (m, 
2H, CHCH2CH2), 1.80 – 1.70 (m, 1H, CHCH2CH2), 1.65 – 1.52 (m, 1H, CHCH2CH2) ppm. 13C NMR (126 MHz, 
CDCl3) δ 148.1 (C*), 144.5 (C*), 142.9 (C*), 141.7 (C*), 134.0 (C*), 133.3 (CH), 132.5 (CH), 131.0 (CH), 127.4 
(C*), 124.9 (CH), 120.3 (CH), 116.0 (CH), 110.8 (C*), 48.1 (CH2), 33.8 (CH), 27.5 (CH2), 23.63 (CH2), 21.6 
(CH2) ppm. IR (neat): vmax (cm-1) = 2939 (w), 1541 (s), 1398 (w), 1361 (w), 1339 (w), 1163 (m), 1043 (w), 
741 (m), 656 (m), 586 (m), 507 (m). HRMS (ESI): m/z calculated for C18H17ClN4NaO4S [M+H]+: 443.0551, 
found: 443.0546. Chiral HPLC: n.d. [Dr. Maisch Chiral AM, heptane/2-propanol = 85/15, v = 0.9 mL/min, λ = 
225 nm, t (major) = 27.787 min, t (minor) = 28.739 min].  Chiral SFC: 98% ee [Daicel Chiralpak ID-3 SFC, 
CO2/MeOH = gradient, v = 1.2 mL/min, column temperature: 40 °C, t (minor) = 5.517 min, t (major) = and 
5.628 min]. Specific rotation: [ߙ]஽ଶ଴ = + 19 ° (c = 0.53, EtOH). 13d: Rf = 0.27 (cHex:acetone 2:1 v/v). m.p.: 
>197 °C (decomposition). 1H NMR (500 MHz, CDCl3) δ 8.78 (s, 1H, C*NH), 8.09 (dd, J = 7.5, 1.5 Hz, 1H, 
C(NO2)CH), 7.87 (dd, 1H, C(NO2)C*CH), 7.78 – 7.68 (m, 2H, C(NO2)CHCHCH), 7.53 (d, J = 8.4 Hz, 1H, 
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NHC*CHCH), 7.04 (d, J = 8.4 Hz, 1H, NHC*CHCH), 5.80 (dd, 1H, NHCH2), 3.40 – 3.27 (m, 2H, NHCH2), 3.25 – 
3.17 (m, 1H, NHCH2CH), 2.87 – 2.78 (m, 1H, NHC*C*CH2), 2.76 – 2.66 (m, 1H, NHC*C*CH2), 2.04 – 1.85 (m, 
2H, CHCH2CH2), 1.81 – 1.71 (m, 1H, CHCH2CH2), 1.65 – 1.57 (m, 1H, CHCH2) ppm. 13C NMR (126 MHz, CDCl3) 
δ 148.1 (C*), 144.7 (C*), 143.7 (C*), 139.6 (C*), 134.2 (CH), 133.2 (CH), 132.8 (C*), 131.3 (CH), 127.7 (C*), 
125.7 (CH), 120.6 (CH), 116.4 (CH), 112.0 (C*), 48.2 (CH2), 34.8 (CH), 27.4(CH2), 21.1(CH2), 20.1(CH2). IR 
(neat): vmax (cm-1) = 2941 (w), 1533 (s), 1340 (m), 1163 (s), 729 (s), 654 (m), 586 (m), 569 (m), 420 (w). 
HRMS (ESI): m/z calculated for C18H17N4NaO4S [M+Na]+: 443.0551, found: 443.0531. Chiral HPLC: 98% ee 
[Dr. Maisch Chiral AM, heptane/2-propanol = 85/15, v = 0.9 mL/min, column temperature: 30 °C, λ = 225 
nm, t (major) = 30.934 min, t (minor) = 38.702 min]. Specific rotation: [ߙ]஽ଶ଴ = −7 ° (c = 0.73, CHCl3). 
 
tricyclic tryptamine 12e: Prepared from 1-pyrroline (±)-2a  (62 mg, 0.57 
mmol, 1.0 eq) and 4-bromophenylhydrazine hydrochloride (135 mg, 
0.60 mmol, 1.05 eq) according to general procedure 3. Purification was 
achieved by flash chromatography (SiO2) with an eluent gradient (12:100 → 
20:100 v/v acetone:cHex), to obtain compound 12e (143 mg [1.1% 
acetone], 0.30 mmol, 53%) as a yellow-brown oil. Rf = 0.32 (cHex:acetone 
2:1 v/v). 1H NMR (500 MHz, CDCl3) δ 8.11 (d, J = 7.5 Hz, 1H, C(NO2)CH), 7.99 (s, 1H, C*NH), 7.79 – 7.69 (m, 
3H, C(NO2)CHCHCHCH), 7.18 (s, 1H, C(Br)CH), 7.12 – 7.05 (m, 2H, C(Br)CHCH), 5.31 – 5.25 (m, 1H, NHCH2), 
3.53 – 3.43 (m, 1H, NHCH2), 3.36 – 3.27 (m, 1H, NHCH2), 3.26 – 3.18 (m, 1H, NHCH2CH), 2.76 – 2.60 (m, 2H, 
NHC*CH2), 2.03 – 1.88 (m, 3H, CHCH2CH2), 1.84 – 1.75 (m, 1H, CHCH2CH2). 13C NMR (126 MHz, CDCl3) δ 
147.5 (C*), 138.3 (C*), 134.5 (C*), 134.1 (CH), 132.9 (CH), 132.6 (C*), 131.2 (CH), 128.2 (C*), 125.8 (CH), 
123.9 (CH), 120.1 (CH), 112.5 (C*), 112.3 (CH), 107.9 (C*), 47.0 (CH2), 32.1 (CH), 26.5 (CH2), 23.1 (CH2), 20.3 
(CH2). IR (neat): vmax (cm-1) =  2927 (w), 1535 (s), 1439 (m), 1339 (m), 1161 (s), 1047 (m), 852 (m), 781 
(m), 731 (s), 584 (s). HRMS (ESI): m/z calculated for C19H18BrN3NaO4S [M+Na]+: 486.0094, found: 486.0091. 
 
tricyclic N-benzyltryptamine 12f: Prepared from 1-pyrroline (±)-2a (31 mg, 
0.28 mmol, 1.0 equiv) and 1-benzyl-1-phenylhydrazine hydrochloride (71 mg, 
0.30 mmol, 1.05 eq) according to general procedure 3. Purification was 
achieved by flash chromatography (SiO2) with an eluent gradient (12:100 → 
20:100 v/v acetone:cHex), to obtain compound 12f (72 mg, 0.15 mmol 54%) a 
yellow oil and debenzylated 12a (17 mg, 0.04 mmol, 16%) as a light yellow 
solid. Rf = 0.38 (cHex:acetone 2:1 v/v). 1H NMR (500 MHz, CDCl3) δ 8.11 (d, J = 
7.0 Hz, 1H, C(NO2)CH), 7.76 – 7.63 (m, 3H, C(NO2)CHCHCHCH), 7.30 – 7.14 (m, 5H, NC*CHCHCHCH, 
CH2C*CHCHCHCH), 7.04 (t, J = 7.6 Hz, 1H, NHC*CHCH), 6.97 (d, J = 7.4 Hz, 2H, CH2C*CH), 6.88 (t, J = 7.5 Hz, 
1H, NHC*C*CHCH), 5.43 – 5.35 (d, J = 5.2 Hz, 1H, NHCH2), 5.22 (s, 2H, NCH2C*), 3.64 – 3.53 (m, 1H, NHCH2), 
3.42 – 3.27 (m, 2H, NHCH2CH), 2.66 – 2.50 (m, 2H, NC*CH2), 1.99 – 1.77 (m, 4H, CHCH2CH2). 13C NMR (126 
MHz, CDCl3) δ 147.8 (C*), 137.8 (C*), 136.9 (C*), 133.5 (CH), 133.5 (C*), 132.8 (CH), 131.2 (CH), 128.9 (CH), 
127.4 (CH), 126.3 (C*), 126.2 (CH), 125.7 (CH), 121.1 (CH), 119.3 (CH), 117.7 (CH), 109.5 (CH), 108.3 (C*), 
47.1 (CH2), 46.4 (CH2), 32.8 (CH), 26.2 (CH2), 22.1 (CH2), 20.0 (CH2). IR (neat): vmax (cm-1) = 2949 (w), 1541 
(m), 1342 (m), 1164 (m), 1124 (m), 1026 (m), 729 (s), 606 (m), 569 (m). HRMS (ESI): m/z calculated for 
C26H25N3NaO4S [M+H]+: 498.1458, found: 498.1439.  
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tetracyclic tryptamine 17a and 18a: To a 
solution of 1-pyrroline (–)-2b  (80 mg, 
0.47 mmol, 1.0 equiv) in toluene (5 mL) were 
added phenylhydrazine hydrochloride 10b (72 
mg, 0.50 mmol, 1.05 equiv) and pyridinium p-
toluenesulfonic acid (121 mg, 0.47 mmol, 1.0 
equiv). The reaction mixture was stirred for 3 h 
at 130 °C under microwave irradiation. The 
suspension was cooled to rt, dissolved in methanol (3 mL), washed with sat. aq. Na2CO3 (20 mL), extracted 
with DCM (3 x 15 mL), dried (Na2SO4) and concentrated in vacuo. The crude product was dissolved DCM (5 
mL), after which Et3N (79 μL, 0.57 mmol, 1.2 equiv) and o-nosyl chloride (128 mg, 0.57 mmol, 1.2 equiv) 
were added. The reaction mixture was stirred for 2 h at rt, washed with brine (20 mL), extracted with DCM 
(3 x 15 mL), dried (Na2SO4) and concentrated in vacuo. The crude product was impregnated on SiO2 and 
purified by flash chromatography with an eluent gradient (10:100 → 15:100 v/v acetone:cHex), to obtain a 
mixture of the compounds 17a and 18a (137 mg, 0.33 mmol, 70%) as a 1:4 ratio as determined by NMR 
analysis of the crude mixture. Pure fractions of both compound 17a (major), a foamy orange oil, and 
compound 18a (minor), a red oil, were used for full identification. 17a: Rf = 0.33 (cHex:acetone 2:1 v/v). 1H 
NMR (500 MHz, CDCl3) δ 8.20 (dd, J = 5.9, 3.3 Hz, 1H, C(NO2)CH), 7.88 (dd, J = 5.8, 3.4 Hz, 1H, C(NO2)C*CH), 
7.82 (s, 1H, C*NH) 7.74 (dd, J = 5.8, 3.4 Hz, 2H, C(NO2)CHCHCH), 7.36 (d, J = 7.8 Hz, 1H, NHC*CHCHCHCH), 
7.28 (d, J = 8.1 Hz, 1H, NHC*CHCH), 7.08 (t, J = 7.1 Hz, 1H, NHC*CHCH), 7.01 (t, J = 7.5 Hz, 1H, NHC*CHCHCH), 
5.50 (t, 1H, NHCH2, 4.13 – 4.02 (m, 1H, NHCH2), 3.52 – 3.41 (m, 1H, NHCH2CH), 3.20 – 3.09 (m, 1H, NHCH2), 
3.05 (s, 1H, NHCH2CHC*C*CH), 2.77 – 2.72 (m, 1H, NHCH2CHCH), 1.96 – 1.83 (m, 3H, CH2CH2), 1.79 (t, J = 
10.0 Hz, 1H, CHCHCH2CH2), 1.71 – 1.54 (m, 2H, CHCHCH2CH2).  13C NMR (126 MHz, CDCl3) δ 148.2 (C*), 
142.5 (C*), 135.4 (C*), 133.7 (C*), 133.7 (CH), 133.0 (CH), 131.4 (CH), 126.9 (C*), 125.6 (CH), 120.8 (CH), 
119.7  (CH), 118.8  (CH), 111.2  (CH), 104.8  (C*), 44.4  (CH2), 40.6 (CH), 38.1 (CH2), 35.9 (CH), 35.3 (CH), 
34.5 (CH2), 22.0 (CH2). IR (neat): vmax (cm-1) = 1533 (s), 1418 (m), 1362 (m), 1339 (m), 1161 (m), 739 (m), 
725 (m), 581 (m). HRMS (ESI): m/z calculated for C21H21N3NaO4S [M+Na]+: 434.1145, found: 434.1140. 
Chiral SFC: 99% ee [Daicel Chiralpak ID-3 SFC, CO2/MeOH = gradient, v = 1.2 mL/min, column temperature: 
40 °C, t (major) = 5.813 min, t (minor) = and 5.958 min]. 18a: Rf = 0.36 (cHex:acetone 2:1 v/v). 1H NMR 
(500 MHz, CDCl3) δ 8.34 (s, 1H, C*NH), 8.20 – 8.14 (m, 1H, C(NO2)CH), 7.94 – 7.87 (m, 1H, C(NO2)C*CH), 7.80 
– 7.73 (m, 2H, C(NO2)CHCHCH), 7.50 (d, J = 7.6 Hz, 1H, NHC*C*CHCH), 7.31 (d, J = 8.0 Hz, 1H, NHC*CHCHCH), 
7.10 (dt, J = 20.6, 7.3 Hz, 2H, NHC*CHCHCH), 5.70 (d, J = 7.4 Hz, 1H, NHCH2), 3.55 – 3.39 (m, 2H, NHCH2CH), 
3.33 (s, 1H, NHC*C*CHCH2), 3.15 – 3.07 (m, 1H, NHCH2), 2.55 (s, 1H, NHCH2CHCH), 1.90 – 1.81 (m, 3H, 
CH2CHCH2CH2), 1.77 (t, J = 10.1 Hz, 1H, CH2CHCH2CH2), 1.71 – 1.62 (m, 1H, CH2CHCH2CH2), 1.51 – 1.44 (m, 
1H, CH2CHCH2CH2). 13C NMR (126 MHz, CDCl3) δ 148.3 (C*), 136.1 (C*), 134.2 (CH), 133.2 (CH), 132.7 (C*), 
131.8 (C*), 131.7 (CH), 125.7 (CH), 125.4 (C*), 121.4 (CH), 119.4 (CH), 118.5 (C*), 117.8 (CH), 111.2 (CH), 
46.5 (CH2), 42.1 (CH), 39.2 (CH2), 37.5 (CH), 34.9 (CH2), 32.6 (CH), 23.0 (CH2). IR (neat): vmax (cm-1) = 1533 
(s), 1362 (m), 1331 (m), 1163 (m), 1122 (m), 656 (m), 584 (m). HRMS (ESI): m/z calculated for 
C21H21N3NaO4S [M+Na]+: 434.1145, found: 434.1142. Chirality 99% ee [Dr. Maisch Chiral AM, heptane/2-
propanol = 85/15, v = 0.9 mL/min, λ = 285 nm, t (minor) = 30.677 min, t (major) = 36.187 min]. 
 
 
 
 
Chapter 4 
 
 
124 
tetracyclic tryptamine 17b: To a solution of 1-pyrroline (+)-2c  (71 mg, 
0.53 mmol, 1.0 equiv) in toluene (5 mL) were added phenylhydrazine 
hydrochloride (81 mg, 0.56 mmol, 1.05 equiv) and pyridinium p-toluenesulfonic 
acid (136 mg, 0.53 mmol, 1.0 equiv). The reaction mixture was stirred for 30 min 
at 130 °C under microwave irradiation. The suspension was cooled to rt, 
dissolved in methanol (3 mL), washed with sat. aq. Na2CO3 (20 mL), extracted 
with DCM (3 x 15 mL), dried (Na2SO4) and concentrated in vacuo. The crude 
product was dissolved DCM (5 mL), after which Et3N (88 μL, 0.64 mmol, 1.2 equiv) and o-nosyl chloride 
(144 mg, 0.64 mmol, 1.2 equiv) were added. The reaction mixture was stirred for 2 h at rt, washed with 
brine (20 mL), extracted with DCM (3 x 15 mL), dried (Na2SO4) and concentrated in vacuo. The crude 
product was impregnated on SiO2 and purified by flash chromatography (SiO2) with an eluent gradient 
(10:100 → 15:100 v/v acetone:cHex), to obtain a mixture of the compound 17b (74 mg, 0.18 mmol, 34%) as 
a brown oil. Rf = 0.29 (cHex:acetone 2:1 v/v). 1H NMR (500 MHz, CDCl3) δ 8.17 – 8.11 (m, 1H, C(NO2)CH), 
7.94 (bs, 1H, NHC*) 7.83 – 7.78 (m, 1H, C(NO2)C*CH), 7.74 – 7.69 (m, 2H, C(NO2)CHCHCH), 7.28 – 7.23 (m, 
1H, NHCH2CHC*C*CHCHCHCH), 7.15 (d, J = 7.9,  1H, NHCH2CHC*C*CH), 7.01 (t, J = 8.1 Hz, 1H, 
NHCH2CHC*C*CHCHCH), 6.86 (t, J = 7.9 Hz, 1H, NHCH2CHC*C*CHCH), 6.49 (dd, J = 5.7, 2.9 Hz, 1H, 
NHC*CHCH=CH), 5.90 (dd, J = 5.6, 2.9 Hz, 1H, NHC*CHCH=CH), 5.49 – 5.44 (m, 1H, NHCH2), 3.81 – 3.73 (m, 
1H, NHCH2), 3.49 – 3.42 (m, 1H, NHCH2CH), 3.38 – 3.34 (m, 1H, NHC*CHCH2), 3.29 – 3.24 (m, 1H, 
NHCH2CHCH), 3.16 – 3.08 (m, 1H, NHCH2), 2.46 – 2.40 (m, 1H, CHCH2CH), 2.02 (d, J = 9.8 Hz, 1H, CHCH2CH) 
ppm. 13C NMR (126 MHz, CDCl3) δ 148.0 (C*), 141.6 (CH), 141.2 (C*), 134.6 (C*), 133.7 (CH), 133.5 (C*), 
132.9 (CH), 131.4 (CH), 130.7 (CH), 127.5 (C*), 125.8 (CH), 120.5 (CH), 119.8 (CH), 117.7 (CH), 111.2 (CH), 
103.5 (C*), 44.4 (CH2), 44.3 (CH2), 42.0 (CH), 39.0 (CH), 37.1 (CH) ppm. IR (neat): vmax (cm-1) = 2953 (w), 
1535 (s), 1404 (w), 1340 (m), 1163 (s), 852 (m), 743 (s), 729 (s), 652 (m), 582 (s). HRMS (ESI): m/z 
calculated for C21H20N3O4S [M+Na]+: 410.1169, found: 410.1173. Chirality 98% ee [Dr. Maisch Chiral AM, 
heptane/2-propanol = 85/15, v = 0.9 mL/min, λ = 225 nm, t (major) = 33.248 min, t (minor) = 40.842 min]. 
Specific rotation: [ߙ]஽ଶ଴ = +22.5 ° (c = 0.4, EtOH). 
Synthesis of pharmaceutically relevant compounds 
 
dimeric pyrroloindoline 20: To a solution of pyrroloindoline 6a (124 mg, 
0.60 mmol, 1.0 equiv) in MeOH (3 mL) was added aq. formaldehyde (45 uL [37%], 
0.60 mmol, 1.0 equiv). The reaction mixture was stirred for 30 min at rt, showing 
(partial) precipitation of the product after 1 min. The suspension was diluted with 
DCM (20 mL), washed with sat. aq. Na2CO3 (20 mL), extracted with DCM (2 x 10 
mL), dried (Na2SO4) and concentrated in vacuo. Purification was achieved by flash 
chromatography (SiO2) with an eluent gradient of EtOAc in cHex (10:1 v/v 
cHex:EtOAc), to obtain compound 20 (108 mg, 0.254 mmol, 84 %) as a white solid. Rf = 0.59 (cHex:EtOAc 
4:1 v/v). m.p.: 194 – 196 °C.  1H NMR (400 MHz, CDCl3) δ 7.08 – 6.94 (m, 4H, NC*C*CHCHCH), 6.66 (t, J = 7.3 
Hz, 2H, NC*C*CHCH), 6.48 (d, J = 7.9 Hz, 2H, NC*CH), 4.69 (s, 2H, NCHN), 4.61 (d, J = 15.2 Hz, 2H, NCH2N), 
4.48 (d, J = 15.2 Hz, 2H, NCH2N), 3.25 – 3.19 (m, 2H, NCH2CH), 2.76 (d, J = 8.7 Hz, 2H, NCH2CH), 2.31 (q, J = 
7.4 Hz, 2H, NCH2CH), 2.28 – 2.18 (m, 2H, CHCH2CH2CH2), 2.18 – 2.05 (m, 2H, NCH2CHCH2), 2.02 – 1.71 (m, 
6H, CHCH2CH2CH2), 1.69 – 1.47 (m, 2H, NCH2CHCH2). 13C NMR (101 MHz, CDCl3): δ 152.4 (C*), 136.2 (C*), 
127.5 (CH), 121.7 (CH), 117.7 (CH), 105.7 (CH), 98.6 (CH), 67.1 (CH2), 62.9 (C*), 54.3 (CH), 53.5 (CH2), 41.5 
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(CH2), 35.6 (CH2), 29.0 (CH2) ppm. IR (neat): vmax (cm-1) = 2941 (m), 2851 (m), 1603 (m), 1481 (s), 1346 (s), 
1273 (s), 1159 (s), 1086 (w), 914 (s), 723 (s), 635 (w), 582 (w). HRMS (ESI): m/z calculated for C28H33N4 
[M+H]+: 425.2700, found: 425.2689. Specific rotation: [ߙ]஽ଶ଴ = +57.0 ° (c = 0.5, CDCl3). 
 
bisamide pyrroloindoline 22 or 22’: To a solution of 
pyrroloindoline 6a (43 mg, 0.21 mmol, 1.0 equiv) in MeOH 
(3 mL) was added ninihydrin (42 mg, 0.23 mmol, 1.1 equiv). 
The reaction mixture was stirred for 30 min at rt. The 
suspension was diluted with DCM (10 mL), washed with sat. 
aq. Na2CO3 (10 mL), extracted with DCM (2 x 5 mL), dried 
(Na2SO4) and concentrated in vacuo. Purification was achieved by flash chromatography (SiO2) with an 
eluent gradient of EtOAc in cHex (10:1 → 4:1 v/v cHex:EtOAc), to obtain compound 22 or 22’ (69 mg, 
0.19 mmol, 91 %) as an off-white solid. Rf = 0.13 (cHex:EtOAc 4:1 v/v). m.p.: 77 – 80 °C. 1H NMR (400 MHz, 
CDCl3) δ 8.23 (d, J = 8.2 Hz, 1H, NC*CHCH), 7.74 (d, J = 7.8 Hz, 1H, CH(OH)C*CH), 7.62 – 7.53 (m, 2H, 
C(O)C*CHCHCH), 7.44 (t, J = 7.5 Hz, 1H, C(O)C*CHCH), 7.31 – 7.23 (m, 1H, NC*CHCH), 7.14 (d, J = 7.1 Hz, 2H, 
NC*C*CHCH), 5.50 – 5.46 (m, 1H, CH(OH)), 5.33 (s, 1H, NCHN), 5.14 (d, J = 2.1 Hz, 1H, CH(OH)), 4.36 (dd, J = 
12.6, 2.1 Hz, 1H, NCH2), 3.53 (dd, J = 12.6, 7.5 Hz, 1H, NCH2), 2.72 – 2.63 (m, 1H, NCH2CH), 2.21 – 2.07 (m, 2H, 
CHCH2CH2), 1.93 – 1.81 (m, 1H, CHC*CH2), 1.79 – 1.58 (m, 3H, CHCH2CH2CH2). 13C NMR (101 MHz, CDCl3) δ 
169.0 (C*), 168.6 (C*), 141.4 (C*), 135.5 (C*), 135.2 (C*), 134.5 (C*), 131.8 (CH), 129.0 (CH), 128.8 (CH), 
126.7 (CH), 126.2 (CH), 125.7 (CH), 122.6 (CH), 116.7 (CH), 86.9 (CH), 70.9 (CH), 64.5 (C*), 52.7 (CH), 50.4 
(CH2), 40.7 (CH2), 33.9 (CH2), 27.3 (CH2). IR (neat): vmax (cm-1) = (2947 (w), 2866 (w), 1645 (s), 1479 (m), 
1418 (m), 1398 (m), 1350 (m), 1271 (m), 1188 (m), 1084 (m), 1063 (m), 744 (s), 470 (m). HRMS (ESI): m/z 
calculated for C22H21N2O3 [M+H]+: 361.1547, found: 361.1535. Specific rotation: [ߙ]஽ଶ଴ = ‒108.0 ° (c = 0.5, 
EtOH). 
 
di-Nα,Nβ-Boc-protected hydrazine S1: To a solution of di-tert-butyl 
azodicarboxylate (3.36 g, 14.6 mmol, 1.0 equiv) in MeOH (0.4 M) were added 
4-(benzyloxy)phenylboronic acid 25 (4.95 g, 21.0 mmol, 1.5 equiv) and 
copper(II) acetate (217 mg, 1.09 mmol, 0.05 equiv). The reaction mixture was 
stirred for 4 h at rt. The crude product was impregnated on SiO2 and purified 
by flash chromatography (SiO2) with an eluent gradient (10:100 → 50:100 v/v 
EtOAc:cHex), to obtain compound S1 (5.05 g, 12.2 mmol, 83%) as a beige solid. Rf = 0.43 (cHex:EtOAc 4:1 
v/v). m.p.: 110 – 118 °C. 1H NMR (500 MHz, CDCl3) δ 7.46 – 7.27 (m, 7H, Ph, NC*CH), 6.92 (d, J = 8.9 Hz, 2H, 
NC*CHCH), 6.78 (s, 1H, NH), 5.05 (s, 2H, OCH2), 1.49 (s, 18H, C(CH3)3) ppm. 13C NMR (126 MHz, CDCl3) δ 
156.9 (C*), 155.5 (C*), 154.1 (C*), 137.0 (C*), 135.6 (C*), 128.7 (CH), 128.1 (CH), 127.6 (CH), 114.8 (CH), 
82.1 (C*), 81.5 (C*), 70.3 (CH2), 28.3 (CH3) ppm. IR (neat): vmax (cm-1) = 3281 (w), 2981 (w), 1734 (m), 1686 
(s), 1510 (m), 1366 (s), 1242 (s), 1153 (s), 1003 (m), 827 (m), 758 (m), 741 (m), 696 (m).  HRMS (ESI): m/z 
calculated for C23H30N2NaO5 [M+Na]+: 437.2047, found: 437.2038.  
Nβ-Boc-Nα-methylhydrazine 26: To a solution of di-Nα,Nβ-Boc-protected 
hydrazine S1 (1.11 g, 2.69 mmol, 1.0 equiv) in THF45 (0.25 M) was slowly 
added LiAlH4 (322 mg, 8.06 mmol, 3 equiv) under inert atmosphere (N2) at 0°C. 
The reaction mixture was stirred for 4 h at rt and quenched by the addition of 
drops of water (stoichiometric). The crude product was filtered over Celite and concentrated in vacuo to 
O
N
NH
O O
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obtain compound 26 (870 mg,  2.65 mmol, 99%) as a beige solid. Rf = 0.43 (cHex:EtOAc 4:1 v/v). m.p.: 90 – 
94 °C. 1H NMR (500 MHz, CDCl3) δ 7.50 – 7.28 (m, 5H, Ph), 6.96 – 6.87 (m, 2H, NC*CHCH), 6.85 – 6.75 (m, 2H, 
NC*CH), 6.40 (s, 1H, NH), 5.01 (s, 2H, OCH2), 3.13 (s, 3H, NCH3), 1.60 – 1.28 (m, 9H, C(CH3)3) ppm. 13C NMR 
(126 MHz, CDCl3) δ 154.9 (C*), 152.8 (C*), 144.5 (C*), 137.5 (C*), 128.6 (CH), 127.9 (CH), 127.6 (CH), 115.8 
(CH), 114.6 (CH), 80.9 (C*) , 70.7 (CH2), 41.8 (CH3), 28.4 (CH3) ppm. IR (neat): vmax (cm-1) = 3366 (w), 2982 
(w), 1712 (m), 1514 (m), 1487 (m), 1452 (m), 1366 (m), 1240 (w), 1163 (w), 1049 (m), 812 (m), 731 (m), 
694 (m), 519 (m), 467 (m). HRMS (ESI): m/z calculated for C19H24N2NaO3 [M+Na]+: 351.1679, found: 
351.1672. 
 
N-methylpyrroloindoline 27: To a solution of Nβ-Boc-Nα-methylhydrazine 
26 (189 mg, 0.58 mmol, 1.1 equiv) in toluene (0.1 M) was added p-
toluenesulfonic acid monohydrate (101 mg, 0.53 mmol, 1.0 equiv). The 
reaction mixture was stirred for 1 h at 60 °C in an oil bath. To this solution 
was added 1-pyrroline (–)-2a (60.4 mg, 0.53 mmol, 1.0 equiv) and PPTS 
(135 mg, 0.53 mmol, 1.0 equiv). The reaction mixture was stirred for 30 min 
at 130 °C under microwave irradiation. The suspension was cooled to rt, dissolved in MeOH (3 mL), washed 
with sat. aq. Na2CO3/brine (3:1, 20 mL), extracted with DCM (3 x 15 mL), dried (Na2SO4) and concentrated 
in vacuo. Purification was achieved by flash chromatography (SiO2) with an eluent gradient (33:100 → 
50:100 v/v EtOAc/cHex and 5:100 → 10:100 v/v MeOH:DCM), to obtain compound 27 (158 mg [3.1% 
CH2Cl2], 0.478 mmol, 46%) as a brown oil. Rf = 0.22 (cHex:acetone 2:1 v/v). 1H NMR (500 MHz, CDCl3): δ 
7.47 (d, J = 7.4 Hz, 2H, CH2C*CH), 7.41 (t, J = 7.5 Hz, 2H, CH2C*CHCH), 7.34 (t, J = 7.3 Hz, 1H, CH2C*CHCHCH), 
6.81 (d, J = 2.6 Hz, 1H, C(OBn)CHC*), 6.75 (dd, J = 8.4, 2.6 Hz, 1H, C(OBn)CHCH), 6.31 (d, J = 8.4 Hz, 1H, 
C(OBn)CHCH), 5.01 (s, 2H, OCH2), 4.49 (s, 1H, NCHNH), 3.16 (dd, J = 10.8, 6.8 Hz, 1H, NHCH2), 2.86 – 2.75 (m, 
5H, N(CH3)CHNHCH2), 2.51 – 2.41 (m, 1H, NHCH2CH), 2.20 – 2.01 (m, 2H, CHCH2CH2CH2), 1.88 – 1.78 (m, 3H, 
CHCH2CH2CH2), 1.51 – 1.40 (m, 1H, CHCH2CH2CH2) ppm. 13C NMR (126 MHz, CDCl3): δ 151.9 (C*), 145.8 (C*), 
137.6 (C*), 137.2 (C*), 128.4 (CH), 127.7 (CH), 127.5 (CH), 112.9 (CH), 111.4 (CH), 105.8 (CH), 95.0 (CH), 
71.1 (CH2), 63.5 (C*), 54.2 (CH), 51.6 (CH2), 40.6 (CH2), 34.0 (CH2), 33.5 (CH), 28.1 (CH2) ppm. IR (neat): vmax 
(cm-1) = 2941 (w), 2856 (w), 1493 (s), 1447 (m), 1271 (m), 1223 (m), 1190 (m), 1024 (m), 735 (m), 696 
(m), 524 (m).  HRMS (ESI): m/z calculated for C21H25N2O [M]: 321.1961, found: 321.1954. Specific rotation: 
[ߙ]஽ଶ଴ = +12 ° (c = 0.5, EtOH). 
 
N,N’-dimethylpyrroloindoline S2: To a solution of N-methylpyrroloindoline 
27 (224 mg, 0.688 mmol, 1.0 equiv) in MeOH (0.2 M) were added sodium 
cyanoborohydride (67 mg, 1.03 mmol, 1.5 equiv), formaldehyde (76.8 µL, 
1.03 mmol, 1.5 equiv) and acetic acid (80.4 µL, 1.38 mmol, 2.0 equiv) under 
inert atmosphere (N2). The reaction mixture was stirred for 2 h at rt. The 
mixture was quenched with sat. aq. Na2CO3 (20 ml), extracted with DCM (3 x 
15 mL), dried (Na2SO4) and concentrated in vacuo. Purification was achieved by flash chromatography 
(SiO2) with an eluent gradient (0:100 → 2:100 v/v MeOH:DCM), to obtain compound S2 (214 mg, 0.640 
mmol, 93%) as a brown oil. Rf = 0.53 (cHex:acetone 2:1 v/v). 1H NMR (500 MHz, CDCl3) δ 7.44 (d, J = 7.6 Hz, 
2H, CH2C*CH), 7.38 (t, J = 7.5 Hz, 2H, CH2C*CHCH), 7.32 (t, J = 7.2 Hz, 1H, CH2C*CHCHCH), 6.75 (d, J = 6.9 Hz, 
2H, OC*CH), 6.41 (d, J = 9.0 Hz, 1H, NC*CH), 4.99 (s, 2H, OCH2), 4.17 (s, 1H, NCHN), 2.93 (s, 3H, C*NCH3), 2.90 
– 2.84 (m, 1H, NCH2), 2.54 (s, 4H, CH2NCH3), 2.48 (s, 1H, NCH2CH), 2.05 – 1.76 (m, 5H, CH2CH2CH2), 1.73 – 
1.64 (m, 2H, CHCH2CH2) ppm. 13C NMR (126 MHz, CDCl3) δ 152.7 (C*), 146.4 (C*), 138.0 (C*), 137.6 (C*), 
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128.5 (CH), 127.8 (CH), 127.6 (CH), 113.3 (CH), 110.7 (CH), 108.0 (CH), 98.9 (CH), 71.1 (CH2), 63.8 (C*), 58.7 
(CH2), 52.2 (CH), 41.0 (CH2), 38.3 (CH3), 37.6 (CH3), 33.5 (CH2), 27.6 (CH2) ppm. IR (neat): vmax (cm-1) = 2941 
(w), 2858 (w), 1491 (s), 1445 (m), 1271 (m), 1221 (m), 1191 (m), 1022 (m), 734 (m), 696 (m), 526 (w). 
HRMS (ESI): m/z calculated for C22H27N2O [M]: 335.2118, found: 335.2132. Specific rotation: [ߙ]஽ଶ଴ = +4 ° (c 
= 0.5, EtOH). 
 
phenserine analog 28: To a solution of N,N’-dimethylpyrroloindoline S2 
(148 mg, 0.443 mmol, 1 equiv) in MeOH (0.2 M) was added 10% 
palladium on carbon (24 mg,  0.022 mmol, 0.05 equiv). The reaction 
mixture was stirred under hydrogen atmosphere overnight at rt. The 
mixture was filtered over Celite and concentrated in vacuo. The crude 
product was dissolved DCM (0.1 M), after which Et3N (254 µL, 1.77 mmol, 4 equiv) and phenyl isocyanate 
(59 uL, 0.53 mmol, 1.5 equiv) were added. The reaction mixture was stirred overnight at rt, washed with 
brine (20 mL), extracted with DCM (3 x 15 mL), dried (Na2SO4) and concentrated in vacuo. Purification was 
achieved by flash chromatography (SiO2) with an eluent gradient (0:100 → 5:100 v/v MeOH:DCM), to obtain 
compound 28 (128 mg [11.7% CH2Cl2], 0.311 mmol, 70%) as a brown oil. Rf = 0.35 (cHex:acetone 2:1 v/v). 
1H NMR (500 MHz, CDCl3) δ 7.41 (d, J = 7.8 Hz, 2H, NHC*CH), 7.29 (t, J = 7.9 Hz, 2H, NHC*CHCH), 7.22 (s, 1H, 
NH), 7.07 (t, J = 7.4 Hz, 1H, NHC*CHCHCH), 6.87 (dd, J = 8.4, 2.4 Hz, 1H, NC*CHCH), 6.83 (d, J = 2.4 Hz, 1H, 
NC*C*CH), 6.39 (d, J = 8.4 Hz, 1H, NC*CH), 4.09 (s, 1H, NCHN), 2.93 (s, 3H, C*NCH3), 2.84 (t, J = 8.9 Hz, 1H, 
NCH2), 2.53 (s, 3H, CH2NCH3), 2.47 – 2.40 (m, 2H, NCH2CH), 2.03 – 1.88 (m, 3H, CHCH2CH2CH2), 1.86 – 1.71 
(m, 2H, CHCH2CH2CH2), 1.61 – 1.51 (m, 1H, CHCH2CH2CH2) ppm. 13C NMR (126 MHz, CDCl3) δ 152.7 (C*), 
149.9 (C*), 142.9 (C*), 138.0 (C*), 137.8 (C*), 129.1 (CH), 123.6 (CH), 120.3 (CH), 118.7 (CH), 115.8 (CH), 
107.1 (CH), 98.9 (CH), 63.6 (C*), 59.1 (CH2), 52.4 (CH), 41.1 (CH2), 38.2 (CH3), 37.6 (CH3), 33.8 (CH2), 27.7 
(CH2) ppm. IR (neat): vmax (cm-1) = 2943 (w), 2858 (w), 1718 (m), 1599 (m), 1541 (m), 1488 (s), 1439 (m), 
1313 (m), 1202 (s), 1178 (s), 1007 (m), 993 (m), 752 (m), 692 (m). HRMS (ESI): m/z calculated for 
C22H26N3O2 [M]: 364.2020, found: 364.2030. Chirality 99% ee [Dr. Maisch Chiral AM, heptane/isopropanol = 
93/7, v = 0.6 mL/min, column temperature: 30 °C, λ = 310 nm, t (minor) = 21.023 min, t (major) = 24.221 
min]. Specific rotation: [ߙ]஽ଶ଴ = −8 ° (c = 0.4, EtOH). 
 
constrained tryptamine (R)-30: To a solution of 1-pyrroline (–)-2a (60 mg, 0.52 
mmol, 1.0 equiv) in toluene (0.1 M) were added 4-methoxyphenylhydrazine 
hydrochloride 35 (98 mg, 0.55 mmol, 1.05 equiv) and pyridinium p-toluenesulfonic 
acid monohydrate (134 mg, 0.52 mmol, 1.0 equiv). The reaction mixture was stirred 
for 30 min at 130 °C under microwave irradiation. After addition of p-
toluenesulfonic acid monohydrate (100 mg, 0.52 mmol, 1.0 equiv), the reaction 
mixture was stirred for an additional 30 min at 130 °C under microwave 
irradiation. The suspension was cooled to rt, dissolved in MeOH (3 mL), washed 
with sat. aq. Na2CO3/brine (3:1, 20 mL), extracted with DCM (3 x 15 mL), dried 
(Na2SO4) and concentrated in vacuo. To a solution of the crude product (36) in MeOH (0.2 M) were added 
sodium cyanoborohydride (68 mg, 1.04 mmol, 2.0 equiv), formaldehyde (121.8 µL, 1.30 mmol, 2.5 equiv) 
and acetic acid (97.0 µL, 2.08 mmol, 4 equiv) under inert atmosphere (N2). The reaction mixture was stirred 
for 2 h at rt and quenched46 with sat. aq. Na2CO3 (20 ml), extracted with DCM (3 x 15 mL), dried (Na2SO4) 
and concentrated in vacuo. To a solution of NaH (60% in mineral oil, 42 mg, 1.04 mmol, 2.0 equiv) in DMF (2 
mL) – that was extracted with pentane (2 x 2 mL) previously – was added a solution of the secondary crude 
H
N
O
N
N
O
H
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product in DMF (2 mL). Subsequently, benzenesulfonyl chloride (100.8 µL, 0.78 mmol, 1.5 equiv) was added 
at 0 °C. The reaction mixture was stirred overnight at rt and quenched with sat. aq. Na2CO3 (20 ml), 
extracted with DCM (3 x 15 mL), dried (Na2SO4) and concentrated in vacuo. Purification was achieved by 
flash chromatography (SiO2) with an eluent gradient (25:100 → 100:100 v/v acetone:cHex), to obtain 
compound (R)-30 (65 mg, 0.16 mmol, 31%) as a brown oil. Rf = 0.24 (cHex:acetone 2:1 v/v). 1H NMR (500 
MHz, CDCl3) δ 8.05 (d, J = 9.0 Hz, 1H, NC*CH), 7.72 (d, J = 8.1 Hz, 2H, SO2C*CH), 7.51 (t, J = 7.5 Hz, 1H, 
SO2C*CHCHCH), 7.40 (t, J = 7.8 Hz, 2H, SO2C*CHCH), 6.93 (d, J = 2.4 Hz, 1H, C(OMe)CHC*), 6.86 (dd, J = 9.0, 
2.5 Hz, 1H, NC*CHCH), 3.83 (s, 3H, OCH3), 3.16 – 3.05 (m, 1H, NC*CH2), 3.04 – 2.96 (m, 1H, NCH2CH), 2.87 – 
2.75 (m, 1H, NC*CH2), 2.45 – 2.37 (m, 2H, NCH2), 2.31 (s, N(CH3)2), 2.07 – 1.98 (m, 1H, NCH2CHCH2), 1.94 – 
1.75 (m, 2H, NC*CH2CH2), 1.72 – 1.58 (m, 1H, NCH2CHCH2) ppm. 13C NMR (126 MHz, CDCl3) δ 156.4 (C*), 
139.1 (C*), 137.2 (C*), 133.6 (CH), 131.1 (C*), 130.9 (C*), 129.3 (CH), 126.4 (CH), 120.7 (CH), 115.5 (C*), 
111.6 (CH), 102.4 (CH), 62.7 (CH2), 55.8 (CH3), 46.1 (CH3), 30.3 (CH), 24.93 (CH2), 24.91 (CH2), 19.0 (CH2) 
ppm. IR (neat): vmax (cm-1) = 2937 (w), 1607 (w), 1472 (m), 1447 (m), 1366 (m), 1209 (m), 1175 (m), 1150 
(s), 1136 (m), 1088 (m), 1034 (m), 725 (s), 685 (m), 561 (s). Chirality 99% ee [Dr. Maisch Chiral AM, 
heptane/EtOH = 97/3, v = 0.7 mL/min, column temperature: 30 °C, λ = 300 nm, t (minor) = 12.267 min, t 
(major) = 12.971 min]. Specific rotation: [ߙ]஽ଶ଴ = −31 ° (c = 0.75 [CHCl3]), Lit.: ߙ஽ଶ଴ = − 62 ° (c = 0.62 
[CHCl3]).39 
 
tricyclic tryptamine S3: To a solution of Nβ-Boc-Nα-
methylhydrazine 26 (143 mg, 0.581 mmol, 1.1 equiv) in 
toluene (0.1 M) was added p-toluenesulfonic acid monohydrate 
(102 mg, 0.528 mmol, 1.0 equiv). The reaction mixture was 
stirred for 1 h in an oil bath (60 °C). To this solution was added 
1-pyrroline (–)-2a (60.6 mg, 0.528 mmol, 1.0 equiv) and PPTS 
(135 mg, 0.528 mmol, 1.0 equiv). The reaction mixture was 
stirred for 30 min at 130 °C under microwave irradiation. 
Subsequently, p-toluenesulfonic acid monohydrate (102 mg, 0.528 mmol, 1.0 equiv) was added and the 
reaction mixture was stirred again for 30 min at 130 °C under microwave irradiation. The suspension was 
cooled to rt, dissolved in MeOH (3 mL), washed with sat. aq. Na2CO3/brine (3:1, 20 mL), extracted with DCM 
(3 x 15 mL), dried (Na2SO4) and concentrated in vacuo. The aforementioned steps were repeated and the 
crude products were combined. The crude product (37) was dissolved DCM (0.1 M), after which Et3N (585 
µL, 4.22 mmol, 4.0 equiv) and 4-(trifluoromethoxy)phenylbenzoyl chloride (204 µL, 1.27 mmol, 1.2 equiv) 
were added. The reaction mixture was stirred overnight at rt, washed with brine (20 mL), extracted with 
DCM (3 x 15 mL), dried (Na2SO4) and concentrated in vacuo. Purification was achieved by flash 
chromatography (SiO2) with an eluent gradient (10:100 → 12.5:100 v/v EtOAc/cHex), to obtain compound 
S2 (170 mg, 0.345 mmol, 33%) as a grey solid. Rf = 0.31 (cHex:acetone 2:1 v/v). 1H NMR (500 MHz, CDCl3) δ 
7.73 (d, J = 7.7 Hz, 2H, C(O)C*CH), 7.42 – 7.25 (m, 5H, Ph), 7.22 – 7.17 (m, 4H, CHC(OBn)CHCH, C(OCF3)CH), 
6.91 (d, J = 8.8 Hz, 1H, C(OBn)CHCH), 6.35 – 6.38 (m, 1H, NH), 5.00 – 4.86 (m, 2H, OCH2), 3.87 – 3.72 (m, 2H, 
NHCH2), 3.61 (s, 3H, NCH3), 3.37 – 3.31 (m, 1H, NHCH2CH), 2.69 (dd, J = 17.1, 10.4 Hz, 2H, NC*CH2), 2.09 – 
1.98 (m, 1H, NC*CH2CH2), 1.91 (dd, J = 29.0, 7.5 Hz, 3H, NC*CH2CH2CH2) ppm. 13C NMR (126 MHz, CDCl3) δ 
166.3 (C*), 153.2 (C*), 151.4 (C*), 137.8 (C*), 137.6 (C*), 133.2 (C*), 132.5 (C*), 129.0 (CH), 128.5 (CH), 
127.9 (CH), 127.8 (CH), 127.0 (C*), 120.6 (CH), 120.3 (q, J = 260 Hz, C*), 111.2 (CH), 109.6 (CH), 109.1 (C*), 
102.4 (CH), 71.0 (CH2), 44.3 (CH2), 32.5 (CH), 29.3 (CH3), 26.9 (CH2), 22.3 (CH2), 19.6 (CH2) ppm. 19F NMR 
(235 MHz, CDCl3): δ -57.70 ppm. HRMS (ESI): m/z calculated for C29H28F3N2O3 [M+H]: 509.2047, found: 
Switchable Cascade Reaction towards either Pyrroloindolines or Constrained Tryptamines 
 
129 
509.2039. 
 
tricyclic tryptamine (R)-31: To a solution of tricyclic tryptamine 
S3 (42 mg, 0.085 mmol, 1 equiv) in EtOAc (0.2 M) was added 10% 
palladium on carbon (5 mg, 0.0043 mmol, 0.05 equiv). The reaction 
mixture was stirred under hydrogen atmosphere overnight at rt. 
The mixture was filtered over Celite and concentrated in vacuo. 
Purification was achieved by flash chromatography (SiO2) with an 
eluent gradient (5:100 → 20:100 v/v EtOAc:cHex), to obtain 
compound (R)-19 (28 mg, 0.068 mmol, 80%) as a yellow solid. Rf = 
0.23 (cHex:acetone 2:1 v/v). m.p.: 84 – 90 °C.  1H NMR (500 MHz, 
CDCl3) δ 7.72 – 7.67 (m, 2H, C(O)C*CH), 7.17 (d, J = 8.3 Hz, 2H, C(OCF3)CH), 7.14 – 7.07 (m, 2H, 
CHC(OH)CHCH), 6.77 (dd, J = 8.7, 2.4 Hz, 1H, C(OH)CHCH), 6.47 (t, J = 5.9 Hz, 1H, NH), 5.91 (bs, 1H, OH), 3.89 
– 3.81 (m, 1H, NHCH2), 3.70 – 3.63 (m, 1H, NHCH2), 3.57 (s, 3H, NCH3), 3.30 – 3.22 (m, 1H, NHCH2CH), 2.75 – 
2.59 (m, 2H, NMeC*CH2), 2.06 – 1.74 (m, 4H, CHCH2CH2) ppm. 13C NMR (126 MHz, CDCl3) δ 166.8 (C*), 151.5 
(C*), 149.9 (C*), 138.0 (C*), 133.0 (C*), 132.3 (C*), 128.9 (CH), 127.2 (C*), 120.7 (CH), 120.4 (q, J = 252 Hz, 
C*), 110.4 (CH), 109.6 (CH), 108.5 (C*), 103.2 (CH), 44.2 (CH2), 32.6 (CH), 29.3 (CH3), 26.9 (CH2), 22.2 (CH2), 
19.7 (CH2) ppm. 19F NMR (235 MHz, CDCl3): δ -57.72 ppm. IR (neat): vmax (cm-1) = 3310 (w), 2932 (w), 1636 
(m), 1541 (m), 1474 (m), 1252 (s), 1207 (s), 1150 (s), 1016 (w), 848 (m), 792 (m), 734 (m), 698 (m), 546 
(m). HRMS (ESI): m/z calculated for C22H22F3N2O3 [M+H]: 419.1577, found: 419.1569. Chirality 99% ee [Dr. 
Maisch Chiral AM, heptane/isopropanol = 80/20, v = 0.9 mL/min, column temperature: 30 °C, λ = 220 nm, t 
(minor) = 43.168 min, t (major) = 46.346 min]. Specific rotation: [ߙ]஽ଶ଴ = +30 ° (c = 0.5, EtOH). 
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5.1 Introduction 
Thus far, we described several novel methods for the synthesis of diverse and complex 
scaffolds using meso-pyrrolidines as a template. For example, bi- and tricyclic imines 
were synthesized in either optically pure or racemic form by biocatalytic (Chapter 2) 
and IBX-mediated oxidation (Chapter 3), respectively. These methods were also 
applied for direct α-functionalizations of meso-pyrrolidines in a diastereoselective 
fashion by oxidative aza-Friedel‒Crafts and Ugi-type reactions. Furthermore, an acid-
switchable chemoenzymatic interrupted Fischer indole synthesis of either 
pyrroloindolines or constrained tryptamines was developed (Chapter 4). Given the 
multiple diversification points that this strategy provides, we could synthesize several 
compounds with conceivable therapeutic applications such as in the treatment of 
Alzheimer’s disease. With these examples, we illustrated the fruitful union of 
biocatalysis and synthetic chemistry. Exploration of the use of other enzymes in 
organic chemistry will certainly lead to major opportunities in the future. 
5.2 Future Directions 
In this Chapter, we describe future directions for the application of biocatalysis in 
organic synthesis. Besides the potential of monoamine oxidase in the synthesis of 
other biologically and synthetically relevant compounds, possibilities for the 
application of other biocatalysts i.e. Baeyer-Villiger monooxygenases and 
transaminases are presented. 
5.2.1 Monoamine oxidases 
Although the applicability of monoamine oxidases in synthetic chemistry was clearly 
demonstrated in this thesis, the ubiquity of 2-substituted pyrrolidines in nature and 
synthetic chemistry promotes further exploration of this methodology. 
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5.2.1.1 Auxiliary-assisted synthesis of dehydropropyl peptides 
Dehydroprolyl peptides constitute the core structure of a family of natural products 
called the phomopsins, isolated from the fungus Phomopsis leptostromiformis (Figure 
1).1 These hexapeptides—displaying a 3,4-dehydroprolyl peptide as their core 
structure—are potent microtubule depolymerizers.2 Moreover, dehydroprolyl 
peptides provide a convenient handle for functionalization towards a class of natural 
products called the astins. Astins A‒C (Figure 1) are cyclic pentapeptides with a 
dichlorinated proline residue exhibiting potent antitumor activity.3 To the best of our 
knowledge, a total synthesis of this interesting class of molecules has not been 
published yet, except for astin G that exhibits a different core structure.4 
 
Figure 1. Phomopsin A‒B and astin A‒C 
Our group previously reported a highly efficient combination of monoamine 
oxidase-N catalyzed desymmetrization of cyclic meso-pyrrolidines with an Ugi-type 
multicomponent reaction (MAO-MCR) to access 3,4-substituted prolyl peptides in 
excellent diastereo- and enantioselectivity (Scheme 1).5,6 Based on this research, we 
envisioned to employ a chiral auxiliary on a pyrrolidine core to induce 
enantioselectivity in the biocatalytic oxidation as well as diastereoselectivity in the 
Ugi-type 3CR. Herein, we describe a chemoenzymatic multicomponent approach to 
the asymmetric synthesis of 3,4-dehydroprolyl peptides using a furan auxiliary. With 
this method, the MAO-MCR sequence is followed by a retro-Diels‒Alder reaction in 
order to remove the auxiliary (MAO-MCR-rDA, Scheme 1). The 3,4-dehydroprolyl 
peptide constitutes a versatile synthon for follow-up chemistry. 
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Scheme 1. MAO-Ugi-retro-DA sequence 
The previously described MAO-MCR sequence uses a cyclopentadiene adduct (1a) for 
chiral induction.6 Therefore, we initially investigated the application of 
cyclopentadiene as an auxiliary in the MAO-MCR sequence (Scheme 1). However, its 
removal from dipeptide 3a by a thermal retro-Diels‒Alder (rDA) reaction proved to be 
challenging, as no conversion was observed at elevated temperature (250 °C). To 
facilitate a more thermodynamically favored rDA reaction, we envisioned the use of a 
diene that contributes to aromaticity, such as furan. Synthesis of the corresponding 
meso-pyrrolidine 1b with an exo-configuration was readily achieved by a Diels‒Alder 
reaction between furan and maleimide followed by reduction of the imide 
functionality.7 IBX-mediated oxidation of 1b afforded the desired imine rac-2b 
(Chapter 3), while biocatalytic oxidation with MAO-N resulted in an interesting 
domino reaction of oxidation, rDA reaction and pyrrole addition to give 2-pyrrolyl 
pyrrolidine 5 (Chapter 2). After extensive screening of the reaction conditions, we 
found that imine 2b has a lower tendency to undergo a rDA reaction when the mixing 
method for the biocatalytic oxidation is stirring instead of shaking (Scheme 2). 
However, we have no plausible explanation for this unusual observation. Under 
optimized conditions (37 °C, 400 rpm stirring), we isolated a surprisingly stable 
hemiaminal (2b’) that results from the addition of water to imine 2b. The rather low 
isolated yield (54%, 2:98 ratio 2b:2b’) can be rationalized by the occurrence of a rDA 
reaction to a certain extent. Since we were not yet successful in scaling up the 
biocatalytic oxidation, we performed the following steps of the MAO-MCR-rDA 
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sequence with the racemic imine. The Ugi-type three-component reaction of readily 
 
 
Scheme 2. Biocatalytic oxidation with mixing by stirring or shaking.  Conditions A: pyrrolidine (0.25 mmol), 
MAO-N D5 freeze-dried whole cells (125 mg), PPB (12.5 mL, 200 mM, pH 7.5), 37 °C, 400 rpm stirring, 17 h. 
Conditions B: Shaken, not stirred. 
 
Scheme 3.  Steric rationalization for diastereoselectivity in the Ugi-type reaction with endo-2a and exo-2b.  
available rac-2b, tert-butyl isocyanide and benzoic acid provided prolyl peptides 3b 
and 3b’. However, the diastereoselectivity was significantly decreased compared to 
the equivalent reaction with endo-configured imine 2a6,7 as a result of the smaller 
difference in steric congestion between the diastereotopic faces of imine 2b (Scheme 
3). Fortunately, the diastereoisomers were readily separated by silica gel 
chromatography, which would allow synthesis of both enantiomers of the target 
molecule 4 starting from (‒)-2b. After a screening with various solvents (Table 1), we 
found that superior diastereoselectivity in the Ugi-type MCR is achieved in MeCN 
(entry 11). The relative stereochemistry of major diastereoisomer 3b was 
corroborated by X-ray crystallography (Chapter 3). 
 With the major diastereoisomer of the Ugi adduct (rac-3b) in hand, we 
performed a temperature screening for the rDA reaction of 3b under microwave 
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irradiation (Table 2). Gratifyingly, high conversion towards rac-4 was achieved in only 
 
Table 1. Solvent screen for the Ugi-type three-component reaction of imine 2b.[a] 
 
Entry[a] Solvent Yield[b] dr[c] Entry[a] Solvent Yield[b] dr[c] 
1 dioxane 48% 1.0:1 7 EtOAc 76% 2.2:1 
2 toluene 89% 1.2:1 8 DMSO 50% 2.9:1 
3 nBuOH 79% 1.8:1 9 MeOH 84% 3.1:1 
4 (MeO)2CO 71% 1.8:1 10 DMF 44% 3.6:1 
5 EtOH 79% 2.0:1 11 MeCN 79% 4.8:1 
6 CH2Cl2 86% 2.2:1     
[a] Conditions: imine rac-2b (1.0 equiv), tert-butyl isocyanide (1.2 equiv) and benzoic acid (1.2 equiv) in 
solvent (0.2 M), rt, 4 days. [b] Yield of the crude 3b/3b’ mixture (>95% purity). [c] Determined with HPLC 
by comparison with a 1:1 mixture of diastereoisomers. 
 
15 minutes at temperatures above 200 °C in DMSO (entries 3‒4). Under optimized 
conditions (225 °C, 15 min), the dehydroprolyl peptide rac-4 was obtained in 86% 
isolated yield (entry 4). Although these preliminary experiments show the high 
potential of our MAO-Ugi-retro-DA sequence with furan as chiral auxiliary, 
optimization of the biocatalytic oxidation of 1b is required to further suppress the 
undesired rDA reaction.  
Table 2. retro-Diels‒Alder reaction of furan-based prolyl peptide 3b.[a] 
Entry T (°C) Conv. [b] Yield[c] 
1 150 1% n.d. 
2 175 27% n.d. 
3 200 90% n.d. 
4 225 100% 86% 
[a] Conditions:  DMSO-d6 (0.3 M), 15 min, T, μW [b] Conversion calculated by the product to substrate ratio 
in the 1H NMR spectrum of the crude mixture. [c] Isolated yield. 
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5.2.1.2 Chemoenzymatic strategy to the synthesis of proline-derived 
tetrazole organocatalysts 
In light of our interest in chiral 2-substituted pyrrolidines with high relevance in 
synthetic chemistry, we investigated the applicability of our biocatalytic meso-
pyrrolidine oxidation in the synthesis of proline-like organocatalysts with a tetrazole 
moiety. Tetrazoles are gaining importance in medicinal chemistry8 as well as in 
organocatalysis.9 Since 5-substituted-1H-tetrazoles are commonly known as isosteres 
of carboxylic acids,10 having a similar pKa value, proline derivatives with a 
1H-tetrazole fragment are becoming a widely used alternative for the well-known 
organocatalyst proline.11 Unlike proline, the corresponding tetrazole derivative is 
soluble in a wide range of organic solvents. As a result, a much wider range of 
reactions can be catalyzed with proline-derived tetrazoles, such as asymmetric 
(nitroso)aldol,12 Mannich13 and nitro-Michael9 reactions. The general strategy for their 
synthesis starts from commercially available proline derivatives, which limits 
molecular diversity. Thus far, only a handful of chiral proline-derived tetrazole 
catalysts have been synthesized (Figure 2).11,14,15 The development of novel sterically 
encumbered proline-derived tetrazole catalysts is of high interest in order to improve 
stereoselectivity in asymmetric organocatalytic transformations. 
 
Figure 2. Examples of chiral proline-derived tetrazole organocatalysts. 
Nenajdenko et al. showed the application of cyclic imines in the azido-Ugi reaction 
with trimethylsilyl azide and isocyanides for the synthesis of racemic organocatalyst 
precursors (Scheme 4).16 Chiral resolution and benzyl deprotection were required to 
provide an optically enriched proline-derived tetrazole organocatalyst.16a We 
envisioned direct access to novel asymmetric organocatalyst precursors 6 by the use 
of enantio-enriched imines 2. Conveniently, bi- and tricyclic imines can be obtained in 
high to excellent enantiopurity by a biocatalytic oxidation of meso-pyrrolidines.5 For 
the synthesis of the corresponding racemic proline-derived tetrazoles, the imine 
substrates can be obtained by IBX-mediated oxidation (Chapter 3).7 
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Scheme 4. Synthesis of novel organocatalysts from cyclic imines via an azido-Ugi reaction. 
 
We started our investigation of the reaction conditions and substrate scope by a 
reaction between readily available rac-2a, isocyanides 8 and trimethylsilyl azide in 
methanol as the reaction medium (2 d, 40 °C). To our surprise, the main product (9) of 
our initial attempts had an isocyanide molecule inserted into a dimer of the imine 
substrate (Table 3). Isocyanide-inserted dimeric structure 9b derived from benzyl 
isocyanide was obtained in high yield (90%) as a single diastereoisomer. However, the 
corresponding dimer derived from tert-butylisocyanide (9a) was obtained in only 
modest yield, together with 42% of tetrazole 6a. Intriguingly, we obtained the desired 
1,5-disubstituted tetrazoles 6 as the sole products after changing the reaction medium 
from methanol to 2,2,2-trifluoroethanol (TFE). Under optimized reaction conditions 
(TFE, 2 d, 40 °C, Table 3), the desired 1,5-disubstituted tetrazoles 6a and 6b derived 
from rac-2a and either tert-butyl or benzyl isocyanide could be isolated in good yields 
(60‒74%) and as single diastereoisomers. Subsequently, the scope of the bicyclic 
imines was further explored with bicyclic imine rac-2c. As a consequence of the 
decreased steric congestion on the concave face of 2c, the adducts 6c and 6c’ were 
obtained as a 8.3:1 diastereoisomeric mixture, albeit in high yield.  
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Table 3. Azido-Ugi reaction for the synthesis of 6a‒c and 9a,b. 
 
[a] Conditions: imine rac-2 (1.0 equiv), TMSN3 (1.1 equiv), isocyanide 8 (1.1 equiv) in TFE, 2 d, 40 °C.  
[b] Conditions: imine rac-2 (1.0 equiv), TMSN3 (2.0 equiv), isocyanide 8 (2.0 equiv) in TFE, 2 d, 40 °C.  
[c] Conditions: imine rac-2 (2.0 equiv), TMSN3 (1.5 equiv), isocyanide 8 (1.5 equiv) in MeOH, 2 d, 40 °C.  
 
Scheme 5. Benzyl deprotection of organocatalyst precursor 6b. 
Synthesis of a novel asymmetric organocatalyst was achieved by employing 
optically-pure imine (+)-2a, derived from the corresponding meso-pyrrolidine by 
biocatalytic oxidation.5 Debenzylation gave access to proline-derived tetrazole 7a as a 
single diastereoisomer (Scheme 5). 
 To conclude, we developed the first stereoselective azido-Ugi reaction with 
cyclic imines. Facile deprotection provided a novel 3,4-substituted multicyclic 
proline-derived tetrazole organocatalyst (7a). We envision its application in the 
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asymmetric Biginelli MCR towards 3,4-dihydropyridimidin-2(1H)-one (DHPM) 
derivatives.15 Thus far, only moderate enantioselectivity (68‒81% ee) was obtained in 
asymmetric Biginelli reactions catalyzed by proline-derived tetrazoles (Scheme 6). 
Since superior results were obtained with a bulky group on the 4-position of the 
pyrrolidine (Figure 2, C), our sterically encumbered 3,4-substituted proline-derived 
tetrazoles appear to have high potential for this application. 
 
Scheme 6. Asymmetric Biginelli MCR catalyzed by proline-derived tetrazole catalyst C.15 
5.2.2 Baeyer-Villiger monooxygenases 
The application of Baeyer-Villiger monooxygenases (BVMOs) in organic chemistry is 
not widespread, but their potential has been demonstrated in several reports 
(Chapter 1).17 Of the known subtypes of BVMOs, the most widely applied are 
cyclohexanone (CHMO), cyclopentanone (CPMO), hydroxyacetophenone (HAPMO) 
and phenylacetone monooxygenase (PAMO).18 Their partially overlapping broad 
substrate scopes are depicted in Figure 3,19a representing the most important 
substrates per subtype. 
As described in Chapter 1, a cofactor regeneration system is essential when 
using BVMOs as a result of the stoichiometrically consumed cofactor. Fraaije et al.  
 
 
Scheme 7. Coenzyme regeneration by PTDH/BVMO fusion enzymes. 
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Figure 3. A representation of the substrate scopes of the four most important BVMO subtypes.19a 
conveniently linked different types of BVMOs to phosphite dehydrogenase (PTDH) 
which is the vital part of the cofactor regeneration system in this case (Scheme 7).19 
The only additional requirements are oxygen and phosphite as a cheap and sacrificial 
electron donor. The application of these self-sufficient BVMOs reduces the labor of 
enzyme cultivation, expression and isolation by half, since a single fusion protein 
performs the task of two separate biocatalysts.  
 A particularly interesting biocatalytic strategy in terms of further applications 
is the dynamic kinetic resolution (DKR) of α-substituted β-ketoesters and β-diketones 
using BVMOs. The fast racemization of these substrates in aqueous medium through a 
keto-enol equilibrium allows an asymmetric and regioselective Baeyer-Villiger 
oxidation with full conversion to generate α-hydroxy esters or ketones (Chapter 1).20 
Further broadening the substrate scope is expected to boost the application of this 
method in the total synthesis of biologically active molecules.  
 We investigated the reaction conditions required for the dynamic kinetic 
resolution of α-substituted β-diketones with different fusion proteins developed by 
Fraaije and coworkers. A symmetric β-diketone (10a) was used for the benchmark  
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Figure 4. Biocatalytic Baeyer-Villiger oxidation of substrate 10a with a PTDH protein fused to a) HAPMO, b) 
CHMO, or c) non-fused PAMO and PTDH. 
 
reaction, in which case the biocatalytic strategy should be annotated 
desymmetrization rather than dynamic kinetic resolution. For the biocatalytic 
monooxygenation of 10a, we observed an interesting correlation between pH and 
activity as well as enantioselectivity (Figure 4). Surprisingly, both HAPMO and CHMO 
showed superior activity (>90% conversion after 2h) and excellent enantioselectivity 
at a particularly high pH of 10. In contrast, PAMO only showed selective conversion to 
the desired product at pH 7 and 8 with up to 88% ee. Next, we investigated the 
substrate scope with an indirect phosphate assay, which indicated high conversion for 
a diverse library of substrates. Thus far, we were not successful in scaling up the 
biocatalytic Baeyer-Villiger oxidation to isolate the products. However, recent 
publications show wide substrate scopes for related compounds.20a,21 It is important  
 
 
Scheme 8. Total synthesis of (nor)ephedrine and hypothesized synthesis of chloramphenicol. 
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Scheme 9. Biocatalytic approach towards the synthesis of epothilone building block 14. 
to note that not much optimization work was performed, because of our lack of 
experience with the required conditions for these isolated enzymes. Furthermore, our 
focus shifted towards the other projects described in this thesis.  
 The potential of this strategy is illustrated by its application in the synthesis 
of stimulant (nor)ephedrine20b and our hypothesized synthesis of antibiotic 
chloramphenicol (Scheme 8). Furthermore, we envision the synthesis of a key chiral 
building block (14) of macrocycle epothilone B,22 a potent anticancer drug. The 
asymmetric element in this building block is hypothesized to be established by a 
biocatalytic Baeyer-Villiger oxidation of 12 followed by a Wittig reaction (Scheme 9). 
Since the proposed syntheses are just examples of the potential utility of BVMOs in 
dynamic kinetic resolution strategies for total syntheses, we expect significant 
progress in the application of BVMOs in organic synthesis in the future. 
5.2.3 Transaminases 
Optically active amines are important building blocks for the preparation of 
pharmaceuticals and agrochemicals. The most appealing biocatalytic strategy for the 
synthesis of α-chiral primary amines is desymmetrization of the corresponding ketone 
with a transaminase (Chapter 1).23 Although the application of many (S)-selective 
transaminases is widely described, only a few (R)-selective transaminases were 
identified, only one of which is commercially available (ATA-117). Bornscheuer et al. 
published the synthesis of enantio-enriched aliphatic, aromatic and arylaliphatic 
amines with (R)-selective amine transaminases.24 Although the reported substrates 
generally have a methyl group as one of the α-substituents, an amine transaminase 
from Chromobacterium violaceum is known to accept a hydroxymethyl substituent on 
that position.25 Interestingly, Nenajdenko et al. showed the utility of such a 
hydroxymethyl substituent in the formation of a zinc chelate to facilitate a  
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Scheme 10. Application of transaminases in organic synthesis. 
 
diastereoselective Ugi MCR for the synthesis of dipeptides.26 With this information in 
hand, we envisioned the biocatalytic desymmetrization of α-hydroxy ketones to give 
optically pure β-hydroxy amines which can be applied as chiral auxiliary for the Ugi 
MCR. An electron-rich aryl group on the chiral auxiliary would allow subsequent 
acidic cleavage to access enantio-enriched dipeptides with three diversification points 
(16). Other opportunities include the cyclization of 15 to provide oxopiperazines 17 
(Scheme 10). We found that the Ugi MCR and subsequent acidic cleavage proceed well, 
as well as the cyclization of 15 to 17. However, the transamination was not explored 
yet and the diastereoselectivity of the Ugi MCR proved to be only moderate in our 
hands. Although just two examples are highlighted in this section, the possibilities for 
the application of optically active primary amines in organic synthesis are limitless. 
Therefore, the use of transaminases in total synthesis is expected to receive increasing 
interest in the future. 
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5.4 Experimental Section 
General comments 
Starting materials were purchased from Sigma Aldrich, Alfa Aesar, Acros Organics and used without 
treatment. Unless stated otherwise, the solvents were purchased from VWR Chemicals or Biosolve and were 
used without further treatment. Cyclohexane (cHex) was purified by distillation before use. The meso-
pyrrolidines and racemic or enantioenriched imines were synthesized according to previously reported 
procedures.5,7 Celite® 512 medium was purchased from Sigma Aldrich. Column Chromatography was 
performed on Silica-P Flash Silica Gel (particle size 40-63 μm, pore diameter 60 Å) from Silicycle. Thin Layer 
Chromatography (TLC) was performed using TLC plates F254 (silica gel 60 on aluminium) from Merck 
Serono KGaA (Darmstadt) and compounds were visualized by UV detection (254 or 366 nm) and stained 
with basic aq. KMnO4 or ninhydrin/ethanol. 1H, 13C, COSY, HSQC, HMBC and NOESY nuclear magnetic 
resonance (NMR) spectra were recorded on a Bruker Avance 500 (500.23 MHz for 1H and 125.78 MHz for 
13C) using the residual solvent as internal standard (CDCl3: δ = 7.26 for 1H NMR and δ = 77.16 for 13C NMR) 
or Bruker Avance 400 (400.13 MHz for 1H and 100.62 MHz for 13C) using the residual solvent as internal 
standard (CDCl3: δ = 7.26 for 1H NMR and δ = 77.16 for 13C NMR, MeOD-d4: δ = 3.31 for 1H NMR and δ = 
49.00 for 13C NMR) or Bruker Avance 250 (250.13 MHz for 1H) in CDCl3 using the residual solvent as 
internal standard (CDCl3: δ = 7.26 for 1H NMR, DMSO-d6: δ = 2.50 for 1H NMR). Chemical shifts (δ) are given 
in ppm and coupling constants (J) are quoted in hertz (Hz). Resonances are described as s (singlet), d 
(doublet), t (triplet), q (quartet), bs (broad singlet) and m (multiplet) or combinations thereof. The COSY-, 
HMBC- and HSQC-NMR spectra were used for the assignment of the proton signals. The APT-NMR spectra 
were used for the assignment of the carbon signals. NMR data was processed using MestReNova. Names of 
chemical structures were deduced from generic names and/or important functionalities. Electrospray 
Ionization (ESI) high resolution mass spectrometry (HRMS) was carried out using a Bruker micrOTOF-Q 
instrument in positive ion mode (capillary potential of 4500 V). Infrared (IR) spectra were recorded neat 
using a FTIR-8400s from Shimadzu. Signal intensities are described as strong (s), medium (m), weak (w) or 
broad (br). Melting points were recorded on a Büchi M-565 and are not corrected.  
 
Synthetic procedures and spectral data 
 
2-hydroxypyrrolidine 2b’ and 1-pyrroline 2b: To a solution of rehydrated 
freeze-dried MAO-N cells (4 x 125 mg, 30 min, 37 °C, 400 rpm) in phosphate 
buffer (4 x 12.5 mL, 200mM, pH 7.5) was added pyrrolidine 1b (147 mg, 1.04 
mmol). The reaction mixture was stirred for 17 hr (400 rpm, 37 °C), after 
which the suspension was centrifuged until the supernatant had clarified (1 hr, 
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4000 rpm, 4 °C). The pH of the supernatant was adjusted to 11 with 2M aq. NaOH and extracted with DCM 
(3 x 100 mL). The combined organic layers were dried (Na2SO4) and concentrated in vacuo, to afford a 
mixture of compounds 2b’ and 2b (85.0 mg, 0.56 mmol, 54%) as a white solid in a 49:1 ratio as determined 
by NMR spectroscopy. IR (cm-1): vmax = 2978 (s), 2797 (s), 1394 (m), 1304 (s), 1129 (s), 1157 (s), 1032 (s), 
949 (s), 897 (s), 814 (s), 723 (s), 692 (s). HRMS (ESI+) calculated for C8H9NO (MH+) 136.0757, found 
136.0762. 2b’:27 1H NMR (CDCl3, 250.1 MHz): δ 6.40-6.32 (m, 2H HC=CH), 4.75 (s, 1H, NCHCHCHO), 4.67 (s, 
1H, NCH2CHCHO), 3.21 (t, J = 7.8 Hz, 1H, NCH2), 2.78 (d, J = 6.0 Hz, 1H, NHCHOH), 2.46-2.37 (m, 1H, 
NCH2CHCHO), 2.26 (t, J = 7.5 Hz, 1H, NCH2), 2.19 (dd, J = 8.0, 6.2 Hz, 1H, NCHOHCH) ppm. 13C NMR (126 
MHz, CDCl3): δ 136.5 (CH), 136.0 (CH), 84.8 (CH), 80.7 (CH), 80.0(CH), 50.1 (CH2), 48.7 (CH), 44.0 (CH). 2b:7 
1H NMR (CDCl3, 250.1 MHz): δ 7.41 (s, 1H, NCH), 6.40-6.34 (m, 2H HC=CH), 4.95 (s, 1H, NCHCHCHO), 4.76 (s, 
1H, NCH2CHCHO), 4.02-3.91 (m, 1H, NCH2), 3.72-3.63 (m, 1H, NCH2), 3.11 (d, J = 7.0 Hz, 1H, NCHCH), 2.53-
2.45 (m, 1H, NCH2CH) ppm. 13C NMR (CDCl3, 126 MHz): δ 164.1 (CH), 137.5 (CH), 136.2 (CH), 84.3 (CH), 
79.8 (CH), 63.7 (CH2), 59.7 (CH), 42.4 (CH).  
 
2,3-trans-prolyl peptide rac-3b (major) and 
2,3-cis-prolyl peptide rac-3b’ (minor): To a solution of 
rac-2b (654 mg, 4.84 mmol, 1.0 equiv) in DCM (25 mL) was 
added benzoic acid (0.71 g, 5.81 mmol, 1.2 equiv) and 
tert-butyl isocyanide (670 µL, 5.81 mmol, 1.2 equiv). The 
reaction mixture was stirred at room temperature for 4 
days, after which it was quenched by the addition of sat. aq. Na2CO3 (25 mL), extracted with DCM (3 x 25 
mL), dried (Na2SO4) and concentrated in vacuo. Purification was achieved by flash chromatography (SiO2) 
with an eluent gradient (4:1 → 1:2 v/v cHex:EtOAc), to obtain compound rac-3b (793 mg, 2.33 mmol, 52%) 
and rac-3b’ (428 mg, 1.26 mmol, 26%) in a 2.0:1 diastereoisomeric ratio as off-white solids. 3b: Rf = 0.14 
(cHex:EtOAc 1:1 v/v). m.p.: 176.8 – 185.3 °C. 1H NMR (500 MHz, CDCl3): δ 7.49 – 7.38 (m, 5H, Ph), 6.93 (s, 
1H, NH), 6.42 (dd, J = 6.1 Hz, J = 1.9 Hz, 1H, NCH2CHCHCH=CH), 6.35 (dd, J = 1.5 Hz, J = 1.5 Hz, 1H, 
NCH2CHCHCH=CH), 4.95 – 4.84 (m, 2H, NCH2CHCHO, NCH), 4.65 (s, 1H, NCHCHCHO), 3.73 (dd, J = 11.9 Hz, J 
= 8.3 Hz, 1H, NCH2), 3.52 (dd, J = 12.0 Hz, J = 1.9 Hz, 1H, NCH2), 2.98 (d, J = 7.1 Hz, 1H, NCHCH), 2.42 (t, J = 7.8 
Hz, 1H, NCH2CH), 1.35 (s, 9H, C(CH3)3) ppm. 13C NMR (126 MHz, CDCl3): δ 170.1 (C*), 169.8 (C*), 137.1 (CH), 
136.6 (CH), 136.2 (CH), 130.3 (CH), 128.6 (CH), 127.0 (C*), 84.0 (CH), 83.7 (CH), 64.1 (CH), 52.9 (CH2), 51.4 
(C*), 44.7 (CH), 44.3 (CH), 28.8 (CH3) ppm. IR (neat): vmax (cm-1) = 3292 (w), 2966 (w), 1676 (s), 1601 (s), 
1570 (s), 1541 (s), 1447 (m), 1425 (s), 1356 (m), 1281 (w), 1259 (w), 1223 (m), 1030 (w), 941 (w), 903 (s), 
868 (w), 847 (w), 719 (s), 692 (s), 665 (s), 619 (m). HRMS (ESI): m/z calculated for C20H25N2O3 [M+H]+: 
341.1860, found: 341.1849. 3b’: Rf = 0.10 (cHex:EtOAc 1:1 v/v). m.p.: 184.0 – 190.0 °C (decomposition). 1H 
NMR (500 MHz, MeOD-d4): δ 7.59 – 7.19 (m, 5H, Ph), 6.50 – 6.31 (m, 2H, HC=CH), 4.86 (s, 1H, CHO), 4.78 – 
4.59 (m, 2H, NCH, CHO), 3.53 (t, J = 9.7 Hz, 1H), 3.40 – 3.30 (m, 1H, NCH2),28 2.68 – 2.56 (m, 1H, NHCH2CH), 
2.54 – 2.40 (m, 1H, NCHCH),28 1.30 (s, 9H, C(CH3)3,) ppm.29 13C NMR (126 MHz, MeOD-d4): δ 168.4 (C*), 
168.0 (C*), 137.2 (CH), 137.1 (C*), 136.7 (CH), 130.3 (CH), 128.7 (CH), 127.6 (CH), 79.4 (CH, CH), 60.5 (CH), 
53.0 (CH2), 50.7 (C*), 47.2 (CH), 45.4 (CH), 29.1 (CH3) ppm. IR (neat): vmax (cm-1) = 2974 (w), 1670 (s), 1624 
(s), 1418 (s), 1313 (w), 1223 (m), 1142 (m), 986 (m), 951 (m), 906 (m), 822 (w), 661 (m). HRMS (ESI): m/z 
calculated for C20H25N2O3 [M+H]+: 341.1860, found: 341.1850. IR (cm-1): vmax = 3294 (m), 2961 (m), 1676 (s), 
1601 (s), 1570 (s), 1541 (s), 1425 (m), 1223 (m), 903 (s), 719 (s), 665 (s). HRMS (ESI+) calculated for 
C20H24N2O3 (MH+) 341.1860, found 341.1864. 
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dehydroprolyl peptide rac-4: A solution of rac-3b (0.35 g, 1.00 mmol) in DMSO 
(3.5 mL) was stirred for 15 min at 225 °C under microwave irradiation, after 
which the reaction was quenched by the addition of  H2O (5 mL), extracted with 
EtOAc (3 x 5 mL), dried (Na2SO4) and concentrated in vacuo to obtain compound 
rac-4 (0.24 g, 0.86 mmol, 86%) as a brown solid. m.p.: 189.3 – 190.1 °C. 1H NMR 
(CDCl3, 500 MHz): δ 7.63 – 7.33 (m, 5H, Ph), 6.87 (s, 1H, NH), 5.99 – 5.85 (m, 2H, CH=CH), 5.48 – 5.40 (m, 1H, 
NCH2CH), 4.52 – 4.41 (m, 1H, NCH2), 4.17 – 4.03 (m, 1H, NCH2), 1.36 (s, 9H, C(CH3)3). 13C NMR (126 MHz, 
CDCl3) δ 171.6 (C*), 169.1 (C*), 135.9 (C*), 130.8 (CH), 128.7 (CH), 127.3 (CH), 126.9 (CH), 126.7 (CH), 68.2 
(CH), 57.1 (CH2), 51.5 (C*), 28.8 (CH3) ppm. IR (cm-1): vmax = 3292 (s),  3067 (m), 2972 (m), 2864 (m), 1682 
(s), 1632 (s), 1610 (s), 1603 (s), 1551 (s), 1418 (s), 1356 (s), 1263 (s), 1223 (m), 1003 (s), 852 (s), 785 (s), 
725 (s), 702 (s), 660 (m). HRMS (ESI+) calculated for C16H20N2O2 (MH+) 273.1598, found 273.1599. 
 
tetrazolyl pyrrolidine rac-6a: To a solution of imine 2a (33 mg, 0.25 mmol, 1.0 equiv) 
in TFE (0.2 M) were added TMSN3 (38 µl, 0.28 mmol, 1.1 equiv) and t-butyl isocyanide 
(32 µL, 0.28 mmol, 1.1 equiv). The reaction mixture was stirred for 48 hr at 40 °C. The 
suspension was concentrated in vacuo. Purification was achieved by flash 
chromatography (SiO2) with an eluent of EtOAc, to obtain compound rac-6a (39 mg, 0.15 mmol, 60 %) as a 
yellow solid. Rf = 0.09 (EtOAc). m.p.: 85.5 – 89.3 °C. 1H NMR (500 MHz, CDCl3): δ 6.36 (dd, J = 5.9 Hz, J = 3.1 
Hz, 1H, NHCH2CHCHCH=), 6.26 (dd, J = 5.9, 3.0 Hz, 1H, NHCHCHCHCH=), 4.11 (d, J = 3.6 Hz, 1H, NHCH), 3.41 
(dt, J = 8.6 Hz, J = 3.9 Hz, 1H, NHCHCH), 3.20 – 3.05 (m, 2H, NHCH2, NHCH2CH), 2.90 (s, 2H, 
NHCH2CHCHCH2CH), 2.54 (dd, J = 11.9 Hz, J = 3.7 Hz, 1H, NHCH2), 2.11 (s, 1H, NH), 1.74 (s, 9H, CH3), 1.63 – 
1.54 (m, 2H, CHCH2CH) ppm. 13C NMR (126 MHz, CDCl3): δ 157.1 (C*), 137.6 (CH), 134.8 (CH), 61.2 (C*), 
56.7 (CH), 54.8 (CH), 53.8 (CH2), 49.9 (CH2), 49.8 (CH), 46.1 (CH), 45.8 (CH), 30.2 (CH3) ppm. IR (neat): vmax 
(cm-1) = 3337 (w), 2964 (m), 2937 (m), 1431 (w), 1389 (m), 1086 (m), 1032 (w), 862 (s), 833 (s), 800 (s), 
748 (s), 708 (s), 681 (s). HRMS (ESI): m/z calculated for C14H22N5 [M+H]+: 260.1870, found: 260.1880. 
 
 tetrazolyl pyrrolidine rac-6b: To a solution of imine 2a (33 mg, 0.25 mmol, 1.0 
equiv) in TFE (0.05 M) were added TMSN3 (70 µl, 0.50 mmol, 2.0 equiv) and benzyl 
isocyanide (59 µL, 0.50 mmol, 2.0 equiv). The reaction mixture was stirred for 48 
hr at 40 °C. The suspension was concentrated in vacuo. Purification was achieved 
by flash chromatography (SiO2) with an eluent of EtOAc, to obtain compound rac-
6b (55 mg, 0.19 mmol, 74 %) as a yellow oil. Rf = 0.09 (EtOAc). 1H NMR (500 MHz, CDCl3): δ 7.44 – 7.31 (m, 
3H, Ph), 7.23 – 7.18 (m, 2H, Ph), 6.33 – 6.25 (m, 1H, NHCH2CHCHCH=), 6.15 – 6.06 (m, 1H, NHCHCHCHCH=), 
5.81 – 5.61 (m, 2H, PhCH2), 3.79 (d, J = 3.5 Hz, 1H, NHCH), 3.51 – 3.43 (m, 1H, NCHCH), 3.03 – 2.94 (m, 1H, 
NHCH2CH), 2.87 (s, 1H NHCH2CHCH), 2.84 – 2.74 (m, 2H, NHCH2, NHCHCHCH), 2.59 (dd, J = 12.4 Hz, J 
= 3.6 Hz, 1H, NHCH2), 1.88 (s, 1H, NH), 1.55 – 1.45 (m, 2H, CHCH2CH) ppm. 13C NMR (126 MHz, CDCl3): δ 
156.5 (C*), 137.0 (CH), 135.4 (CH), 134.3 (C*), 129.2 (CH), 128.8 (CH), 127.8 (CH), 55.6 (CH), 53.4 (CH2), 
52.6 (CH), 51.2 (CH2), 49.6 (CH2), 48.8 (CH), 46.4 (CH), 46.0 (CH) ppm. IR (neat): vmax (cm-1) = 2962 (w), 
1497 (m), 1481 (w), 1456 (m), 1437 (m), 1248, 1165 (m), 1101 (s), 1076 (w), 864 (w), 723 (s), 710 (s), 662 
(m), 619 (m). HRMS (ESI): m/z calculated for C17H20N5 [M+H]+: 294.1713, found: 294.1705.  
 
 2,3-trans-tetrazolyl pyrrolidine rac-6c (major) 
2,3-cis-tetrazolyl pyrrolidine rac-6c’ (minor): To a solution of 
imine 2c (28 mg, 0.25 mmol, 1.0 equiv) in TFE (0.2 M) were added 
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TMSN3 (38 µl, 0.28 mmol, 1.1 equiv) and t-butyl isocyanide (32 µL, 0.28 mmol, 1.1 equiv). The reaction 
mixture was stirred for 48 hr at 40 °C. The suspension was concentrated in vacuo. Purification was achieved 
by flash chromatography (SiO2) with an eluent gradient (100:5 → 100:10 v/v DCM:MeOH), to obtain 
compounds rac-6c (44 mg, 0.19 mmol, 75 %) as a yellow solid and rac-6c’ (6 mg, 0.02 mmol, 9 %) as a 
yellow oil in a 8.3:1 diastereoisomeric ratio. 6c: Rf = 0.18 (EtOAc). m.p.: 70.2 – 76.6 °C. 1H NMR (500 MHz, 
CDCl3): δ 4.14 (d, J = 4.9 Hz, 1H, NHCH), 3.45 (dd, J = 11.4 Hz, J = 8.2 Hz, 1H, CH2NH), 3.18 – 3.08 (m, 1H, 
NHCHCH), 2.94 – 2.80 (m, 1H, NHCH2CH), 2.58 (dd, J = 11.6 Hz, J = 5.8 Hz, 1H, CH2NH), 2.30 – 2.15 (m, 1H, 
NH), 1.87 – 1.79 (m, 2H, NHCH2CHCH2CH2CH2), 1.77 (s, 9H, (CH3)3), 1.72 – 1.59 (m, 2H, CHCH2CH2), 1.51 – 
1.38 (m, 2H, NHCH2CHCH2CH2CH2) ppm. 13C NMR (126 MHz, CDCl3): δ 156.5 (C*), 61.5 (C*), 61.1 (CH), 54.8 
(CH2), 51.5 (CH), 45.3 (CH), 32.7 (CH2), 32.5 (CH2), 30.3 (CH3), 26.4 (CH2) ppm. IR (neat): vmax (cm-1) = 3288 
(w), 2961 (m), 1458 (w), 1389 (m), 1294 (w), 1236 (m), 1144 (m), 1115 (w), 1101 (m), 1082 (w), 860 (s), 
837 (m), 708 (m), 609 (m), 581 (m). HRMS (ESI): m/z calculated for C12H22N5 [M+H]+: 236.1870, found: 
236.1875. 6c’: Rf = 0.01 (EtOAc). 1H NMR (500 MHz, CDCl3): δ 4.55 (d, J = 7.3 Hz, 1H, NHCH), 3.15 – 3.08 (m, 
1H, NH), 3.00 (d, J = 4.5 Hz, 2H, NHCH2), 2.90 – 2.81 (m, 1H, NHCHCH), 2.79 – 2.71 (m, 1H, NHCH2CH), 2.03 – 
1.96 (m, 1H, NHCH2CHCH2), 1.75 (s, 9H, (CH3)3), 1.73 – 1.68 (m, 1H, NHCH2CHCH2CH2), 1.40 – 1.20 (m, 3H, 
NHCH2CHCH2CH2CH2), 1.11 – 1.00 (m, 1H NHCHCHCH2) ppm. 13C-NMR (126 MHz, CDCl3): δ 153.8 (C*), 61.4 
(C*), 58.4 (CH), 53.2 (CH2), 48.9 (CH), 46.4 (CH), 34.2 (CH2), 30.2 (CH3), 28.8 (CH2), 28.1 (CH2) ppm. IR 
(neat): vmax (cm-1) = 2941 (s), 2862 (s), 1448 (m), 1340 (m), 1211 (w), 1059 (w), 633 (s), 534 (s). HRMS 
(ESI): m/z calculated for C12H22N5 [M+H]+: 236.1870, found: 236.1866. 
 
imidazolidin-4-imine rac-9a:30 To a solution of imine 2a (66 mg, 0.50 mmol, 2.0 
equiv) in TFE (0.4 M) were added TMSN3 (52 µl, 0.38 mmol, 1.5 equiv) and t-butyl 
isocyanide (43 µL, 0.38 mmol, 1.5 equiv). The reaction mixture was stirred for 48 hr at 
40 °C. The suspension was concentrated in vacuo. Purification was achieved by flash 
chromatography (SiO2) with an eluent gradient of MeOH in DCM (100:0.5 → 100:20 
v/v DCM:MeOH), to obtain compound rac-9a (37 mg, 0.11 mmol, 42 %) as a yellow 
solid. Rf = 0.27 (DCM:MeOH 20:1 v/v). m.p.: 105.0 – 118.4 °C. 1H NMR (500 MHz, 
CDCl3): δ 6.31 – 6.12 (m, 4H, CH=CH), 3.83 (t, J = 11.1 Hz, 1H, CH), 3.78 – 3.65 (m, 2H,CH), 3.39 – 3.16 (m, 2H, 
C*NCH2CH, CH), 3.04 – 2.98 (m, 2H, CH), 2.92 – 2.62 (m, 7H, C*NCH2CH, CH), 2.22 (dd, J = 13.0 Hz, J = 8.6 Hz, 
1H, CH), 1.81 (d, J = 8.3 Hz, 1H, CH2), 1.64 (dd, J = 13.3 Hz, J = 8.5 Hz, 2H, CH2, CH), 1.48 (d, J = 8.4 Hz, 1H, CH), 
1.36 (s, 9H, (CH3)3) ppm. 13C NMR (126 MHz, CDCl3): δ 161.9 (C*), 138.0 (CH), 137.6 (CH), 136.3 (CH), 134.9 
(CH), 85.3 (CH), 54.4 (CH2), 50.4 (CH2), 50.1 (CH), 49.7 (CH), 45.5 (CH), 45.0 (CH), 44.5 (CH), 31.5 (CH3), 29.8 
(C*) ppm. IR (neat): vmax (cm-1) = 3053 (w), 2959 (m), 2868 (m), 2008 (s), 1649 (s), 1450 (w), 1387 (w), 
1339 (w), 1221 (m), 1186 (m), 1107 (w), 1094 (w), 843 (w), 793 (m), 731 (s). HRMS (ESI): m/z calculated 
for C23H32N3 [M+H]+: 350.2591, found: 350.2597. 
 
 imidazolidin-4-imine rac-9b:30 To a solution of imine 2a (66 mg, 0.50 mmol, 2.0 
equiv) in TFE (0.4 M) were added TMSN3 (52 µl, 0.38 mmol, 1.5 equiv) and benzyl 
isocyanide (44 µL, 0.38 mmol, 1.5 equiv). The reaction mixture was stirred for 48 hr 
at 40 °C. The suspension was concentrated in vacuo. Purification was achieved by 
flash chromatography (SiO2) with an eluent gradient of MeOH in DCM (100:0.5 → 
100:20 v/v DCM:MeOH), to obtain compound rac-9b (87 mg, 0.23 mmol, 90 %) as a 
yellow solid. Rf = 0.61 (DCM:MeOH 20:1 v/v). m.p.: 77.7 – 88.7 °C. 1H NMR (500 MHz, 
CDCl3): δ 7.35 – 7.16 (m, 5H, Ph), 6.17 (d, J = 21.2 Hz, 4H, CH=CH), 4.48 (d, J = 14.9 Hz, 1H, CH2Ph), 4.33 (d, J = 
N
N
N
PhHH
H
H
N
H
NH
H
N
H
Future Directions 
 
151 
15.0 Hz, 1H, CH2Ph), 3.83 (t, J = 10.8 Hz, 1H, C*NCH2), 3.77 (d, J = 4.1 Hz, 1H, CH), 3.52 (d, J = 7.0 Hz, 1H, 
C*NCH), 3.29 – 3.17 (m, 2H, C*NCH2CH, CH), 2.85 (d, J = 3.9 Hz, 1H, CH), 2.80 – 2.73 (m, 3H, CH), 2.71 (s, 1H, 
CH), 2.64 – 2.59 (m, 2H, C*NCH2, C*CHNCH2), 2.28 (dd, J = 13.0 Hz, J = 7.7 Hz, 1H, C*CHNCH2), 1.69 (d, J = 8.0 
Hz, 1H, CHCH2CH), 1.60 (d, J = 8.4 Hz, 1H, CHCH2CH), 1.54 (d, J = 8.4 Hz, 1H, CHCH2CH), 1.45 (d, J = 8.6 Hz, 
1H, CHCH2CH) ppm. 13C NMR (126 MHz, CDCl3): δ 165.5 (C*), 140.5 (C*), 137.3 (CH), 137.1 (CH), 136.7 (CH), 
135.5 (CH), 128.6 (CH), 127.3 (CH), 126.9 (CH), 87.6 (CH), 69.0 (CH), 55.4 (CH), 54.3 (CH2), 54.1 (CH2), 53.4 
(CH2), 52.8 (CH2), 52.7 (CH2), 49.9 (CH), 48.9 (CH2), 45.3 (CH), 45.0 (CH), 44.5 (CH), 44.3 (CH) ppm. IR 
(neat): vmax (cm-1) = 2015 (w), 1649 (s), 1452 (m), 1310 (w), 1296 (m), 1254 (m), 1219 (w), 1090 (w), 1022 
(w), 731 (s), 696 (s), 696 (s), 577 (m). HRMS (ESI): m/z calculated for C26H30N3 [M+H]+: 384.2434, found: 
384.2430. 
 
proline-derived tetrazole 7b: To a solution of 10% palladium on carbon (38 mg, 0.1 
equiv) in DCM (0.1 mL) and methanol (4 mL) was added 1,5-disubstituted tetrazole 6b 
(23 mg, 0.07 mmol). The reaction mixture was stirred for 72 hr at rt under a hydrogen 
atmosphere (1 atm.). The reaction mixture was filtered over Celite®, washed with 
methanol and concentrated in vacuo. No purification was necessary. Compound 7b (14 mg, 0.07 mmol) was 
obtained as a yellow solid. 
 
General procedure for screening in Figure 4: A 50 mM aq. Tris-HCl buffer solution (total volume: 500 μL) 
containing 2.5 mM substrate 10a, 1 µM BVMO, 10 mM phosphite, 5 µM PTDH (only for PAMO), 20 µM 
NADPH, 0.25 mM acetanilide as internal standard and DMSO (5% v/v) was shaken at 400 rpm for 4 h at rt. 
The solution was extracted with EtOAc (3 x 500 μL), dried (Na2SO4) and concentrated in vacuo. The crude 
product was dissolved in iso-propanol and analyzed with HPLC. 
 
dipeptide rac-15a (major): To a solution of rac-2-amino-
2-(4-methoxyphenyl)ethan-1-o l (0.08 g, 0.50 mmol) in the solvent of choice 
(4.5 mL), were added isobutyraldehyde (46.0 μL, 0.50 mmol), benzoic acid 
(61 mg, 0.50 mmol) and 2-isocyano-2-methylpropane (70 μL, 0.60 mmol). 
The mixture was stirred for 72 h at rt and the solvent was evaporated in 
vacuo. Purification by flash chromatography (SiO2) with an eluent gradient 
(3:1 → 0:1 v/v c-Hex:EtOAc) yielded compound rac-15a (154 mg, 0.18 mmol, 
36%) as a white solid. 1H NMR (CDCl3, 400.1 MHz) : δ 7.79 (bs, 1H, OH), 7.56–7.53 (m, 2H, Ph), 7.50–7.43 
(m, 3H, Ph), 7.10 (d, J = 8.4 Hz, 2H, C(OMe)CHCH), 6.80 (d, J = 8.4 Hz, 2H, C(OMe)CH), 5.08 – 5.04 (m, 1H, 
CHCH2), 4.43 (dd, J = 11.2, 10.8 Hz, 1H, CH2), 3.80 – 3.74 (m, 1H, CH2), 3.77 (s, 3H, OCH3), 3.25 (d, J = 10.8 Hz, 
1H, NCHCH), 2.92 – 2.84 (m, 1H, CH(CH3)2), 1.39 (s, 9H, C(CH3)3), 0.85 (d, J = 6.4 Hz, 3H, CHCH3), 0.22 (d, J = 
6.8 Hz, 3H, CHCH3) ppm. 13C NMR  (CDCl3, 500.2 MHz):  δ  174.3 (C*), 172.3 (C*), 159.4 (C*), 137.6 (C*), 
133.3 (CH), 129.9 (CH), 129.0 (CH), 128.2 (C*), 127.0 (CH), 114.2 (CH), 68.6 (CH), 63.3 (CH), 61.2 (CH2), 55.3 
(CH3), 51.3 (C*), 28.6 (CH3), 27.5 (CH), 20.3 (CH3), 19.2(CH3) ppm. 
 
dipeptide rac-16a: Dipeptide 15a (0.11 g, 0.25 mmol) was dissolved in TFA (1 mL) 
and the mixture was stirred for 1 h at rt. After evaporation of the solvent in vacuo, 
purification by flash chromatography (SiO2) with an eluent system of cHex and EtOAc 
(4:1 v/v) yielded the compound rac-16a  (0.04 g, 0.14 mmol, 55%)  as a white solid. 
1H NMR (CDCl3, 400.1 MHz) : δ 8.83 (d, 2H, J = 7.6 Hz, C(O)C*CH), 7.51 – 7.42 (m, 5H, 
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Ph), 5.83 (bs, 1H, NH), 4.33 (dd, J = 7.6, 8.0 Hz, 1H, NHCH), 3.81 (bs, 1H, NH), 2.20 – 2.05 (m, 1H, CHCH3), 
1.37 (s, 9H, C(CH3)3), 1.01 (d, J = 6.8 Hz, 3H, CHCH3) ppm. 
 
piperazin-2-one rac-17a: To a solution of dipeptide 15a (184 mg, 0.4 mmol) in 
THF (4 mL), were added DEAD (469 mg, 1.1 mmol) and PPh3 (229, 0.9 mmol). 
The mixture was stirred for 2 h at 55 °C, after which the solvent was evaporated 
in vacuo. Purification by flash chromatography (SiO2) with an eluent system of 
MeOH in CH2Cl2 (1:100 v/v) yielded compound rac-17a (124 mg, 0.3 mmol, 
76%) as a white solid. 1H NMR (CDCl3, 400.1 MHz): δ 7.54 – 7.52 (m, 2H, 
C(O)C*CH), 7.44 – 7.37 (m, 3H, Ph), 7.13 (d, J = 8.4 Hz, 2H, C(OMe)CHCH), 6.78 (d, 
J = 8.4 Hz, 2H, C(OMe)CH), 4.48 – 4.42 (m, 2H, CHCH2), 4.03 – 3.98 (m, 1H, 
CHCH2), 3.76 (s, 3H, OCH3), 3.41 (d, J = 7.6 Hz, 1H, NCHCH), 2.11 – 2.06 (m, 1H, CHCH3), 1.38 (s, 9H, C(CH3)3), 
1.21 (d, J = 6.8 Hz, 3H, CHCH3), 0.71 (d, J = 6.8 Hz, 3H, CHCH3) ppm. 
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The synthesis of complex biologically relevant molecules is often achieved with 
lengthy linear syntheses. In this respect, the development of more sophisticated and 
efficient synthetic methods is a continuing challenge. The use of convergent strategies 
starting from small building blocks presents the opportunity to build novel analogs 
with several diversification points. Furthermore, the number of synthetic steps and 
the related waste production and energy consumption can be reduced by combining 
several chemical transformations in one pot. Important tools to achieve these goals 
are cascade and multicomponent reactions. Cascade reactions are defined as 
sequenced conversions using the product of one transformation as the substrate for 
the next and so on. The consecutive series of intra- or intermolecular steps of these 
domino reactions proceeds through highly reactive intermediates until a stable 
product is reached. Multicomponent reactions involve the well-defined condensation 
of more than two reactants to form a product that contains significant portions of all 
reactants, ideally all atoms. 
 The asymmetry in the synthesis of bioactive compounds is often introduced 
under the influence of organocatalysts and heavy metals, but the application of Nature 
as a chiral template can be an elegant alternative. This approach may involve the use 
of compounds that are represented in the chiral pool. Another widely applicable  
 
 
 
Scheme 1. meso-Pyrrolidines as templates for oxidative cascade processes. 
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strategy uses enzymes, the asymmetric catalysts from Nature, which offer unrivaled 
chemo-, regio- and stereoselectivity. The key objective of the research in this thesis is 
the development of novel and efficient methods for the synthesis of pharmaceutically 
and biologically interesting compounds. In particular, the application of biocatalysis 
for the synthesis of substrates for novel cascade reactions was envisioned. For an 
overview of the diversity of scaffolds that were synthesized with novel methods 
during the research for this thesis, see Scheme 1.  
The high potential for the application of biocatalysts in organic synthesis has 
been clearly demonstrated in the past decades, but enzymes are still not fully 
integrated in the synthetic toolbox yet. We provided a guideline on how to implement 
biocatalysis in synthetic chemistry in Chapter 1. For this purpose, the most important 
biocatalytic strategies are summarized for the biocatalysts with the highest potential 
to be applied. The fruitful union of biocatalysis and organic synthesis is illustrated 
with some relevant highlights from the literature. Herewith, we hope to inspire the 
reader to think out of the box and consider biocatalysis as a reliable tool in 
asymmetric synthetic transformations. 
Previously, we described the oxidation of meso-pyrrolidines with an 
engineered variant of monoamine oxidase (MAO-N D5) to give the corresponding 
bicyclic imines in high to excellent enantioselectivity (Scheme 2). Since only 
carbocycle-fused pyrrolidines were shown to be suitable substrates for the 
biocatalyst, we investigated the incorporation of an additional heteroatom in het 
substrate skeleton. Attractively, a meso-pyrrolidine derived from furan was suitable 
for the biocatalytic oxidation, giving stable hemiaminal 2d in 95% ee and 81% yield 
(Chapter 2). 
 From the overview in Chapter 1, we noticed that the one-pot combination of 
enzymatic activation with synthetic transformation in benign media receives 
particular interest. Intriguingly, we discovered that subjecting the furan-derived 
meso-pyrrolidine 1a to the biocatalyst in aqueous buffer results in a domino sequence 
 
 
Scheme 2. Biocatalytic oxidation of a range of meso-pyrrolidines. 
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Scheme 3. MAO-rDA-aza-FC sequence. PPB = potassium phoshate buffer 
of biocatalytic oxidation followed by a retro-Diels‒Alder reaction and an 
aza-Friedel‒Crafts addition (MAO-rDA-aza-FC, Scheme 3). Apparently, the aqueous 
buffer is a sufficiently good proton donor and/or hydrogen bond acceptor to activate 
the intermediate imine (2a) for an aza-FC reaction (and a rDA), while activation of this 
species with a strong Lewis or Brønsted acid is required in organic solvents. We opted 
to circumvent the rDA side reaction of the intermediate imine by employing 
meso-pyrrolidines that are unable to undergo this reaction. With an optimized 
two-stage one-pot procedure, the α-functionalization of a broad range of pyrrolidines 
with a variety of aromatic C-nucleophiles was achieved under benign conditions 
(Scheme 4, Chapter 2). The desired 2-substituted pyrrolidines were obtained in 
reasonable to good yield as single diastereoisomers and generally with high 
enantioselectivity. As for most synthetic methods, this strategy has some limitations 
i.e. low enantioselectivity for tertiary amines (R2 = Me) and restriction to the substrate 
scope of the biocatalyst. However, our chemoenzymatic oxidative aza-FC reaction has 
clear advantages, since it is significantly more benign than many other direct 
α-functionalizations of pyrrolidines. 
 
 
Scheme 4. Chemoenzymatic oxidative aza-Friedel-Crafts reaction. 
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In light of our continued interest in the functionalization of imines, in particular 
1-pyrrolines, we envisioned a clean and fast chemical oxidation of unactivated 
meso-pyrrolidines. Given the recent regained interest in hypervalent iodine reagents, 
we explored their ability to oxidize aliphatic amines. Gratifyingly, we developed the 
first o-iodoxybenzoic acid (IBX) mediated oxidation of unactivated amines (Scheme 5, 
Chapter 3). This convenient method gives access to bi- and tricyclic imines rac-2, but 
is limited to 1-pyrrolines that do not tautomerize under the reaction conditions. The 
chemical space was further explored with one-pot oxidative Ugi-type and 
aza-Friedel‒Crafts reactions, which proved to be highly diastereoselective. 
 
Scheme 5. Oxidative α-functionalizaton of meso-pyrrolidines 1 with IBX. 
In order to develop novel methods for the synthesis of complex molecules, we 
explored the utility of our biocatalytically generated chiral building blocks 2 in 
cascade reactions by considering them as amino aldehyde synthons. We developed an 
asymmetric chemoenzymatic synthesis of natural product-like pyrroloindolines 5 
with cis-junction of both [3.3.0] bicyclic systems using an interrupted Fischer indole 
synthesis between arylhydrazines and bicyclic imines (Scheme 6, Chapter 4). A wide 
range of electron-rich as well as electron-deficient arylhydrazines were suitable 
substrates for this reaction, showing an interesting trend in regioselectivity for 
meta-substituted arylhydrazines depending on the steric size of the substituent.  
We serendipitously discovered that a subtle change in the reaction conditions 
of the interrupted Fischer indole synthesis in terms of stoichiometry of the acid 
mediator resulted in a rearrangement of the polycyclic scaffold to afford constrained 
tryptamine derivatives 6 and 7 selectively (Scheme 6, Chapter 4). This 
rearrangement proved quite general, as demonstrated for relatively electron-rich as 
well as electron-deficient systems and even heterocyclic compounds. 
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Scheme 6. Interrupted Fischer indole synthesis towards either pyrroloindolines or constrained 
tryptamines and key intermediates of the proposed mechanism. 
For the rearrangement, interesting results in terms of regioselectivity of the migrating 
C-C bond were observed that were reasonably explained by electronic factors. A 
plausible mechanistic pathway for the formation of the pyrroloindolines and 
constrained tryptamines was also provided, but a thorough computational study is 
required to provide a better understanding of the influence of steric factors. This 
acid-switchable chemoenzymatic synthesis of either pyrroloindolines or serotonin 
analogs underlines the fruitful union of biocatalysis with cascade reactions even 
further.  
As a result of the high therapeutic potential of phenserine and 
norcymserine—which exhibit a pyrroloindoline core—for Alzheimer’s disease and 
other neurodegenerative diseases, we set out to synthesize analogs of these important 
lead compounds. We employed an Nα-methylated hydrazine for the cascade reaction 
towards phenserine analog 13 (Scheme 7), which was synthesized via a novel 
chemoselective Boc-reduction. After the interrupted Fischer indolization between  
(–)-2a and Nα-methylated hydrazine 12, compound 13 was obtained by 
N-methylation, hydrogenolysis and carbamoylation.  
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Scheme 7. Cholinesterase inhibitors phenserine and phenethylnorcymserine analog 11 as well as our 
strategy for the synthesis of phenserine analog 13. 
 
As certain constrained tryptamines act on the 5-HT6 receptor, an important target for 
novel therapeutics in the treatment of Alzheimer’s disease, this compound class has 
several conceivable therapeutic applications. Furthermore, potent and selective 
inhibitors of melatonin receptors as well as the TRPV1 ion channel with the same core 
structure have been reported. We synthesized an antagonist of the 5-HT6 receptor  
 
 
Figure 1. Examples of pharmaceutically relevant constrained tryptamines. 
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(14), known as the constrained analog of MS-245, by a convenient three-step 
synthesis based on the interrupted Fischer indole synthesis. Also, TRPV1 ion channel 
inhibitor 15 could be synthesized using our novel methodology. These bioactive 
compounds are easily accessible with our strategy in either optically pure or racemic 
form by employing a bicyclic imine synthesized by either biocatalytic (Chapter 2) or 
IBX-mediated oxidation (Chapter 3).  
Future efforts will focus on investigation of the biological activity of new 
analogs such as 13 to identify lead compounds in drug discovery. Since both the 
pyrroloindolines 5 and constrained tryptamines 7 and 8 have several diversification 
points (see Scheme 6), a range of compounds with high therapeutic potential can be 
generated using our strategy. 
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De synthese van complexe en biologisch relevante moleculen wordt vaak gerealiseerd 
met lange lineaire syntheses. De ontwikkeling van slimmere en efficiëntere 
synthetische methoden is in dit opzicht een voortdurende uitdaging. Het gebruik van 
convergente strategieën vanuit kleine chemische bouwstenen stelt ons in staat om 
nieuwe analogen met meerdere punten voor diversificatie te synthetiseren. 
Bovendien kunnen het aantal synthetische stappen en de daaraan gerelateerde 
afvalproductie en energieverbruik gereduceerd worden door meerdere chemische 
omzettingen te combineren in één reactievat. Cascade- en multicomponentreacties 
zijn belangrijke hulpmiddelen om deze doelen te bereiken. Cascadereacties worden 
gedefinieerd als sequentiële conversies waarbij het product van de eerste 
transformatie gebruikt wordt als het substraat van de volgende, enzovoorts. Deze 
dominoreeks van intra- en intermoleculaire reactiestappen verloopt via reactieve 
intermediairen totdat een stabiel product gevormd wordt. Multicomponentreacties 
zijn selectieve reacties tussen meer dan twee reactanten waarbij een product 
gevormd wordt dat significante delen (idealiter alle atomen) van alle reagentia bevat. 
 De asymmetrie in de synthese van bioactieve verbindingen wordt vaak 
geïntroduceerd door het gebruik van organokatalysatoren en zware metalen, terwijl 
de toepassing van de natuur als chiraal template vaak een elegant alternatief is. Deze 
 
 
Schema 1. meso-Pyrrolidines als startpunt voor oxidatieve cascadereacties. 
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aanpak kan worden gerealiseerd door het gebruik van chirale moleculen uit de natuur 
als uitgangsmateriaal. Een andere veel gebruikte aanpak is het gebruik van enzymen, 
de asymmetrische katalysatoren van de natuur, die ongeëvenaarde chemo-, regio- en 
stereoselectiviteit bieden. De doelstelling van het onderzoek in dit proefschrift is de 
ontwikkeling van nieuwe en efficiënte methoden voor de synthese van farmaceutisch 
en biologisch interessante verbindingen. De toepassing van biokatalyse voor de 
synthese van substraten voor innovatieve cascadereacties was daarbij een 
belangrijke doelstelling. Voor een overzicht van de diversiteit aan verbindingen die 
met innovatieve methoden tijdens het onderzoek voor dit proefschrift 
gesynthetiseerd zijn, zie Schema 1. 
 Het hoge potentieel voor de toepassing van biokatalysatoren in organische 
synthese is in de laatste decennia duidelijk aangetoond, maar enzymen zijn nog steeds 
niet volledig geïntegreerd in de zgn. synthetische toolbox. In Hoofdstuk 1 hebben wij 
een handleiding geschreven voor de toepassing van biokatalyse in de synthetische 
chemie. Hiervoor hebben we de belangrijkste biokatalytische strategieën achter 
elkaar gezet. De vruchtbare vereniging van biokatalyse en organische synthese is 
geïllustreerd met een aantal relevante voorbeelden. Hiermee hopen we de lezer te 
inspireren om buiten hun referentiekader te denken en biokatalyse te beschouwen als 
een betrouwbaar middel in asymmetrische synthetische transformaties. 
 De oxidatie van meso-pyrrolidines met een gemodificeerde variant van 
monoamine oxidase (MAO-N D5) voor de synthese van bicyclische imines in (zeer) 
hoge enantioselectiviteit was eerder beschreven door onze groep. Wij hebben 
vervolgens onderzocht of het enzym een substraat met een extra heteroatoom 
accepteert, omdat alleen koolstofring-gefuseerde pyrrolidines bekend zijn als 
geschikte substraten voor de biokatalysator (Schema 2). Tot onze tevredenheid bleek 
een substraat met een zuurstof atoom in de gefuseerde ring van het meso-pyrrolidine 
ook geschikt voor de biokatalytische oxidatie. Hemiaminal 2d werd geïsoleerd als het  
 
 
Schema 2. Biokatalytische oxidatie van verschillende meso-pyrrolidines. 
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Schema 3. MAO-rDA-aza-FC cascadereactie. PPB = kalium fosfaatbuffer 
product van deze reactie is 95% enantiomere overmaat (ee) en 81% opbrengst 
(Hoofdstuk 2). 
Het overzicht in Hoofdstuk 1 geeft onder andere weer dat de combinatie van 
enzymatische activering met synthetische transformaties in milieuvriendelijke 
oplosmiddelen bijzonder interessant is. Wij ondervonden dat de biokatalytische 
oxidatie van het furaan-gebaseerde meso-pyrrolidine 1a in een waterige buffer 
resulteerde in een dominoreactie van oxidatie gevolgd door een retro-Diels‒Alder 
reactie en een aza-Friedel‒Crafts additie (MAO-rDA-aza-FC, Schema 3). Blijkbaar is de 
waterige buffer een voldoende effectieve proton en/of waterstofbrug donor om het 
intermediaire imine 2a te activeren voor een aza-FC reactie (en een rDA), terwijl 
activering van deze verbinding met een sterk Lewis- of Brønstedzuur nodig is in 
organische oplosmiddelen. We voorzagen de mogelijkheid om de rDA nevenreactie 
van het intermediaire imine te voorkomen door een meso-pyrrolidine te gebruiken die 
deze reactie niet kan ondergaan. Met een geoptimaliseerde twee-fase procedure in 
één reactievat hebben we de α-functionalisering van een reeks pyrrolidines met een 
verscheidenheid aan koolstof nucleofielen onder milieuvriendelijke condities 
gerealiseerd (Schema 4, Hoofdstuk 2). De gewenste 2-gesubstitueerde pyrrolidines 
werden verkregen als enkele diastereoisomeren in redelijke tot goede opbrengst en 
een over het algemeen hoge enantioselectiviteit. Deze strategie heeft net zoals de 
meeste methoden een aantal beperkingen, namelijk de lage enantioselectiviteit met 
tertiaire amines (R2 = Me) en de beperking tot het substraatbereik van de 
biokatalysator. Onze chemoenzymatische oxidatieve aza-FC reactie heeft echter 
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Schema 4. Chemoenzymatische oxidatieve aza-Friedel-Crafts reactie. 
 
duidelijke voordelen, omdat deze significant milieuvriendelijker is dan de gemiddelde 
α-functionalisering van pyrrolidines. 
 Gezien onze interesse in de functionalisering van imines, met name 
1-pyrrolines, wilden we een snelle en schone chemische oxidatie  van ongeactiveerde 
meso-pyrrolidines ontwikkelen. Vanwege de recente hernieuwde interesse in 
hypervalente joodreagentia hebben we hun vermogen om alifatische amines te 
oxideren onderzocht. Tot ons genoegen hebben we de eerste o-jodoxybenzoëzuur 
(IBX) gemedieerde oxidatie van ongeactiveerde amines ontwikkeld (Schema 5, 
Hoofdstuk 3). Deze doeltreffende methode geeft toegang tot bi- en tricyclische imines 
(±)-2, maar beperkt zich tot 1-pyrrolines die niet tautomeriseren onder de 
reactiecondities. De chemische ruimte is verder onderzocht door middel van 
oxidatieve Ugi-type en aza-FC reacties, welke zeer diastereoselectief bleken te zijn. 
 
Schema 5. Oxidatieve α-functionalisering van meso-pyrrolidines 1 met IBX. 
Om nieuwe methoden voor de synthese van complexe moleculen te ontwikkelen, 
hebben we de toepasbaarheid van onze biokatalytisch gegenereerde chirale 
bouwstenen 2 in cascadereacties onderzocht door ze als aminoaldehydes te 
beschouwen. We hebben een asymmetrische chemoenzymatische synthese van 
natuurstofachtige pyrroloindolines 5 met een cis-configuratie van beide [3.3.0] 
bicyclische systemen ontwikkeld door middel van een onderbroken Fischer 
indoolsynthese tussen arylhydrazines en bicyclische imines (Schema 6, Hoofdstuk 4). 
Een breed scala aan elektronenrijke en elektronenarme arylhydrazines bleken 
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geschikte substraten voor deze reactie. Voor meta-gesubstitueerde arylhydrazines 
was een interessante trend zichtbaar afhankelijk van de sterische grootte van het 
substituent. 
 We ontdekten dat een kleine verandering in de reactiecondities van de 
onderbroken Fischer indoolsynthese wat betreft de stoechiometrie van het zuur 
resulteerde in een selectieve omlegging van het polycyclische molecuul 5 naar de 
gefixeerde tryptaminederivaten 6 en 7 (Schema 6, Hoofdstuk 4). Deze omlegging 
bleek te werken voor relatief elektronenrijke en elektronenarme systemen en zelfs 
voor heteroaromatische verbindingen en is dus breed toepasbaar. 
 
Schema 6. Onderbroken Fischer indoolsynthese van pyrroloindolines of gefixeerde tryptamines en 
essentiële intermediairen in het voorgestelde mechanisme. 
De omlegging gaf interessante resultaten qua regioselectiviteit van de migrerende 
koolstof‒koolstof binding, die goed verklaarbaar zijn op basis van elektronische 
argumenten. Verder hebben we ook een plausibel mechanisme omschreven voor de 
vorming van de pyrroloindolines en gefixeerde tryptamines, maar een uitgebreide 
computationele studie is nodig om de invloed van sterische factoren te onderzoeken. 
Deze schakelbare chemoenzymatische synthese van pyrroloindolines of serotonine 
analogen onderstreept de vruchtbare combinatie van biokatalyse en cascadereacties. 
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De pyrroloindoline-gebaseerde verbindingen phenserine en norcymserine hebben 
een hoog therapeutisch potentieel tegen de ziekte van Alzheimer en andere 
neurodegeneratieve ziektes. Daarom wilden we analogen synthetiseren van deze 
farmaceutisch relevante verbindingen. Via een innovatieve chemoselectieve Boc-
reductie konden we het Nα-gemethyleerde hydrazine 12 genereren als 
uitgangsmateriaal voor de cascadesynthese van phenserine-analoog 13 (Scheme 7). 
Na de onderbroken Fischer indoolreactie tussen 12 en het imine (–)-2a werd analoog 
13 verkregen na N-methylering, hydrogenolyse en carbamoylering. 
 
Schema 7. Cholinesterase remmers phenserine en phenethylnorcymserine analoog 11 en onze strategie 
voor de synthese van phenserine-analoog 13. 
Aangezien bepaalde gefixeerde tryptamines invloed kunnen uitoefenen op de  5-HT6 
receptor, een belangrijk doelwit van nieuwe medicijnen voor onder andere de 
behandeling van de ziekte van Alzheimer, hebben deze verbindingen veel denkbare 
therapeutische toepassingen. Daarnaast zijn moleculen met deze basisstructuur 
bekend als selectieve remmers van melatonine receptoren en ook het TRPV1 
ionkanaal. Wij hebben een bekende antagonist van de 5-HT6 receptor (14), beter 
bekend als het gefixeerde analoog van MS-245, gesynthetiseerd door middel van een 
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driestapssynthese gebaseerd op de onderbroken Fischer indoolsynthese. Daarnaast 
hebben we de TRPV1 ionkanaal remmer 15 gesynthetiseerd met onze innovatieve 
methodologie. Deze bioactieve verbindingen zijn met onze methode goed toegankelijk 
in optisch zuivere of racemische vorm door de toepassing van het bicyclische imine 
gesynthetiseerd door middel van biokatalytische (Hoofdstuk 2) of IBX-gemedieerde 
oxidatie (Hoofdstuk 3). 
 
 
Figuur 1. Farmaceutisch relevante gefixeerde tryptamines. 
Toekomstig onderzoek zal zich voornamelijk richten op de biologische activiteit van 
nieuwe analogen zoals 13 om nieuwe derivaten voor de farmaceutische industrie te 
identificeren. Aangezien zowel pyrroloindolines 5 als gefixeerde tryptamines 7 en 8 
meerdere diversificatiepunten hebben, kunnen we een reeks van verbindingen met 
hoog therapeutisch potentieel genereren met onze strategie. 
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